
<html lang="en"     class="pb-page"  data-request-id="2ab7c948-9410-4b18-a0bf-a5e39c5884f8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.8b00189;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-7;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy" /></meta><meta name="dc.Creator" content="Yepeng  Luan" /></meta><meta name="dc.Creator" content="Jerry  Li" /></meta><meta name="dc.Creator" content="Jean A.  Bernatchez" /></meta><meta name="dc.Creator" content="Rongshi  Li" /></meta><meta name="dc.Description" content="Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development. To date, five histone deacetylase inhibitors (HDACis) have been ..." /></meta><meta name="Description" content="Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development. To date, five histone deacetylase inhibitors (HDACis) have been ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 12, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00189" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00189" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00189" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00189" /></link>
        
    
    

<title>Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00189" /></meta><meta property="og:title" content="Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0015.jpeg" /></meta><meta property="og:description" content="Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. It has been well validated that an agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and in potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDAC inhibitor. In this perspective, the authors review the majority of reported kinase/HDAC hybrid inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00189"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00189">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00189&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00189&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00189&amp;href=/doi/10.1021/acs.jmedchem.8b00189" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3171-3183</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b01093" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yepeng Luan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yepeng Luan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao 266071, Shandong Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yepeng++Luan">Yepeng Luan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jerry Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jerry Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jerry++Li">Jerry Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jean A. Bernatchez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jean A. Bernatchez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Skaggs School of Pharmacy and Pharmaceutical Sciences,  Center for Discovery and Innovation in Parasitic Diseases, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jean+A.++Bernatchez">Jean A. Bernatchez</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Rongshi Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rongshi Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao 266071, Shandong Province, China</div><div class="loa-info-affiliations-info">UNMC Center for Drug Discovery, Department of Pharmaceutical Sciences, College of Pharmacy, Fred and Pamela Buffett Cancer Center, and Center for Staphylococcal Research, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (402)559-6609. E-mail: <a href="/cdn-cgi/l/email-protection#bbe9d4d5dcc8d3d295d7d2fbced5d6d895dedfce"><span class="__cf_email__" data-cfemail="99cbf6f7feeaf1f0b7f5f0d9ecf7f4fab7fcfdec">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rongshi++Li">Rongshi Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1774-7827" title="Orcid link">http://orcid.org/0000-0002-1774-7827</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00189&amp;href=/doi/10.1021%2Facs.jmedchem.8b00189" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3171–3183</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 12, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 February 2018</li><li><span class="item_label"><b>Published</b> online</span>12 November 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 April 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00189" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00189</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3171%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYepeng%2BLuan%252C%2BJerry%2BLi%252C%2BJean%2BA.%2BBernatchez%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D7%26contentID%3Dacs.jmedchem.8b00189%26title%3DKinase%2Band%2BHistone%2BDeacetylase%2BHybrid%2BInhibitors%2Bfor%2BCancer%2BTherapy%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3183%26publicationDate%3DApril%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00189"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4284</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">54</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00189" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yepeng&quot;,&quot;last_name&quot;:&quot;Luan&quot;},{&quot;first_name&quot;:&quot;Jerry&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jean&quot;,&quot;last_name&quot;:&quot;A. Bernatchez&quot;},{&quot;first_name&quot;:&quot;Rongshi&quot;,&quot;last_name&quot;:&quot;Li&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;3171-3183&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00189&quot;},&quot;abstract&quot;:&quot;Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. It has been well validated that an agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and in potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDAC inhibitor. In this perspective, the authors review the majority of reported kinase/HDAC hybrid inhibitors.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00189&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00189" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00189&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00189" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00189&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00189" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00189&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00189&amp;href=/doi/10.1021/acs.jmedchem.8b00189" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00189" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00189" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00189%26sid%3Dliteratum%253Aachs%26pmid%3D30418766%26genre%3Darticle%26aulast%3DLuan%26date%3D2019%26atitle%3DKinase%2Band%2BHistone%2BDeacetylase%2BHybrid%2BInhibitors%2Bfor%2BCancer%2BTherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D7%26spage%3D3171%26epage%3D3183%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/jmcmar.2019.62.issue-7/20190411/jmcmar.2019.62.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. It has been well validated that an agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and in potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDAC inhibitor. In this perspective, the authors review the majority of reported kinase/HDAC hybrid inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Epigenetics is classically defined as the reversible changes in gene expression that do not result from changing DNA sequences. Epigenetics has been found to play an important role in the origin, development, and metastasis of cancer. Epigenetic writer, eraser, and reader enzymes, including histone deacetylase, DNA methyltransferase, and histone methyltransferase, have received increasing attention and are frequently studied as targets for drug discovery in cancer therapy.</div><div class="NLM_p">Of these epigenetics modifications, acetylation is the most common, playing important roles in the regulation of normal cellular processes such as cell differentiation, proliferation, angiogenesis, and apoptosis. Dysregulation of acetylation has been associated with diverse cellular events in cancer pathologies. Global hypoacetylation of H4 is one such common hallmark of tumors.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">The level of acetylation of histones and nonhistone proteins is governed by two antagonistic families of enzymes: histone deacetylases (HDACs) and histone acetyltransferases (HATs). HDACs are a family of ubiquitous enzymes found in bacteria, fungi, plants, and animals that are capable of removing an acetyl group from the ε-amino groups of lysine residues present within core histones and many nonhistone proteins. Consequently, the positive charge in the N-terminal region of histone cores increases and strengthens interactions with negatively charged DNA while blocking access of transcriptional machinery to the DNA template, leading to gene silencing (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Histone acetylation is regulated by HAT and HDAC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The known HDACs are divided into four classes based on their sequence homology: class I HDACs include HDAC1, 2, 3, and 8; class II HDACs include classes IIa (HDAC4, 5, 7, and 9) and IIb (HDAC6 and 10); class III HDACs, known as sirtuins (sirt1–7); class IV HDAC (HDAC11).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Silencing or inhibiting HDACs has been shown to affect cell cycle, cell growth, chromatin decondensation, cell differentiation, apoptosis, and angiogenesis in several cancer cell types.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Thus, HDACs have emerged as important therapeutic targets in treating cancers. Accompanied by the extensive elucidation of mechanisms and functions of HDAC in tumorigenesis, the development of histone deacetylase inhibitors (HDACis) represents a powerful approach for cancer therapy. Apart from cancer, HDACs have also demonstrated value as targets for the treatment of diseases including Alzheimer’s,<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> HIV-1 infection,<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> and cardiovascular disease.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">In October 2006, the FDA approved the first HDACi, SAHA (vorinostat, <b>1</b> in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), used in treating rare cutaneous T-cell lymphoma. Currently, four HDAC inhibitors: <b>1</b>, romidepsin (<b>2</b>), belinostat (<b>3</b>), and panobinostat (<b>4</b>) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) have been approved by the FDA for the treatment of cancers including cutaneous T-cell lymphoma, peripheral T-cell lymphoma (PTCL), and multiple myeloma.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The benzamide-based class I HDAC-selective inhibitor chidamide (<b>5</b> in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) has recently been approved in China for the treatment of relapsed or refractory PTCL.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Apart from these five approved treatments, there are several HDAC inhibitors at various stages of clinical trials against different cancers. In general, the canonical pharmacophore of the HDAC inhibitor is composed of three parts as shown in <b>1</b> in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>: a cap structure that can interact with the rim at the entrance of the active pocket of HDACs, a zinc ion binding group (ZBG), and a linker responsible for the connection between the cap and the ZBG and for interaction with the hydrophobic tunnel of the active site.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Of these three constitutive parts of the HDACi, the cap can adopt extensive structural variation, making it possible to design HDAC inhibitors with great variety of structures.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Five approved HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Hybrid HDACis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18558" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18558" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although HDACis have shown potent anticancer activities and five of them are in clinical use, side effects still exist, including thrombocytopenia, neutropenia, diarrhea, nausea, vomiting, fatigue, and cardiotoxicity.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> HDACis also tend to be less potent against solid tumors, which severely limits their employment in cancer therapy.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> To overcome these flaws, the development of new generation HDACis has thus far mainly focused on isoform-selective HDACis and multitarget HDACis which can also be termed as hybrid or bifunctional HDACis, with the latter gaining increasing attention.</div><div class="NLM_p">The mechanism of pathogenesis in cancer is known to be extremely complicated, with diverse enzymes, structural proteins, and transcription factors cooperating in the onset process. Although bioactive molecules that act on a single antitumor target are mostly used to suppress existing tumors, this approach is frequently unable to provide effective and durable tumor suppression. Cancer cells can trigger other compensatory pathways for survival, and this accounts for much of the drug insensitivity and resistance. Several strategies may be applicable to solve this problem. One is a combination drug approach, but this strategy faces poor patient compliance, complex pharmacokinetics, and the challenge of drug–drug interactions that can severely affect the efficacy of one or more of the drugs administered.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Another strategy is the development of therapeutic agents that incorporate several bioactive groups into a single molecule, which can produce compounds able to modulate multiple cellular pathways and which possess elevated efficacy compared to single-target agents. These can effectively overcome pharmacokinetic drawbacks and reduce development costs as well.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> Hybrid agents are thus powerful tools for anticancer drug discovery and in the authors’ view should have superior claims to be exploited.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">Treatment of tumor cells with HDACis can effectively induce a range of effects, including tumor cell apoptosis, cell cycle arrest, differentiation and senescence, modulation of immune responses, and blockade of angiogenesis.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> HDACis can thus be reasonably used in combination with other anticancer drugs, including cytotoxic drugs and small molecule inhibitors of defined targets.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Co-administration of an HDACi with other anticancer drugs has already displayed promising augmented anticancer effects.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Considering the direct tumoricidal activity of HDACis and their synergistic effect with other anticancer drugs, the hybrid HDACis, which combine two key fragments (i.e., the cap and ZBG groups) with an appropriate linker into a single molecule as a hybrid and that eventually act on two or more antitumor targets, have been validated and should offer the greatest advantage of the combined or additive effects of two drugs. Thus, the design of hybrid HDACis has attracted considerable attention.</div><div class="NLM_p">The main features of the published hybrid HDACis include: (i) an essential fragment of the inhibitor against another cancer target usually acting as the cap group of the hybrid HDACi, (ii) ZBG groups (the most commonly used are hydroxamic acid and benzamide), (iii) a linker that is the key factor affecting the activities for both targets, and (iv) the newly formed hybrids always showing potent and balanced inhibitory activities against HDACs and another cancer target.</div><div class="NLM_p">The fragments of the cap groups in reported hybrid HDACis are mainly from (i) kinase inhibitors, (ii) cytotoxic compounds,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (iii) hormone receptor modulators,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (iv) epigenetic modulators,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (v) natural products,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and (vi) other anticancer drugs or agents.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> Because the same strategy of hybrid HDACis applies to all six categories mentioned above, the general design of kinase/HDAC inhibitor hybrids is shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. In this Perspective, only those hybrid HDACis using the fragments from kinase inhibitors as cap groups are discussed while the hybrid HDACis derived from other anticancer agents (ii–vi) can be found elsewhere in the literature.<a onclick="showRef(event, 'ref21 ref22 ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24 ref25 ref26">(21−26)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural features of kinase/HDAC hybrid inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Kinase/HDAC Hybrid Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Kinases are responsible for transferring phosphate groups from ATP to specific target molecules and have been among the most intensively pursued classes of drug targets, mainly for the treatment of cancers.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> More than 30 kinase inhibitor drugs have been approved.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Among all kinase inhibitors, receptor tyrosine kinase (RTK) inhibitors have become important therapeutic agents in the fight against various cancers. Several RTK inhibitors have been approved by the FDA, and many others are in different phases of clinical trials. However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of kinase inhibitors is often impaired by poor response rates and acquired drug resistance.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> To overcome these limitations, a number of strategies have been tested, including combination therapy and the development of multitarget inhibitors.</div><div class="NLM_p">HDACis were shown to synergize with RTK inhibitors by suppressing proliferation and inducing apoptosis in tumor cells, making tumor cells more susceptible to RTK inhibitor treatment and even overcoming RTK inhibitor resistance.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35 ref36 ref37">(32−37)</a> Dual-acting hybrids that inhibit both HDAC and RTK have been widely reported.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35 ref36 ref37">(32−37)</a> The structural features of such hybrids consist of a key fragment from the kinase inhibitors and a ZBG group from the HDACis with an appropriate linker as shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. The resulting kinase/HDAC hybrid inhibitors can simultaneously inhibit both HDACs and kinases.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">A.  Erlotinib-Based Hybrid HDACis</h3><div class="NLM_p">Cai et al. designed and synthesized a series of compounds by integrating the hydroxamic acid group of an HDACi into the known epidermal growth factor receptor/human epidermal growth factor receptor 2 (EGFR/HER2) inhibitor erlotinib (<b>6</b> in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Both the quinazoline and phenyl-amino groups of <b>6</b> have key interactions in the ATP binding pocket with EGFR. However, the two methoxy–ethoxy groups at C-6 and C-7 do not bind directly to the receptor. This allows for structure modification at these positions without sacrificing the EGFR affinity. As a result, linkers with different spacers (ether, amide, sulfur ether, and sulfone) and lengths (three to five carbons) that terminated with a hydroxamic acid as a ZBG group were substituted on either C-6 or C-7 to inhibit HDACs.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Erlotinib-based hybrid HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several hybrid compounds showed potent inhibitory activity toward three enzymes: EGFR, HER2, and HDACs.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Structure–activity relationships (SAR) showed that the HDAC inhibitory activity correlated well with the linker length, with longer lengths being better and a length of six carbons being optimal. The structure of the linker could also affect the HDAC inhibitory activities. An ether linker is more potent than an amide linker, which is more potent than a thioether linker; a sulfone linker had the lowest potency. C-6 substituted compounds showed better inhibitory activity toward HDACs than those on C-7. Interestingly, substitution patterns of the quinazoline ring did not significantly affect HDAC inhibition.</div><div class="NLM_p">Among all these compounds, CUDC-101 (<b>7</b> in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) was the most promising multitarget anticancer drug candidate. It is a first-in-class hybrid inhibitor of HDAC, EGFR, and HER2, with IC<sub>50</sub> values of 4.4, 2.4, and 15.7 nM, respectively. <b>7</b> suppressed the proliferation of a panel of 11 human tumor cell types (including lung, liver, pancreas, and breast, with IC<sub>50</sub> values lower than 1 μM) much better than <b>6</b> alone or a combination of <b>1</b> and <b>6</b>. This was due to the ability of <b>7</b> to directly inhibit both EGFR and HER2 signaling and indirectly attenuate other survival signaling pathways, such as Akt, HER3, and MET.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> In addition to a potent antiproliferation effect, <b>7</b> could also prevent cancer cell migration and invasion that are lethal characteristics of cancer.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In vivo, the antitumor efficacy of <b>7</b> was evaluated in a Hep-G2 liver cancer model at a daily dose of 120 mg/kg administered intravenously (iv). <b>7</b> induced 30% tumor regression and was more efficacious than <b>6</b> at its maximum tolerated dose (25 mg/kg, per os (po), daily) and <b>1</b> at a dose of 75 mg/kg (iv, daily).</div><div class="NLM_p">The phase I clinical trial study of the safety, pharmacokinetics, and antitumor activity of <b>7</b> was completed in 2010, where it displayed promising single-agent activity against advanced solid tumors and favorable pharmacodynamic profiles. The maximum tolerated dose was determined to be 275 mg/m<sup>2</sup>. The principal toxicities included transient reversible nausea (24%), fatigue (24%), dry skin (16%), serum creatinine elevation (12%), and serum AST elevation (12%).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p last">A subsequent phase I dose escalation study of <b>7</b> in combination with cisplatin administered intravenously and radiation therapy in patients with head and neck squamous cell cancer (HNSCC) was also completed in 2013. EGFR is overexpressed in up to 90% of HNSCC and HER2 is overexpressed in 20% to 40% of HSNCC; overexpression of both factors is associated with chemotherapy resistance. Twelve patients with intermediate or high-risk HNSCC enrolled. The initial dose of <b>7</b> for this clinical trial was 225 mg/m<sup>2</sup>, and the second dose was escalated to 275 mg/m<sup>2</sup>. <b>7</b> was administered by intravenous infusion over 1 h three times per week for 1 week, and cisplatin 100 mg/m<sup>2</sup> was administered every 3 weeks. Results showed that the combination of <b>7</b> and conventional chemoradiation was feasible and tolerated at biologically efficacious doses.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">B.  Lapatinib-Based Hybrid HDACis</h3><div class="NLM_p">Mahboobi et al. reported a series of multifunctional inhibitors simultaneously targeted to EGFR/HER2/HDAC via combining the pharmacological activities of kinase and HDAC inhibitors. The structural element of either a hydroxamic acid or a benzamide derived from reported HDACis was transferred to the core structure of lapatinib (<b>8</b> in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), a dual EGRF/HER2 small molecular inhibitor, to obtain new hybrid entities.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The hybrids <b>9</b> and <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), bearing an (<i>E</i>)-3-(aryl)-<i>N</i>-hydroxyacrylamide motif, exhibited the most potent inhibitory activities toward HeLa nuclear extract HDACs (IC<sub>50</sub> values of 630 and 47 nM, respectively). This may be due to the structural similarities between their ZBG groups and <b>3</b>; the substitution patterns of the <i>N</i>-hydroxyacrylamide moiety in <b>9</b>, <b>10</b>, and <b>3</b> are all <i>meta</i> to another substituent on the furan (<b>9</b>) or benzene ring (<b>10</b> or <b>3</b>). A transfer of this moiety from the <i>meta</i> to the <i>para</i> position drastically reduced the HDAC inhibitory potency. These two hybrid compounds also displayed very potent and specific inhibition of EGFR (IC<sub>50</sub> = 25 and 18 nM, respectively) and HER2 (IC<sub>50</sub> = 41 and 11 nM, respectively) kinase activities in biochemical assays. Hybrid <b>10</b> induced histone H3 hyperacetylation at 1 μM concentration, demonstrating that it is indeed a cellularly active, pharmacologically bifunctional compound. With regards to its cytotoxicity profile, hybrid <b>10</b> was broadly active, with IC<sub>50</sub> values less than 1 μM, and was able to kill tumor cells completely at higher concentrations.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Lapatinib-based hybrid HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One very recent study completed by Ding et al. reported a novel series of EGFR/HDAC multitarget inhibitors containing the 4-anilinoquinazoline skeleton of <b>8</b>, a ZGB, and a 1,2,3-triazole as the linker<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> that is relatively resistant to metabolic degradation.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Compounds with side chains of five or six carbons exhibited the best potency toward HDACs, and almost all compounds with a six-carbon chain displayed better potencies than counterparts having a five-carbon chain for the inhibition of HDAC1 and HDAC6. However, inhibition of EGFR and HER2 was not dramatically affected following changes to side chain length. Regarding the aniline elements, size determined selectivity between EGRF and HER2. Among all compounds in this work, <b>11</b>(<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) displayed the best potency to EGFR, HER2, and HDAC1/6, with IC<sub>50</sub> values of 0.12, 174.9, 0.72, and 3.2 nM, respectively.</div><div class="NLM_p last">The antiproliferative activities of all synthetic compounds in this work were evaluated against A549 cells (EGFR overexpressed, k-Ras mutation) and BT-474 cells (HER2 overexpressed) with <b>1</b> and <b>8</b> as positive controls. Most of the compounds suppressed the growth of both cancer cell lines with IC<sub>50</sub> values in the micromolar range, with almost all six-carbon chain length compounds displaying better efficacies than the corresponding five-carbon chain length compounds. Moreover, <b>11</b> strongly inhibited the proliferation of A549 cells with an IC<sub>50</sub> value of 0.63 μM, more effectively than <b>1</b> or <b>8</b> (IC<sub>50</sub> = 2.57 and 1.74 μM for <b>1</b> and <b>8</b>, respectively). However, <b>11</b> was less active against BT-474 cells (IC<sub>50</sub> = 3.88 μM) due to its comparatively low potency toward HER2. In addition, <b>11</b> was able to block cellular EGFR and HER2 phosphorylation and induced histone H3 hyperacetylation and remarkable apoptosis in BT-474 cancer cells.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">C.  Vandetanib-Based Hybrid HDACis</h3><div class="NLM_p">In Shi’s group, much effort was devoted to exploiting VEGFR/HDAC dual inhibitors, using 4-anilinoquinazoline as the template.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In one study, a series of hybrids bearing <i>N</i>-phenylquinazolin-4-amine and hydroxamic acid moieties was designed by combining the fragments of vandetanib (<b>12</b> in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) and <b>1</b> and were identified as dual VEGFR-2/HDAC inhibitors.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Linker length was still a dominant factor that could also remarkably affect the inhibitory activity of HDACs. Compounds with a six-carbon linker were found to display the best activities. Furthermore, with respect to VEGFR-2 inhibition, all target compounds exhibited mild-to-moderate VEGFR-2 inhibitory activities compared to <b>12</b>. The type and position of the substituent could dramatically influence VEGFR-2 inhibitory activity: introduction of 2, 4-Cl on the phenyl ring was preferred for the VEGFR-2 inhibition. Of all these novel hybrids, <b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) exhibited the most potent inhibitory activity against HDACs, with an IC<sub>50</sub> value of 2.8 nM, and strong inhibitory effects against VEGFR-2, with an IC<sub>50</sub> value of 84 nM. In vitro cell growth inhibition screening demonstrated that <b>13</b> also exhibited the greatest activity against the MCF-7 tumor cell line with an IC<sub>50</sub> value of 1.2 μM (the IC<sub>50</sub> values of <b>1</b> and <b>12</b> were 4.5 and 18.5 μM).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. A vandetanib-based hybrid HDAC inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">D.  Pazopanib-Based Hybrid HDACis</h3><div class="NLM_p">Pazopanib (<b>14</b> in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B) is a potent RTK inhibitor acting on VEGFR-1 to 3 and can block tumor growth and inhibit angiogenesis. It was approved by the FDA in 2009 with indication for renal cell carcinoma. Combination therapies using <b>14</b> and diverse HDACis have been tested and have shown encouraging results,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> suggesting an attractive approach for the design of hybrid anticancer molecules.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) The proposed binding mode of pazopanib in the ATP pocket of VEGFR-2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3CJG">3CJG</a>). (B) Pazopanib-based hybrid HDAC inhibitor <b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In work from Zhang’s lab, a series of novel hybrid HDACis was designed and synthesized based on the structure of <b>14</b> with the purpose of circumventing the poor efficacy of HDACis in solid tumors. <b>14</b> inhibited angiogenesis, a key physiological property required for growth and metastasis in solid tumors.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><div class="NLM_p">The proposed binding mode (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A) indicated that the indazole moiety of <b>14</b> fits well into the interior pocket of VEGFR-2. The 2-aminopyrimidine moiety forms two hydrogen bonds with Cys917 in the hinge region, but the benzenesulfonamide is projected toward the solvent region. HDACis were designed based on the key fragment of <b>14</b> with ZBG being either hydroxamic acid or <i>ortho</i>-aminoanilide.</div><div class="NLM_p last">Out of all compounds tested, the lead <b>15</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B) with aminoanilide as ZBG showed the most balanced inhibitory activities against HDACs and VEGFR-1 to 3, with IC<sub>50</sub> values of 4.6 μM, 37 nM, 22 nM, and 46 nM, respectively. Selectivity was achieved for <b>15</b> against HDAC1–3 over isoforms 6 and 8. Consistent with the authors’ predictions, <b>15</b> displayed potent antiproliferative activities not only to hematological tumors cell lines but also to solid tumor cell lines, with the most sensitive being HT-29 (IC<sub>50</sub> = 1.07 μM). In an in vitro HUVEC tube formation assay, <b>15</b> inhibited tube formation as effectively as <b>14</b> at a concentration of 100 nM due to the former compound’s remarkable capability to inhibit VEGFRs. In addition, in an HT-29 xenograft model in nude mice, <b>15</b> effectively suppressed tumor growth at the dose of 50 mg/kg (po); inhibition was roughly half that of <b>14</b> (44%, po) at the same dose.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">E.  c-Met/HDAC Hybrid Inhibitors</h3><div class="NLM_p">c-Met, which is encoded by the <i>Met</i> proto-oncogene, is an RTK that binds hepatocyte growth factor (HGF), resulting in activation of the receptor and recruitment of a number of adaptor proteins or effectors through downstream signaling pathways, including RAS/MAPK and PI3K/AKT. These latter pathways mediate several cellular properties including proliferation, survival, migration, mitogenesis, and angiogenesis.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> In contrast, aberrant c-Met activation, mutation, amplification, and translocation play important roles in cancer formation, progression, dissemination, and drug resistance.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> Moreover, increased levels of both c-Met and HGF are associated with poor clinical outcomes in cancer patients.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> c-Met kinase has thus received considerable attention as an intriguing target for cancer treatment,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> but, similar to other RTK inhibitors, the use of the c-Met inhibitor alone also causes problems of insufficiency in blocking tumor progression, and exhibits low efficacy and acquired resistance.</div><div class="NLM_p">c-Met inhibitors have emerged as an alternative option for hepatocellular cancer therapy,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> even as HDACis have been shown to exert a complementary effect when combined with other drugs to combat hepatocellular cancer.<a onclick="showRef(event, 'ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60">(58−60)</a> Using a successful RTK/HDAC hybrid inhibitor design, Lu et al. reported the first potent c-Met and HDAC hybrid inhibitor.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> A selective c-Met inhibitor<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> (<b>16</b> in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) was employed as the parental scaffold. Given that the SAR of <b>16</b> showed that the substituent at C-7 of the quinoline moiety extends into the solvent-exposed region of the protein and modification toward this position had no significant detrimental effect on inhibitory activity,<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> the linker and ZBG for HDAC inhibition were incorporated here. Structural modification work verified the authors’ design concept that varying the linker at the C-7 position did not affect c-Met inhibition significantly. Different kinds of ZBG were investigated in this work, and it was found that the most potent was <b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), which inhibited c-Met kinase and HDAC1 with IC<sub>50</sub> values of 0.71 and 38 nM, respectively. This hybrid also showed efficient antiproliferative activities against two tumor cell lines, EBC-1 (IC<sub>50</sub> = 0.058 μM) and HCT-116 (IC<sub>50</sub> = 1.3 μM), with greater potency than the reference compound <b>5</b> (IC<sub>50</sub> = 2.9 and 7.8 μM) along with the parent compound <b>16</b>(IC<sub>50</sub> = 0.06 and >10 μM). The inhibition of phosphorylation of c-Met and its downstream signaling, as well as increased expression of Ac-H3 and p21 in EBC-1 cells were all evidence that <b>17</b> functioned well as a hybrid inhibitor.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. A selective c-Met-derived hybrid HDAC inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">F.  Abl/HDAC Hybrid Inhibitors</h3><div class="NLM_p">Imatinib (<b>18</b> in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) is an approved Abl, PDGFR, and Kit inhibitor used in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphocytic leukemia, which showed additive and synergistic effects when combined with HDACis.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> Mahboobi et al. reported the design and synthesis of a series of compounds that fused features of HDACis and <b>18</b> for the purpose of overcoming drug resistance.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a><b>19</b> is one such example where a ZBG (<i>ortho</i>-amino benzamide) moiety from HDACis is appended to the structure of <b>18</b>.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Hybrid HDAC inhibitor based on the structure of imatinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The HDAC inhibition profile of most hybrids remained conserved in biochemical and cellular assays, and their potency was comparable to that of <b>1</b>. Inhibition of active Abl kinase was also conserved in most cases. Hybrid <b>19</b> exhibited high selectivity toward HDAC1 (class I, IC<sub>50</sub> = 0.208 μM) over HDAC6 (class IIb, IC<sub>50</sub> ≥ 32 μM).</div><div class="NLM_p last">With regards to Abl kinase inhibition, hybrid <b>19</b> was the most active compound among all those synthesized with an IC<sub>50</sub> value of 2 μM, comparable to that of <b>18</b> (IC<sub>50</sub> = 1 μM). <b>19</b> could also inhibit Abl<sup>T315I</sup>, a frequent mutation that causes resistance to <b>18</b>, with an IC<sub>50</sub> value of 1.1 μM. <b>19</b> also showed potent cellular inhibition of PDGFR (IC<sub>50</sub> = 2.7 μM) and cytotoxicity toward EOL-1 cells (IC<sub>50</sub> = 0.1 μM).</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">G.  PI3K/HDAC Hybrid Inhibitors</h3><div class="NLM_p">The phosphatidylinositol 3-kinases (PI3Ks) are a family of related intracellular signal transducer enzymes that are able to phosphorylate the 3-hydroxyl group of the inositol ring of phosphatidylinositol. The PI3K family is divided into three classes according to sequence homology and substrate specificity. Dysregulation of PI3Ks and their downstream molecules plays an important role in cancer cell initiation, growth, proliferation, and survival.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Thus, PI3Ks are frequently found to be in an activated state in many types of cancer.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Several PI3K inhibitors are currently in clinical trials as monotherapy or in combination with other drugs for the treatment of cancer, including apitolisib and pictilisib (<b>20</b> and <b>21</b> in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68,69)</a> However, sole inhibition of the PI3K pathway is always problematic given the fact that other survival- and growth-related pathways are concurrently activated. Extensive evidence has implicated HDACis in the disruption of multiple pathways and HDACis are known to synergize with PI3K inhibitors.<a onclick="showRef(event, 'ref70 ref71 ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref70 ref71 ref72 ref73 ref74">(70−74)</a></div><div class="NLM_p">To overcome the limitations of targeting the PI3K pathway, Qian et al. first reported the rational design of a multitargeted compound, CUDC-907 (<b>24</b> in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), as a drug candidate.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><div class="NLM_p">An experiment was first performed to confirm that the combination of an HDACi (<b>1</b>) and a potent PI3K inhibitor (<b>21</b>) can exert a synergistic effect on growth inhibition of PC-3 prostate cancer cells. The combination index was significantly less than 1, which provided the rationale for the development of dual PI3K and HDAC inhibitors.</div><div class="NLM_p">On the basis of the result above, the authors incorporated a ZBG (hydroxamic acid) into the morpholinopyrimidine pharmacophore which is found frequently in reported PI3K inhibitors such as <b>20</b>, <b>21</b>, PI-103 (<b>22</b> in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), and BKM-120 (<b>23</b> in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). It is noteworthy that the morpholine ring has proved to be essential for the inhibitory activity toward PI3K, due to the fact that a key hydrogen bond is formed between the oxygen atom of the morpholine and the hinge region of the ATP binding domain, as exemplified by the binding modes of <b>21</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of PI3K inhibitors containing a morpholine group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compound <b>21</b> binds the PI3K isoform p110γ active site with a critical H-bond (green dotted line) formed between the oxygen atom of the morpholine moiety and the hydrogen of the Val882 residue (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DBS">3DBS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>24</b>, a first-in-class, orally active, multitargeted inhibitor was obtained via this aforementioned structural modification. First, <b>24</b> is a potent inhibitor of class I PI3K kinases with IC<sub>50</sub> values of 19, 54, and 39 nM for PI3Kα, PI3Kβ, and PI3Kδ, respectively. Second, <b>24</b> is also a potent pan-HDACi against classes I and II HDACs. Its potency against class I HDACs was like that of <b>4</b> and greater than that of <b>1</b>, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibition of the Enzymatic Activities of HDACs <b>1</b> through <b>11</b> by <b>24</b> and Reference Compounds <b>1</b> and <b>4</b><a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="11" align="center">HDAC isoforms (IC<sub>50</sub> in nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">1</th><th class="colsep0 rowsep0" align="center">2</th><th class="colsep0 rowsep0" align="center">3</th><th class="colsep0 rowsep0" align="center">4</th><th class="colsep0 rowsep0" align="center">5</th><th class="colsep0 rowsep0" align="center">6</th><th class="colsep0 rowsep0" align="center">7</th><th class="colsep0 rowsep0" align="center">8</th><th class="colsep0 rowsep0" align="center">9</th><th class="colsep0 rowsep0" align="center">10</th><th class="colsep0 rowsep0" align="center">11</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center">42.5</td><td class="colsep0 rowsep0" align="center">156</td><td class="colsep0 rowsep0" align="center">33.1</td><td class="colsep0 rowsep0" align="center">113</td><td class="colsep0 rowsep0" align="center">NA<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">21.6</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">68.4</td><td class="colsep0 rowsep0" align="center">51.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="center">1.4</td><td class="colsep0 rowsep0" align="center">6.8</td><td class="colsep0 rowsep0" align="center">1.5</td><td class="colsep0 rowsep0" align="center">26.7</td><td class="colsep0 rowsep0" align="center">195.6</td><td class="colsep0 rowsep0" align="center">123.8</td><td class="colsep0 rowsep0" align="center">8.2</td><td class="colsep0 rowsep0" align="center">1864</td><td class="colsep0 rowsep0" align="center">922.2</td><td class="colsep0 rowsep0" align="center">2.1</td><td class="colsep0 rowsep0" align="center">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="center">1.7</td><td class="colsep0 rowsep0" align="center">5.0</td><td class="colsep0 rowsep0" align="center">1.8</td><td class="colsep0 rowsep0" align="center">191</td><td class="colsep0 rowsep0" align="center">406</td><td class="colsep0 rowsep0" align="center">674</td><td class="colsep0 rowsep0" align="center">27</td><td class="colsep0 rowsep0" align="center">426</td><td class="colsep0 rowsep0" align="center">554</td><td class="colsep0 rowsep0" align="center">2.8</td><td class="colsep0 rowsep0" align="center">5.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">NA: not active.</p></div></div></div><div class="NLM_p">Through its integrated HDAC inhibitory activity, <b>24</b> could durably inhibit the activation of the PI3K-AKT-mTOR pathway and compensatory signaling molecules, including RAF, MEK, MAPK, and STAT-3, as well as upstream RTKs in Western blot analysis with a concentration of 100 nM. In vitro, <b>24</b> induced apoptosis and G2–M cell-cycle arrest in HCT-116 cancer cells by activation of caspase-3 and -7. <b>24</b> also displayed a promising therapeutic index in MYC-dependent cancers<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> such as B-cell lymphoma.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> In an in vivo animal model of Daudi non-Hodgkin’s lymphoma, tumor growth was inhibited by oral administration of <b>24</b> in a dose-dependent manner. Tumor stasis was observed at 100 mg/kg without obvious toxicity. Notably, <b>24</b> (100 mg/kg) achieved better efficacy than <b>1</b> or <b>21</b> given at their maximal tolerated doses of 120 and 150 mg/kg, respectively, and a combination of <b>1</b> and <b>21</b> (doses of 60 and 75 mg/kg, respectively). The study of in vivo antitumor activity showed that <b>24</b> inhibited HDACs as demonstrated by the accumulation of acetylated histone H3 and PI3K resulting from a decrease in p-AKT. In addition, mouse pharmacokinetic studies showed that <b>24</b> had an oral bioavailability approximately 2-fold higher than <b>1</b>.</div><div class="NLM_p">In a phase I study to evaluate the safety, tolerability, and preliminary activity of <b>24</b> in patients with relapsed or refractory lymphoma or multiple myeloma, five of 37 (14%) evaluable patients achieved an objective response (two complete responses and three partial responses).<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a><b>24</b> is currently undergoing a phase II clinical trial in patients with lymphoma and in patients with advanced thyroid cancer. However, acquired resistance remains a challenge for its therapeutic use. In this regard, the ATP-binding cassette (ABC) drug transporter ABCG2 is one of the central players in the development of resistance to <b>24</b>; combination therapy with an ABCG2 inhibitor should be a good choice for improving the pharmacokinetics and efficacy of <b>24</b>.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><div class="NLM_p">Inspired by the discovery of <b>24</b>, Chen et al. designed and synthesized a group of novel PI3K/HDAC hybrid inhibitors. Considering that purines are employed as the core scaffold in many PI3Ks inhibitors,<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> and the morpholine group is imperative for activity, the authors designed new hybrids by replacing the morpholinopyrimidine moiety in <b>24</b> with a morpholinopurine scaffold.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> All obtained compounds showed strong inhibitory activity toward HDAC1, with the substituent at the C-2 position of the morpholinopurine having a profound effect on PI3K inhibition. A phenyl group at this position was found to be detrimental, while <b>25</b> and <b>26</b> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), which have a pyrimidine at the C-2 position of the morpholinopurine moiety, displayed the expected dual PI3Kα and HDAC1 inhibitory activities. The IC<sub>50</sub> values for <b>25</b> against HDAC1 and PI3Kα were 1.14 and 28.06 nM, respectively. <b>26</b> showed lower and balanced IC<sub>50</sub> values for HDAC1 and PI3Kα, 1.04 and 1.33 nM, respectively, compared to 1.7 and 19 nM for <b>24</b>, which was the positive control. <b>26</b> also exhibited good in vivo antiproliferative activity in a MV4–11 xenograft NOD/SCID mouse model at a dose of 10 mg/kg (iv); the tumor mass inhibition rate was 45.1%. In contrast, compound <b>1</b> (acting as a positive control) had no inhibitory activity at 50 mg/kg intraperitoneal (ip) dosing in this model.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of PI3K/HDAC hybrid inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">H.  c-Src/HDAC Hybrid Inhibitors</h3><div class="NLM_p">Proto-oncogene tyrosine–protein kinase Src (c-Src) plays a key role in many aspects of cell physiology, regulating diverse cellular processes including division, motility, adhesion, angiogenesis, and survival. c-Src is frequently overexpressed in cancers. The extent of overexpression of c-Src correlates with malignant potential.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div class="NLM_p">To search for drugs that would affect c-Src inhibition, Soellner et al. evaluated a small library of targeted inhibitors and identified the HDACi <b>4</b> as highly synergistic with c-Src inhibition. This result was attributed to the ability of HDACis to down-regulate c-Src levels via repression of SRC transcription.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div><div class="NLM_p">On the basis of the effects that occur between c-Src and HDACis, a small series of chimeric inhibitors that inhibited both c-Src kinase and HDACs was designed and synthesized.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> In this work, the PP2-alkyne (<b>27</b> in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), a selective c-Src kinase inhibitor with an alkyne group in its structure, was used as the template, and the ZBG was appended by a triazole group formed by “click chemistry.” In fact, several published HDACis containing a triazole as cap or linker have displayed excellent HDAC inhibitory activities.<a onclick="showRef(event, 'ref86 ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref86 ref87 ref88">(86−88)</a> In all of the target compounds synthesized, <b>28</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) was shown to be a potent and dual inhibitor of c-Src kinase and HDAC1 (<i>K</i><sub>i</sub> = 138 and 0.26 nM, respectively). At the cellular level, <b>28</b> could potently inhibit the proliferation of SK-BR-3 cells with GI<sub>50</sub> value of 0.2 μM, better than treatment with <b>1</b> (GI<sub>50</sub> = 1.2 μM), <b>27</b> (GI<sub>50</sub> = 4.8 μM), and their 1:1 combination (GI<sub>50</sub> = 0.8 μM). In the following NCI-60 panel screening, <b>28</b> still displayed high efficacy against all cancer cell lines including MCF-7 (GI<sub>50</sub> = 0.35 μM) and KM12 (GI<sub>50</sub> = 0.47 μM), which were less susceptible to single treatment with <b>1</b> (GI<sub>50</sub> = 2.19/1.88 μM), or dasatinib, a dual Abl/Src inhibitor (GI<sub>50</sub> = 8.32/7.44 μM). All these results fully validated <b>28</b> as a successful example of a hybrid Src/HDAC inhibitor.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. A c-Src/HDAC hybrid inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">I.  Janus Kinase/HDAC Hybrid Inhibitors</h3><div class="NLM_p">The Janus kinase (JAK) proteins, a family of intracellular, nonreceptor tyrosine kinases including JAK1, JAK2, JAK3, and TYK2, are involved in cell growth, survival, development, and differentiation of a variety of cells.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Genetic studies have identified a somatic JAK2<sup>V617F</sup> mutation that activates the JAK–STAT signaling pathway in most patients with myeloproliferative neoplasms (MPNs, and have resulted in a molecular classification and an improved understanding of pathogenesis.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Following the discovery of this mutation, JAK inhibitors have been rapidly developed for the treatment of MPNs. On the other hand, some HDACis have been shown to be effective against MPNs both as a single agent and in conjunction with JAK2 inhibitors.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Therefore, dual inhibition of JAKs and HDACs in a single molecule represent a compelling new anticancer strategy.</div><div class="NLM_p">Inspired by the concept of multitarget HDACis and with the aim of improving the therapeutic effectiveness for MPNs, Dymock’s group designed novel hybrid HDACis by merging the structures of a selective JAK2 inhibitor, pacritinib (<b>29</b> in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), and <b>1</b> to create single molecules with both JAK2 and HDAC inhibitory activities.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Because many potent HDACis possess a macrocycle structure, such as <b>2</b>, it was postulated that the macrocyclic ring of <b>29</b> could be also a desirable cap group for HDACi design. Furthermore, it was believed that isoform selectivity could be achieved by those HDACis having a large cap group.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> On the other hand, it is known that the pyrolidine ring on the side chain of <b>29</b> is located in a solvent exposed region lacking any interaction with JAK2.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Thus, the authors chose to insert the HDAC binding group here to retain the inhibitory activity toward JAK2. Although the structure of the side chain was diversified, significant inhibition of JAK2 was retained by all synthesized compounds. The result was consistent with the authors’ postulate that for HDAC inhibition, the bulk and length of the side chain had a profound effect on activity. <b>30</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), with a long-chain aliphatic hydroxamic acid, had the best HDAC6 inhibitory activity of this series, with an IC<sub>50</sub> of 2.1 nM and good selectivity over other HDAC isoforms, which can be explained by the larger lip of the substrate binding pocket of HDAC6 in our view. A good balance was also achieved for inhibition of JAK2, with the IC<sub>50</sub> value reaching 1.4 nM. The induction of Ac-H3 and decreased expression of STAT3 in intracellular assays further showed that <b>30</b> was a bifunctional inhibitor.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. JAK2/HDAC hybrid inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an extended work by the same group, a novel series of dual JAK and HDACis was designed and synthesized based on the core features of ruxolitinib (<b>31</b> in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), a marketed JAK1/2 inhibitor, and <b>1</b>.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> In their design, the pyrrolpyrimidine motif that mediates a critical donor–acceptor hydrogen-bonding interaction between <b>31</b> and the hinge region of JAK1/2 kinases was retained, and flexible alkyl chains were appended to the pyrazole moiety of <b>31</b>. The ZBG was located at the end point, occupying a tolerated position near the solvent region, and various alkyl chains were also evaluated. The compound with a six-carbon linker exhibited the most potent inhibitory activities toward both HDACs and JAK2.</div><div class="NLM_p">Hybrid <b>32</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) inhibits HDAC1, HDAC6, and JAK2 with IC<sub>50</sub> values in the nanomolar range (6.9, 1.4, and 75 nM, respectively), while the IC<sub>50</sub> of <b>31</b> as a control was 56 pM against JAK2, which demonstrated that the existence of a long chain and the ZBG somehow hindered the interaction between the hybrids and JAK2, but no inhibition of HDACs 1 or 6 was observed for <b>31</b>. In addition, <b>32</b> was also a potent inhibitor toward HDAC2, HDAC3, and HDAC10, with IC<sub>50</sub> values of 5.8, 3.9, and 19 nM, respectively. <b>32</b> was selective for the JAK family against a panel of 97 other kinases including FLT3, which can be inhibited by <b>31</b>.</div><div class="NLM_p"><b>32</b> showed broad antiproliferative activity toward different solid and hematological tumor cell lines such as MDA-MB-231, MCF7, and Jurkat, with IC<sub>50</sub> values of 0.79, 0.84, 0.47 μM, respectively. The broad cellular antiproliferative potency of <b>32</b> is also supported by the JAK-STAT and HDAC pathway blockade in hematological cell lines. Of note, another hybrid, <b>33</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), a methylated analogue of <b>32</b>, had an even more selective inhibitory profile toward HDAC6 (IC<sub>50</sub> = 1 nM) and HDAC1 (IC<sub>50</sub> = 6 nM) over other HDACs.</div><div class="NLM_p last">Because there are still no published crystal structures of <b>31</b> in complex with JAK kinases, this work not only provides two new leads <b>32</b> and <b>33</b> for simultaneous inhibition of the JAK2 and HDAC pathways achieved by a single molecule but also paves a way for the design of novel JAK2/HDAC hybrid inhibitors with stronger activity.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion and Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77645" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77645" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It is not our intention to cover all kinase/HDAC hybrid inhibitors in the public domain. The nine case studies discussed here vide supra illustrate how hybrid HDACis are designed. There are always potential risks when two molecules are combined into a single agent because the resulting hybrid compound may not be able to exhibit desirable biological and/or pharmacological functions due to steric or repulsive interactions with the targets. To design effective kinase/HDAC hybrid inhibitors, certain general procedures include (i) discovery of multitarget synergy for anticancer agents, (ii) identification of the key fragments (or scaffolds) from both kinase inhibitors and HDACis, (iii) identification of an appropriate spacer to link the fragments at positions where substitution does not affect the activity,(iv) SAR studies of derivatives and iterative optimization, and (v) selection of lead compounds for further development into a therapeutic agent. Synergy of multitarget agents can be discovered by counter-screening either kinase inhibitors or HDACis against each other’s target enzymes or through combination therapy. The key fragments of kinase inhibitors that act as a cap for hybrid agents must possess functional groups or scaffolds that can interact with kinases in the hinge region through hydrogen bonding, usually in ATP binding pockets. Disruption of such interactions is detrimental and can result in a loss of affinity. The key fragments for HDACis are ZBG hydroxamic acid and <i>ortho</i>-amino benzamide functional groups. Fortunately, HDACs can tolerate a variety of structures as a cap. Bulky and flat kinase inhibitor cap structures can be accommodated by HDACs. An appropriate spacer, usually a five- or six-carbon chain, can link the cap and ZBG fragments. The points of substitution for kinase inhibitor fragments should be those that least affect kinase inhibition after substitution (usually in solvent accessible regions). Iterative SAR optimization can help identify critical structural elements in lead compounds to further develop these molecules into therapeutic agents.</div><div class="NLM_p">As one of the most important tumor-promoting enzymes in the area of epigenetics, HDACs are responsible for deacetylation of acetyllysine (KAc) residues in histones and nonhistone substrates. They have emerged as attractive targets for the development of novel anticancer agents, some of which have been used clinically. Even so, old-generation HDACis are usually isoform nonselective or partially selective, often accompanied by unwanted side effects. In addition to these drawbacks, most old-generation HDACis show limited efficacy against solid tumors, which seriously limits their application for the treatment of a broader spectrum of cancers. To overcome these flaws, the development of new generations of HDACis can be divided into two areas, the first of which is the isoform selective HDACis, while the second is hybrid HDACis.</div><div class="NLM_p last">The poor pharmacokinetic profile of the hybrid HDACis due to inactivation by glucuronidation of hydroxamic acid and <i>ortho</i>-amino benzamide ZBG is a problem to be addressed. Fortunately, an alternative ZBG (hydrazide) with potent activity and improved properties has been reported,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> which can be utilized for the design of novel hybrid HDACis in the future. So far, the number of hybrid HDACis that have entered clinical trials is still limited. Even so, two hybrid HDACis, <b>7</b> and <b>24</b>,<a onclick="showRef(event, 'ref42 ref43 ref96'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref96">(42,43,96)</a> are currently in clinical trials, which provides validation for this design strategy. It is anticipated that hybrid HDACis will attract increasing attention, and their development is likely to flourish soon.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00189" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12254" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12254" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rongshi Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao 266071, Shandong Province, China</span>; 
    <span class="hlFld-Affiliation affiliation">UNMC
Center for Drug Discovery, Department of Pharmaceutical Sciences,
College of Pharmacy, Fred and Pamela Buffett Cancer Center, and Center
for Staphylococcal Research, University
of Nebraska Medical Center, Omaha, Nebraska 68198, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1774-7827" title="Orcid link">http://orcid.org/0000-0002-1774-7827</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0d5f62636a7e65642361644d7863606e23686978"><span class="__cf_email__" data-cfemail="e8ba87868f9b8081c68481a89d86858bc68d8c9d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yepeng Luan</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao 266071, Shandong Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jerry Li</span> - <span class="hlFld-Affiliation affiliation">Skaggs School of Pharmacy and Pharmaceutical
Sciences, , University
of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean A. Bernatchez</span> - <span class="hlFld-Affiliation affiliation">Skaggs School of Pharmacy and Pharmaceutical
Sciences, 
    Center for Discovery
and Innovation in Parasitic Diseases, 
    , , University
of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.L., J.L., and J.A.B. contributed equally. All authors wrote and revised the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00207" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00207" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Yepeng Luan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=BIO-d7e1709-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yepeng Luan</b> (Ph.D.) received his doctoral degree in 2010 from the Department of Medicinal Chemistry, School of Pharmacy, Shandong University, China. During this period, he did a year of research as a visiting student at the Department of Pharmaceutics at the University of Kansas. His postdoctoral training was at Ocean University of China (2010–2012) and the University of Georgia (2012–2015). Dr. Luan is a lecturer in the Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, China. His research focuses on the design, synthesis, and activity evaluation of novel isoform-selective HDAC inhibitors and hybrid HDAC inhibitors. He is also interested in designing novel antagonists against other epigenetic targets, including HAT and protein arginine methyltransferases.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Jerry Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=BIO-d7e1714-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jerry Li</b> (Pharm.D.) received his Bachelor of Arts degree in molecular cell biology at the University of California, Berkeley, and his Doctor of Pharmacy degree at the University of Michigan College of Pharmacy. He is currently completing a postdoctoral fellowship in clinical pharmacology at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego, and Pfizer Global Research and Development, La Jolla Laboratories.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Jean A. Bernatchez</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=BIO-d7e1719-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jean A. Bernatchez</b> (Ph.D.) completed his B.Sc. (First-Class Honors) in Biochemistry at McGill University in Montreal, Quebec, Canada, in 2008. He then pursued Ph.D. studies at McGill in Biochemistry as part of the Chemical Biology Interdepartmental Graduate Program and graduated in 2015. Currently, Dr. Bernatchez is a Postdoctoral Scholar at the Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego. His current research focus is on the development and use of phenotypic, cell-based high-throughput screening assays for the discovery of novel anticancer, antiviral and antiparasitic agents.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Rongshi Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=BIO-d7e1724-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Rongshi Li</b> is a Professor of Chemistry and Medicinal Chemistry at the University of Nebraska Medical Center (UNMC). After 14 years in industry, advancing from Scientist to Senior Vice President, Dr. Li moved to Moffitt Cancer Center in Tampa, Florida. In 2013, he was recruited to UNMC, where he has received the Distinguished Scientist Award (2016) and New Invention Awards (2014, 2016, 2018). Dr. Li has over 200 scientific contributions including peer-reviewed articles, patents, reviews/Perspectives, book and book chapters, editorial, and published scientific presentations. Dr. Li has delivered more than one hundred lectures as a keynote or invited speaker at numerous universities and research institutions and at national and international symposia, and he has been a Guest Editor for <i>Medicinal Research Reviews</i>.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56720" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56720" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge the financial support from the National Science Foundation for Young Scientists of China to Y. L. (NSFC no. 81602947). This work is partially supported by startup funds to R.L. provided by the University of Nebraska Medical Center.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP-binding cassette</p></td></tr><tr><td class="NLM_term">ABCG2</td><td class="NLM_def"><p class="first last">ATP-binding cassette subfamily G member 2</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Food and Drug Administration</p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">histone acetyltransferase</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HDACi</td><td class="NLM_def"><p class="first last">histone deacetylase inhibitor</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">MPN</td><td class="NLM_def"><p class="first last">myeloproliferative neoplasm</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase</p></td></tr><tr><td class="NLM_term">PTCL</td><td class="NLM_def"><p class="first last">peripheral T-cell lymphoma</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAHA</td><td class="NLM_def"><p class="first last">suberoylanilide hydroxamic acid</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">ZBG</td><td class="NLM_def"><p class="first last">zinc ion binding group</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06121" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06121" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 96 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballestar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villar-Garea, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boix-Chornet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schotta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaldi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haydon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ropero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Rosado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calasanz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colomer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piris, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imhof, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenuwein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/ng1531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fng1531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=15765097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislCmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2005&pages=391-400&author=M.+F.+Fragaauthor=E.+Ballestarauthor=A.+Villar-Gareaauthor=M.+Boix-Chornetauthor=J.+Espadaauthor=G.+Schottaauthor=T.+Bonaldiauthor=C.+Haydonauthor=S.+Roperoauthor=K.+Petrieauthor=N.+G.+Iyerauthor=A.+Perez-Rosadoauthor=E.+Calvoauthor=J.+A.+Lopezauthor=A.+Canoauthor=M.+J.+Calasanzauthor=D.+Colomerauthor=M.+A.+Pirisauthor=N.+Ahnauthor=A.+Imhofauthor=C.+Caldasauthor=T.+Jenuweinauthor=M.+Esteller&title=Loss+of+acetylation+at+Lys16+and+trimethylation+at+Lys20+of+histone+H4+is+a+common+hallmark+of+human+cancer&doi=10.1038%2Fng1531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer</span></div><div class="casAuthors">Fraga, Mario F.; Ballestar, Esteban; Villar-Garea, Ana; Boix-Chornet, Manuel; Espada, Jesus; Schotta, Gunnar; Bonaldi, Tiziana; Haydon, Claire; Ropero, Santiago; Petrie, Kevin; Iyer, N. Gopalakrishna; Perez-Rosado, Alberto; Calvo, Enrique; Lopez, Juan A.; Cano, Amparo; Calasanz, Maria J.; Colomer, Dolors; Piris, Miguel Angel; Ahn, Natalie; Imhof, Axel; Caldas, Carlos; Jenuwein, Thomas; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">391-400</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CpG island hypermethylation and global genomic hypomethylation are common epigenetic features of cancer cells.  Less attention has been focused on histone modifications in cancer cells.  We characterized post-translational modifications to histone H4 in a comprehensive panel of normal tissues, cancer cell lines and primary tumors.  Using immunodetection, high-performance capillary electrophoresis and mass spectrometry, we found that cancer cells had a loss of mono-acetylated and tri-methylated forms of histone H4.  These changes appeared early and accumulated during the tumorigenic process, as we showed in a mouse model of multistage skin carcinogenesis.  The losses occurred predominantly at the acetylated Lys16 and tri-methylated Lys20 residues of histone H4 and were assocd. with the hypomethylation of DNA repetitive sequences, a well-known characteristic of cancer cells.  Our data suggest that the global loss of mono-acetylation and trimethylation of histone H4 is a common hallmark of human tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu31lIr4J0I7Vg90H21EOLACvtfcHk0lgse9N5StDe_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislCmurg%253D&md5=073e669384a63eaac751c9ad1ebf4449</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fng1531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1531%26sid%3Dliteratum%253Aachs%26aulast%3DFraga%26aufirst%3DM.%2BF.%26aulast%3DBallestar%26aufirst%3DE.%26aulast%3DVillar-Garea%26aufirst%3DA.%26aulast%3DBoix-Chornet%26aufirst%3DM.%26aulast%3DEspada%26aufirst%3DJ.%26aulast%3DSchotta%26aufirst%3DG.%26aulast%3DBonaldi%26aufirst%3DT.%26aulast%3DHaydon%26aufirst%3DC.%26aulast%3DRopero%26aufirst%3DS.%26aulast%3DPetrie%26aufirst%3DK.%26aulast%3DIyer%26aufirst%3DN.%2BG.%26aulast%3DPerez-Rosado%26aufirst%3DA.%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DLopez%26aufirst%3DJ.%2BA.%26aulast%3DCano%26aufirst%3DA.%26aulast%3DCalasanz%26aufirst%3DM.%2BJ.%26aulast%3DColomer%26aufirst%3DD.%26aulast%3DPiris%26aufirst%3DM.%2BA.%26aulast%3DAhn%26aufirst%3DN.%26aulast%3DImhof%26aufirst%3DA.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DJenuwein%26aufirst%3DT.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DLoss%2520of%2520acetylation%2520at%2520Lys16%2520and%2520trimethylation%2520at%2520Lys20%2520of%2520histone%2520H4%2520is%2520a%2520common%2520hallmark%2520of%2520human%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2005%26volume%3D37%26spage%3D391%26epage%3D400%26doi%3D10.1038%2Fng1531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ropero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">The role of histone deacetylases (HDACs) in human cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2007.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.molonc.2007.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=19383284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=19-25&author=S.+Roperoauthor=M.+Esteller&title=The+role+of+histone+deacetylases+%28HDACs%29+in+human+cancer&doi=10.1016%2Fj.molonc.2007.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histone deacetylases (HDACs) in human cancer</span></div><div class="casAuthors">Ropero, Santiago; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The balance of histone acetylation and deacetylation is an epigenetic layer with a crit. role in the regulation of gene expression.  Histone acetylation induced by histone acetyl transferases (HATs) is assocd. with gene transcription, while histone hypoacetylation induced by histone deacetylase (HDAC) activity is assocd. with gene silencing.  Altered expression and mutations of genes that encode HDACs have been linked to tumor development since they both induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell-cycle regulation and apoptosis.  Thus, HDACs are among the most promising therapeutic targets for cancer treatment, and they have inspired researchers to study and develop HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvbJD8bqroSLVg90H21EOLACvtfcHk0lgse9N5StDe_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI&md5=d925bcde258dce7d53cbb98563e1f2ae</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2007.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2007.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DRopero%26aufirst%3DS.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520histone%2520deacetylases%2520%2528HDACs%2529%2520in%2520human%2520cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2007%26volume%3D1%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.molonc.2007.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span> <span> </span><span class="NLM_article-title">Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1002/med.21320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1002%2Fmed.21320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24782318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVClsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=63-84&author=L.+Zhangauthor=Y.+Hanauthor=Q.+Jiangauthor=C.+Wangauthor=X.+Chenauthor=X.+Liauthor=F.+Xuauthor=Y.+Jiangauthor=Q.+Wangauthor=W.+Xu&title=Trend+of+histone+deacetylase+inhibitors+in+cancer+therapy%3A+isoform+selectivity+or+multitargeted+strategy&doi=10.1002%2Fmed.21320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy</span></div><div class="casAuthors">Zhang, Lei; Han, Yantao; Jiang, Qixiao; Wang, Chunbo; Chen, Xuehong; Li, Xiaoguang; Xu, Fuming; Jiang, Yuqi; Wang, Qiang; Xu, Wenfang</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-84</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Pharmacol. inhibition of histone deacetylases (HDACs) has been successfully applied in the treatment of a wide range of disorders, including Parkinson's disease, infection, cardiac diseases, inflammation, and esp. cancer.  HDAC inhibitors (HDACIs) have been proved to be effective antitumor agents by various stages of investigation.  At present, there are two opposite focuses of HDACI design in the cancer therapy, highly selective inhibitor strategy and dual- or multitargeted inhibitors.  The former method, which is supposed to elucidate the function of individual HDAC and provide candidate inhibitors with fewer side effects, has been widely accepted by the inhibitor developer.  The latter approach, though less practiced, has promising potential for the antitumor therapy based on HDACIs.  Effective HDACIs, some of which are in clinic anticancer research, have been developed by both methods.  In order to gain insight into HDACI design, the strategies and achievements of the two diverse methods are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm6HJUNw_9dLVg90H21EOLACvtfcHk0liCFuhYMo0k5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVClsb3M&md5=791e7d6b057c92f206c8d0d75099e021</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fmed.21320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21320%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DTrend%2520of%2520histone%2520deacetylase%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520isoform%2520selectivity%2520or%2520multitargeted%2520strategy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2015%26volume%3D35%26spage%3D63%26epage%3D84%26doi%3D10.1002%2Fmed.21320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcelloni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binaschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattori, D.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: from bench to clinic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1529</span>, <span class="refDoi"> DOI: 10.1021/jm7011408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7011408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1505-1529&author=M.+Parisauthor=M.+Porcelloniauthor=M.+Binaschiauthor=D.+Fattori&title=Histone+deacetylase+inhibitors%3A+from+bench+to+clinic&doi=10.1021%2Fjm7011408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: From Bench to Clinic</span></div><div class="casAuthors">Paris, Marielle; Porcelloni, Marina; Binaschi, Monica; Fattori, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1505-1529</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Advances in the design and pharmacol. of Histone deacetylase inhibitors is discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMej4R03jKbVg90H21EOLACvtfcHk0liCFuhYMo0k5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D&md5=fd5e8c74c510835517fe5255c5c7dc5b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm7011408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7011408%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DM.%26aulast%3DPorcelloni%26aufirst%3DM.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DFattori%26aufirst%3DD.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520from%2520bench%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1505%26epage%3D1529%26doi%3D10.1021%2Fjm7011408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsin, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span> <span> </span><span class="NLM_article-title">Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">6775</span>– <span class="NLM_lpage">6791</span>, <span class="refDoi"> DOI: 10.1021/jm400564j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400564j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Slsb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6775-6791&author=C.+W.+Yuauthor=P.+T.+Changauthor=L.+W.+Hsinauthor=J.+W.+Chern&title=Quinazolin-4-one+derivatives+as+selective+histone+deacetylase-6+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm400564j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Quinazolin-4-one Derivatives as Selective Histone Deacetylase-6 Inhibitors for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Yu, Chao-Wu; Chang, Pei-Teh; Hsin, Ling-Wei; Chern, Ji-Wang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6775-6791</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel quinazolin-4-one derivs. contg. a hydroxamic acid moiety were designed and synthesized.  All compds. were subjected to histone deacetylase (HDAC) enzymic assays to identify selective HDAC6 inhibitors with nanomolar IC50 values.  (E)-3-(2-Ethyl-7-fluoro-4-oxo-3-phenethyl-3,4-dihydroquinazolin-6-yl)-N-hydroxyacrylamide (I) is the most potent HDAC6 inhibitor (IC50, 8 nM).  In vitro, these compds. induced neurite outgrowth accompanied by growth-assocd. protein 43 expression, and they enhanced the synaptic activities of PC12 and SH-SY5Y neuronal cells without producing toxic or mitogenic effects.  Several of the compds. dramatically increased nonhistone protein acetylation, specifically of α-tubulin.  Some of the more potent HDAC6 inhibitors decreased zinc-mediated β-amyloid aggregation in vitro.  N-Hydroxy-3-(2-methyl-4-oxo-3-phenethyl-3,4-dihydro-quinazolin-7-yl)-acrylamide (II) the most promising drug candidate, selectively inhibits HDAC6 (IC50, 29 nM), practically does not affect human ether-a-go-go-related membrane channel activity (IC50 >10 μM) or cytochrome P 450 activity (IC50 >6.5 μM) in vitro, and significantly improves learning-based performances of mice with β-amyloid-induced hippocampal lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ZyFO0SBaDLVg90H21EOLACvtfcHk0lglKG98xsRsog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Slsb7J&md5=bcc20d956982b1e4e9a706327087f233</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm400564j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400564j%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DP.%2BT.%26aulast%3DHsin%26aufirst%3DL.%2BW.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26atitle%3DQuinazolin-4-one%2520derivatives%2520as%2520selective%2520histone%2520deacetylase-6%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6775%26epage%3D6791%26doi%3D10.1021%2Fjm400564j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camarillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span> <span> </span><span class="NLM_article-title">The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e85570</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0085570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1371%2Fjournal.pone.0085570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24409332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFOjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=J.+Mengauthor=Y.+Liauthor=C.+Camarilloauthor=Y.+Yaoauthor=Y.+Zhangauthor=C.+Xuauthor=L.+Jiang&title=The+anti-tumor+histone+deacetylase+inhibitor+SAHA+and+the+natural+flavonoid+curcumin+exhibit+synergistic+neuroprotection+against+amyloid-beta+toxicity&doi=10.1371%2Fjournal.pone.0085570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity</span></div><div class="casAuthors">Meng, Jia; Li, Yan; Camarillo, Cynthia; Yao, Yue; Zhang, Yina; Xu, Chun; Jiang, Lihong</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e85570/1-e85570/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">With the trend of an increasing aged population worldwide, Alzheimer's disease (AD), an age-related neurodegenerative disorder, as one of the major causes of dementia in elderly people is of growing concern.  Despite the many hard efforts attempted during the past several decades in trying to elucidate the pathol. mechanisms underlying AD and putting forward potential therapeutic strategies, there is still a lack of effective treatments for AD.  The efficacy of many potential therapeutic drugs for AD is of main concern in clin. practice.  For example, large bodies of evidence show that the anti-tumor histone deacetylase (HDAC) inhibitor, suberoylanilidehydroxamic acid (SAHA), may be of benefit for the treatment of AD; however, its extensive inhibition of HDACs makes it a poor therapeutic.  Moreover, the natural flavonoid, curcumin, may also have a potential therapeutic benefit against AD; however, it is plagued by low bioavailability.  Therefore, the integrative effects of SAHA and curcumin were investigated as a protection against amyloid-beta neurotoxicity in vitro.  We hypothesized that at low doses their synergistic effect would improve therapeutic selectivity, based on expts. that showed that at low concns. SAHA and curcumin could provide comprehensive protection against Aβ25-35-induced neuronal damage in PC12 cells, strongly implying potent synergism.  Furthermore, network anal. suggested that the possible mechanism underlying their synergistic action might be derived from restoration of the damaged functional link between Akt and the CBP/p300 pathway, which plays a crucial role in the pathol. development of AD.  Thus, our findings provided a feasible avenue for the application of a synergistic drug combination, SAHA and curcumin, in the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFi8tFoPATybVg90H21EOLACvtfcHk0lglKG98xsRsog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFOjsLg%253D&md5=42024059eba2216cd6f1cf1e048a82d6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0085570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0085570%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCamarillo%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DL.%26atitle%3DThe%2520anti-tumor%2520histone%2520deacetylase%2520inhibitor%2520SAHA%2520and%2520the%2520natural%2520flavonoid%2520curcumin%2520exhibit%2520synergistic%2520neuroprotection%2520against%2520amyloid-beta%2520toxicity%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0085570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvanese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span> <span> </span><span class="NLM_article-title">Reactivation of latent HIV by histone deacetylase inhibitors</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2013.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.tim.2013.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23517573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlSjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=277-285&author=K.+Shirakawaauthor=L.+Chavezauthor=S.+Hakreauthor=V.+Calvaneseauthor=E.+Verdin&title=Reactivation+of+latent+HIV+by+histone+deacetylase+inhibitors&doi=10.1016%2Fj.tim.2013.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Reactivation of latent HIV by histone deacetylase inhibitors</span></div><div class="casAuthors">Shirakawa, Kotaro; Chavez, Leonard; Hakre, Shweta; Calvanese, Vincenzo; Verdin, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">277-285</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Latent HIV persists in CD4+ T cells in infected patients under antiretroviral therapy (ART).  Latency is assocd. with transcriptional silencing of the integrated provirus and driven, at least in part, by histone deacetylases (HDACs), a family of chromatin-assocd. proteins that regulate histone acetylation and the accessibility of DNA to transcription factors.  Remarkably, inhibition of HDACs is sufficient to reactivate a fraction of latent HIV in a variety of exptl. systems.  This basic observation led to the shock and kill idea that forcing the transcriptional activation of HIV might lead to virus expression, to virus- or host-induced cell death of the reactivated cells, and to the eradication of the pool of latently infected cells.  Such intervention might possibly lead to a cure for HIV-infected patients.  Here, we review the basic biol. of HDACs and their inhibitors, the role of HDACs in HIV latency, and recent efforts to use HDAC inhibitors to reactivate latent HIV in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQF9-sQLDUE7Vg90H21EOLACvtfcHk0lglKG98xsRsog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlSjtbk%253D&md5=39bc7bd9e112acf1217e7a5c4ba238fa</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2013.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2013.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DShirakawa%26aufirst%3DK.%26aulast%3DChavez%26aufirst%3DL.%26aulast%3DHakre%26aufirst%3DS.%26aulast%3DCalvanese%26aufirst%3DV.%26aulast%3DVerdin%26aufirst%3DE.%26atitle%3DReactivation%2520of%2520latent%2520HIV%2520by%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DTrends%2520Microbiol.%26date%3D2013%26volume%3D21%26spage%3D277%26epage%3D285%26doi%3D10.1016%2Fj.tim.2013.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vad-Nielsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laustsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogaard, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostergaard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, M. R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3984</span>– <span class="NLM_lpage">3994</span>, <span class="refDoi"> DOI: 10.1128/AAC.00574-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1128%2FAAC.00574-15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=3984-3994&author=K.+L.+Jonssonauthor=M.+Tolstrupauthor=J.+Vad-Nielsenauthor=K.+Kjaerauthor=A.+Laustsenauthor=M.+N.+Andersenauthor=T.+A.+Rasmussenauthor=O.+S.+Sogaardauthor=L.+Ostergaardauthor=P.+W.+Dentonauthor=M.+R.+Jakobsen&title=Histone+deacetylase+inhibitor+romidepsin+inhibits+de+novo+HIV-1+infections&doi=10.1128%2FAAC.00574-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FAAC.00574-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00574-15%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DK.%2BL.%26aulast%3DTolstrup%26aufirst%3DM.%26aulast%3DVad-Nielsen%26aufirst%3DJ.%26aulast%3DKjaer%26aufirst%3DK.%26aulast%3DLaustsen%26aufirst%3DA.%26aulast%3DAndersen%26aufirst%3DM.%2BN.%26aulast%3DRasmussen%26aufirst%3DT.%2BA.%26aulast%3DSogaard%26aufirst%3DO.%2BS.%26aulast%3DOstergaard%26aufirst%3DL.%26aulast%3DDenton%26aufirst%3DP.%2BW.%26aulast%3DJakobsen%26aufirst%3DM.%2BR.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520romidepsin%2520inhibits%2520de%2520novo%2520HIV-1%2520infections%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D3984%26epage%3D3994%26doi%3D10.1128%2FAAC.00574-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiattarella, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sannino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toscano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trimarco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrino, C.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>219</i></span>,  <span class="NLM_fpage">396</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1016/j.ijcard.2016.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ijcard.2016.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27362830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ltFersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2016&pages=396-403&author=G.+G.+Schiattarellaauthor=A.+Sanninoauthor=E.+Toscanoauthor=F.+Cattaneoauthor=B.+Trimarcoauthor=G.+Espositoauthor=C.+Perrino&title=Cardiovascular+effects+of+histone+deacetylase+inhibitors+epigenetic+therapies%3A+Systematic+review+of+62+studies+and+new+hypotheses+for+future+research&doi=10.1016%2Fj.ijcard.2016.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research</span></div><div class="casAuthors">Schiattarella Gabriele Giacomo; Sannino Anna; Toscano Evelina; Cattaneo Fabio; Trimarco Bruno; Esposito Giovanni; Perrino Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">396-403</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHU9cOCIEYRA8IxFYvehhofW6udTcc2eaRHzo6Be-KBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ltFersg%253D%253D&md5=f85f4a989a24f78a755011d554434cde</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2016.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2016.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DSchiattarella%26aufirst%3DG.%2BG.%26aulast%3DSannino%26aufirst%3DA.%26aulast%3DToscano%26aufirst%3DE.%26aulast%3DCattaneo%26aufirst%3DF.%26aulast%3DTrimarco%26aufirst%3DB.%26aulast%3DEsposito%26aufirst%3DG.%26aulast%3DPerrino%26aufirst%3DC.%26atitle%3DCardiovascular%2520effects%2520of%2520histone%2520deacetylase%2520inhibitors%2520epigenetic%2520therapies%253A%2520Systematic%2520review%2520of%252062%2520studies%2520and%2520new%2520hypotheses%2520for%2520future%2520research%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2016%26volume%3D219%26spage%3D396%26epage%3D403%26doi%3D10.1016%2Fj.ijcard.2016.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stenzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertzen, C. G.W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquardt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohlke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span> <span> </span><span class="NLM_article-title">Alkoxyurea-based histone deacetylase inhibitors increase cisplatin potency in chemoresistant cancer cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5334</span>– <span class="NLM_lpage">5348</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01538</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01538" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Kgurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5334-5348&author=K.+Stenzelauthor=A.+Hamacherauthor=F.+K.+Hansenauthor=C.+G.W.+Gertzenauthor=J.+Sengerauthor=V.+Marquardtauthor=L.+Marekauthor=M.+Marekauthor=C.+Romierauthor=M.+Remkeauthor=M.+Jungauthor=H.+Gohlkeauthor=M.+U.+Kassackauthor=T.+Kurz&title=Alkoxyurea-based+histone+deacetylase+inhibitors+increase+cisplatin+potency+in+chemoresistant+cancer+cell+lines&doi=10.1021%2Facs.jmedchem.6b01538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines</span></div><div class="casAuthors">Stenzel, Katharina; Hamacher, Alexandra; Hansen, Finn K.; Gertzen, Christoph G. W.; Senger, Johanna; Marquardt, Viktoria; Marek, Linda; Marek, Martin; Romier, Christophe; Remke, Marc; Jung, Manfred; Gohlke, Holger; Kassack, Matthias U.; Kurz, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5334-5348</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and biol. evaluation of potent hydroxamate-based dual HDAC1/6 inhibitors with modest HDAC6 preference and a novel alkoxyurea connecting unit linker region are described.  The biol. studies included the evaluation of antiproliferative effects and HDAC inhibitory activity in the human ovarian cancer cell line A2780, the human squamous carcinoma cell line Cal27, and their cisplatin resistant sublines A2780CisR and Cal27CisR.  The three most potent compds. 1g-i showed IC50 values in the low μM and sub-μM range. 1g-i revealed low nM IC50 values for HDAC6 with up to 15-fold preference over HDAC1, >3500-fold selectivity over HDAC4, and >100-fold selectivity over HDAC8.  Furthermore, their ability to enhance cisplatin sensitivity was analyzed in Cal27 and Cal27CisR cells.  Notably, a 48 h preincubation of 1g-i significantly enhanced the antiproliferative effects of cisplatin in Cal27 and Cal27CisR. 1g-i interacted synergistically with cisplatin.  These effects were more pronounced for the cisplatin resistant subline Cal27CisR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCmxo7R1pOG7Vg90H21EOLACvtfcHk0lh8vkY6Q9sWjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Kgurw%253D&md5=abec66940d84646599bdb4b1660a5b9e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01538%26sid%3Dliteratum%253Aachs%26aulast%3DStenzel%26aufirst%3DK.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26aulast%3DGertzen%26aufirst%3DC.%2BG.W.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DMarquardt%26aufirst%3DV.%26aulast%3DMarek%26aufirst%3DL.%26aulast%3DMarek%26aufirst%3DM.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DRemke%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DGohlke%26aufirst%3DH.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DKurz%26aufirst%3DT.%26atitle%3DAlkoxyurea-based%2520histone%2520deacetylase%2520inhibitors%2520increase%2520cisplatin%2520potency%2520in%2520chemoresistant%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5334%26epage%3D5348%26doi%3D10.1021%2Facs.jmedchem.6b01538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marson, C. M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.2174/187152009788679976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.2174%2F187152009788679976" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=661-692&author=C.+M.+Marson&title=Histone+deacetylase+inhibitors%3A+design%2C+structure-activity+relationships+and+therapeutic+implications+for+cancer&doi=10.2174%2F187152009788679976"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F187152009788679976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152009788679976%26sid%3Dliteratum%253Aachs%26aulast%3DMarson%26aufirst%3DC.%2BM.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520design%252C%2520structure-activity%2520relationships%2520and%2520therapeutic%2520implications%2520for%2520cancer%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D661%26epage%3D692%26doi%3D10.2174%2F187152009788679976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thurn, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.2217/fon.11.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.2217%2Ffon.11.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=21345145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=263-283&author=K.+T.+Thurnauthor=S.+Thomasauthor=A.+Mooreauthor=P.+N.+Munster&title=Rational+therapeutic+combinations+with+histone+deacetylase+inhibitors+for+the+treatment+of+cancer&doi=10.2217%2Ffon.11.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer</span></div><div class="casAuthors">Thurn, K. Ted; Thomas, Scott; Moore, Amy; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-283</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) regulate the acetylation of a variety of histone and nonhistone proteins, controlling the transcription and regulation of genes involved in cell cycle control, proliferation, survival, DNA repair and differentiation.  Unsurprisingly, HDAC expression is frequently altered in hematol. and solid tumor malignancies.  Two HDAC inhibitors (vorinostat and romidepsin) have been approved by the US FDA for the treatment of cutaneous T-cell lymphoma.  As single agents, treatment with HDAC inhibitors has demonstrated limited clin. benefit for patients with solid tumors, prompting the investigation of novel treatment combinations with other cancer therapeutics.  In this article, the rationales and clin. progress of several combinations with HDAC inhibitors are presented, including DNA-damaging chemotherapeutic agents, radiotherapy, hormonal therapies, DNA methyltransferase inhibitors and various small-mol. inhibitors.  The future application of HDAC inhibitors as a treatment for cancer is discussed, examg. current hurdles to overcome before realizing the potential of this new approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn7EKQGlvu_LVg90H21EOLACvtfcHk0licOlq5ENd1jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWlurs%253D&md5=193fc07f4e19bf16fcd7ee202057ef7c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2217%2Ffon.11.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.11.2%26sid%3Dliteratum%253Aachs%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DRational%2520therapeutic%2520combinations%2520with%2520histone%2520deacetylase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2011%26volume%3D7%26spage%3D263%26epage%3D283%26doi%3D10.2217%2Ffon.11.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niegisch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M. J.</span></span> <span> </span><span class="NLM_article-title">Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.4161/cbt.28469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.4161%2Fcbt.28469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24618845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A280%3ADC%252BC2crislOgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=742-757&author=L.+Rosikauthor=G.+Niegischauthor=U.+Fischerauthor=M.+Jungauthor=W.+A.+Schulzauthor=M.+J.+Hoffmann&title=Limited+efficacy+of+specific+HDAC6+inhibition+in+urothelial+cancer+cells&doi=10.4161%2Fcbt.28469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells</span></div><div class="casAuthors">Rosik Lorena; Niegisch Gunter; Schulz Wolfgang Arthur; Hoffmann Michele Janine; Fischer Ute; Jung Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Cancer biology & therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">742-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epigenetic modifiers such as histone deacetylases (HDACs) have come into focus as novel drug targets for cancer therapy due to their functional role in tumor progression.  Since common pan-HDAC inhibitors have adverse side effects and minor anti-cancer activity against solid tumors, enzyme-specific inhibitors were developed.  HDAC6 is especially well-suited for specific inhibition due to its unique domain structure and mode of action and has been suggested to provide an exceptionally suitable target for cancer therapy.  However, expression and function of HDACs have been insufficiently studied in urothelial cancers (UC), a disease urgently requiring new therapeutic approaches.  The present study sought to evaluate HDAC6 as a target for treatment of urothelial cancers with enzyme-specific inhibitors.  We observed moderate HDAC6 overexpression in urothelial cancer tissues and a broad range of expression in urothelial cancer cell lines.  In the cell lines Tubacin was the most potent inhibitor, compared with Tubastatin and ST-80, but still active only at high micromolar concentrations.  HDAC6 expression levels correlated poorly with sensitivity to enzyme inhibition.  Combined treatments with heat shock, HSP90 inhibition by 17-AAG, proteasome inhibition by bortezomib, or DNA-damaging agents did not result in significant synergistic effects.  Experiments with siRNA-mediated knockdown further underlined that urothelial cancer cells do not critically depend on HDAC6 expression for survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAn8Ee1u_sn--MdeMhXAHkfW6udTcc2ebB6guCF05Qurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crislOgsg%253D%253D&md5=0e7ecd26290e1c9fee19259b278c940e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4161%2Fcbt.28469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.28469%26sid%3Dliteratum%253Aachs%26aulast%3DRosik%26aufirst%3DL.%26aulast%3DNiegisch%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DU.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DSchulz%26aufirst%3DW.%2BA.%26aulast%3DHoffmann%26aufirst%3DM.%2BJ.%26atitle%3DLimited%2520efficacy%2520of%2520specific%2520HDAC6%2520inhibition%2520in%2520urothelial%2520cancer%2520cells%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2014%26volume%3D15%26spage%3D742%26epage%3D757%26doi%3D10.4161%2Fcbt.28469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D. F.</span></span> <span> </span><span class="NLM_article-title">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ejmech.2017.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=28494256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=195-211&author=R.+G.+Fuauthor=Y.+Sunauthor=W.+B.+Shengauthor=D.+F.+Liao&title=Designing+multi-targeted+agents%3A+An+emerging+anticancer+drug+discovery+paradigm&doi=10.1016%2Fj.ejmech.2017.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span></div><div class="casAuthors">Fu, Rong-geng; Sun, Yuan; Sheng, Wen-bing; Liao, Duan-fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-211</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is to design ligands with max. selectivity to act on individual drug targets.  With the target-based approach, many new chem. entities have been discovered, developed, and further approved as drugs.  However, there are a large no. of complex diseases such as cancer that cannot be effectively treated or cured only with one medicine to modulate the biol. function of a single target.  As simultaneous intervention of two (or multiple) cancer progression relevant targets has shown improved therapeutic efficacy, the innovation of multi-targeted drugs has become a promising and prevailing research topic and numerous multi-targeted anticancer agents are currently at various developmental stages.  However, most multi-pharmacophore scaffolds are usually discovered by serendipity or screening, while rational design by combining existing pharmacophore scaffolds remains an enormous challenge.  In this review, four types of multi-pharmacophore modes are discussed, and the examples from literature will be used to introduce attractive lead compds. with the capability of simultaneously interfering with different enzyme or signaling pathway of cancer progression, which will reveal the trends and insights to help the design of the next generation multi-targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjXR-zscrArVg90H21EOLACvtfcHk0licOlq5ENd1jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D&md5=511561bd2cd186d5dafa905b7257bf32</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DR.%2BG.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DW.%2BB.%26aulast%3DLiao%26aufirst%3DD.%2BF.%26atitle%3DDesigning%2520multi-targeted%2520agents%253A%2520An%2520emerging%2520anticancer%2520drug%2520discovery%2520paradigm%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D195%26epage%3D211%26doi%3D10.1016%2Fj.ejmech.2017.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lgTGbDfVwaq9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berube, G.</span></span> <span> </span><span class="NLM_article-title">Advances in the development of hybrid anticancer drugs</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.798296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1517%2F17460441.2013.798296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23646979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOitL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1029-1047&author=S.+Fortinauthor=G.+Berube&title=Advances+in+the+development+of+hybrid+anticancer+drugs&doi=10.1517%2F17460441.2013.798296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the development of hybrid anticancer drugs</span></div><div class="casAuthors">Fortin, Sebastien; Berube, Gervais</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1029-1047</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Hybrid anticancer drugs are of great therapeutic interests as they can potentially overcome most of the pharmacokinetic drawbacks encountered when using conventional anticancer drugs.  In fact, the future of hybrid anticancer drugs is very bright for the discovery of highly potent and selective mols. that triggers two or more cytocidal pharmacol. mechanisms of action acting in synergy to inhibit cancer tumor growth.  Areas covered: This review represents the most advanced and recent data in the field of hybrid anticancer agents covering mainly the past 5 years of research.  It also accounts for other significant reviews already published on the topic of anticancer hybrids.  The review showcases the research that is at the leading edge of hybrid anticancer drug discovery.  The main areas covered by the present review are: DNA alkylating agent hybrids (e.g., platinum(II), nitrogen mustard, etc.), vitamin-D receptor, agonist-histone deacetylase inhibitors, combi-mol. therapies and other types of hybrid anticancer agents.  Expert opinion: The current development in the field describes strategies that have never been used before for the design of hybrid anticancer drugs.  The information currently available and described in this section allows us to identify the main parameters required to design such mols.  It also provides a clear view of the future directions that must be explored for the successful development and discovery of useful hybrid anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1FoQV3stg57Vg90H21EOLACvtfcHk0lgTGbDfVwaq9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOitL7E&md5=d5157ee2d3cc8778f9129b051bf52e0d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.798296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.798296%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DBerube%26aufirst%3DG.%26atitle%3DAdvances%2520in%2520the%2520development%2520of%2520hybrid%2520anticancer%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D1029%26epage%3D1047%26doi%3D10.1517%2F17460441.2013.798296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berube, G.</span></span> <span> </span><span class="NLM_article-title">An overview of molecular hybrids in drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1517/17460441.2016.1135125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1517%2F17460441.2016.1135125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=281-305&author=G.+Berube&title=An+overview+of+molecular+hybrids+in+drug+discovery&doi=10.1517%2F17460441.2016.1135125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1517%2F17460441.2016.1135125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2016.1135125%26sid%3Dliteratum%253Aachs%26aulast%3DBerube%26aufirst%3DG.%26atitle%3DAn%2520overview%2520of%2520molecular%2520hybrids%2520in%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D281%26epage%3D305%26doi%3D10.1517%2F17460441.2016.1135125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Anticancer activities of histone deacetylase inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nrd2133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+W.+Johnstone&title=Anticancer+activities+of+histone+deacetylase+inhibitors&doi=10.1038%2Fnrd2133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0lgTGbDfVwaq9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DAnticancer%2520activities%2520of%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784%26doi%3D10.1038%2Fnrd2133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bots, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Rational combinations using HDAC inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3970</span>– <span class="NLM_lpage">3977</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-08-2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=19509171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntlOis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3970-3977&author=M.+Botsauthor=R.+W.+Johnstone&title=Rational+combinations+using+HDAC+inhibitors&doi=10.1158%2F1078-0432.CCR-08-2786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Combinations Using HDAC Inhibitors</span></div><div class="casAuthors">Bots, Michael; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3970-3977</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  In addn. to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis.  As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as anticancer drugs.  In numerous in vitro and preclin. settings, these compds. have shown their vast potential as single agent anticancer therapies, but unfortunately equiv. responses have not always been obsd. in patients.  Given the pleiotropic effects HDACi have on malignant cells, their true therapeutic potential most likely lies in combination with other anticancer drugs.  In this review we will focus on the anticancer effects of HDACi when combined with other cancer therapeutics with an emphasis on those combinations based on a strong mol. rationale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhLnwCXjHtPbVg90H21EOLACvtfcHk0ljg4pETz9Ew7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntlOis7w%253D&md5=117c52a204aa45615eb04c8600e51c10</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2786%26sid%3Dliteratum%253Aachs%26aulast%3DBots%26aufirst%3DM.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DRational%2520combinations%2520using%2520HDAC%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3970%26epage%3D3977%26doi%3D10.1158%2F1078-0432.CCR-08-2786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frew, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. E.</span></span> <span> </span><span class="NLM_article-title">Enhancing the apoptotic and therapeutic effects of HDAC inhibitors</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2009.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.canlet.2009.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=19359091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=125-133&author=A.+J.+Frewauthor=R.+W.+Johnstoneauthor=J.+E.+Bolden&title=Enhancing+the+apoptotic+and+therapeutic+effects+of+HDAC+inhibitors&doi=10.1016%2Fj.canlet.2009.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing the apoptotic and therapeutic effects of HDAC inhibitors</span></div><div class="casAuthors">Frew, Ailsa J.; Johnstone, Ricky W.; Bolden, Jessica E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-133</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACi) are anti-cancer drugs that have moved rapidly through clin. development and in 2006 vorinostat (SAHA, Zolinza) was given FDA approval for the treatment of cutaneous T cell lymphoma.  Class I, II and IV HDACs that are targets for these compds. deacetylate histone proteins, resulting in chromatin remodelling and altered gene transcription.  In addn., numerous non-histone proteins are modified by acetylation and the inhibition of HDAC activity can therefore affect various mol. processes.  This broad effect on protein function may account for the pleiotropic anti-tumor responses elicited by HDACi that include induction of tumor cell apoptosis, cell cycle arrest, differentiation and senescence, modulation of immune responses and altered angiogenesis.  The ability of HDACi to selectively induce tumor cells to undergo apoptosis is important for the therapeutic efficacy obsd. in pre-clin. models.  Moreover, HDACi can augment the apoptotic effects of other anti-cancer agents that have diverse mol. targets.  While HDACi are promising anti-cancer drugs, particularly given the scope to combine HDACi with other agents, identifying the key mol. events that det. the biol. response of cells to HDACi treatment remains a challenge.  Herein we focus on HDACi-induced apoptosis and discuss the various proteins and pathways that are affected by HDACi to mediate this programmed cell death response.  In addn., we highlight the ability of HDACi to synergise with other anti-cancer agents to potently kill tumor cells and discuss the possible mol. processes that underpin the combination effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp45hSsI-BaJ7Vg90H21EOLACvtfcHk0ljg4pETz9Ew7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtrY%253D&md5=2c647b927be73f7882b745b4edd1791f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DFrew%26aufirst%3DA.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26atitle%3DEnhancing%2520the%2520apoptotic%2520and%2520therapeutic%2520effects%2520of%2520HDAC%2520inhibitors%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D125%26epage%3D133%26doi%3D10.1016%2Fj.canlet.2009.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauvais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levaique, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamlard, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouaissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasselouri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayat-Vignoles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mouhammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuillard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benihoud, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamze, A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tubulin and histone deacetylase inhibitor based on iso-combretastatin A-4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6574</span>– <span class="NLM_lpage">6591</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6574-6591&author=D.+Lamaaauthor=H.+P.+Linauthor=L.+Zigauthor=C.+Bauvaisauthor=G.+Bollotauthor=J.+Bignonauthor=H.+Levaiqueauthor=O.+Pamlardauthor=J.+Duboisauthor=M.+Ouaissiauthor=M.+Souceauthor=A.+Kasselouriauthor=F.+Sallerauthor=D.+Borgelauthor=C.+Jayat-Vignolesauthor=H.+Al-Mouhammadauthor=J.+Feuillardauthor=K.+Benihoudauthor=M.+Alamiauthor=A.+Hamze&title=Design+and+synthesis+of+tubulin+and+histone+deacetylase+inhibitor+based+on+iso-combretastatin+A-4&doi=10.1021%2Facs.jmedchem.8b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4</span></div><div class="casAuthors">Lamaa, Diana; Lin, Hsin-Ping; Zig, Lena; Bauvais, Cyril; Bollot, Guillaume; Bignon, Jerome; Levaique, Helene; Pamlard, Olivier; Dubois, Joelle; Ouaissi, Mehdi; Souce, Martin; Kasselouri, Athena; Saller, Francois; Borgel, Delphine; Jayat-Vignoles, Chantal; Al-Mouhammad, Hazar; Feuillard, Jean; Benihoud, Karim; Alami, Mouad; Hamze, Abdallah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6574-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs have raised considerable interest due to their advantages in the treatment of complex diseases such as cancer.  Their design constitutes a challenge in antitumor drug discovery.  The present study reports a dual inhibition of tubulin polymn. and HDAC activity.  On the basis of 1,1-diarylethylenes (isoCA-4) and belinostat, a series of hybrid mols. was successfully designed and synthesized.  In particular compds., 5f and 5h were proven to be potent inhibitors of both tubulin polymn. and HDAC8 leading to excellent antiproliferative activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGq5rq0opowLVg90H21EOLACvtfcHk0ljg4pETz9Ew7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN&md5=9d7ffe7d11f3dc2e55adcd8d0c511606</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00050%26sid%3Dliteratum%253Aachs%26aulast%3DLamaa%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DH.%2BP.%26aulast%3DZig%26aufirst%3DL.%26aulast%3DBauvais%26aufirst%3DC.%26aulast%3DBollot%26aufirst%3DG.%26aulast%3DBignon%26aufirst%3DJ.%26aulast%3DLevaique%26aufirst%3DH.%26aulast%3DPamlard%26aufirst%3DO.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DOuaissi%26aufirst%3DM.%26aulast%3DSouce%26aufirst%3DM.%26aulast%3DKasselouri%26aufirst%3DA.%26aulast%3DSaller%26aufirst%3DF.%26aulast%3DBorgel%26aufirst%3DD.%26aulast%3DJayat-Vignoles%26aufirst%3DC.%26aulast%3DAl-Mouhammad%26aufirst%3DH.%26aulast%3DFeuillard%26aufirst%3DJ.%26aulast%3DBenihoud%26aufirst%3DK.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DHamze%26aufirst%3DA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tubulin%2520and%2520histone%2520deacetylase%2520inhibitor%2520based%2520on%2520iso-combretastatin%2520A-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6574%26epage%3D6591%26doi%3D10.1021%2Facs.jmedchem.8b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gryder, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rood, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raftery, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azizi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors equipped with estrogen receptor modulation activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5782</span>– <span class="NLM_lpage">5796</span>, <span class="refDoi"> DOI: 10.1021/jm400467w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400467w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5782-5796&author=B.+E.+Gryderauthor=M.+K.+Roodauthor=K.+A.+Johnsonauthor=V.+Patilauthor=E.+D.+Rafteryauthor=L.+P.+Yaoauthor=M.+Riceauthor=B.+Aziziauthor=D.+F.+Doyleauthor=A.+K.+Oyelere&title=Histone+deacetylase+inhibitors+equipped+with+estrogen+receptor+modulation+activity&doi=10.1021%2Fjm400467w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm400467w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400467w%26sid%3Dliteratum%253Aachs%26aulast%3DGryder%26aufirst%3DB.%2BE.%26aulast%3DRood%26aufirst%3DM.%2BK.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DRaftery%26aufirst%3DE.%2BD.%26aulast%3DYao%26aufirst%3DL.%2BP.%26aulast%3DRice%26aufirst%3DM.%26aulast%3DAzizi%26aufirst%3DB.%26aulast%3DDoyle%26aufirst%3DD.%2BF.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520equipped%2520with%2520estrogen%2520receptor%2520modulation%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5782%26epage%3D5796%26doi%3D10.1021%2Fjm400467w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soden, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giblin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furze, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span> <span> </span><span class="NLM_article-title">The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">342</span>, <span class="refDoi"> DOI: 10.1039/c3md00285c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1039%2Fc3md00285c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=342&author=S.+J.+Atkinsonauthor=P.+E.+Sodenauthor=D.+C.+Angellauthor=M.+Bantscheffauthor=C.-w.+Chungauthor=K.+A.+Giblinauthor=N.+Smithersauthor=R.+C.+Furzeauthor=L.+Gordonauthor=G.+Drewesauthor=I.+Riojaauthor=J.+Witheringtonauthor=N.+J.+Parrauthor=R.+K.+Prinjha&title=The+structure+based+design+of+dual+HDAC%2FBET+inhibitors+as+novel+epigenetic+probes&doi=10.1039%2Fc3md00285c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1039%2Fc3md00285c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3md00285c%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DS.%2BJ.%26aulast%3DSoden%26aufirst%3DP.%2BE.%26aulast%3DAngell%26aufirst%3DD.%2BC.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DGiblin%26aufirst%3DK.%2BA.%26aulast%3DSmithers%26aufirst%3DN.%26aulast%3DFurze%26aufirst%3DR.%2BC.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26atitle%3DThe%2520structure%2520based%2520design%2520of%2520dual%2520HDAC%252FBET%2520inhibitors%2520as%2520novel%2520epigenetic%2520probes%26jtitle%3DMedChemComm%26date%3D2014%26volume%3D5%26spage%3D342%26doi%3D10.1039%2Fc3md00285c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taub, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antileukemic activities of piperlongumine and HDAC inhibitor hybrids against acute myeloid leukemia cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7974</span>– <span class="NLM_lpage">7990</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00772</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00772" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7974-7990&author=Y.+Liaoauthor=X.+Niuauthor=B.+Chenauthor=H.+Edwardsauthor=L.+Xuauthor=C.+Xieauthor=H.+Linauthor=L.+Polinauthor=J.+W.+Taubauthor=Y.+Geauthor=Z.+Qin&title=Synthesis+and+antileukemic+activities+of+piperlongumine+and+HDAC+inhibitor+hybrids+against+acute+myeloid+leukemia+cells&doi=10.1021%2Facs.jmedchem.6b00772"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00772%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DTaub%26aufirst%3DJ.%2BW.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520antileukemic%2520activities%2520of%2520piperlongumine%2520and%2520HDAC%2520inhibitor%2520hybrids%2520against%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7974%26epage%3D7990%26doi%3D10.1021%2Facs.jmedchem.6b00772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7965</span>– <span class="NLM_lpage">7983</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7965-7983&author=G.+Dongauthor=W.+Chenauthor=X.+Wangauthor=X.+Yangauthor=T.+Xuauthor=P.+Wangauthor=W.+Zhangauthor=Y.+Raoauthor=C.+Miaoauthor=C.+Sheng&title=Small+molecule+inhibitors+simultaneously+targeting+cancer+metabolism+and+epigenetics%3A+discovery+of+novel+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facs.jmedchem.7b00467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Dong, Guoqiang; Chen, Wei; Wang, Xia; Yang, Xinglin; Xu, Tianying; Wang, Pei; Zhang, Wannian; Rao, Yu; Miao, Chaoyu; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7965-7983</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer metab. and epigenetics are among the most intensely pursued research areas in anticancer drug discovery.  Here we report the first small mols. that simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT)and histone deacetylase (HDAC), two important targets of cancer metab. and epigenetics, resp.  Through iterative structure-based drug design, chem. synthesis, and biol. assays, a highly potent dual NAMPT and HDAC inhibitor was successfully identified.  Compd. 35 possessed excellent and balanced activities against both NAMPT (IC50 = 31 nM) and HDAC1 (IC50 = 55 nM).  It could effectively induce cell apoptosis and autophagy and ultimately led to cell death.  Importantly, compd. 35 showed excellent in vivo antitumor efficacy in the HCT116 xenograft model.  This proof-of-concept study demonstrates the feasibility of discovering an inhibitor targeting cancer metab. and epigenetics and provides an efficient strategy for multitarget antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9UvfGattu1rVg90H21EOLACvtfcHk0lhsVFXVqZsSUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO&md5=65df0b485cbbc169886d34ae4421f814</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00467%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DC.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520inhibitors%2520simultaneously%2520targeting%2520cancer%2520metabolism%2520and%2520epigenetics%253A%2520discovery%2520of%2520novel%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7965%26epage%3D7983%26doi%3D10.1021%2Facs.jmedchem.7b00467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HuangFu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ejmech.2018.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=29567459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1OhtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=667-677&author=R.+Ojhaauthor=H.+L.+Huangauthor=W.+C.+HuangFuauthor=Y.+W.+Wuauthor=K.+Nepaliauthor=M.+J.+Laiauthor=C.+J.+Suauthor=T.+Y.+Sungauthor=Y.+L.+Chenauthor=S.+L.+Panauthor=J.+P.+Liou&title=1-Aroylindoline-hydroxamic+acids+as+anticancer+agents%2C+inhibitors+of+HSP90+and+HDAC&doi=10.1016%2Fj.ejmech.2018.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC</span></div><div class="casAuthors">Ojha, Ritu; Huang, Han-Li; Huang Fu, Wei-Chun; Wu, Yi-Wen; Nepali, Kunal; Lai, Mei-Jung; Su, Chih-Jou; Sung, Ting-Yi; Chen, Yi-Lin; Pan, Shiow-Lin; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">667-677</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 1-aroylindoline-hydroxamic acids I [n = 2 - 8] and II were synthesized.  The results of the biol. evaluation led to the identification of compd. I [n = 6] as dual HDAC6/HSP90 inhibitor.  Compd. I [n = 6] displayed striking inhibitory effects towards the HDAC6 isoform and HSP90 protein with IC50 values of 1.15 nM (HDAC6) and 46.3 nM (HSP90).  Compd. I [n = 6] also exhibited 113, 139 and 246 fold higher selectivity for HDAC6 over HDAC 1, HDAC 3 and HDAC 8 isoforms and was endowed with significant cytotoxic effects with GI50 values ranging 1.04-1.61 μM against lung A549, colorectal HCT116, leukemia HL60 and EGFR T790M mutant lung H1975 cell lines.  Another interesting finding of the study was substantial cytotoxic effects of compd. I particularly against lung H1975 (NSCLC) cell lines with IC50 = 0.26 μM which was mediated through HSP90 inhibition.  Compd. I [n = 2] as such was devoid of HDAC inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgF2Cb1sTQY7Vg90H21EOLACvtfcHk0lhsVFXVqZsSUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1OhtLk%253D&md5=7c6b877c774d207150bf49c45f9a9303</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DOjha%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DHuangFu%26aufirst%3DW.%2BC.%26aulast%3DWu%26aufirst%3DY.%2BW.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DSu%26aufirst%3DC.%2BJ.%26aulast%3DSung%26aufirst%3DT.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D1-Aroylindoline-hydroxamic%2520acids%2520as%2520anticancer%2520agents%252C%2520inhibitors%2520of%2520HSP90%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D667%26epage%3D677%26doi%3D10.1016%2Fj.ejmech.2018.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span>; <span class="NLM_string-name">Stafford, J. A.</span></span> <i>Kinase Inhibitor Drugs</i>, <span class="NLM_edition">1st</span> ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1002%2F9780470524961" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Li&author=J.+A.+Stafford&title=Kinase+Inhibitor+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2F9780470524961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470524961%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26btitle%3DKinase%2520Inhibitor%2520Drugs%26pub%3DWiley%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caflisch, A.</span></span> <span> </span><span class="NLM_article-title">Current kinase inhibitors cover a tiny fraction of fragment space</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2372</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.bmcl.2015.04.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2372-2376&author=H.+Zhaoauthor=A.+Caflisch&title=Current+kinase+inhibitors+cover+a+tiny+fraction+of+fragment+space&doi=10.1016%2Fj.bmcl.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCaflisch%26aufirst%3DA.%26atitle%3DCurrent%2520kinase%2520inhibitors%2520cover%2520a%2520tiny%2520fraction%2520of%2520fragment%2520space%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2372%26epage%3D2376%26doi%3D10.1016%2Fj.bmcl.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defert, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span> <span> </span><span class="NLM_article-title">Rho kinase (ROCK) inhibitors and their therapeutic potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2269</span>– <span class="NLM_lpage">2300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00683</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00683" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Oqtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2269-2300&author=Y.+Fengauthor=P.+V.+LoGrassoauthor=O.+Defertauthor=R.+Li&title=Rho+kinase+%28ROCK%29+inhibitors+and+their+therapeutic+potential&doi=10.1021%2Facs.jmedchem.5b00683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential</span></div><div class="casAuthors">Feng, Yangbo; LoGrasso, Philip V.; Defert, Olivier; Li, Rongshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2269-2300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rho kinases (ROCKs) belong to the serine-threonine family, the inhibition of which affects the function of many downstream substrates.  As such, ROCK inhibitors have potential therapeutic applicability in a wide variety of pathol. conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis.  To date, two ROCK inhibitors have been approved for clin. use in Japan (fasudil and ripasudil) and one in China (fasudil).  In 1995 fasudil was approved for the treatment of cerebral vasospasm, and more recently, ripasudil was approved for the treatment of glaucoma in 2014.  In this Perspective, we present a comprehensive review of the physiol. and biol. functions for ROCK, the properties and development of over 170 ROCK inhibitors as well as their therapeutic potential, the current status, and future considerations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXh2BorYftcbVg90H21EOLACvtfcHk0lgcuKt28H_CJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Oqtb%252FJ&md5=99b0e10dca303023b1bf382fcb255771</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00683%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DLoGrasso%26aufirst%3DP.%2BV.%26aulast%3DDefert%26aufirst%3DO.%26aulast%3DLi%26aufirst%3DR.%26atitle%3DRho%2520kinase%2520%2528ROCK%2529%2520inhibitors%2520and%2520their%2520therapeutic%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2269%26epage%3D2300%26doi%3D10.1021%2Facs.jmedchem.5b00683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e73</span> <span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2ebuOB8yQoQMwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avizienyte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A. P.</span></span> <span> </span><span class="NLM_article-title">Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1042/BJ20080728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1042%2FBJ20080728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=18588508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKhsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2008&pages=197-206&author=E.+Avizienyteauthor=R.+A.+Wardauthor=A.+P.+Garner&title=Comparison+of+the+EGFR+resistance+mutation+profiles+generated+by+EGFR-targeted+tyrosine+kinase+inhibitors+and+the+impact+of+drug+combinations&doi=10.1042%2FBJ20080728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations</span></div><div class="casAuthors">Avizienyte, Egle; Ward, Richard A.; Garner, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">415</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-206</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Recent clin. data indicates that the emergence of mutant drug-resistant kinase alleles may be particularly relevant for targeted kinase inhibitors.  In order to explore how different classes of targeted therapies impact upon resistance mutations, we performed EGFR (epidermal-growth-factor receptor) resistance mutation screens with erlotinib, lapatinib and CI-1033.  Distinct mutation spectra were generated with each inhibitor and were reflective of their resp. mechanisms of action.  Lapatinib yielded the widest variety of mutations, whereas mutational variability was lower in the erlotinib and CI-1033 screens.  Lapatinib was uniquely sensitive to mutations of residues located deep within the selectivity pocket, whereas mutation of either Gly796 or Cys797 resulted in a dramatic loss of CI-1033 potency.  The clin. obsd. T790M mutation was common to all inhibitors, but occurred with varying frequencies.  Importantly, the presence of C797S with T790M in the same EGFR allele conferred complete resistance to erlotinib, lapatinib and CI-1033.  The combination of erlotinib and CI-1033 effectively reduced the no. of drug-resistant clones, suggesting a possible clin. strategy to overcome drug resistance.  Interestingly, our results also indicate that co-expression of ErbB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2) has an impact upon the EGFR resistance mutations obtained, suggesting that ErbB2 may play an active role in the acquisition of drug-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQxFxDD2-BWbVg90H21EOLACvtfcHk0lhu7dp6MMgH-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKhsbnL&md5=bf7ac8190153eb07d94d67b7037be3ab</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1042%2FBJ20080728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20080728%26sid%3Dliteratum%253Aachs%26aulast%3DAvizienyte%26aufirst%3DE.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DGarner%26aufirst%3DA.%2BP.%26atitle%3DComparison%2520of%2520the%2520EGFR%2520resistance%2520mutation%2520profiles%2520generated%2520by%2520EGFR-targeted%2520tyrosine%2520kinase%2520inhibitors%2520and%2520the%2520impact%2520of%2520drug%2520combinations%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D415%26spage%3D197%26epage%3D206%26doi%3D10.1042%2FBJ20080728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. S.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">3161</span>– <span class="NLM_lpage">3168</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=22843888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kmu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=3161-3168&author=M.+J.+Kimauthor=D.+E.+Kimauthor=I.+G.+Jeongauthor=J.+Choiauthor=S.+Jangauthor=J.+H.+Leeauthor=S.+Roauthor=J.+J.+Hwangauthor=C.+S.+Kim&title=HDAC+inhibitors+synergize+antiproliferative+effect+of+sorafenib+in+renal+cell+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells</span></div><div class="casAuthors">Kim, Mi Joung; Kim, Dong Eun; Jeong, In Gab; Choi, Jene; Jang, Sejin; Lee, Je-Hwan; Ro, Seonggu; Hwang, Jung Jin; Kim, Choung-Soo</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3161-3168</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Aim: To investigate the anticancer effect of histone deacetylase inhibitors (HDACIs) in combination with sorafenib in wild-type and mutant von Hippel-Lindau (VHL)-expressing renal cell carcinomas (RCCs).  Materials and Methods: We exposed clear cell RCC cells to HDACIs (vorinostat or belinostat) or sorafenib.  We performed 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assays, western blotting, flow cytometry and enzyme-linked immunosorbent assays (ELISA) to evaluate mechanisms of cell death, and used CalcuSyn to analyze the potential synergism.  Results: HDACIs alone inhibited the growth of clear cell RCC cell lines, increased acetylation of histone 3 and of tubulin, activated caspases-8, -9, and -3, and augmented the sub-G1 population, independently of VHL and permeability glycoprotein (P-gp).  Moreover, pre-treatment of Caki-1 (wild-type VHL) and 786-O (mutant VHL) with HDACIs followed by sorafenib reduced cell viability synergistically via activation of caspases and downregulation of the levels of myeloid leukemia cell differentiation protein (MCL1), phospho-extracellular signal-regulated kinase (ERK), and secreted vascular endothelial growth factor (VEGF).  Conclusion: Sorafenib is more effective in combination with HDACIs even for clear cell RCCs harboring mutant VHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfFkuxF1uM0rVg90H21EOLACvtfcHk0lhu7dp6MMgH-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kmu77K&md5=5d9900ad6923e3a7f2f8714a72718cc6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DJeong%26aufirst%3DI.%2BG.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DJang%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DRo%26aufirst%3DS.%26aulast%3DHwang%26aufirst%3DJ.%2BJ.%26aulast%3DKim%26aufirst%3DC.%2BS.%26atitle%3DHDAC%2520inhibitors%2520synergize%2520antiproliferative%2520effect%2520of%2520sorafenib%2520in%2520renal%2520cell%2520carcinoma%2520cells%26jtitle%3DAnticancer%2520Res.%26date%3D2012%26volume%3D32%26spage%3D3161%26epage%3D3168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, S.</span></span> <span> </span><span class="NLM_article-title">EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2428</span>– <span class="NLM_lpage">2434</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-3479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F0008-5472.CAN-12-3479" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=2428-2434&author=T.+Nakagawaauthor=S.+Takeuchiauthor=T.+Yamadaauthor=H.+Ebiauthor=T.+Sanoauthor=S.+Nanjoauthor=D.+Ishikawaauthor=M.+Satoauthor=Y.+Hasegawaauthor=Y.+Sekidoauthor=S.+Yano&title=EGFR-TKI+resistance+due+to+BIM+polymorphism+can+be+circumvented+in+combination+with+HDAC+inhibition&doi=10.1158%2F0008-5472.CAN-12-3479"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-3479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-3479%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DSano%26aufirst%3DT.%26aulast%3DNanjo%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DD.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DSekido%26aufirst%3DY.%26aulast%3DYano%26aufirst%3DS.%26atitle%3DEGFR-TKI%2520resistance%2520due%2520to%2520BIM%2520polymorphism%2520can%2520be%2520circumvented%2520in%2520combination%2520with%2520HDAC%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D2428%26epage%3D2434%26doi%3D10.1158%2F0008-5472.CAN-12-3479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e810</span> <span class="refDoi"> DOI: 10.1038/cddis.2013.330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fcddis.2013.330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24052078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2mtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&author=M.+C.+Chenauthor=C.+H.+Chenauthor=J.+C.+Wangauthor=A.+C.+Tsaiauthor=J.+P.+Liouauthor=S.+L.+Panauthor=C.+M.+Teng&title=The+HDAC+inhibitor%2C+MPT0E028%2C+enhances+erlotinib-induced+cell+death+in+EGFR-TKI-resistant+NSCLC+cells&doi=10.1038%2Fcddis.2013.330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells</span></div><div class="casAuthors">Chen, M.-C.; Chen, C.-H.; Wang, J.-C.; Tsai, A.-C.; Liou, J.-P.; Pan, S.-L.; Teng, C.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Sept.</span>),
    <span class="NLM_cas:pages">e810</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR), which promotes cell survival and division, is found at abnormally high levels on the surface of many cancer cell types, including many cases of non-small cell lung cancer.  Erlotinib (Tarceva), an oral small-mol. tyrosine kinase inhibitor, is a so-called targeted drug that inhibits the tyrosine kinase domain of EGFR, and thus targets cancer cells with some specificity while doing less damage to normal cells.  However, erlotinib resistance can occur, reducing the efficacy of this treatment.  To develop more effective therapeutic interventions by overcoming this resistance problem, we combined the histone deacetylase inhibitor, MPT0E028, with erlotinib in an effort to increase their antitumor effects in erlotinib-resistant lung adenocarcinoma cells.  This combined treatment yielded significant growth inhibition, induced the expression of apoptotic proteins (PARP, γH2AX, and caspase-3), increased the levels of acetylated histone H3, and showed synergistic effects in vitro and in vivo.  These effects were independent of the mutation status of the genes encoding EGFR or K-Ras.  MPT0E028 synergistically blocked key regulators of the EGFR/HER2 signaling pathways, attenuating multiple compensatory pathways (e.g., AKT, extracellular signal-regulated kinase, and c-MET).  Our results indicate that this combination therapy might be a promising strategy for facilitating the effects of erlotinib monotherapy by activating various networks.  Taken together, our data provide compelling evidence that MPT0E028 has the potential to improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohUhwZb0vDhbVg90H21EOLACvtfcHk0liQQtOJXt5eDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2mtb7J&md5=5fca3b66a1178f8086b61bcb42eacaa0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.330%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DTsai%26aufirst%3DA.%2BC.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DThe%2520HDAC%2520inhibitor%252C%2520MPT0E028%252C%2520enhances%2520erlotinib-induced%2520cell%2520death%2520in%2520EGFR-TKI-resistant%2520NSCLC%2520cells%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26doi%3D10.1038%2Fcddis.2013.330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1274</span>– <span class="NLM_lpage">1287</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-12-3909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24520095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXks1Ohurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1274-1287&author=C.+H.+Chenauthor=M.+C.+Chenauthor=J.+C.+Wangauthor=A.+C.+Tsaiauthor=C.+S.+Chenauthor=J.+P.+Liouauthor=S.+L.+Panauthor=C.+M.+Teng&title=Synergistic+interaction+between+the+HDAC+inhibitor%2C+MPT0E028%2C+and+sorafenib+in+liver+cancer+cells+in+vitro+and+in+vivo&doi=10.1158%2F1078-0432.CCR-12-3909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo</span></div><div class="casAuthors">Chen, Chun-Han; Chen, Mei-Chuan; Wang, Jing-Chi; Tsai, An-Chi; Chen, Ching-Shih; Liou, Jing-Ping; Pan, Shiow-Lin; Teng, Che-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1274-1287</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To investigate the antitumor activities of a histone deacetylase (HDAC) inhibitor, MPT0E028, plus sorafenib in liver cancer cells in vitro and in vivo.  Exptl. Design: Different liver cancer cell lines were exposed to sorafenib in the presence or absence of MPT0E028, and cell viability was detd. by MTT assay.  Effects of combined treatment on cell cycle and intracellular signaling pathways were assessed by flow cytometry and Western blot anal.  The Hep3B xenograft model was used to examine the antitumor activity in vivo.  Results: Our data indicate that sorafenib and MPT0E028 synergistically reduced cell viability in liver cancer cells, and also markedly induced apoptotic cell death in these cells, as evidenced by the cleavage of caspase-3, PARP, and DNA fragmentation.  MPT0E028 altered the global modifications of histone and nonhistone proteins regardless of the presence of sorafenib.  However, sorafenib blocked MPT0E028-induced Erk activation and its downstream signaling cascades, such as Stat3 phosphorylation (Ser727) and Mcl-1 upregulation.  Ectopic expression of constitutively active Mek successively reversed the apoptosis triggered by the combined treatment.  Pharmacol. inhibition of Mek by PD98059 potentiated MPT0E028-induced apoptosis, suggesting that the synergistic interaction between MPT0E028 and sorafenib occurs at least partly through inhibition of Erk signaling.  The data demonstrated that transcriptional activation of fibroblast growth factor receptor 3 (FGFR3) contributes to MPT0E028-mediated Erk phosphorylation.  Finally, MPT0E028 plus sorafenib significantly improved the tumor growth delay (TGD) in a Hep3B xenograft model.  Conclusions: These findings suggest that MPT0E028 in combination with sorafenib has significant anti-hepatocellular carcinoma activity in preclin. models, potentially suggesting a novel therapeutic strategy for patients with advanced hepatocellular carcinoma.  Clin Cancer Res; 20(5); 1274-87. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3-eBzwYVsbrVg90H21EOLACvtfcHk0liQQtOJXt5eDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXks1Ohurc%253D&md5=35005d2a12294749b98bea5966c388f9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3909%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DTsai%26aufirst%3DA.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BS.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DSynergistic%2520interaction%2520between%2520the%2520HDAC%2520inhibitor%252C%2520MPT0E028%252C%2520and%2520sorafenib%2520in%2520liver%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D1274%26epage%3D1287%26doi%3D10.1158%2F1078-0432.CCR-12-3909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greve, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeifer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubbert, M.</span></span> <span> </span><span class="NLM_article-title">The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">947</span>, <span class="refDoi"> DOI: 10.1186/s12885-015-1967-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1186%2Fs12885-015-1967-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=26675484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGls7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=947&author=G.+Greveauthor=I.+Schiffmannauthor=D.+Pfeiferauthor=M.+Panticauthor=J.+Schulerauthor=M.+Lubbert&title=The+pan-HDAC+inhibitor+panobinostat+acts+as+a+sensitizer+for+erlotinib+activity+in+EGFR-mutated+and+-wildtype+non-small+cell+lung+cancer+cells&doi=10.1186%2Fs12885-015-1967-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells</span></div><div class="casAuthors">Greve, Gabriele; Schiffmann, Insa; Pfeifer, Dietmar; Pantic, Milena; Schueler, Julia; Luebbert, Michael</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">947/1-947/10</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in NSCLC.  These mutations can be targeted by RTK inhibitors (TKIs) such as erlotinib.  Chromatin-modifying agents may offer a novel therapeutic approach by sensitizing tumor cells to TKIs.  Methods: The NSCLC cell lines HCC827 (EGFR mutant, adenocarcinoma), A549 (EGFR wt, adenocarcinoma) and NCI-H460 (EGFR wt, large cell carcinoma) were analyzed by SNP6.0 array.  Changes in proliferation after panobinostat (LBH-589, PS) and erlotinib treatment were quantified by WST-1 assay and apoptosis by Annexin V/7-AAD flow cytometry.  Abundance of target proteins and histone marks (acH3, H3K4me1/2/3) was detd. by immunoblotting.  Results: As expected, the EGFR wt cell lines A549 and NCI-H460 were quite insensitive to the growth-inhibitory effect of erlotinib (IC50 70-100 μM), compared to HCC827 (IC50 < 0.02 μM).  All three cell lines were sensitive to PS treatment (IC50: HCC827 10 nM, A549 20 nM and NCI-H460 35 nM).  The combination of both drugs further reduced proliferation in HCC827 and in A549, but not in NCI-H460.  PS alone induced differentiation and expression of p21WAF1/CIP1 and p53 and decreased CHK1 in all three cell lines, with almost no further effect when combined with erlotinib.  In contrast, combination treatment additively decreased pEGFR, pERK and pAKT in A549.  Both drugs synergistically induced acH3 in the adenocarcinoma lines.  Surprisingly, we also obsd. induction of H3K4 methylation marks after erlotinib treatment in HCC827 and in A549 that was further enhanced by combination with PS.  Conclusion: PS sensitized lung adenocarcinoma cells to the antiproliferative effects of erlotinib.  In these cell lines, the drug combination also had a robust, not previously described effect on histone H3 acetylation and H3K4 methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8pg5eIDl-d7Vg90H21EOLACvtfcHk0liQQtOJXt5eDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGls7bK&md5=d1cf2c00537c0b64419e9b00ad3bc935</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1967-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1967-5%26sid%3Dliteratum%253Aachs%26aulast%3DGreve%26aufirst%3DG.%26aulast%3DSchiffmann%26aufirst%3DI.%26aulast%3DPfeifer%26aufirst%3DD.%26aulast%3DPantic%26aufirst%3DM.%26aulast%3DSchuler%26aufirst%3DJ.%26aulast%3DLubbert%26aufirst%3DM.%26atitle%3DThe%2520pan-HDAC%2520inhibitor%2520panobinostat%2520acts%2520as%2520a%2520sensitizer%2520for%2520erlotinib%2520activity%2520in%2520EGFR-mutated%2520and%2520-wildtype%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D947%26doi%3D10.1186%2Fs12885-015-1967-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, S.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated Osimertinib resistance in EGFR-mutant lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3139</span>– <span class="NLM_lpage">3149</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-16-2271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27986747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVSqurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3139-3149&author=A.+Tanimotoauthor=S.+Takeuchiauthor=S.+Araiauthor=K.+Fukudaauthor=T.+Yamadaauthor=X.+Rocaauthor=S.+T.+Ongauthor=S.+Yano&title=Histone+deacetylase+3+inhibition+overcomes+BIM+deletion+polymorphism-mediated+Osimertinib+resistance+in+EGFR-mutant+lung+cancer&doi=10.1158%2F1078-0432.CCR-16-2271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer</span></div><div class="casAuthors">Tanimoto, Azusa; Takeuchi, Shinji; Arai, Sachiko; Fukuda, Koji; Yamada, Tadaaki; Roca, Xavier; Ong, S. Tiong; Yano, Seiji</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3139-3149</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The BIM deletion polymorphism is assocd. with apoptosis resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI), such as gefitinib and erlotinib, in non-small cell lung cancer (NSCLC) harboring EGFR mutations.  Here, we investigated whether the BIM deletion polymorphism contributes to resistance against osimertinib, a third-generation EGFR-TKI.  In addn., we detd. the efficacy of a histone deacetylase (HDAC) inhibitor, vorinostat, against this form of resistance and elucidated the underlying mechanism.  Exptl. Design: We used EGFR-mutated NSCLC cell lines, which were either heterozygous or homozygous for the BIM deletion polymorphism, to evaluate the effect of osimertinib in vitro and in vivo.  Protein expression was examd. by Western blotting.  Alternative splicing of BIM mRNA was analyzed by RT-PCR.  Results: EGFR-mutated NSCLC cell lines with the BIM deletion polymorphism exhibited apoptosis resistance to osimertinib in a polymorphism dosage-dependent manner, and this resistance was overcome by combined use with vorinostat.  Expts. with homozygous BIM deletion-pos. cells revealed that vorinostat affected the alternative splicing of BIM mRNA in the deletion allele, increased the expression of active BIM protein, and thereby induced apoptosis in osimertinib-treated cells.  These effects were mediated predominantly by HDAC3 inhibition.  In xenograft models, combined use of vorinostat with osimertinib could regress tumors in EGFR-mutated NSCLC cells homozygous for the BIM deletion polymorphism.  Moreover, this combination could induce apoptosis even when tumor cells acquired EGFR-T790M mutations.  Conclusions: These findings indicate the importance of developing HDAC3-selective inhibitors, and their combined use with osimertinib, for treating EGFR-mutated lung cancers carrying the BIM deletion polymorphism.  Clin Cancer Res; 23(12); 3139-49. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqawp9knnH7T7Vg90H21EOLACvtfcHk0lgxKHJ3hV19fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVSqurbF&md5=3c08f63c5d8e2860169489294fa87f64</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2271%26sid%3Dliteratum%253Aachs%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DArai%26aufirst%3DS.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DRoca%26aufirst%3DX.%26aulast%3DOng%26aufirst%3DS.%2BT.%26aulast%3DYano%26aufirst%3DS.%26atitle%3DHistone%2520deacetylase%25203%2520inhibition%2520overcomes%2520BIM%2520deletion%2520polymorphism-mediated%2520Osimertinib%2520resistance%2520in%2520EGFR-mutant%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D3139%26epage%3D3149%26doi%3D10.1158%2F1078-0432.CCR-16-2271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilsl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span> <span> </span><span class="NLM_article-title">Generation and assessment of fusions between HDACi and TKi</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1510</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-6527-4_31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1007%2F978-1-4939-6527-4_31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27761839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFCnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1510&publication_year=2017&pages=405-412&author=S.+Mahboobiauthor=B.+Pilslauthor=A.+Sellmer&title=Generation+and+assessment+of+fusions+between+HDACi+and+TKi&doi=10.1007%2F978-1-4939-6527-4_31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Generation and assessment of fusions between HDACi and TKi</span></div><div class="casAuthors">Mahboobi, Siavosh; Pilsl, Bernadette; Sellmer, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1510</span>
        (<span class="NLM_cas:issue">HDAC/HAT Function Assessment and Inhibitor Development</span>),
    <span class="NLM_cas:pages">405-412</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Chimeric compds. combine the structural features of inhibitors of histone deacetylases (HDACi) and tyrosine kinase inhibitors (TKi), and therefore unite the effects of a dual-targeting strategy in one compd.  Here, we describe the generation of such hybrid mols.  Small mols., known as TKi, are combined with a Zn2+ chelating motive, preferentially a hydroxamic acid, in addn.  The resulting small mols. also can inhibit histone deacetylases, which are dependent on the catalytically active Zn2+.  Moreover, we summarize how the growth-inhibitory effects of these combined compds. can be detd. with a simple proliferation assay with a leukemic cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxJ_aSeCzu5LVg90H21EOLACvtfcHk0lgxKHJ3hV19fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFCnsro%253D&md5=f2e6e29292f9c26c5796d848dd39d9c8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-6527-4_31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-6527-4_31%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DPilsl%26aufirst%3DB.%26aulast%3DSellmer%26aufirst%3DA.%26atitle%3DGeneration%2520and%2520assessment%2520of%2520fusions%2520between%2520HDACi%2520and%2520TKi%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2017%26volume%3D1510%26spage%3D405%26epage%3D412%26doi%3D10.1007%2F978-1-4939-6527-4_31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.+X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.+J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDc-101%29+as+a+potent+multi-acting+HDAC%2C+EGFR%2C+and+HER2+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lgxKHJ3hV19fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDc-101%2529%2520as%2520a%2520potent%2520multi-acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munger, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepicelli, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">3647</span>– <span class="NLM_lpage">3656</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.+J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.+G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.+X.+Xuauthor=S.+DellaRoccaauthor=H.+X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0ljuEfKTfeMgwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pursell, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selmi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savagner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span> <span> </span><span class="NLM_article-title">Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">925</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1535-7163.MCT-12-1045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23536719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=925-936&author=J.+Wangauthor=N.+W.+Pursellauthor=M.+E.+Samsonauthor=R.+Atoyanauthor=A.+W.+Maauthor=A.+Selmiauthor=W.+Xuauthor=X.+Caiauthor=M.+Voiauthor=P.+Savagnerauthor=C.+J.+Lai&title=Potential+advantages+of+CUDC-101%2C+a+multitargeted+HDAC%2C+EGFR%2C+and+HER2+inhibitor%2C+in+treating+drug+resistance+and+preventing+cancer+cell+migration+and+invasion&doi=10.1158%2F1535-7163.MCT-12-1045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion</span></div><div class="casAuthors">Wang, Jing; Pursell, Natalie W.; Samson, Maria Elena S.; Atoyan, Ruzanna; Ma, Anna W.; Selmi, Abdelkader; Xu, Wanlu; Cai, Xiong; Voi, Maurizio; Savagner, Pierre; Lai, Cheng-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">925-936</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CUDC-101 is a novel, small-mol., anticancer agent targeting histone deacetylase (HDAC), EGF receptor (EGFR), and HER2.  It is currently in phase I clin. development in patients with solid tumors.  Previously, we reported that CUDC-101 has potent antiproliferative and proapoptotic activity in cultured tumor cells and in vivo xenograft models.  We now show that cancer cells that have acquired resistance to single-target EGFR inhibitors through upregulation of AXL or loss of E-cadherin remain sensitive to CUDC-101, which inhibits MET- and AXL-mediated signaling, restores E-cadherin expression, and reduces cell migration.  CUDC-101 also efficiently inhibited the proliferation of MET-overexpressing non-small cell lung cancer and gastric cancer cell lines and inhibited the migration and invasion of invasive tumor cells.  Taken together, these results suggest that coupling HDAC and HER2 inhibitory activities to an EGFR inhibitor may potentially be effective in overcoming drug resistance and preventing cancer cell migration.  Mol Cancer Ther; 12(6); 925-36. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgzk8IJVCcT7Vg90H21EOLACvtfcHk0ljuEfKTfeMgwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOks70%253D&md5=3d2d647e92c06c6f4c5293c6d0e1285d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPursell%26aufirst%3DN.%2BW.%26aulast%3DSamson%26aufirst%3DM.%2BE.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DSelmi%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DSavagner%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26atitle%3DPotential%2520advantages%2520of%2520CUDC-101%252C%2520a%2520multitargeted%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%252C%2520in%2520treating%2520drug%2520resistance%2520and%2520preventing%2520cancer%2520cell%2520migration%2520and%2520invasion%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D925%26epage%3D936%26doi%3D10.1158%2F1535-7163.MCT-12-1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mays, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laliberte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span> <span> </span><span class="NLM_article-title">Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5032</span>– <span class="NLM_lpage">5040</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-0570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-14-0570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=25107918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5032-5040&author=T.+Shimizuauthor=P.+M.+LoRussoauthor=K.+P.+Papadopoulosauthor=A.+Patnaikauthor=M.+Beeramauthor=L.+S.+Smithauthor=D.+W.+Rascoauthor=T.+A.+Maysauthor=G.+Chambersauthor=A.+Maauthor=J.+Wangauthor=R.+Laliberteauthor=M.+Voiauthor=A.+W.+Tolcher&title=Phase+I+first-in-human+study+of+CUDC-101%2C+a+multitargeted+inhibitor+of+HDACs%2C+EGFR%2C+and+HER2+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-14-0570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Shimizu, Toshio; LoRusso, Patricia M.; Papadopoulos, Kyri P.; Patnaik, Amita; Beeram, Muralidhar; Smith, Lon S.; Rasco, Drew W.; Mays, Theresa A.; Chambers, Glenda; Ma, Anna; Wang, Jing; Laliberte, Robert; Voi, Maurizio; Tolcher, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5032-5040</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This first-in-human phase I study evaluated dose-limiting toxicities (DLT) and defined a phase II recommended dose (RD) for CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 as a 1-h i.v. (i.v.) infusion for 5 consecutive days every 2 wk.  Exptl. Design: Twenty-five patients with advanced solid tumors received escalating doses of CUDC-101 (range, 75-300 mg/m2/day) following a std. 3 + 3 dose escalation design.  Results: The MTD was detd. to be 275 mg/m2.  Common grade 1/2 adverse events included nausea, fatigue, vomiting, dyspnea, pyrexia, and dry skin.  DLTs occurred in 1 patient in the 275-mg/m2 dose cohort (grade 2 serum creatinine elevation, n = 1) and 3 patients in the 300-mg/m2 dose cohort (grade 2 serum creatinine elevation, n = 2; pericarditis, n = 1), all of which were transient and reversible.  CUDC-101 exposure increased linearly with the mean max. concn. (Cmax), clearance (CL), vol. of distribution at steady-state (Vdss), area under curve (AUC), and terminal elimination half-life (t1/2) at the MTD dose of 9.3 mg/L, 51.2 L/h, 39.6 L, 9.95 h·ng/mL and 4.4 h, resp.  Acetylated histone H3 induction was obsd. in posttreatment skin samples from 3 patients in the 275-mg/m2 dose cohort, suggesting adequate systemic exposure and target inhibition.  One patient with gastric cancer had a partial response and 6 patients had stable disease.  Conclusion: CUDC-101 administered by 1-h i.v. infusion for 5 consecutive days every 2 wk was generally well tolerated with preliminary evidence of antitumor activity.  A dose of 275 mg/m2 is recommended for further clin. testing.  Clin Cancer Res; 20(19); 5032-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUrKXLHOzT6LVg90H21EOLACvtfcHk0ljuEfKTfeMgwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzP&md5=62860afa08733980f47047880e11a5ba</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0570%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DL.%2BS.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DMays%26aufirst%3DT.%2BA.%26aulast%3DChambers%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLaliberte%26aufirst%3DR.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DPhase%2520I%2520first-in-human%2520study%2520of%2520CUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520HDACs%252C%2520EGFR%252C%2520and%2520HER2%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5032%26epage%3D5040%26doi%3D10.1158%2F1078-0432.CCR-14-0570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colevas, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saba, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtness, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span> <span> </span><span class="NLM_article-title">A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1573</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-14-2820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=25573383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1566-1573&author=T.+J.+Gallowayauthor=L.+J.+Wirthauthor=A.+D.+Colevasauthor=J.+Gilbertauthor=J.+E.+Baumanauthor=N.+F.+Sabaauthor=D.+Rabenauthor=R.+Mehraauthor=A.+W.+Maauthor=R.+Atoyanauthor=J.+Wangauthor=B.+Burtnessauthor=A.+Jimeno&title=A+phase+I+study+of+CUDC-101%2C+a+multitarget+inhibitor+of+HDACs%2C+EGFR%2C+and+HER2%2C+in+combination+with+chemoradiation+in+patients+with+head+and+neck+squamous+cell+carcinoma&doi=10.1158%2F1078-0432.CCR-14-2820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma</span></div><div class="casAuthors">Galloway, Thomas J.; Wirth, Lori J.; Colevas, Alexander D.; Gilbert, Jill; Bauman, Julie E.; Saba, Nabil F.; Raben, David; Mehra, Ranee; Ma, Anna W.; Atoyan, Ruzanna; Wang, Jing; Burtness, Barbara; Jimeno, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1566-1573</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CUDC-101 is a small mol. that simultaneously inhibits the epidermal growth factor receptor (EGFR), human growth factor receptor 2 (HER2), and histone deacetylase (HDAC) with preclin. activity in head and neck squamous cell cancer (HNSCC).  The primary objective of this investigation is to det. the max. tolerated dose (MTD) of CUDC-101 with cisplatin-radiotherapy in the treatment of HNSCC.  CUDC-101 monotherapy was administered i.v. three times weekly (Monday, Wednesday, Friday) for a one-week run-in, then continued with concurrent cisplatin (100 mg/m2 every 3 wk) and external beam radiation (70 Gy to gross disease) over 7 wk.  Twelve patients with intermediate or high-risk HNSCC enrolled.  Eleven were p16INKa (p16)-neg.  The MTD of CUDC-101-based combination therapy was established at 275 mg/m2/dose.  Five patients discontinued CUDC-101 due to an adverse event (AE); only one was considered a dose-limiting toxicity (DLT), at the MTD.  Pharmacokinetic evaluation suggested low accumulation with this dosing regimen.  HDAC inhibition was demonstrated by pharmacodynamic analyses in peripheral blood mononuclear cells (PBMC), tumor biopsies, and paired skin biopsies.  Paired tumor biopsies demonstrated a trend of EGFR inhibition.  At 1.5 years of median follow-up, there has been one recurrence and two patient deaths (neither attributed to CUDC-101).  The remaining nine patients are free of progression.  CUDC-101, cisplatin, and radiation were feasible in intermediate-/high-risk patients with HNSCC, with no unexpected patterns of AE.  Although the MTD was identified, a high rate of DLT-independent discontinuation of CUDC-101 suggests a need for alternate schedules or routes of administration.  Clin Cancer Res; 21(7); 1566-73. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRDbfIvcyF87Vg90H21EOLACvtfcHk0lj78OUegZq_Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D&md5=dd6b5663ffbf995b5def843a8b8b7556</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2820%26sid%3Dliteratum%253Aachs%26aulast%3DGalloway%26aufirst%3DT.%2BJ.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26aulast%3DGilbert%26aufirst%3DJ.%26aulast%3DBauman%26aufirst%3DJ.%2BE.%26aulast%3DSaba%26aufirst%3DN.%2BF.%26aulast%3DRaben%26aufirst%3DD.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBurtness%26aufirst%3DB.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520CUDC-101%252C%2520a%2520multitarget%2520inhibitor%2520of%2520HDACs%252C%2520EGFR%252C%2520and%2520HER2%252C%2520in%2520combination%2520with%2520chemoradiation%2520in%2520patients%2520with%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1566%26epage%3D1573%26doi%3D10.1158%2F1078-0432.CCR-14-2820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span> <span> </span><span class="NLM_article-title">Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8546</span>– <span class="NLM_lpage">8555</span>, <span class="refDoi"> DOI: 10.1021/jm100665z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100665z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8546-8555&author=S.+Mahboobiauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Novel+chimeric+histone+deacetylase+inhibitors%3A+a+series+of+lapatinib+hybrides+as+potent+inhibitors+of+epidermal+growth+factor+receptor+%28EGFR%29%2C+human+epidermal+growth+factor+receptor+2+%28HER2%29%2C+and+histone+deacetylase+activity&doi=10.1021%2Fjm100665z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrids as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity</span></div><div class="casAuthors">Mahboobi, Siavosh; Sellmer, Andreas; Winkler, Matthias; Eichhorn, Emerich; Pongratz, Herwig; Ciossek, Thomas; Baer, Thomas; Maier, Thomas; Beckers, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8546-8555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reversible lysine-specific acetylation has been described as an important posttranslational modification, regulating chromatin structure and transcriptional activity in the case of core histone proteins.  Histone deacetylases (HDAC) are considered as a promising target for anticancer drug development, with I as pan-HDAC inhibitor approved for cutaneous T-cell lymphoma therapy and several other HDAC inhibitors currently in preclin. and clin. development.  Protein kinases are a well-established target for cancer therapy with the EGFR/HER2 inhibitor II approved for treatment of advanced, HER2 pos. breast cancer as a prominent example.  The present report presents a novel strategy for cancer drug development by combination of EGFR/HER2 kinase and HDAC inhibitory activity in one mol.  By combining the structural features of II with an (E)-3-(aryl)-N-hydroxyacrylamide motif known from HDAC inhibitors like III or IV, selective inhibitors were obtained for both targets with potent cellular activity (target inhibition and cytotoxicity) of selected compds. V (X = m-phenylene, 2,5-furandiyl).  By combining two distinct pharmacol. properties in one mol., a broader activity spectrum is postulated and less likelihood of drug resistance in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEElZRNfAQZ7Vg90H21EOLACvtfcHk0lj78OUegZq_Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I&md5=81bba7c00bb26b42c54075acce5ba525</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm100665z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100665z%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DNovel%2520chimeric%2520histone%2520deacetylase%2520inhibitors%253A%2520a%2520series%2520of%2520lapatinib%2520hybrides%2520as%2520potent%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%252C%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252C%2520and%2520histone%2520deacetylase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8546%26epage%3D8555%26doi%3D10.1021%2Fjm100665z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.bmc.2016.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27769671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=27-37&author=C.+Dingauthor=S.+Chenauthor=C.+Zhangauthor=G.+Huauthor=W.+Zhangauthor=L.+Liauthor=Y.+Z.+Chenauthor=C.+Tanauthor=Y.+Jiang&title=Synthesis+and+investigation+of+novel+6-%281%2C2%2C3-triazol-4-yl%29-4-aminoquinazolin+derivatives+possessing+hydroxamic+acid+moiety+for+cancer+therapy&doi=10.1016%2Fj.bmc.2016.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy</span></div><div class="casAuthors">Ding, Chao; Chen, Shaopeng; Zhang, Cunlong; Hu, Guangnan; Zhang, Wei; Li, Lulu; Chen, Yu Zong; Tan, Chunyan; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">By merging the crit. pharmacophore of EGFR/HER2 and HDAC inhibitors into one compd., a novel series of EGFR, HER-2, and HDAC multitarget inhibitors were synthesized.  Compds. 9a-l contained 4-anilinoquinazolines with C-6 triazole-linked long alkyl chains of hydroxamic acid and displayed excellent inhibition against these enzymes (compd. 9d exhibited the best inhibitory potency on wild-type EGFR, HDAC1, and HDAC6 with IC50 values 0.12 nM, 0.72 nM and 3.2 nM individually).  Furthermore, compds. 9b and 9d potently inhibited proliferation of five human cancer cell lines (with IC50 values between 0.49 and 8.76 μM).  Further mechanistic study revealed that compd. 9d also regulated the phosphorylation of EGFR and HER2 and histone H3 hyperacetylation on the cellular level and induced remarkable apoptosis in BT-474 cells.  Therefore, our study suggested that a system network-based multi-target drug design strategy might provided an alternate drug design method, by taking into account the synergy effect of EGFR, HER-2 and HDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Ow9m5nCSsbVg90H21EOLACvtfcHk0liWOwAuAV5BEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FO&md5=8be7d3dbffe5f5b9b305280864e5b633</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520investigation%2520of%2520novel%25206-%25281%252C2%252C3-triazol-4-yl%2529-4-aminoquinazolin%2520derivatives%2520possessing%2520hydroxamic%2520acid%2520moiety%2520for%2520cancer%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.bmc.2016.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tron, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canonico, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span> <span> </span><span class="NLM_article-title">Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1002/med.20107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1002%2Fmed.20107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=17763363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsVerurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=278-308&author=G.+C.+Tronauthor=T.+Piraliauthor=R.+A.+Billingtonauthor=P.+L.+Canonicoauthor=G.+Sorbaauthor=A.+A.+Genazzani&title=Click+chemistry+reactions+in+medicinal+chemistry%3A+applications+of+the+1%2C3-dipolar+cycloaddition+between+azides+and+alkynes&doi=10.1002%2Fmed.20107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes</span></div><div class="casAuthors">Tron, Gian Cesare; Pirali, Tracey; Billington, Richard A.; Canonico, Pier Luigi; Sorba, Giovanni; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-308</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  In recent years, there has been an ever-increasing need for rapid reactions that meet the three main criteria of an ideal synthesis: efficiency, versatility, and selectivity.  Such reactions would allow medicinal chem. to keep pace with the multitude of information derived from modern biol. screening techniques.  The present review describes one of these reactions, the 1,3-dipolar cycloaddn. ("click-reaction") between azides and alkynes catalyzed by copper (I) salts.  The simplicity of this reaction and the ease of purifn. of the resulting products have opened new opportunities in generating vast arrays of compds. with biol. potential.  The present review will outline the accomplishments of this strategy achieved so far and outline some of medicinal chem. applications in which click-chem. might be relevant in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbqDBrdkhYXrVg90H21EOLACvtfcHk0liWOwAuAV5BEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsVerurg%253D&md5=ef565fc46c50047a6181e85711cb5c37</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fmed.20107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20107%26sid%3Dliteratum%253Aachs%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DBillington%26aufirst%3DR.%2BA.%26aulast%3DCanonico%26aufirst%3DP.%2BL.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DClick%2520chemistry%2520reactions%2520in%2520medicinal%2520chemistry%253A%2520applications%2520of%2520the%25201%252C3-dipolar%2520cycloaddition%2520between%2520azides%2520and%2520alkynes%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2008%26volume%3D28%26spage%3D278%26epage%3D308%26doi%3D10.1002%2Fmed.20107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5137</span>– <span class="NLM_lpage">5141</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.bmcl.2015.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=26475519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GkurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5137-5141&author=F.+W.+Pengauthor=T.+T.+Wuauthor=Z.+W.+Renauthor=J.+Y.+Xueauthor=L.+Shi&title=Hybrids+from+4-anilinoquinazoline+and+hydroxamic+acid+as+dual+inhibitors+of+vascular+endothelial+growth+factor+receptor-2+and+histone+deacetylase&doi=10.1016%2Fj.bmcl.2015.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase</span></div><div class="casAuthors">Peng, Fan-Wei; Wu, Ting-Ting; Ren, Zi-Wei; Xue, Jia-Yu; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5137-5141</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of hybrids derived from 4-anilinoquinazoline and hydroxamic acid were designed, synthesized, and evaluated as dual inhibitors of vascular endothelia growth factor receptor-2 (VEGFR-2) tyrosine kinase and histone deacetylase (HDAC).  Most of these compds. exhibited potent HDAC inhibition and moderate VEGFR-2 inhibition.  Among them, compd. I exhibited the most potent inhibitory activities against VEGFR-2 (IC50 = 84 nM) and HDAC (IC50 = 2.8 nM).  It also showed the most potent antiproliferative ability against MCF-7, a human breast cancer line, with IC50 of 1.2 μM.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction of compd. I at the active binding sites of VEGFR-2 and HDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojSWQqbu8Qg7Vg90H21EOLACvtfcHk0liWOwAuAV5BEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GkurfI&md5=f20d34f8da22e171419b48299e253fb8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DHybrids%2520from%25204-anilinoquinazoline%2520and%2520hydroxamic%2520acid%2520as%2520dual%2520inhibitors%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520and%2520histone%2520deacetylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5137%26epage%3D5141%26doi%3D10.1016%2Fj.bmcl.2015.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ejmech.2015.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=26741358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=1-12&author=F.+W.+Pengauthor=J.+Xuanauthor=T.+T.+Wuauthor=J.+Y.+Xueauthor=Z.+W.+Renauthor=D.+K.+Liuauthor=X.+Q.+Wangauthor=X.+H.+Chenauthor=J.+W.+Zhangauthor=Y.+G.+Xuauthor=L.+Shi&title=Design%2C+synthesis+and+biological+evaluation+of+N-phenylquinazolin-4-amine+hybrids+as+dual+inhibitors+of+VEGFR-2+and+HDAC&doi=10.1016%2Fj.ejmech.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span></div><div class="casAuthors">Peng, Fan-Wei; Xuan, Ji; Wu, Ting-Ting; Xue, Jia-Yu; Ren, Zi-Wei; Liu, Da-Ke; Wang, Xiu-Qi; Chen, Xin-Hang; Zhang, Jia-Wei; Xu, Yun-Gen; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, a series of hybrids bearing N-phenylquinazolin-4-amine and hydroxamic acid moieties I (R1, R2 = H, F, Cl, Br, n = 2, 3, 4, 5) were designed and identified as dual VEGFR-2/HDAC inhibitors.  Compd. I (R1 = H, R2 = Br, n = 5) exhibited the most potent inhibitory activity against HDAC with IC50 of 2.2 nM and strong inhibitory effect against VEGFR-2 with IC50 of 74 nM.  It also showed the most potent inhibitory activity against a human breast cancer cell line MCF-7 with IC50 of 0.85 μM.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the active binding sites of VEGFR-2 and HDLP (Histone Deacetylase-Like Protein), which demonstrates that compd. I (R1 = H, R2 = Br, n = 5) is a potential agent for cancer therapy deserving further researching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_jbaom_UR7Vg90H21EOLACvtfcHk0lhOUHzpka0nKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOj&md5=1a0c299ec484daa522da5969e8a35cec</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DXuan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DLiu%26aufirst%3DD.%2BK.%26aulast%3DWang%26aufirst%3DX.%2BQ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DXu%26aufirst%3DY.%2BG.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520N-phenylquinazolin-4-amine%2520hybrids%2520as%2520dual%2520inhibitors%2520of%2520VEGFR-2%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.ejmech.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowska, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartelink, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cripps, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastroserio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of Abexinostat plus Pazopanib in advanced solid tumor malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1239</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.70.5350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1200%2FJCO.2016.70.5350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=28221861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFGrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=1231-1239&author=R.+Aggarwalauthor=S.+Thomasauthor=N.+Pawlowskaauthor=I.+Bartelinkauthor=J.+Grabowskyauthor=T.+Jahanauthor=A.+Crippsauthor=A.+Harbauthor=J.+Lengauthor=A.+Reinertauthor=I.+Mastroserioauthor=T.+G.+Truongauthor=C.+J.+Ryanauthor=P.+N.+Munster&title=Inhibiting+histone+deacetylase+as+a+means+to+reverse+resistance+to+angiogenesis+inhibitors%3A+phase+I+study+of+Abexinostat+plus+Pazopanib+in+advanced+solid+tumor+malignancies&doi=10.1200%2FJCO.2016.70.5350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of abexinostat plus pazopanib in advanced solid tumor malignancies</span></div><div class="casAuthors">Aggarwal, Rahul; Thomas, Scott; Pawlowska, Nela; Bartelink, Imke; Grabowsky, Jennifer; Jahan, Thierry; Cripps, Amy; Harb, Armand; Leng, Jim; Reinert, Anne; Mastroserio, Ilaria; Truong, Thach-Giao; Ryan, Charles J.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1231-1239,S1-S2</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor by using a histone deacetylase abexinostat in combination with pazopanib to enhance response and reverse resistance.  Patients and Methods: Pazopanib was administered once a day on days 1 to 28 and abexinostat was administered orally twice a day on days 1 to 5, 8 to 12, and 15 to 19 (schedule A) or on days 1 to 4, 8 to 11, and 15 to 18 (schedule B).  Dose escalation (3 + 3 design) in all solid tumors was followed by dose expansion in renal cell carcinoma (RCC).  Results: Fifty-one patients with RCC (N = 22) were enrolled, including 30 (59%) with one or more lines of prior VEGF-targeting therapy.  Five dose-limiting toxicities, including fatigue (n = 2), thrombocytopenia (n = 2), and elevated AST/ALT (n = 1), were obsd. with schedule A; one dose-limiting toxicity was obsd. (elevated AST/ALT) was obsd. with schedule B.  Grade ≥ 3 related adverse events included fatigue (16%), thrombocytopenia (16%), and neutropenia (10%).  The recommended phase II dose was established as abexinostat 45 mg/m2 twice a day administered per schedule B plus pazopanib 800 mg/d.  Objective response rate was 21% overall and 27% in the RCC subset.  Median duration of response was 9.1 mo (1.2 to > 49 mo).  Eight patients (16%) had durable control of disease for > 12 mo.  Durable tumor regressions were obsd. in seven (70%) of 10 patients with pazopanib-refractory disease, including one patients with RCC with ongoing response > 3.5 years.  Peripheral blood histone acetylation and HDAC2 gene expression were assocd. with durable response to treatment.  Conclusion: Abexinostat is well tolerated in combination with pazopanib, allowing prolonged exposure and promising durable responses in pazopanib- and other VEGF inhibitor-refractory tumors, which supports epigenetically mediated reversal of treatment resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotzop0Tif1NLVg90H21EOLACvtfcHk0lhOUHzpka0nKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFGrt7Y%253D&md5=31cf19bad52faca73593d583c71e4a6f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.70.5350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.70.5350%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DPawlowska%26aufirst%3DN.%26aulast%3DBartelink%26aufirst%3DI.%26aulast%3DGrabowsky%26aufirst%3DJ.%26aulast%3DJahan%26aufirst%3DT.%26aulast%3DCripps%26aufirst%3DA.%26aulast%3DHarb%26aufirst%3DA.%26aulast%3DLeng%26aufirst%3DJ.%26aulast%3DReinert%26aufirst%3DA.%26aulast%3DMastroserio%26aufirst%3DI.%26aulast%3DTruong%26aufirst%3DT.%2BG.%26aulast%3DRyan%26aufirst%3DC.%2BJ.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DInhibiting%2520histone%2520deacetylase%2520as%2520a%2520means%2520to%2520reverse%2520resistance%2520to%2520angiogenesis%2520inhibitors%253A%2520phase%2520I%2520study%2520of%2520Abexinostat%2520plus%2520Pazopanib%2520in%2520advanced%2520solid%2520tumor%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D1231%26epage%3D1239%26doi%3D10.1200%2FJCO.2016.70.5350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel Pazopanib-based HDAC and VEGFR dual inhibitors targeting cancer epigenetics and angiogenesis simultaneously</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5304</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00384</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00384" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5304-5322&author=J.+Zangauthor=X.+Liangauthor=Y.+Huangauthor=Y.+Jiaauthor=X.+Liauthor=W.+Xuauthor=C.+J.+Chouauthor=Y.+Zhang&title=Discovery+of+novel+Pazopanib-based+HDAC+and+VEGFR+dual+inhibitors+targeting+cancer+epigenetics+and+angiogenesis+simultaneously&doi=10.1021%2Facs.jmedchem.8b00384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously</span></div><div class="casAuthors">Zang, Jie; Liang, Xuewu; Huang, Yongxue; Jia, Yuping; Li, Xiaoyang; Xu, Wenfang; Chou, C. James; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5304-5322</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein a novel series of pazopanib hybrids as polypharmacol. antitumor agents were developed based on the crosstalk between histone deacetylases (HDACs) and vascular endothelial growth factor (VEGF) pathway.  Among them, one ortho-aminoanilide 6d and one hydroxamic acid 13f exhibited considerable total HDACs and VEGFR-2 inhibitory activities.  The HDAC inhibitory activities endowed 6d and 13f with potent antiproliferative activities, which was not obsd. in the approved VEGFR inhibitor pazopanib.  Compds. 6d and 13f possessed comparable HDAC isoform selectivity profiles to the clin. class I HDAC inhibitor MS-275 and the approved pan-HDAC inhibitor SAHA, resp. 6d and 13f also exhibited uncompromised multiple tyrosine kinases inhibitory activities relative to pazopanib.  The intracellular dual inhibition to HDAC and VEGFR of 6d and 13f was validated by Western blot anal.  In both HUVECs tube formation assay and rat thoracic aorta rings assay, 6d and 13f showed comparable antiangiogenic potencies to pazopanib.  What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpmz6rwKiKSbVg90H21EOLACvtfcHk0lhOUHzpka0nKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D&md5=437da0a6cca1ec211219aef87a6ddbc5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520Pazopanib-based%2520HDAC%2520and%2520VEGFR%2520dual%2520inhibitors%2520targeting%2520cancer%2520epigenetics%2520and%2520angiogenesis%2520simultaneously%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5304%26epage%3D5322%26doi%3D10.1021%2Facs.jmedchem.8b00384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokudo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2011.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.phrs.2011.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=22138044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ont7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2012&pages=23-30&author=J.+Gaoauthor=Y.+Inagakiauthor=P.+Songauthor=X.+Quauthor=N.+Kokudoauthor=W.+Tang&title=Targeting+c-Met+as+a+promising+strategy+for+the+treatment+of+hepatocellular+carcinoma&doi=10.1016%2Fj.phrs.2011.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma</span></div><div class="casAuthors">Gao, Jianjun; Inagaki, Yoshinori; Song, Peipei; Qu, Xianjun; Kokudo, Norihiro; Tang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-30</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Hepatocellular carcinoma (HCC) is a severe condition that is found worldwide.  Liver transplantation, surgical resection, and local-regional therapy such as transarterial chemoembolization have made great progress and play a dominant role in HCC management.  However, the high frequency of tumor recurrence and/or metastasis after those treatments acquires systematic drug intervention.  The approval of sorafenib, an agent that targets receptor tyrosine kinases (RTKs), as the first effective drug for systemic treatment of HCC represents a milestone in treatment of this disease.  As a typical member of the RTK family, c-Met represents an intriguing target for cancer therapy.  However, the role of the c-Met signal transduction pathway is less unambiguous in HCC pathol., giving rise to concerns about the feasibility of utilizing c-Met targeting approaches for HCC treatment.  Recently, studies on des-γ-carboxy prothrombin, an abnormal cytokine secreted by HCC cells, by the current authors and other researchers have highlighted the crit. role of c-Met signaling in HCC progression.  This review takes a second look at the c-Met signal transduction pathway and discusses the possibility of targeting c-Met as a therapeutic strategy for HCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-B1kalo8HrVg90H21EOLACvtfcHk0ljAN_qL8GoZjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ont7Y%253D&md5=1d65fc77f0d54bfe803a968923da0175</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2011.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2011.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DInagaki%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DP.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DKokudo%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DTargeting%2520c-Met%2520as%2520a%2520promising%2520strategy%2520for%2520the%2520treatment%2520of%2520hepatocellular%2520carcinoma%26jtitle%3DPharmacol.%2520Res.%26date%3D2012%26volume%3D65%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.phrs.2011.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okuma, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, S.</span></span> <span> </span><span class="NLM_article-title">Trends in the development of MET inhibitors for hepatocellular carcinoma</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1275</span>– <span class="NLM_lpage">1286</span>, <span class="refDoi"> DOI: 10.2217/fon.16.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.2217%2Ffon.16.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=26984595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVams7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1275-1286&author=H.+S.+Okumaauthor=S.+Kondo&title=Trends+in+the+development+of+MET+inhibitors+for+hepatocellular+carcinoma&doi=10.2217%2Ffon.16.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in the development of MET inhibitors for hepatocellular carcinoma</span></div><div class="casAuthors">Okuma, Hitomi S.; Kondo, Shunsuke</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1275-1286</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Hepatocellular carcinoma is the third most common cause of cancer-related deaths worldwide.  The multikinase inhibitor sorafenib has improved survival and is now considered the std. of care; however, the benefits are still disappointing, and thus, new effective treatments are required.  In human hepatocellular carcinoma, MET, which is encoded by the HGFR gene, is activated by amplification, overexpression or mutation, and it has recently emerged as a possible therapeutic target in various tumors including hepatocellular carcinoma.  In fact, some drugs targeting the HGF/MET axis are currently under investigation in clin. trials.  Here, we review the role of MET and trends in the development of MET inhibitors for hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUR8t9UYovhLVg90H21EOLACvtfcHk0ljAN_qL8GoZjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVams7s%253D&md5=903c7e0a8977fc82c4f72f6f5fd6b666</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2217%2Ffon.16.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.16.3%26sid%3Dliteratum%253Aachs%26aulast%3DOkuma%26aufirst%3DH.%2BS.%26aulast%3DKondo%26aufirst%3DS.%26atitle%3DTrends%2520in%2520the%2520development%2520of%2520MET%2520inhibitors%2520for%2520hepatocellular%2520carcinoma%26jtitle%3DFuture%2520Oncol.%26date%3D2016%26volume%3D12%26spage%3D1275%26epage%3D1286%26doi%3D10.2217%2Ffon.16.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bahrami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidsales, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghayour-Mobarhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maftouh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassanian, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avan, A.</span></span> <span> </span><span class="NLM_article-title">C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">2657</span>– <span class="NLM_lpage">2673</span>, <span class="refDoi"> DOI: 10.1002/jcp.25794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1002%2Fjcp.25794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=28075018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslyhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2017&pages=2657-2673&author=A.+Bahramiauthor=S.+Shahidsalesauthor=M.+Khazaeiauthor=M.+Ghayour-Mobarhanauthor=M.+Maftouhauthor=S.+M.+Hassanianauthor=A.+Avan&title=C-Met+as+a+potential+target+for+the+treatment+of+gastrointestinal+cancer%3A+Current+status+and+future+perspectives&doi=10.1002%2Fjcp.25794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives</span></div><div class="casAuthors">Bahrami, Afsane; Shahidsales, Soodabeh; Khazaei, Majid; Ghayour-Mobarhan, Majid; Maftouh, Mina; Hassanian, Seyed Mahdi; Avan, Amir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2657-2673</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aberrant activation of the HGF/c-Met signalling pathways is shown to be related with cell proliferation, progression, metastasis, and worse prognosis in several tumor types, including gastrointestinal cancers, suggesting its value as a stimulating-target for cancer-therapy.  Several approaches have been developed for targeting HGF and/or c-Met, and one of them, crizotinib (dual c-Met/ALK inhibitor), is recently been approved by FDA for lung-cancers with ALK-rearrangement.  The main aim of current review is to give an overview on the role of c-Met/HGF pathway in gastrointestinal cancer, in preclin. and clin. trials.  Although several important matters is still remained to be elucidated on the mol. pathways underlying the antitumor effects of this therapy in gastrointestinal-cancers.  Further investigations are warranted to recognize the main determinants of the activity of c-Met inhibitors, for parallel targeting signalling pathway assocd./activated via MET/HGF pathway or in response to the cell resistance to anti-c-Met agents.  Addnl., identification of patients that might benefit from therapy could help to increase the selectivity and efficacy of the therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2qJr0yS7y1rVg90H21EOLACvtfcHk0ljAN_qL8GoZjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslyhsrw%253D&md5=3eeaa30bae8c45950c12cc31024959a1</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fjcp.25794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.25794%26sid%3Dliteratum%253Aachs%26aulast%3DBahrami%26aufirst%3DA.%26aulast%3DShahidsales%26aufirst%3DS.%26aulast%3DKhazaei%26aufirst%3DM.%26aulast%3DGhayour-Mobarhan%26aufirst%3DM.%26aulast%3DMaftouh%26aufirst%3DM.%26aulast%3DHassanian%26aufirst%3DS.%2BM.%26aulast%3DAvan%26aufirst%3DA.%26atitle%3DC-Met%2520as%2520a%2520potential%2520target%2520for%2520the%2520treatment%2520of%2520gastrointestinal%2520cancer%253A%2520Current%2520status%2520and%2520future%2520perspectives%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2017%26volume%3D232%26spage%3D2657%26epage%3D2673%26doi%3D10.1002%2Fjcp.25794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warbrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vojtesk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D. P.</span></span> <span> </span><span class="NLM_article-title">Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.18632%2Foncotarget.1075" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1019-1036&author=J.+S.+Wongauthor=E.+Warbrickauthor=B.+Vojteskauthor=J.+Hillauthor=D.+P.+Lane&title=Anti-c-Met+antibodies+recognising+a+temperature+sensitive+epitope%2C+inhibit+cell+growth&doi=10.18632%2Foncotarget.1075"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1075%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DJ.%2BS.%26aulast%3DWarbrick%26aufirst%3DE.%26aulast%3DVojtesk%26aufirst%3DB.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DD.%2BP.%26atitle%3DAnti-c-Met%2520antibodies%2520recognising%2520a%2520temperature%2520sensitive%2520epitope%252C%2520inhibit%2520cell%2520growth%26jtitle%3DOncotarget%26date%3D2013%26volume%3D4%26spage%3D1019%26epage%3D1036%26doi%3D10.18632%2Foncotarget.1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetsch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oleksijew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boghaert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappano, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhathena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naumovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvaia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, E. B.</span></span> <span> </span><span class="NLM_article-title">Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.1186/s12885-016-2138-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1186%2Fs12885-016-2138-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=26879245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisFWmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=105&author=J.+Wangauthor=L.+Goetschauthor=L.+Tuckerauthor=Q.+Zhangauthor=A.+Gonzalezauthor=K.+S.+Vaidyaauthor=A.+Oleksijewauthor=E.+Boghaertauthor=M.+Songauthor=I.+Sokolovaauthor=E.+Pestovaauthor=M.+Andersonauthor=W.+N.+Pappanoauthor=P.+Ansellauthor=A.+Bhathenaauthor=L.+Naumovskiauthor=N.+Corvaiaauthor=E.+B.+Reilly&title=Anti-c-Met+monoclonal+antibody+ABT-700+breaks+oncogene+addiction+in+tumors+with+MET+amplification&doi=10.1186%2Fs12885-016-2138-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification</span></div><div class="casAuthors">Wang, Jieyi; Goetsch, Liliane; Tucker, Lora; Zhang, Qian; Gonzalez, Alexandra; Vaidya, Kedar S.; Oleksijew, Anatol; Boghaert, Erwin; Song, Minghao; Sokolova, Irina; Pestova, Ekaterina; Anderson, Mark; Pappano, William N.; Ansell, Peter; Bhathena, Anahita; Naumovski, Louie; Corvaia, Nathalie; Reilly, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105/1-105/14</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: c-Met is the receptor tyrosine kinase for hepatocyte growth factor (HGF) encoded by the MET proto-oncogene.  Aberrant activation of c-Met resulting from MET amplification and c-Met overexpression is assocd. with poor clin. outcome in multiple malignancies underscoring the importance of c-Met signaling in cancer progression.  Several c-Met inhibitors have advanced to the clinic; however, the development of inhibitory c-Met-directed therapeutic antibodies has been hampered by inherent agonistic activity.  Method: We generated and tested a bivalent anti-c-Met monoclonal antibody ABT-700 in vitro for binding potency and antagonistic activity and in vivo for antitumor efficacy in human tumor xenografts.  Human cancer cell lines and gastric cancer tissue microarrays were examd. for MET amplification by fluorescence in situ hybridization (FISH).  Results: ABT-700 exhibits a distinctive ability to block both HGF-independent constitutive c-Met signaling and HGF-dependent activation of c-Met.  Cancer cells addicted to the constitutively activated c-Met signaling driven by MET amplification undergo apoptosis upon exposure to ABT-700.  ABT-700 induces tumor regression and tumor growth delay in preclin. tumor models of gastric and lung cancers harboring amplified MET.  ABT-700 in combination with chemotherapeutics also shows additive antitumor effect.  Amplification of MET in human cancer tissues can be identified by FISH.  Conclusions: The preclin. attributes of ABT-700 in blocking c-Met signaling, inducing apoptosis and suppressing tumor growth in cancers with amplified MET provide rationale for examg. its potential clin. utility for the treatment of cancers harboring MET amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotNem_0ds2IbVg90H21EOLACvtfcHk0ljBUc7WJWYyUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisFWmtL8%253D&md5=d7fc415d4f21e39d3f112511fcc38e5f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1186%2Fs12885-016-2138-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-016-2138-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DTucker%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGonzalez%26aufirst%3DA.%26aulast%3DVaidya%26aufirst%3DK.%2BS.%26aulast%3DOleksijew%26aufirst%3DA.%26aulast%3DBoghaert%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DSokolova%26aufirst%3DI.%26aulast%3DPestova%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DPappano%26aufirst%3DW.%2BN.%26aulast%3DAnsell%26aufirst%3DP.%26aulast%3DBhathena%26aufirst%3DA.%26aulast%3DNaumovski%26aufirst%3DL.%26aulast%3DCorvaia%26aufirst%3DN.%26aulast%3DReilly%26aufirst%3DE.%2BB.%26atitle%3DAnti-c-Met%2520monoclonal%2520antibody%2520ABT-700%2520breaks%2520oncogene%2520addiction%2520in%2520tumors%2520with%2520MET%2520amplification%26jtitle%3DBMC%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D105%26doi%3D10.1186%2Fs12885-016-2138-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">c-MET kinase inhibitors: a patent review (2011 - 2013)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.864279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1517%2F13543776.2014.864279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24266843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=217-230&author=K.+Zhuauthor=X.+Kongauthor=D.+Zhaoauthor=Z.+Liangauthor=C.+Luo&title=c-MET+kinase+inhibitors%3A+a+patent+review+%282011+-+2013%29&doi=10.1517%2F13543776.2014.864279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">c-MET kinase inhibitors: a patent review (2011 - 2013)</span></div><div class="casAuthors">Zhu, Kongkai; Kong, Xiangqian; Zhao, Dan; Liang, Zhongjie; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-230</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The receptor tyrosine kinase c-MET displays aberrant activation in the malignant phenotype of various tumors, and thus, has drawn considerable attention as drug target for cancer therapy.  Many c-MET inhibitors are now under clin. investment, and one of them - Cabozantinib - has been approved by US FDA in 2012 for the treatment of medullary thyroid cancer, which further proved the feasibility of c-MET inhibition method in cancer therapy.  Areas covered: This article briefly outlines the role of c-MET in oncogenesis and provides a broad overview of the assays used to characterize new inhibitors.  Then, a series of representative small-mol. inhibitors of c-MET, esp. from the published patent literature from 2011 to 2013, are recorded.  Herein, the challenges in the kinase inhibitor design, such as the inhibitor selectivity and resistance mutations, are also discussed.  Expert opinion: Up to now, at least 17 inhibitors of c-MET are under clin. evaluation, and several agents exhibit encouraging results.  Thus, inhibiting c-MET signaling has major therapeutic value in cancer therapy.  Focus on the selectivity of both types of inhibitors, with potent selectivity or multi-targets, have demonstrated antitumor efficacy.  The network pharmacol. and clin. trials integrated would provide powerful tools to further evaluate the superiority of both inhibitors in continued efficacy and toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQQxUsT3aF2LVg90H21EOLACvtfcHk0ljBUc7WJWYyUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlWgug%253D%253D&md5=1408de34b8567924107b45a0765ad60d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.864279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.864279%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3Dc-MET%2520kinase%2520inhibitors%253A%2520a%2520patent%2520review%2520%25282011%2520-%25202013%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D217%26epage%3D230%26doi%3D10.1517%2F13543776.2014.864279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimassa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borbath, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvagni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laethem, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Vlierberghe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolligs, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasbarrini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lencioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicalese, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gridelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggisch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerken, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Personeni, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassoun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadessa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Roemeling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamar, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span> <span> </span><span class="NLM_article-title">Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(12)70490-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2FS1470-2045%2812%2970490-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23182627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2nug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=55-63&author=A.+Santoroauthor=L.+Rimassaauthor=I.+Borbathauthor=B.+Danieleauthor=S.+Salvagniauthor=J.+L.+Van+Laethemauthor=H.+Van+Vlierbergheauthor=J.+Trojanauthor=F.+T.+Kolligsauthor=A.+Weissauthor=S.+Milesauthor=A.+Gasbarriniauthor=M.+Lencioniauthor=L.+Cicaleseauthor=M.+Shermanauthor=C.+Gridelliauthor=P.+Buggischauthor=G.+Gerkenauthor=R.+M.+Schmidauthor=C.+Boniauthor=N.+Personeniauthor=Z.+Hassounauthor=G.+Abbadessaauthor=B.+Schwartzauthor=R.+Von+Roemelingauthor=M.+E.+Lamarauthor=Y.+Chenauthor=C.+Porta&title=Tivantinib+for+second-line+treatment+of+advanced+hepatocellular+carcinoma%3A+a+randomised%2C+placebo-controlled+phase+2+study&doi=10.1016%2FS1470-2045%2812%2970490-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study</span></div><div class="casAuthors">Santoro, Armando; Rimassa, Lorenza; Borbath, Ivan; Daniele, Bruno; Salvagni, Stefania; Van Laethem, Jean Luc; Van Vlierberghe, Hans; Trojan, Joerg; Kolligs, Frank T.; Weiss, Alan; Miles, Steven; Gasbarrini, Antonio; Lencioni, Monica; Cicalese, Luca; Sherman, Morris; Gridelli, Cesare; Buggisch, Peter; Gerken, Guido; Schmid, Roland M.; Boni, Corrado; Personeni, Nicola; Hassoun, Ziad; Abbadessa, Giovanni; Schwartz, Brian; Von Roemeling, Reinhard; Lamar, Maria E.; Chen, Yinpu; Porta, Camillo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-63</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumor activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib.  We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma.  Methods: In this completed, multicenter, randomized, placebo-controlled, double-blind, phase 2 study, we enrolled patients with advanced hepatocellular carcinoma and Child-Pugh A cirrhosis who had progressed on or were unable to tolerate first-line systemic therapy.  We randomly allocated patients 2:1 to receive tivantinib (360 mg twice-daily) or placebo until disease progression.  The tivantinib dose was amended to 240 mg twice-daily because of high incidence of treatment-emergent grade 3 or worse neutropenia.  Randomisation was done centrally by an interactive voice-response system, stratified by Eastern Cooperative Oncol. Group performance status and vascular invasion.  The primary endpoint was time to progression, according to independent radiol. review in the intention-to-treat population.  We assessed tumor samples for MET expression with immunohistochem. (high expression was regarded as ≥2+ in ≥50% of tumor cells).  This study is registered with ClinicalTrials.gov, no. NCT00988741.  Findings: 71 patients were randomly assigned to receive tivantinib (38 at 360 mg twice-daily and 33 at 240 mg twice-daily); 36 patients were randomly assigned to receive placebo.  At the time of anal., 46 (65%) patients in the tivantinib group and 26 (72%) of those in the placebo group had progressive disease.  Time to progression was longer for patients treated with tivantinib (1·6 mo [95% CI 1·4-2·8]) than placebo (1·4 mo [1·4-1·5]; hazard ratio [HR] 0·64, 90% CI 0·43-0·94; p=0·04).  For patients with MET-high tumors, median time to progression was longer with tivantinib than for those on placebo (2·7 mo [95% CI 1·4-8·5] for 22 MET-high patients on tivantinib vs 1·4 mo [1·4-1·6] for 15 MET-high patients on placebo; HR 0·43, 95% CI 0·19-0·97; p=0·03).  The most common grade 3 or worse adverse events in the tivantinib group were neutropenia (ten patients [14%] vs none in the placebo group) and anemia (eight [11%] vs none in the placebo group).  Eight patients (21%) in the tivantinib 360 mg group had grade 3 or worse neutropenia compared with two (6%) patients in the 240 mg group.  Four deaths related to tivantinib occurred from severe neutropenia. 24 (34%) patients in the tivantinib group and 14 (39%) patients in the placebo group had serious adverse events.  Interpretation: Tivantinib could provide an option for second-line treatment of patients with advanced hepatocellular carcinoma and well-compensated liver cirrhosis, particularly for patients with MET-high tumors.  Confirmation in a phase 3 trial is needed, with a starting dose of tivantinib 240 mg twice-daily.  Funding: ArQule, Daiichi Sankyo (Daiichi Sankyo Group).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQJjnKdNvQorVg90H21EOLACvtfcHk0ljBUc7WJWYyUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2nug%253D%253D&md5=a2d552b7cd69b578b76962d015bfac2a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970490-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970490-4%26sid%3Dliteratum%253Aachs%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DRimassa%26aufirst%3DL.%26aulast%3DBorbath%26aufirst%3DI.%26aulast%3DDaniele%26aufirst%3DB.%26aulast%3DSalvagni%26aufirst%3DS.%26aulast%3DVan%2BLaethem%26aufirst%3DJ.%2BL.%26aulast%3DVan%2BVlierberghe%26aufirst%3DH.%26aulast%3DTrojan%26aufirst%3DJ.%26aulast%3DKolligs%26aufirst%3DF.%2BT.%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DMiles%26aufirst%3DS.%26aulast%3DGasbarrini%26aufirst%3DA.%26aulast%3DLencioni%26aufirst%3DM.%26aulast%3DCicalese%26aufirst%3DL.%26aulast%3DSherman%26aufirst%3DM.%26aulast%3DGridelli%26aufirst%3DC.%26aulast%3DBuggisch%26aufirst%3DP.%26aulast%3DGerken%26aufirst%3DG.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26aulast%3DBoni%26aufirst%3DC.%26aulast%3DPersoneni%26aufirst%3DN.%26aulast%3DHassoun%26aufirst%3DZ.%26aulast%3DAbbadessa%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DVon%2BRoemeling%26aufirst%3DR.%26aulast%3DLamar%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DPorta%26aufirst%3DC.%26atitle%3DTivantinib%2520for%2520second-line%2520treatment%2520of%2520advanced%2520hepatocellular%2520carcinoma%253A%2520a%2520randomised%252C%2520placebo-controlled%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D55%26epage%3D63%26doi%3D10.1016%2FS1470-2045%2812%2970490-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lachenmayer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toffanin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabellos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsinet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minguez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llovet, J. M.</span></span> <span> </span><span class="NLM_article-title">Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1343</span>– <span class="NLM_lpage">1350</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2012.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.jhep.2012.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=22322234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt12mtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=1343-1350&author=A.+Lachenmayerauthor=S.+Toffaninauthor=L.+Cabellosauthor=C.+Alsinetauthor=Y.+Hoshidaauthor=A.+Villanuevaauthor=B.+Minguezauthor=H.+W.+Tsaiauthor=S.+C.+Wardauthor=S.+Thungauthor=S.+L.+Friedmanauthor=J.+M.+Llovet&title=Combination+therapy+for+hepatocellular+carcinoma%3A+additive+preclinical+efficacy+of+the+HDAC+inhibitor+panobinostat+with+sorafenib&doi=10.1016%2Fj.jhep.2012.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib</span></div><div class="casAuthors">Lachenmayer, Anja; Toffanin, Sara; Cabellos, Laia; Alsinet, Clara; Hoshida, Yujin; Villanueva, Augusto; Minguez, Beatriz; Tsai, Hung-Wen; Ward, Stephen C.; Thung, Swan; Friedman, Scott L.; Llovet, Josep M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1343-1350</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy.  Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is still unknown.  We analyzed the expression of 11 HDACs in human HCCs and assessed the efficacy of the pan-HDAC inhibitor panobinostat alone and in combination with sorafenib in preclin. models of liver cancer.  Methods: Gene expression and copy no. changes were analyzed in a cohort of 334 human HCCs, while the effects of panobinostat and sorafenib were evaluated in three liver cancer cell lines and a murine xenograft model.  Results: Aberrant HDAC expression was identified and validated in 91 and 243 HCCs, resp.  Upregulation of HDAC3 and HDAC5 mRNAs was significantly correlated with DNA copy no. gains.  Inhibiting HDACs with panobinostat led to strong anti-tumoral effects in vitro and vivo, enhanced by the addn. of sorafenib.  Cell viability and proliferation declined, while apoptosis and autophagy increased.  Panobinostat increased histone H3 and HSP90 acetylation, downregulated BIRC5 (survivin) and upregulated CDH1.  Combination therapy with panobinostat and sorafenib significantly decreased vessel d., and most significantly decreased tumor vol. and increased survival in HCC xenografts.  Conclusions: Aberrant expression of several HDACs and copy no. gains of HDAC3 and HDAC5 occur in HCC.  Treatment with panobinostat combined with sorafenib demonstrated the highest preclin. efficacy in HCC models, providing the rationale for clin. studies with this novel combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZoC3lwqUXBrVg90H21EOLACvtfcHk0lgPMq-d3uJPMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt12mtrc%253D&md5=ac47fb06e16c2b7ec1f4c868a983b752</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DLachenmayer%26aufirst%3DA.%26aulast%3DToffanin%26aufirst%3DS.%26aulast%3DCabellos%26aufirst%3DL.%26aulast%3DAlsinet%26aufirst%3DC.%26aulast%3DHoshida%26aufirst%3DY.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DMinguez%26aufirst%3DB.%26aulast%3DTsai%26aufirst%3DH.%2BW.%26aulast%3DWard%26aufirst%3DS.%2BC.%26aulast%3DThung%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DS.%2BL.%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26atitle%3DCombination%2520therapy%2520for%2520hepatocellular%2520carcinoma%253A%2520additive%2520preclinical%2520efficacy%2520of%2520the%2520HDAC%2520inhibitor%2520panobinostat%2520with%2520sorafenib%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D56%26spage%3D1343%26epage%3D1350%26doi%3D10.1016%2Fj.jhep.2012.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>436</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2013.05.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.bbrc.2013.05.088" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2013&pages=259-264&author=X.+Liauthor=Y.+Zhuauthor=H.+Heauthor=L.+Louauthor=W.+Yeauthor=Y.+Chenauthor=J.+Wang&title=Synergistically+killing+activity+of+aspirin+and+histone+deacetylase+inhibitor+valproic+acid+%28VPA%29+on+hepatocellular+cancer+cells&doi=10.1016%2Fj.bbrc.2013.05.088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.05.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.05.088%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLou%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DSynergistically%2520killing%2520activity%2520of%2520aspirin%2520and%2520histone%2520deacetylase%2520inhibitor%2520valproic%2520acid%2520%2528VPA%2529%2520on%2520hepatocellular%2520cancer%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D436%26spage%3D259%26epage%3D264%26doi%3D10.1016%2Fj.bbrc.2013.05.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span> <span> </span><span class="NLM_article-title">Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.18632%2Foncotarget.6352" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=402-417&author=M.+C.+Chenauthor=H.+H.+Huangauthor=C.+Y.+Laiauthor=Y.+J.+Linauthor=J.+P.+Liouauthor=M.+J.+Laiauthor=Y.+H.+Liauthor=C.+M.+Tengauthor=C.+R.+Yang&title=Novel+histone+deacetylase+inhibitor+MPT0G009+induces+cell+apoptosis+and+synergistic+anticancer+activity+with+tumor+necrosis+factor-related+apoptosis-inducing+ligand+against+human+hepatocellular+carcinoma&doi=10.18632%2Foncotarget.6352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6352%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DHuang%26aufirst%3DH.%2BH.%26aulast%3DLai%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DY.%2BJ.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26aulast%3DYang%26aufirst%3DC.%2BR.%26atitle%3DNovel%2520histone%2520deacetylase%2520inhibitor%2520MPT0G009%2520induces%2520cell%2520apoptosis%2520and%2520synergistic%2520anticancer%2520activity%2520with%2520tumor%2520necrosis%2520factor-related%2520apoptosis-inducing%2520ligand%2520against%2520human%2520hepatocellular%2520carcinoma%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D402%26epage%3D417%26doi%3D10.18632%2Foncotarget.6352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of the first c-Met/HDAC inhibitors based on pyridazinone derivatives</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">830</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00172</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00172" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=830-834&author=D.+Luauthor=J.+Yanauthor=L.+Wangauthor=H.+Liuauthor=L.+Zengauthor=M.+Zhangauthor=W.+Duanauthor=Y.+Jiauthor=J.+Caoauthor=M.+Gengauthor=A.+Shenauthor=Y.+Hu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+the+first+c-Met%2FHDAC+inhibitors+based+on+pyridazinone+derivatives&doi=10.1021%2Facsmedchemlett.7b00172"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00172%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520the%2520first%2520c-Met%252FHDAC%2520inhibitors%2520based%2520on%2520pyridazinone%2520derivatives%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D830%26epage%3D834%26doi%3D10.1021%2Facsmedchemlett.7b00172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ejmech.2015.03.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=302-312&author=W.+Xingauthor=J.+Aiauthor=S.+Jinauthor=Z.+Shiauthor=X.+Pengauthor=L.+Wangauthor=Y.+Jiauthor=D.+Luauthor=Y.+Liuauthor=M.+Gengauthor=Y.+Hu&title=Enhancing+the+cellular+anti-proliferation+activity+of+pyridazinones+as+c-met+inhibitors+using+docking+analysis&doi=10.1016%2Fj.ejmech.2015.03.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DW.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DEnhancing%2520the%2520cellular%2520anti-proliferation%2520activity%2520of%2520pyridazinones%2520as%2520c-met%2520inhibitors%2520using%2520docking%2520analysis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D302%26epage%3D312%26doi%3D10.1016%2Fj.ejmech.2015.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nimmanapalli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bali, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparetto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glozak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscinski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5126</span>– <span class="NLM_lpage">5135</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=12941844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms12ntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=5126-5135&author=R.+Nimmanapalliauthor=L.+Fuinoauthor=P.+Baliauthor=M.+Gasparettoauthor=M.+Glozakauthor=J.+Taoauthor=L.+Moscinskiauthor=C.+Smithauthor=J.+Wuauthor=R.+Joveauthor=P.+Atadjaauthor=K.+Bhalla&title=Histone+deacetylase+inhibitor+LAQ824+both+lowers+expression+and+promotes+proteasomal+degradation+of+Bcr-Abl+and+induces+apoptosis+of+imatinib+mesylate-sensitive+or+-refractory+chronic+myelogenous+leukemia-blast+crisis+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells</span></div><div class="casAuthors">Nimmanapalli, Ramadevi; Fuino, Lianne; Bali, Purva; Gasparetto, Maura; Glozak, Michele; Tao, Jianguo; Moscinski, Lynn; Smith, Clayton; Wu, Jie; Jove, Richard; Atadja, Peter; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5126-5135</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Treatment with LAQ824, a cinnamyl hydroxamic acid analog inhibitor of histone deacetylases, depleted the mRNA and protein expression of Bcr-Abl in human chronic myeloid leukemia blast crisis (CML-BC) cells.  Exposure to LAQ824 induced the expression of the cell cycle-dependent kinase inhibitors p21 and p27 and caused cell cycle G1-phase accumulation and apoptosis of CML-BC cells.  LAQ824 also induced acetylation of heat shock protein 90.  This inhibited the chaperone assocn. of Bcr-Abl with heat shock protein 90, thereby promoting the proteasomal degrdn. of Bcr-Abl.  Cotreatment with LAQ824 increased imatinib mesylate-induced apoptosis of CML-BC cells.  Addnl., LAQ824 down-regulated the levels of mutant Bcr-Abl possessing the T315I point mutation, as well as induced apoptosis of imatinib-refractory primary CML-BC cells.  Therefore, LAQ824 may be a promising therapeutic agent in the treatment of imatinib-sensitive or -refractory human leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ6KT6nvt9-bVg90H21EOLACvtfcHk0liwbhU0q2IVaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms12ntro%253D&md5=a908e21560e9ec289e8a8ab651ba4e24</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNimmanapalli%26aufirst%3DR.%26aulast%3DFuino%26aufirst%3DL.%26aulast%3DBali%26aufirst%3DP.%26aulast%3DGasparetto%26aufirst%3DM.%26aulast%3DGlozak%26aufirst%3DM.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DMoscinski%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520LAQ824%2520both%2520lowers%2520expression%2520and%2520promotes%2520proteasomal%2520degradation%2520of%2520Bcr-Abl%2520and%2520induces%2520apoptosis%2520of%2520imatinib%2520mesylate-sensitive%2520or%2520-refractory%2520chronic%2520myelogenous%2520leukemia-blast%2520crisis%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D5126%26epage%3D5135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nimmanapalli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stobaugh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span> <span> </span><span class="NLM_article-title">Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">3236</span>– <span class="NLM_lpage">3239</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-08-2675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1182%2Fblood-2002-08-2675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=12446442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtFCqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3236-3239&author=R.+Nimmanapalliauthor=L.+Fuinoauthor=C.+Stobaughauthor=V.+Richonauthor=K.+Bhalla&title=Cotreatment+with+the+histone+deacetylase+inhibitor+suberoylanilide+hydroxamic+acid+%28SAHA%29+enhances+imatinib-induced+apoptosis+of+Bcr-Abl-positive+human+acute+leukemia+cells&doi=10.1182%2Fblood-2002-08-2675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells</span></div><div class="casAuthors">Nimmanapalli, Ramadevi; Fuino, Lianne; Stobaugh, Corinne; Richon, Victoria; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3236-3239</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Here we demonstrate that treatment with SAHA (suberoylanilide hydroxamic acid), a known inhibitor of histone deacetylases (HDACs), alone induced p21 and/or p27 expressions but decreased the mRNA and protein levels of Bcr-Abl, which was assocd. with apoptosis of Bcr-Abl-expressing K562 and LAMA-84 cells.  Co-treatment with SAHA and imatinib (Gleevec) caused more down-regulation of the levels and auto-tyrosine phosphorylation of Bcr-Abl and apoptosis of these cell types, as compared with treatment with either agent alone (P <.05).  This finding was also assocd. with a greater decline in the levels of phospho-AKT and Bcl-xL.  Significantly, treatment with SAHA also down-regulated Bcr-Abl levels and induced apoptosis of CD34+ leukemia blast progenitor cells derived from patients who had developed progressive blast crisis (BC) of chronic myelocytic leukemia (CML) while receiving therapy with imatinib.  Taken together, these findings indicate that cotreatment with SAHA enhances the cytotoxic effects of imatinib and may have activity against imatinib-refractory CML-BC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbMV3jjXO6LVg90H21EOLACvtfcHk0liwbhU0q2IVaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtFCqtbg%253D&md5=539966340cce2f4cacc9fe29c9796b58</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-08-2675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-08-2675%26sid%3Dliteratum%253Aachs%26aulast%3DNimmanapalli%26aufirst%3DR.%26aulast%3DFuino%26aufirst%3DL.%26aulast%3DStobaugh%26aufirst%3DC.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DCotreatment%2520with%2520the%2520histone%2520deacetylase%2520inhibitor%2520suberoylanilide%2520hydroxamic%2520acid%2520%2528SAHA%2529%2520enhances%2520imatinib-induced%2520apoptosis%2520of%2520Bcr-Abl-positive%2520human%2520acute%2520leukemia%2520cells%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D3236%26epage%3D3239%26doi%3D10.1182%2Fblood-2002-08-2675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dove, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span> <span> </span><span class="NLM_article-title">Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2279</span>, <span class="refDoi"> DOI: 10.1021/jm800988r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800988r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFemurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2265-2279&author=S.+Mahboobiauthor=S.+Doveauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Design+of+chimeric+histone+deacetylase-+and+tyrosine+kinase-inhibitors%3A+a+series+of+imatinib+hybrides+as+potent+inhibitors+of+wild-type+and+mutant+BCR-ABL%2C+PDGF-Rbeta%2C+and+histone+deacetylases&doi=10.1021%2Fjm800988r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases</span></div><div class="casAuthors">Mahboobi, Siavosh; Dove, Stefan; Sellmer, Andreas; Winkler, Matthias; Eichhorn, Emerich; Pongratz, Herwig; Ciossek, Thomas; Baer, Thomas; Maier, Thomas; Beckers, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2265-2279</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of histone deacetylases are a new class of cancer therapeutics with possibly broad applicability.  Combinations of HDAC inhibitors with the kinase inhibitor 1 (Imatinib) in recent studies showed additive and synergistic effects.  Here we present a new concept by combining inhibition of protein kinases and HDACs, two independent pharmacol. activities, in one synthetic small mol.  In general, the HDAC inhibition profile, the potencies, and the probable binding modes to HDAC1 and HDAC6 were similar as for 6 (SAHA).  Inhibition of Abl kinase in biochem. assays was maintained for most compds., but in general the kinase selectivity profile differed from that of 1 with nearly equipotent inhibition of the wild-type and the Imatinib resistant Abl T315I mutant.  A potent cellular inhibition of PDGFR and cytotoxicity toward EOL-1 cells, a model for idiopathic hypereosinophilic syndrome (HES), are restored or enhanced for selected analogs (12b, 14b, and 18b).  Cytotoxicity was evaluated by using a broad panel of tumor cell lines, with selected analogs displaying mean IC50 values between 3.6 and 7.1 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCa_uPm33uzLVg90H21EOLACvtfcHk0liPXti2XW2cpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFemurc%253D&md5=2e65e8c0cf3daed2cc7415173209d630</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm800988r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800988r%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DDove%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DDesign%2520of%2520chimeric%2520histone%2520deacetylase-%2520and%2520tyrosine%2520kinase-inhibitors%253A%2520a%2520series%2520of%2520imatinib%2520hybrides%2520as%2520potent%2520inhibitors%2520of%2520wild-type%2520and%2520mutant%2520BCR-ABL%252C%2520PDGF-Rbeta%252C%2520and%2520histone%2520deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2265%26epage%3D2279%26doi%3D10.1021%2Fjm800988r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7524</span>– <span class="NLM_lpage">7538</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00930</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00930" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7524-7538&author=F.+Beaufilsauthor=N.+Cmiljanovicauthor=V.+Cmiljanovicauthor=T.+Bohnackerauthor=A.+Meloneauthor=R.+Maroneauthor=E.+Jacksonauthor=X.+Zhangauthor=A.+Seleauthor=C.+Borsariauthor=J.+Mestanauthor=P.+Hebeisenauthor=P.+Hillmannauthor=B.+Gieseauthor=M.+Zvelebilauthor=D.+Fabbroauthor=R.+L.+Williamsauthor=D.+Rageotauthor=M.+P.+Wymann&title=5-%284%2C6-Dimorpholino-1%2C3%2C5-triazin-2-yl%29-4-%28trifluoromethyl%29pyridin-2-amine+%28PQR309%29%2C+a+potent%2C+brain-penetrant%2C+orally+bioavailable%2C+pan-class+I+PI3K%2FmTOR+inhibitor+as+clinical+candidate+in+oncology&doi=10.1021%2Facs.jmedchem.7b00930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology</span></div><div class="casAuthors">Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jurgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7524-7538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR).  Here we describe the preclin. characterization of compd. 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concns.  No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays.  Moreover, 1 did not bind tubulin, which was obsd. for the structurally related 4 (BKM120, buparlisib).  Compd. 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs.  Compd. 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model.  This, together with the compd.'s safety profile, identifies 1 as a clin. candidate with a broad application range in oncol., including treatment of brain tumors or CNS metastasis.  Compd. 1 is currently in phase II clin. trials for advanced solid tumors and refractory lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtvYAarVqsarVg90H21EOLACvtfcHk0liPXti2XW2cpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP&md5=54d4db75f6a8bda3f12eaf1d196352fd</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00930%26sid%3Dliteratum%253Aachs%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3D5-%25284%252C6-Dimorpholino-1%252C3%252C5-triazin-2-yl%2529-4-%2528trifluoromethyl%2529pyridin-2-amine%2520%2528PQR309%2529%252C%2520a%2520potent%252C%2520brain-penetrant%252C%2520orally%2520bioavailable%252C%2520pan-class%2520I%2520PI3K%252FmTOR%2520inhibitor%2520as%2520clinical%2520candidate%2520in%2520oncology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7524%26epage%3D7538%26doi%3D10.1021%2Facs.jmedchem.7b00930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The phosphoinositide 3-kinase pathway</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1126/science.296.5573.1655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1126%2Fscience.296.5573.1655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=12040186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=1655-1657&author=L.+C.+Cantley&title=The+phosphoinositide+3-kinase+pathway&doi=10.1126%2Fscience.296.5573.1655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphoinositide 3-kinase pathway</span></div><div class="casAuthors">Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5573</span>),
    <span class="NLM_cas:pages">1655-1657</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 8 refs.  Phosphorylated lipids are produced at cellular membranes during signaling events and contribute to the recruitment and activation of various signaling components.  The role of phosphoinositide 3-kinase (PI3K), which catalyzes the prodn. of phosphatidylinositol 3,4,5-trisphosphate, in cell survival pathways; the regulation of gene expression and cell metab.; and cytoskeletal rearrangements are highlighted.  The PI3K pathway is implicated in human diseases including diabetes and cancer, and understanding the intricacies of this pathway may provide new avenues for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9pxSplxmS1rVg90H21EOLACvtfcHk0ljMldEJNYAlBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D&md5=110c8a351448aed6ab938b9ccf90a655</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1126%2Fscience.296.5573.1655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.296.5573.1655%26sid%3Dliteratum%253Aachs%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520phosphoinositide%25203-kinase%2520pathway%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D1655%26epage%3D1657%26doi%3D10.1126%2Fscience.296.5573.1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heavey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuffe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVeigh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gately, K.</span></span> <span> </span><span class="NLM_article-title">In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">79526</span>– <span class="NLM_lpage">79543</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.18632%2Foncotarget.12755" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=79526-79543&author=S.+Heaveyauthor=S.+Cuffeauthor=S.+Finnauthor=V.+Youngauthor=R.+Ryanauthor=S.+Nicholsonauthor=N.+Leonardauthor=N.+McVeighauthor=M.+Barrauthor=K.+O%E2%80%99Byrneauthor=K.+Gately&title=In+pursuit+of+synergy%3A+An+investigation+of+the+PI3K%2FmTOR%2FMEK+co-targeted+inhibition+strategy+in+NSCLC&doi=10.18632%2Foncotarget.12755"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12755%26sid%3Dliteratum%253Aachs%26aulast%3DHeavey%26aufirst%3DS.%26aulast%3DCuffe%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DV.%26aulast%3DRyan%26aufirst%3DR.%26aulast%3DNicholson%26aufirst%3DS.%26aulast%3DLeonard%26aufirst%3DN.%26aulast%3DMcVeigh%26aufirst%3DN.%26aulast%3DBarr%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DGately%26aufirst%3DK.%26atitle%3DIn%2520pursuit%2520of%2520synergy%253A%2520An%2520investigation%2520of%2520the%2520PI3K%252FmTOR%252FMEK%2520co-targeted%2520inhibition%2520strategy%2520in%2520NSCLC%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D79526%26epage%3D79543%26doi%3D10.18632%2Foncotarget.12755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutzman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Noll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voest, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.M.</span></span> <span> </span><span class="NLM_article-title">A phase I dose-escalation study of the safety and pharmacokinetics of Pictilisib in combination with Erlotinib in patients with advanced solid tumors</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1499</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2017-0090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1634%2Ftheoncologist.2017-0090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=28798270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovFCnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1491-1499&author=S.+Leongauthor=R.+A.+Mossauthor=D.+W.+Bowlesauthor=J.+A.+Wareauthor=J.+Zhouauthor=J.+M.+Spoerkeauthor=M.+R.+Lacknerauthor=G.+Shankarauthor=J.+L.+Schutzmanauthor=R.+van+der+Nollauthor=E.+E.+Voestauthor=J.+H.M.+Schellens&title=A+phase+I+dose-escalation+study+of+the+safety+and+pharmacokinetics+of+Pictilisib+in+combination+with+Erlotinib+in+patients+with+advanced+solid+tumors&doi=10.1634%2Ftheoncologist.2017-0090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Leong, Stephen; Moss, Rebecca A.; Bowles, Daniel W.; Ware, Joseph A.; Zhou, Jing; Spoerke, Jill M.; Lackner, Mark R.; Shankar, Geetha; Schutzman, Jennifer L.; van der Noll, Ruud; Voest, Emile E.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1491-1499</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1549-490X</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Background : Epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K) are involved in the proliferation and survival of many cancer types.  Enhanced antitumor activity may be achieved through combined inhibition of these pathways.  We report results for pictilisib (GDC-0941, a class I pan-PI3K inhibitor) plus erlotinib (an EGFR tyrosine kinase inhibitor) in patients with advanced solid tumors.  Materials and Methods : A 3 + 3 dose-escalation study was carried out at a starting daily dose of 60 mg pictilisib on days 1-21 of a 28-day cycle and 150 mg erlotinib from day 2 of cycle 1.  The primary objectives of the study were to assess safety and tolerability, identify dose-limiting toxicities (DLTs), est. the max. tolerated dose, and identify the recommended phase II dose (RP2D).  Evaluation of a dose-expansion cohort at the RP2D was performed.  Results : Fifty-seven patients were treated in the study.  All patients experienced at least one adverse event (AE).  Grade ≥3 AEs, serious AEs, and deaths were reported in 38 (66.7%), 19 (33.3%), and 4 (7.0%) patients, resp.  DLTs occurred in nine patients across eight cohorts and the RP2D was detd. to be 340 mg pictilisib on a "5 days on, 2 days off" schedule plus 100 mg erlotinib.  Two patients (3.5%) experienced partial response and 19 (33.3%) had stable disease.  Conclusion : Combining pictilisib with erlotinib in patients with advanced solid tumors is feasible; however, antitumor activity is limited.  Addnl. studies may identify patients likely to benefit from combined inhibition of EGFR and PI3K pathways.  Implications for Practice : Combining drugs targeting different signaling pathways in cancer growth and survival could overcome drug resistance and improve antitumor activity.  In this first-in-human study for the combination, addn. of the PI3K inhibitor pictilisib to the EGFR tyrosine kinase inhibitor erlotinib resulted in toxicity that led to dose and schedule modifications to identify a tolerable recommended phase II dose of 340 mg pictilisib on a "5 days on, 2 days off" schedule plus 100 mg erlotinib daily.  The limited antitumor activity obsd., however, suggests that addnl. studies are needed to identify patients most likely to benefit from combined EGFR and PI3K inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-IZe4X1hOO7Vg90H21EOLACvtfcHk0ljMldEJNYAlBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovFCnt7o%253D&md5=848e95827934194af997498bdccb4c2d</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2017-0090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2017-0090%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DS.%26aulast%3DMoss%26aufirst%3DR.%2BA.%26aulast%3DBowles%26aufirst%3DD.%2BW.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DShankar%26aufirst%3DG.%26aulast%3DSchutzman%26aufirst%3DJ.%2BL.%26aulast%3Dvan%2Bder%2BNoll%26aufirst%3DR.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.M.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520study%2520of%2520the%2520safety%2520and%2520pharmacokinetics%2520of%2520Pictilisib%2520in%2520combination%2520with%2520Erlotinib%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DOncologist%26date%3D2017%26volume%3D22%26spage%3D1491%26epage%3D1499%26doi%3D10.1634%2Ftheoncologist.2017-0090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmigiani, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: molecular mechanisms of action</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5541</span>– <span class="NLM_lpage">5552</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fsj.onc.1210620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=17694093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFersrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5541-5552&author=W.+S.+Xuauthor=R.+B.+Parmigianiauthor=P.+A.+Marks&title=Histone+deacetylase+inhibitors%3A+molecular+mechanisms+of+action&doi=10.1038%2Fsj.onc.1210620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: molecular mechanisms of action</span></div><div class="casAuthors">Xu, W. S.; Parmigiani, R. B.; Marks, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5541-5552</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  This review focuses on the mechanisms of action of histone deacetylase (HDAC) inhibitors (HDACi), a group of recently discovered targeted' anticancer agents.  There are 18 HDACs, which are generally divided into four classes, based on sequence homol. to yeast counterparts.  Classical HDACi such as the hydroxamic acid-based vorinostat (also known as SAHA and Zolinza) inhibits classes I, II and IV, but not the NAD+-dependent class III enzymes.  In clin. trials, vorinostat has activity against hematol. and solid cancers at doses well tolerated by patients.  In addn. to histones, HDACs have many other protein substrates involved in regulation of gene expression, cell proliferation and cell death.  Inhibition of HDACs causes accumulation of acetylated forms of these proteins, altering their function.  Thus, HDACs are more properly called 'lysine deacetylases.'.  HDACi induces different phenotypes in various transformed cells, including growth arrest, activation of the extrinsic and/or intrinsic apoptotic pathways, autophagic cell death, reactive oxygen species (ROS)-induced cell death, mitotic cell death and senescence.  In comparison, normal cells are relatively more resistant to HDACi-induced cell death.  The plurality of mechanisms of HDACi-induced cell death reflects both the multiple substrates of HDACs and the heterogeneous patterns of mol. alterations present in different cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ircqtUCkCLVg90H21EOLACvtfcHk0ljFHBcytfXFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFersrY%253D&md5=227a7c5d26028e99d412441596ba02ae</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210620%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%2BS.%26aulast%3DParmigiani%26aufirst%3DR.%2BB.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520molecular%2520mechanisms%2520of%2520action%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5541%26epage%3D5552%26doi%3D10.1038%2Fsj.onc.1210620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S. C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs</span>. <i>Am. J. Transl Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=21416059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtVSqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=166-179&author=H.+J.+Kimauthor=S.+C.+Bae&title=Histone+deacetylase+inhibitors%3A+molecular+mechanisms+of+action+and+clinical+trials+as+anti-cancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs</span></div><div class="casAuthors">Kim, Hyun-Jung; Bae, Suk-Chul</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">166-179</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells.  Recently, their use has been clin. validated in cancer patients resulting in the approval of two HDAC inhibitors, vorinostat and depsipetide, by the FDA.  Also, clin. trials of several HDAC inhibitors for use as anti-cancer drugs (alone or in combination with other anti-cancer therapeutics) are ongoing.  However, the mol. mechanisms underlying the response to HDAC inhibitors in cancer patients are not fully understood.  In this review, we summarize our understanding of the mol. and biol. events that underpin the anti-cancer effects of HDAC inhibitors and the outcomes of recent clin. trials involving these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6o4vH0OXL7bVg90H21EOLACvtfcHk0ljFHBcytfXFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtVSqur0%253D&md5=2f4388dec15ec9b517836f4f3b225641</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DBae%26aufirst%3DS.%2BC.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520molecular%2520mechanisms%2520of%2520action%2520and%2520clinical%2520trials%2520as%2520anti-cancer%2520drugs%26jtitle%3DAm.%2520J.%2520Transl%2520Res.%26date%3D2011%26volume%3D3%26spage%3D166%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horinaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinnoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span> <span> </span><span class="NLM_article-title">A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1080</span>– <span class="NLM_lpage">1086</span>, <span class="refDoi"> DOI: 10.3892/ijo.2013.2042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.3892%2Fijo.2013.2042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23900601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CmsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=1080-1086&author=T.+Yamadaauthor=M.+Horinakaauthor=M.+Shinnohauthor=T.+Yoshiokaauthor=T.+Mikiauthor=T.+Sakai&title=A+novel+HDAC+inhibitor+OBP-801+and+a+PI3K+inhibitor+LY294002+synergistically+induce+apoptosis+via+the+suppression+of+survivin+and+XIAP+in+renal+cell+carcinoma&doi=10.3892%2Fijo.2013.2042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma</span></div><div class="casAuthors">Yamada, Takeshi; Horinaka, Mano; Shinnoh, Masahide; Yoshioka, Takashi; Miki, Tsuneharu; Sakai, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1080-1086</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Renal cell carcinoma (RCC) is resistant to traditional cancer therapies such as radiation therapy and chemotherapy.  The use of targeted therapies has improved the clin. outcomes of patients with metastatic RCC.  However, most patients acquire resistance against targeted therapies over time.  We report that the combination of the novel histone deacetylase (HDAC) inhibitor OBP-801, also known as YM753 and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 synergistically inhibits cell growth and induces apoptosis in RCC cells.  This combination activated caspase-3, -8 and -9 and the pan-caspase inhibitor zVAD-fmk significantly reduced the apoptotic response to the treatment with OBP-801 and LY294002.  Moreover, the combined treatment induced intracellular reactive oxygen species (ROS) and the radical scavenger N-acetyl-L-cysteine (NAC) blocked the intracellular ROS and apoptosis induced by OBP-801 and LY294002.  The co-treatment with OBP-801 and LY294002 markedly decreased survivin and the X-linked inhibitor of apoptosis protein (XIAP) protein levels, but Bcl-2 family members were not altered by the OBP-801/LY294002 co-treatment.  These alterations were restored by NAC treatment.  The transient transfection of survivin and XIAP reduced the apoptotic response to the OBP-801/LY294002 co-treatment.  Addnl., OBP-801 was significantly more effective than SAHA, another HDAC inhibitor, in the combination with LY294002 against 786-O cells.  Taken together, these results strongly suggest the combination of OBP-801 and LY294002 to be a promising treatment for RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsaAUuVoRqkrVg90H21EOLACvtfcHk0ljFHBcytfXFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CmsbjK&md5=3f17423d3b17adaa7dd319da8024ec5f</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.3892%2Fijo.2013.2042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2013.2042%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DHorinaka%26aufirst%3DM.%26aulast%3DShinnoh%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DT.%26atitle%3DA%2520novel%2520HDAC%2520inhibitor%2520OBP-801%2520and%2520a%2520PI3K%2520inhibitor%2520LY294002%2520synergistically%2520induce%2520apoptosis%2520via%2520the%2520suppression%2520of%2520survivin%2520and%2520XIAP%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2013%26volume%3D43%26spage%3D1080%26epage%3D1086%26doi%3D10.3892%2Fijo.2013.2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasorsa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azabdaftari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pili, R.</span></span> <span> </span><span class="NLM_article-title">Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2225</span>– <span class="NLM_lpage">2236</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.18632%2Foncotarget.1314" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=2225-2236&author=L.+Ellisauthor=S.+Y.+Kuauthor=S.+Ramakrishnanauthor=E.+Lasorsaauthor=G.+Azabdaftariauthor=A.+Godoyauthor=R.+Pili&title=Combinatorial+antitumor+effect+of+HDAC+and+the+PI3K-Akt-mTOR+pathway+inhibition+in+a+Pten+defecient+model+of+prostate+cancer&doi=10.18632%2Foncotarget.1314"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1314%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DKu%26aufirst%3DS.%2BY.%26aulast%3DRamakrishnan%26aufirst%3DS.%26aulast%3DLasorsa%26aufirst%3DE.%26aulast%3DAzabdaftari%26aufirst%3DG.%26aulast%3DGodoy%26aufirst%3DA.%26aulast%3DPili%26aufirst%3DR.%26atitle%3DCombinatorial%2520antitumor%2520effect%2520of%2520HDAC%2520and%2520the%2520PI3K-Akt-mTOR%2520pathway%2520inhibition%2520in%2520a%2520Pten%2520defecient%2520model%2520of%2520prostate%2520cancer%26jtitle%3DOncotarget%26date%3D2013%26volume%3D4%26spage%3D2225%26epage%3D2236%26doi%3D10.18632%2Foncotarget.1314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogosawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitawaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span> <span> </span><span class="NLM_article-title">Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2013.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ygyno.2013.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23403163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFeqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2013&pages=425-432&author=T.+Yoshiokaauthor=S.+Yogosawaauthor=T.+Yamadaauthor=J.+Kitawakiauthor=T.+Sakai&title=Combination+of+a+novel+HDAC+inhibitor+OBP-801%2FYM753+and+a+PI3K+inhibitor+LY294002+synergistically+induces+apoptosis+in+human+endometrial+carcinoma+cells+due+to+increase+of+Bim+with+accumulation+of+ROS&doi=10.1016%2Fj.ygyno.2013.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS</span></div><div class="casAuthors">Yoshioka, Takashi; Yogosawa, Shingo; Yamada, Takeshi; Kitawaki, Jo; Sakai, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">In most endometrial carcinoma, it has been obsd. that the PI3K/Akt pathway is abnormally accelerated in assocn. with mutations in PIK3CA and PTEN.  The present study aimed to examine the combined effect of a novel histone deacetylase (HDAC) inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 against human endometrial carcinoma cells.The effects of OBP-801/YM753 and LY294002 on the growth of human endometrial carcinoma HEC-1A cells were examd. using WST-8 and colony formation assays.  The distribution of the cell cycle or apoptosis was analyzed by flow cytometry.  The accumulation of intracellular reactive oxygen species (ROS) was measured with a 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) dye.  The expression of apoptosis-related proteins was investigated by Western blotting.  Mice engrafted with 1 × 108 HEC-1A cells were treated with OBP-801/YM753, LY294002 or the combination, and tumor vols. were measured.The combination of OBP-801/YM753 and LY294002 significantly inhibited the cell growth on comparison with each agent alone and synergistically increased apoptosis with the induction of Bim, a well-known apoptosis inducer.  Addnl., the apoptosis induced by the combination was shown to be dependent on intracellular ROS accumulation and Bim induction.  Moreover, the apoptosis-inducing effect of OBP-801/YM753 with LY294002 was more potent than that of SAHA with LY294002.  Combined treatment with OBP-801/YM753 and LY294002 significantly suppressed tumor growth compared to the control in vivo.The combination of OBP-801/YM753 and LY294002 is effective on the inhibition of the growth of HEC-1A cells, and we suggest that this combination is promising a novel therapeutic strategy for endometrial carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-9GAbjAPJsbVg90H21EOLACvtfcHk0liK09aN6ARGGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFeqtbo%253D&md5=dc05b4fab8cc8157d8ccb6234a3dc6ed</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2013.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2013.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DYoshioka%26aufirst%3DT.%26aulast%3DYogosawa%26aufirst%3DS.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DKitawaki%26aufirst%3DJ.%26aulast%3DSakai%26aufirst%3DT.%26atitle%3DCombination%2520of%2520a%2520novel%2520HDAC%2520inhibitor%2520OBP-801%252FYM753%2520and%2520a%2520PI3K%2520inhibitor%2520LY294002%2520synergistically%2520induces%2520apoptosis%2520in%2520human%2520endometrial%2520carcinoma%2520cells%2520due%2520to%2520increase%2520of%2520Bim%2520with%2520accumulation%2520of%2520ROS%26jtitle%3DGynecol.%2520Oncol.%26date%3D2013%26volume%3D129%26spage%3D425%26epage%3D432%26doi%3D10.1016%2Fj.ygyno.2013.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span> <span> </span><span class="NLM_article-title">Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4104</span>– <span class="NLM_lpage">4113</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&author=C.+Qianauthor=C.+J.+Laiauthor=R.+Baoauthor=D.+G.+Wangauthor=J.+Wangauthor=G.+X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samsonauthor=B.+Zifcakauthor=A.+W.+Maauthor=S.+DellaRoccaauthor=M.+Borekauthor=H.+X.+Zhaiauthor=X.+Caiauthor=M.+Voi&title=Cancer+network+disruption+by+a+single+molecule+inhibitor+targeting+both+histone+deacetylase+activity+and+phosphatidylinositol+3-kinase+signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0liK09aN6ARGGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DBorek%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DCancer%2520network%2520disruption%2520by%2520a%2520single%2520molecule%2520inhibitor%2520targeting%2520both%2520histone%2520deacetylase%2520activity%2520and%2520phosphatidylinositol%25203-kinase%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodny, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1021/jm501026z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501026z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=41-71&author=M.+Andrsauthor=J.+Korabecnyauthor=D.+Junauthor=Z.+Hodnyauthor=J.+Bartekauthor=K.+Kuca&title=Phosphatidylinositol+3-Kinase+%28PI3K%29+and+phosphatidylinositol+3-kinase-related+kinase+%28PIKK%29+inhibitors%3A+importance+of+the+morpholine+ring&doi=10.1021%2Fjm501026z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring</span></div><div class="casAuthors">Andrs, Martin; Korabecny, Jan; Jun, Daniel; Hodny, Zdenek; Bartek, Jiri; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-71</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related protein kinases (PIKKs) are two related families of kinases that play key roles in regulation of cell proliferation, metab., migration, survival, and responses to diverse stresses including DNA damage.  To design novel efficient strategies for treatment of cancer and other diseases, these kinases have been extensively studied.  Despite their different nature, these two kinase families have related origin and share very similar kinase domains.  Therefore, chem. inhibitors of these kinases usually carry analogous structural motifs.  The most common feature of these inhibitors is a crit. hydrogen bond to morpholine oxygen, initially present in the early nonspecific PI3K and PIKK inhibitor 3 (LY294002), which served as a valuable chem. tool for development of many addnl. PI3K and PIKK inhibitors.  While several PI3K pathway inhibitors have recently shown promising clin. responses, inhibitors of the DNA damage-related PIKKs remain thus far largely in preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPlvsq-HTebVg90H21EOLACvtfcHk0liK09aN6ARGGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE&md5=a8c22f580691084554036dec7d0cc95b</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm501026z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501026z%26sid%3Dliteratum%253Aachs%26aulast%3DAndrs%26aufirst%3DM.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DJun%26aufirst%3DD.%26aulast%3DHodny%26aufirst%3DZ.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DPhosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520and%2520phosphatidylinositol%25203-kinase-related%2520kinase%2520%2528PIKK%2529%2520inhibitors%253A%2520importance%2520of%2520the%2520morpholine%2520ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D41%26epage%3D71%26doi%3D10.1021%2Fjm501026z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellarocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Dual HDAC and PI3K inhibitor CUDC-907 downregulates MYC and suppresses growth of MYC-dependent cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1535-7163.MCT-16-0390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27980108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=285-299&author=K.+Sunauthor=R.+Atoyanauthor=M.+A.+Borekauthor=S.+Dellaroccaauthor=M.+E.+Samsonauthor=A.+W.+Maauthor=G.+X.+Xuauthor=T.+Pattersonauthor=D.+P.+Tuckauthor=J.+L.+Vinerauthor=A.+Fattaeyauthor=J.+Wang&title=Dual+HDAC+and+PI3K+inhibitor+CUDC-907+downregulates+MYC+and+suppresses+growth+of+MYC-dependent+cancers&doi=10.1158%2F1535-7163.MCT-16-0390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers</span></div><div class="casAuthors">Sun, Kaiming; Atoyan, Ruzanna; Borek, Mylissa A.; Dellarocca, Steven; Samson, Maria Elena S.; Ma, Anna W.; Xu, Guang-Xin; Patterson, Troy; Tuck, David P.; Viner, Jaye L.; Fattaey, Ali; Wang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-299</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs that promote cell growth and proliferation.  Preclin. studies have suggested that individually targeting upstream regulators of MYC, such as histone deacetylases (HDAC) and phosphoinositide 3-kinases (PI3K), can reduce MYC protein levels and suppress the growth of MYC-driven cancers.  Synergy between HDAC and PI3K inhibition in inducing cancer cell death has also been reported, but the involvement of MYC regulation is unclear.  In this study, we demonstrated that HDAC and PI3K inhibition synergistically downregulates MYC protein levels and induces apoptosis in "double-hit" (DH) diffuse large B-cell lymphoma (DLBCL) cells.  Furthermore, CUDC-907, a small-mol. dual-acting inhibitor of both class I and II HDACs and class I PI3Ks, effectively suppresses the growth and survival of MYC-altered or MYC-dependent cancer cells, such as DH DLBCL and BRD-NUT fusion-pos. NUT midline carcinoma (NMC) cells, and MYC protein downregulation is an early event induced by CUDC-907 treatment.  Consistently, the antitumor activity of CUDC-907 against multiple MYC-driven cancer types was also demonstrated in animal models, including DLBCL and NMC xenograft models, Myc transgenic tumor syngeneic models, and MYC-amplified solid tumor patient-derived xenograft (PDX) models.  Our findings suggest that dual function HDAC and PI3K inhibitor CUDC-907 is an effective agent targeting MYC and thus may be developed as potential therapy for MYC-dependent cancers.  Mol Cancer Ther; 16(2); 285-99. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo82AzF-jV397Vg90H21EOLACvtfcHk0lhqEhAMzQpxew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D&md5=d4ffd5f39546fa076448dbfb36406183</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0390%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DK.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DBorek%26aufirst%3DM.%2BA.%26aulast%3DDellarocca%26aufirst%3DS.%26aulast%3DSamson%26aufirst%3DM.%2BE.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DPatterson%26aufirst%3DT.%26aulast%3DTuck%26aufirst%3DD.%2BP.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDual%2520HDAC%2520and%2520PI3K%2520inhibitor%2520CUDC-907%2520downregulates%2520MYC%2520and%2520suppresses%2520growth%2520of%2520MYC-dependent%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D285%26epage%3D299%26doi%3D10.1158%2F1535-7163.MCT-16-0390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derenzini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asgari, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinberg, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14017</span>– <span class="NLM_lpage">14028</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.18632%2Foncotarget.14876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=28147336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A280%3ADC%252BC1c3hslamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14017-14028&author=P.+Mondelloauthor=E.+Derenziniauthor=Z.+Asgariauthor=J.+Philipauthor=E.+J.+Breaauthor=V.+Seshanauthor=R.+C.+Hendricksonauthor=E.+de+Stanchinaauthor=D.+A.+Scheinbergauthor=A.+Younes&title=Dual+inhibition+of+histone+deacetylases+and+phosphoinositide+3-kinase+enhances+therapeutic+activity+against+B+cell+lymphoma&doi=10.18632%2Foncotarget.14876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma</span></div><div class="casAuthors">Mondello Patrizia; Derenzini Enrico; Asgari Zahra; Younes Anas; Philip John; Hendrickson Ronald C; Brea Elliott J; Scheinberg David A; Seshan Venkatraman; de Stanchina Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">14017-14028</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) and Myc are known to cooperate in promoting the survival and growth of a variety of B-cell lymphomas.  While currently there are no small molecule inhibitors of Myc protein, histone deacetylase (HDAC) inhibitors have been shown to reduce levels of Myc protein by suppressing its transcription.  We assessed the efficacy of CUDC-907, a new rationally designed dual inhibitor of PI3K and HDACs, in a panel of lymphoma cell lines.  CUDC-907 treatment resulted in a dose- and time-dependent growth inhibition and cell death of DLBCL cell lines, irrespective of the cell of origin.  CUDC-907 treatment down-regulated the phosphorylation of PI3K downstream targets, including AKT, PRAS40, S6, and 4EBP1, increased histone 3 acetylation, and decreased Myc protein levels.  SILAC-based quantitative mass spectrometry demonstrated that CUDC-907 treatment decreased the protein levels of several components of the B cell receptor (BCR) and Toll like receptor (TLR) pathways, including BTK, SYK, and MyD88 proteins.  These cellular changes were associated with an inhibition of NF-kB activation.  CUDC-907 demonstrated in vivo efficacy with no significant toxicity in a human DLBCL xenograft mouse model.  Collectively, these data provide a mechanistic rationale for evaluating CUDC-907 for the treatment of patients with Myc and PI3K-dependent lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHhpmYpq2kzUwlCcfExbvbfW6udTcc2ebG_M2N5CJxhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3hslamtg%253D%253D&md5=57e637ca88cd4a23c0c069a8564404d1</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14876%26sid%3Dliteratum%253Aachs%26aulast%3DMondello%26aufirst%3DP.%26aulast%3DDerenzini%26aufirst%3DE.%26aulast%3DAsgari%26aufirst%3DZ.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DBrea%26aufirst%3DE.%2BJ.%26aulast%3DSeshan%26aufirst%3DV.%26aulast%3DHendrickson%26aufirst%3DR.%2BC.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DScheinberg%26aufirst%3DD.%2BA.%26aulast%3DYounes%26aufirst%3DA.%26atitle%3DDual%2520inhibition%2520of%2520histone%2520deacetylases%2520and%2520phosphoinositide%25203-kinase%2520enhances%2520therapeutic%2520activity%2520against%2520B%2520cell%2520lymphoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D14017%26epage%3D14028%26doi%3D10.18632%2Foncotarget.14876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. S.</span></span> <span> </span><span class="NLM_article-title">Human ATP-binding cassette transporter ABCG2 confers resistance to CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol 3-kinase</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00687</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00687" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=784-794&author=C.+P.+Wuauthor=Y.+J.+Hsiehauthor=S.+H.+Hsiaoauthor=C.+Y.+Suauthor=Y.+Q.+Liauthor=Y.+H.+Huangauthor=C.+W.+Huangauthor=C.+H.+Hsiehauthor=J.+S.+Yuauthor=Y.+S.+Wu&title=Human+ATP-binding+cassette+transporter+ABCG2+confers+resistance+to+CUDC-907%2C+a+dual+inhibitor+of+histone+deacetylase+and+phosphatidylinositol+3-kinase&doi=10.1021%2Facs.molpharmaceut.5b00687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase</span></div><div class="casAuthors">Wu, Chung-Pu; Hsieh, Ya-Ju; Hsiao, Sung-Han; Su, Ching-Ya; Li, Yan-Qing; Huang, Yang-Hui; Huang, Chiun-Wei; Hsieh, Chia-Hung; Yu, Jau-Song; Wu, Yu-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-794</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CUDC-907 is a novel, dual-acting small mol. compd. designed to simultaneously inhibit the activity of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).  Treatment with CUDC-907 led to sustained inhibition of HDAC and PI3K activity, inhibition of RAF-MEK-MAPK signaling pathway, and inhibition of cancer cell growth.  CUDC-907 is currently under evaluation in phase I clin. trials in patients with lymphoma or multiple myeloma, and in patients with advanced solid tumors.  However, the risk of developing acquired resistance to CUDC-907 can present a significant therapeutic challenge to clinicians in the future and should be investigated.  The overexpression of ATP-binding cassette (ABC) drug transporter ABCB1, ABCC1, or ABCG2 is one of the most common mechanisms of developing multidrug resistance (MDR) in cancers and a major obstacle in chemotherapy.  In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells.  Moreover, although CUDC-907 affects the transport function of ABCG2, it was not potent enough to reverse drug resistance mediated by ABCG2 or affect the expression level of ABCG2 in human cancer cells.  Taken together, our findings indicate that ABCG2-mediated CUDC-907 resistance can have serious clin. implications and should be further investigated.  More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn2RGaHVNxGrVg90H21EOLACvtfcHk0lgDd0-jUYjQoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOjsLY%253D&md5=036e089fb6690dde8c3de691140dff9b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00687%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BP.%26aulast%3DHsieh%26aufirst%3DY.%2BJ.%26aulast%3DHsiao%26aufirst%3DS.%2BH.%26aulast%3DSu%26aufirst%3DC.%2BY.%26aulast%3DLi%26aufirst%3DY.%2BQ.%26aulast%3DHuang%26aufirst%3DY.%2BH.%26aulast%3DHuang%26aufirst%3DC.%2BW.%26aulast%3DHsieh%26aufirst%3DC.%2BH.%26aulast%3DYu%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BS.%26atitle%3DHuman%2520ATP-binding%2520cassette%2520transporter%2520ABCG2%2520confers%2520resistance%2520to%2520CUDC-907%252C%2520a%2520dual%2520inhibitor%2520of%2520histone%2520deacetylase%2520and%2520phosphatidylinositol%25203-kinase%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D784%26epage%3D794%26doi%3D10.1021%2Facs.molpharmaceut.5b00687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whye, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efimenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Keersmaecker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordon-Cardo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dave, U. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span> <span> </span><span class="NLM_article-title">Targeting nonclassical oncogenes for therapy in T-ALL</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ccr.2012.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=22516257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVSnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=459-472&author=P.+S.+Subramaniamauthor=D.+W.+Whyeauthor=E.+Efimenkoauthor=J.+Chenauthor=V.+Toselloauthor=K.+De+Keersmaeckerauthor=A.+Kashishianauthor=M.+A.+Thompsonauthor=M.+Castilloauthor=C.+Cordon-Cardoauthor=U.+P.+Daveauthor=A.+Ferrandoauthor=B.+J.+Lannuttiauthor=T.+G.+Diacovo&title=Targeting+nonclassical+oncogenes+for+therapy+in+T-ALL&doi=10.1016%2Fj.ccr.2012.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Nonclassical Oncogenes for Therapy in T-ALL</span></div><div class="casAuthors">Subramaniam, Prem S.; Whye, Dosh W.; Efimenko, Evgeni; Chen, Jianchung; Tosello, Valeria; De Keersmaecker, Kim; Kashishian, Adam; Thompson, Mary Ann; Castillo, Mireia; Cordon-Cardo, Carlos; Dave, Utpal P.; Ferrando, Adolfo; Lannutti, Brian J.; Diacovo, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-472</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Constitutive phosphoinositide 3-kinase (PI3K)/Akt activation is common in T cell acute lymphoblastic leukemia (T-ALL).  Although four distinct class I PI3K isoforms (α, β, γ, δ) could participate in T-ALL pathogenesis, none has been implicated in this process.  We report that in the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed tumor formation.  The reliance of PTEN null T-ALL on the combined activities of PI3Kγ/δ was further demonstrated by the ability of a dual inhibitor to reduce disease burden and prolong survival in mice as well as prevent proliferation and promote activation of proapoptotic pathways in human tumors.  These results support combined inhibition of PI3Kγ/δ as therapy for T-ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosNmXI2hkyJLVg90H21EOLACvtfcHk0ljJtYnBzrmDfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVSnsr8%253D&md5=398af95a5213dd668b882bf33b222a8c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DSubramaniam%26aufirst%3DP.%2BS.%26aulast%3DWhye%26aufirst%3DD.%2BW.%26aulast%3DEfimenko%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTosello%26aufirst%3DV.%26aulast%3DDe%2BKeersmaecker%26aufirst%3DK.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DM.%2BA.%26aulast%3DCastillo%26aufirst%3DM.%26aulast%3DCordon-Cardo%26aufirst%3DC.%26aulast%3DDave%26aufirst%3DU.%2BP.%26aulast%3DFerrando%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26atitle%3DTargeting%2520nonclassical%2520oncogenes%2520for%2520therapy%2520in%2520T-ALL%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D21%26spage%3D459%26epage%3D472%26doi%3D10.1016%2Fj.ccr.2012.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolev, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricono, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padval, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span> <span> </span><span class="NLM_article-title">PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F0008-5472.CAN-14-1223" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=446-455&author=V.+N.+Kolevauthor=Q.+G.+Wrightauthor=C.+M.+Vidalauthor=J.+E.+Ringauthor=I.+M.+Shapiroauthor=J.+Riconoauthor=D.+T.+Weaverauthor=M.+V.+Padvalauthor=J.+A.+Pachterauthor=Q.+Xu&title=PI3K%2FmTOR+dual+inhibitor+VS-5584+preferentially+targets+cancer+stem+cells&doi=10.1158%2F0008-5472.CAN-14-1223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1223%26sid%3Dliteratum%253Aachs%26aulast%3DKolev%26aufirst%3DV.%2BN.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DVidal%26aufirst%3DC.%2BM.%26aulast%3DRing%26aufirst%3DJ.%2BE.%26aulast%3DShapiro%26aufirst%3DI.%2BM.%26aulast%3DRicono%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DD.%2BT.%26aulast%3DPadval%26aufirst%3DM.%2BV.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DXu%26aufirst%3DQ.%26atitle%3DPI3K%252FmTOR%2520dual%2520inhibitor%2520VS-5584%2520preferentially%2520targets%2520cancer%2520stem%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D446%26epage%3D455%26doi%3D10.1158%2F0008-5472.CAN-14-1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5488</span>– <span class="NLM_lpage">5504</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00579</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00579" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XotVyks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5488-5504&author=Y.+Chenauthor=X.+Wangauthor=W.+Xiangauthor=L.+Heauthor=M.+Tangauthor=F.+Wangauthor=T.+Wangauthor=Z.+Yangauthor=Y.+Yiauthor=H.+Wangauthor=T.+Niuauthor=L.+Zhengauthor=L.+Leiauthor=X.+Liauthor=H.+Songauthor=L.+Chen&title=Development+of+purine-based+hydroxamic+acid+derivatives%3A+potent+histone+deacetylase+inhibitors+with+marked+in+vitro+and+in+vivo+antitumor+activities&doi=10.1021%2Facs.jmedchem.6b00579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities</span></div><div class="casAuthors">Chen, Yong; Wang, Xiaoyan; Xiang, Wei; He, Lin; Tang, Minghai; Wang, Fang; Wang, Taijin; Yang, Zhuang; Yi, Yuyao; Wang, Hairong; Niu, Ting; Zheng, Li; Lei, Lei; Li, Xiaobin; Song, Hang; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5488-5504</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present study, a series of novel histone deacetylase (HDAC) inhibitors using the morpholinopurine as the capping group were designed and synthesized.  Several compds. demonstrated significant HDAC inhibitory activities and antiproliferative effects against diverse human tumor cell lines.  Among them, compd. 10o was identified as a potent class I and class IIb HDAC inhibitor with good pharmaceutical profile and druglike properties.  Western blot anal. further confirmed that 10o more effectively increased acetylated histone H3 than panobinostat (LBH-589) and vorinostat (SAHA) at the same concn. in vitro.  In in vivo efficacy evaluations of HCT116, MV4-11, Ramos, and MM1S xenograft models, 10o showed higher efficacy than SAHA or LBH-589 without causing significant loss of body wt. and toxicity.  All the results indicated that 10o could be a suitable candidate for treatment of both solid and hematol. cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIrTRI5NXFfLVg90H21EOLACvtfcHk0ljJtYnBzrmDfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotVyks7w%253D&md5=3400d6c13519392827c72bba6f044121</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00579%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520purine-based%2520hydroxamic%2520acid%2520derivatives%253A%2520potent%2520histone%2520deacetylase%2520inhibitors%2520with%2520marked%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5488%26epage%3D5504%26doi%3D10.1021%2Facs.jmedchem.6b00579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alper, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden, E. T.</span></span> <span> </span><span class="NLM_article-title">Novel insights into c-Src</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1130</span>, <span class="refDoi"> DOI: 10.2174/1381612053507576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.2174%2F1381612053507576" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1119-1130&author=O.+Alperauthor=E.+T.+Bowden&title=Novel+insights+into+c-Src&doi=10.2174%2F1381612053507576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.2174%2F1381612053507576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612053507576%26sid%3Dliteratum%253Aachs%26aulast%3DAlper%26aufirst%3DO.%26aulast%3DBowden%26aufirst%3DE.%2BT.%26atitle%3DNovel%2520insights%2520into%2520c-Src%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2005%26volume%3D11%26spage%3D1119%26epage%3D1130%26doi%3D10.2174%2F1381612053507576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostyniuk, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonham, K.</span></span> <span> </span><span class="NLM_article-title">The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6340</span>– <span class="NLM_lpage">6347</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fsj.onc.1205787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=12214274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1yrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=6340-6347&author=C.+L.+Kostyniukauthor=S.+M.+Dehmauthor=D.+Battenauthor=K.+Bonham&title=The+ubiquitous+and+tissue+specific+promoters+of+the+human+SRC+gene+are+repressed+by+inhibitors+of+histone+deacetylases&doi=10.1038%2Fsj.onc.1205787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases</span></div><div class="casAuthors">Kostyniuk, Calley L.; Dehm, Scott M.; Batten, Danielle; Bonham, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">6340-6347</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors have generated keen interest as potential chemopreventive and chemotherapeutic agents due to their ability to induce cell cycle arrest, differentiation, and apoptosis in a diverse group of cancer derived cell lines.  Activation of the 60 kDa non-receptor tyrosine kinase, c-Src, has been a consistent finding in many tumors and tumor derived cell lines, and has been implicated in these same cellular processes.  We have shown that the histone deacetylase inhibitors, sodium butyrate and Trichostatin A, repressed c-Src mRNA and protein expression in a dose-dependent manner in cell lines derived from cancers of the colon, breast and liver.  Our group has previously identified two distinct promoters that are responsible for SRC transcription, sepd. by a distance of approx. 1 kb.  Sodium butyrate and Trichostatin A strongly inhibited activity of each of these highly disparate SRC promoters, demonstrating histone deacetylase inhibitors directly repress SRC transcription.  This repression did not require protein neosynthesis and was not assocd. with a decrease in binding of protein factors essential for either promoter's activity.  Our finding that sodium butyrate and Trichostatin A inhibit both SRC promoters suggest this oncogene may be a major target of these agents, and may explain in part their anti-cancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMGOnAYoAa6bVg90H21EOLACvtfcHk0ljDTodjUttA3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1yrsrY%253D&md5=8ee01116950b182b849d5d84ce1213fc</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205787%26sid%3Dliteratum%253Aachs%26aulast%3DKostyniuk%26aufirst%3DC.%2BL.%26aulast%3DDehm%26aufirst%3DS.%2BM.%26aulast%3DBatten%26aufirst%3DD.%26aulast%3DBonham%26aufirst%3DK.%26atitle%3DThe%2520ubiquitous%2520and%2520tissue%2520specific%2520promoters%2520of%2520the%2520human%2520SRC%2520gene%2520are%2520repressed%2520by%2520inhibitors%2520of%2520histone%2520deacetylases%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D6340%26epage%3D6347%26doi%3D10.1038%2Fsj.onc.1205787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandvold, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Development of a chimeric c-Src kinase and HDAC inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.1021/ml400175d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400175d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=779-783&author=K.+S.+Koauthor=M.+E.+Steffeyauthor=K.+R.+Brandvoldauthor=M.+B.+Soellner&title=Development+of+a+chimeric+c-Src+kinase+and+HDAC+inhibitor&doi=10.1021%2Fml400175d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Chimeric c-Src Kinase and HDAC Inhibitor</span></div><div class="casAuthors">Ko, Kristin S.; Steffey, Michael E.; Brandvold, Kristoffer R.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">779-783</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of synergism obsd. between a selective c-Src kinase inhibitor with an HDAC inhibitor, the development of the first chimeric c-Src kinase and HDAC inhibitor is described.  The optimized chimeric inhibitor is shown to be a potent c-Src and HDAC inhibitor.  Chimeric inhibitor (I) is further shown to be highly efficacious in cancer cell lines and significantly more efficacious than a dual-targeting strategy using discrete c-Src and HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzi2suGn-7ErVg90H21EOLACvtfcHk0ljDTodjUttA3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL&md5=5f34ce3b1f65a8ac1a4341f563a5e1d9</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fml400175d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400175d%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DK.%2BS.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DBrandvold%26aufirst%3DK.%2BR.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520chimeric%2520c-Src%2520kinase%2520and%2520HDAC%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D779%26epage%3D783%26doi%3D10.1021%2Fml400175d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4839</span>– <span class="NLM_lpage">4853</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.03.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.bmc.2008.03.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=4839-4853&author=P.+C.+Chenauthor=V.+Patilauthor=W.+Guerrantauthor=P.+Greenauthor=A.+K.+Oyelere&title=Synthesis+and+structure-activity+relationship+of+histone+deacetylase+%28HDAC%29+inhibitors+with+triazole-linked+cap+group&doi=10.1016%2Fj.bmc.2008.03.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.03.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.03.050%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%2BC.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DGreen%26aufirst%3DP.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520of%2520histone%2520deacetylase%2520%2528HDAC%2529%2520inhibitors%2520with%2520triazole-linked%2520cap%2520group%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D4839%26epage%3D4853%26doi%3D10.1016%2Fj.bmc.2008.03.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedenburg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors through click chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7417</span>– <span class="NLM_lpage">7427</span>, <span class="refDoi"> DOI: 10.1021/jm8005355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8005355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7417-7427&author=J.+Shenauthor=R.+Woodwardauthor=J.+P.+Kedenburgauthor=X.+Liuauthor=M.+Chenauthor=L.+Fangauthor=D.+Sunauthor=P.+G.+Wang&title=Histone+deacetylase+inhibitors+through+click+chemistry&doi=10.1021%2Fjm8005355"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm8005355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8005355%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DWoodward%26aufirst%3DR.%26aulast%3DKedenburg%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DP.%2BG.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520through%2520click%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7417%26epage%3D7427%26doi%3D10.1021%2Fjm8005355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mwakwari, S.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tekwani, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurard-Levin, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrksich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6100</span>– <span class="NLM_lpage">6111</span>, <span class="refDoi"> DOI: 10.1021/jm100507q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100507q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6100-6111&author=S.%0AC.+Mwakwariauthor=W.+Guerrantauthor=V.+Patilauthor=S.+I.+Khanauthor=B.+L.+Tekwaniauthor=Z.+A.+Gurard-Levinauthor=M.+Mrksichauthor=A.+K.+Oyelere&title=Non-peptide+macrocyclic+histone+deacetylase+inhibitors+derived+from+tricyclic+ketolide+skeleton&doi=10.1021%2Fjm100507q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide Skeleton</span></div><div class="casAuthors">Mwakwari, Sandra C.; Guerrant, William; Patil, Vishal; Khan, Shabana I.; Tekwani, Babu L.; Gurard-Levin, Zachary A.; Mrksich, Milan; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6100-6111</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of histone deacetylase (HDAC) function is a validated therapeutic strategy for cancer treatment.  Of the several structurally distinct small mol. histone deacetylase inhibitors (HDACi) reported, macrocyclic depsipeptides possess the most complex cap groups and have demonstrated excellent HDAC inhibition potency and isoform selectivity.  Unfortunately, the development of macrocyclic depsipeptides has been hampered in part because of development problems characteristic of large peptides and the complex reaction schemes required for their synthesis.  Herein we report that tricyclic ketolide TE-802 is an excellent mimetic for the peptide backbone of macrocyclic HDACi.  Compds. derived from this template are particularly selective against HDACs 1 and 2 with nanomolar inhibitory activity.  Interrogation of the assocn. between a subset of these compds. and key HDAC isoforms, using AutoDock, enables a mol. description of the interaction between the HDAC enzyme's outer rim and the inhibitors' macrocyclic cap group that are responsible for compd. affinity and presumably isoform selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt9QPKI33jvbVg90H21EOLACvtfcHk0lh8Qd6KV6PCFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtLk%253D&md5=6407dc82e9fb2dab6313d32956600659</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm100507q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100507q%26sid%3Dliteratum%253Aachs%26aulast%3DMwakwari%26aufirst%3DS.%2BC.%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DKhan%26aufirst%3DS.%2BI.%26aulast%3DTekwani%26aufirst%3DB.%2BL.%26aulast%3DGurard-Levin%26aufirst%3DZ.%2BA.%26aulast%3DMrksich%26aufirst%3DM.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DNon-peptide%2520macrocyclic%2520histone%2520deacetylase%2520inhibitors%2520derived%2520from%2520tricyclic%2520ketolide%2520skeleton%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6100%26epage%3D6111%26doi%3D10.1021%2Fjm100507q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trelinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span> <span> </span><span class="NLM_article-title">JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">1161</span>, <span class="refDoi"> DOI: 10.2174/0929867311320090004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.2174%2F0929867311320090004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23317159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslGlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1147-1161&author=J.+Trelinskiauthor=T.+Robak&title=JAK+inhibitors%3A+pharmacology+and+clinical+activity+in+chronic+myeloprolipherative+neoplasms&doi=10.2174%2F0929867311320090004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms</span></div><div class="casAuthors">Trelinski, J.; Robak, T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1147-1161</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (JAKs), JAK1, JAK2, JAK3, and TYK2, are involved in cell growth, survival, development, and differentiation of a variety of cells, particularly immune cells and hematopoietic cells.  They form a subgroup of the non-receptor protein tyrosine kinases.  Activating mutations within each of the JAKs is assocd. with malignant transformations; the most common are mutations of JAK2 in polycythemia vera (PV) and other myeloproliferative neoplasms (MPN).  Identification of the V617F mutation of the JAK2 gene (JAK2 V617F) led to an important breakthrough in the understanding of MPN disease pathogenesis.  The JAK2 V617F mutation is present in the majority of PV patients, and about 50% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF) are affected.  This mutation leads to hyperactivation of JAK2, cytokine-independent signaling, and subsequent activation of downstream signaling networks.  JAK2 ATP-competitive inhibitors that indirectly inhibit the JAK-STAT pathway are new candidates for the treatment of MPN.  JAK2 inhibitors in development for the treatment of MPN have demonstrated clin. activity with minimal toxicity.  These agents consistently alleviate constitutional symptoms and reduce spleen size in PMF and other MPN.  However, some of these inhibitors have addnl. unique effects.  Ruxolitinib causes a significant redn. in the level of pro-inflammatory cytokines.  Another inhibitor, CYT387, improves anemia.  Many other JAK2 inhibitors such as TG101348 or SAR302503, SB1518, CEP701 and LY2784544 are now under investigation for MPN development.  In contrast tasocitinib, a predominantly JAK3 inhibitor, is being evaluated in a no. of inflammatory and immunol. diseases, including rheumatoid arthritis, psoriasis, ulcerative colitis, dry eye disease and in kidney transplant patients.  In conclusion the use of JAK inhibitors in MPN and some of the immune-mediated disorders is a promising new strategy for therapy.  However, definitive data from ongoing and future preclin. and clin. trials will aid in better defining the status of these drugs in the treatment of these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqknrRTtegtubVg90H21EOLACvtfcHk0lh8Qd6KV6PCFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslGlsbY%253D&md5=a79da3c1d67f0b2be73ff1a80203f90c</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.2174%2F0929867311320090004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320090004%26sid%3Dliteratum%253Aachs%26aulast%3DTrelinski%26aufirst%3DJ.%26aulast%3DRobak%26aufirst%3DT.%26atitle%3DJAK%2520inhibitors%253A%2520pharmacology%2520and%2520clinical%2520activity%2520in%2520chronic%2520myeloprolipherative%2520neoplasms%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1147%26epage%3D1161%26doi%3D10.2174%2F0929867311320090004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crispino, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moliterno, A. R.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms</span>. <i>Curr. Opin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1097/CCO.0b013e32834d1b22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1097%2FCCO.0b013e32834d1b22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=21993415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12rtrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=609-616&author=B.+L.+Steinauthor=J.+D.+Crispinoauthor=A.+R.+Moliterno&title=Janus+kinase+inhibitors%3A+an+update+on+the+progress+and+promise+of+targeted+therapy+in+the+myeloproliferative+neoplasms&doi=10.1097%2FCCO.0b013e32834d1b22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms</span></div><div class="casAuthors">Stein, Brady L.; Crispino, John D.; Moliterno, Alison R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">609-616</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The discovery of the JAK2 V617F mutation in the classical myeloproliferative neoplasms (MPNs) essential thrombocytosis, polycythemia vera, and primary myelofibrosis has ushered in a new era of scientific discovery in these diseases, resulting in a mol. classification and an improved understanding of disease pathogenesis.  Alongside this period of discovery has been the rapid development of targeted therapy and, here, we summarize results from clin. trials involving these small mol. Janus family of tyrosine kinase (JAK) inhibitors.  Recent findings: The JAK inhibitors consistently alleviate constitutional symptoms and reduce spleen size.  Early phase testing indicates that some of these inhibitors have addnl. unique effects: INCB018424 results in a significant redn. in the level of pro-inflammatory cytokines; TG101348 may modify disease burden as assessed by JAK2 allele measurements; and CYT387 ameliorates anemia.  Summary: The initial enthusiasm for these agents has been tempered by recognition that JAK2 V617F may represent only one component of lesions driving the heterogeneity of the MPN.  Clin. trial design cannot address important disease endpoints such as thrombosis or leukemia transformation, but it appears that JAK inhibitors will offer an important palliative option and because of the mol. complexity in these diseases, it might be rational to give these inhibitors along with other agents that target alternate mechanisms of the disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9CHRkn6f18LVg90H21EOLACvtfcHk0lh8Qd6KV6PCFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12rtrjE&md5=3e285c17603fc94799264d6fbc9fa6eb</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e32834d1b22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e32834d1b22%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DB.%2BL.%26aulast%3DCrispino%26aufirst%3DJ.%2BD.%26aulast%3DMoliterno%26aufirst%3DA.%2BR.%26atitle%3DJanus%2520kinase%2520inhibitors%253A%2520an%2520update%2520on%2520the%2520progress%2520and%2520promise%2520of%2520targeted%2520therapy%2520in%2520the%2520myeloproliferative%2520neoplasms%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2011%26volume%3D23%26spage%3D609%26epage%3D616%26doi%3D10.1097%2FCCO.0b013e32834d1b22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellacasa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carobbio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Introna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaldi, A.</span></span> <span> </span><span class="NLM_article-title">The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2405049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fsj.leu.2405049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=18079739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=740-747&author=V.+Gueriniauthor=V.+Barbuiauthor=O.+Spinelliauthor=A.+Salviauthor=C.+Dellacasaauthor=A.+Carobbioauthor=M.+Intronaauthor=T.+Barbuiauthor=J.+Golayauthor=A.+Rambaldi&title=The+histone+deacetylase+inhibitor+ITF2357+selectively+targets+cells+bearing+mutated+JAK2%28V617F%29&doi=10.1038%2Fsj.leu.2405049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F</span></div><div class="casAuthors">Guerini, V.; Barbui, V.; Spinelli, O.; Salvi, A.; Dellacasa, C.; Carobbio, A.; Introna, M.; Barbui, T.; Golay, J.; Rambaldi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-747</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors investigated the activity of ITF2357, a novel histone deacetylase inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2V617F mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line.  The clonogenic activity of JAK2V617F mutated cells was inhibited by low concns. of ITF2357 (IC50 0.001-0.01 μ), 100- to 250-fold lower than required to inhibit growth of normal or tumor cells lacking this mutation.  Under these conditions, ITF2357 allowed a seven fold increase in the outgrowth of unmutated over mutated colonies.  By western blotting the authors showed that in HEL cells, ITF2357 led to the disappearance of total and phosphorylated JAK2V617F as well as pSTAT5 and pSTAT3, but it did not affect the wild-type JAK2 or STAT proteins in the control K562 cell line.  By real-time PCR, the authors showed that, upon exposure to ITF2357, JAK2V617F mRNA was not modified in granulocytes from PV patients while the expression of the PRV-1 gene, a known target of JAK2, was rapidly downmodulated.  Altogether, the data presented suggest that ITF2357 inhibits proliferation of cells bearing the JAK2V617F mutation through a specific down-modulation of the JAK2V617F protein and inhibition of its downstream signaling.  Leukemia (2008) 22, 740-747; doi:10.1038/sj.leu.2405049; published online 13 Dec. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJVQmHmDb8RLVg90H21EOLACvtfcHk0lhviOqfeB4NNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D&md5=de59fdaf20ec85e733052c09733b9193</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2405049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2405049%26sid%3Dliteratum%253Aachs%26aulast%3DGuerini%26aufirst%3DV.%26aulast%3DBarbui%26aufirst%3DV.%26aulast%3DSpinelli%26aufirst%3DO.%26aulast%3DSalvi%26aufirst%3DA.%26aulast%3DDellacasa%26aufirst%3DC.%26aulast%3DCarobbio%26aufirst%3DA.%26aulast%3DIntrona%26aufirst%3DM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DGolay%26aufirst%3DJ.%26aulast%3DRambaldi%26aufirst%3DA.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520ITF2357%2520selectively%2520targets%2520cells%2520bearing%2520mutated%2520JAK2%2528V617F%2529%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D740%26epage%3D747%26doi%3D10.1038%2Fsj.leu.2405049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on Pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+Janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+Pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0lhviOqfeB4NNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520Pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>– <span class="NLM_lpage">10846</span>, <span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+design+and+simple+chemistry+yield+a+superior%2C+neuroprotective+HDAC6+inhibitor%2C+tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0lhviOqfeB4NNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520design%2520and%2520simple%2520chemistry%2520yield%2520a%2520superior%252C%2520neuroprotective%2520HDAC6%2520inhibitor%252C%2520tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X.T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of Janus kinase (JAK) and histone deacetylase (HDAC) based on Ruxolitinib and Vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+Janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+Ruxolitinib+and+Vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0lh1oC7x3fFOqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.T.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.Y.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520Ruxolitinib%2520and%2520Vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClure, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inks, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span> <span> </span><span class="NLM_article-title">Development of allosteric hydrazide-containing class I histone deacetylase inhibitors for use in acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9942</span>– <span class="NLM_lpage">9959</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01385</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01385" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs12gtbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9942-9959&author=J.+J.+McClureauthor=C.+Zhangauthor=E.+S.+Inksauthor=Y.+K.+Petersonauthor=J.+Liauthor=C.+J.+Chou&title=Development+of+allosteric+hydrazide-containing+class+I+histone+deacetylase+inhibitors+for+use+in+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.6b01385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia</span></div><div class="casAuthors">McClure, Jesse J.; Zhang, Cheng; Inks, Elizabeth S.; Peterson, Yuri K.; Li, Jiaying; Chou, C. James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9942-9959</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the biggest hurdles yet to be overcome for the continued improvement of Histone Deacetylase (HDAC) inhibitors is finding alternative motifs equipotent to the classic and ubiquitously used hydroxamic acid.  The N-hydroxyl group of this motif is highly subject to sulfation/glucoronidation-based inactivation in humans; compds. contg. this motif require much higher dosing in clinic to achieve therapeutic concns.  With the goal of developing a second generation of HDAC inhibitors, lacking this hydroxamate, the authors designed a series of potent and selective class I HDAC inhibitors using a hydrazide motif.  These inhibitors are impervious to glucuronidation and demonstrate allosteric inhibition.  In vitro and ex vivo characterization of the authors' lead analogs' efficacy, selectivity, and toxicity profiles demonstrate they possess low nanomolar activity against models of Acute Myeloid Leukemia (AML) and are at least 100-fold more selective for AML than solid immortalized cells such as HEK293 or human peripheral blood mononuclear cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdee-0DZN6zbVg90H21EOLACvtfcHk0lh1oC7x3fFOqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs12gtbrE&md5=52d5222010a0de3cfecde9a04c3efb84</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01385%26sid%3Dliteratum%253Aachs%26aulast%3DMcClure%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DInks%26aufirst%3DE.%2BS.%26aulast%3DPeterson%26aufirst%3DY.%2BK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26atitle%3DDevelopment%2520of%2520allosteric%2520hydrazide-containing%2520class%2520I%2520histone%2520deacetylase%2520inhibitors%2520for%2520use%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9942%26epage%3D9959%26doi%3D10.1021%2Facs.jmedchem.6b01385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00584-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2FS1470-2045%2815%2900584-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27049457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=622-631&author=A.+Younesauthor=J.+G.+Berdejaauthor=M.+R.+Patelauthor=I.+Flinnauthor=J.+F.+Gerecitanoauthor=S.+S.+Neelapuauthor=K.+R.+Kellyauthor=A.+R.+Copelandauthor=A.+Akinsauthor=M.+S.+Clancyauthor=L.+Gongauthor=J.+Wangauthor=A.+Maauthor=J.+L.+Vinerauthor=Y.+Oki&title=Safety%2C+tolerability%2C+and+preliminary+activity+of+CUDC-907%2C+a+first-in-class%2C+oral%2C+dual+inhibitor+of+HDAC+and+PI3K%2C+in+patients+with+relapsed+or+refractory+lymphoma+or+multiple+myeloma%3A+an+open-label%2C+dose-escalation%2C+phase+1+trial&doi=10.1016%2FS1470-2045%2815%2900584-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span></div><div class="casAuthors">Younes, Anas; Berdeja, Jesus G.; Patel, Manish R.; Flinn, Ian; Gerecitano, John F.; Neelapu, Sattva S.; Kelly, Kevin R.; Copeland, Amanda R.; Akins, Amy; Clancy, Myles S.; Gong, Lucy; Wang, Jing; Ma, Anna; Viner, Jaye L.; Oki, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-631</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited.  CUDC-907 is an oral, first-in-class, small mol. that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematol. malignancies.  We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma.  This open-label, first-in-man, phase 1 trial recruited adult patients (aged ≥18 years) with lymphoma or multiple myeloma who were refractory to or had relapsed after two or more previous regimens, from four US cancer centers.  CUDC-907 was orally administered in a std. 3 + 3 dose-escalation design at four different dosing schedules, to which participants were sequentially assigned as follows: once daily, intermittently (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day break (5/2), in 21-day cycles.  Dosing started at 30 mg for the once-daily schedule and 60 mg for other schedules, escalating in 30 mg increments.  Patients continued to receive CUDC-907 until disease progression or until other treatment discontinuation criteria were met.  The primary objective was to det. the max. tolerated dose (MTD) and recommended phase 2 dose, assessed in patients who received at least 66% of cycle 1 doses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irresp. of dose modification.  We assessed safety in all patients who received at least one dose of study drug.  This ongoing trial is registered at ClinicalTrials.gov, no. NCT01742988.  Between Jan 23, 2013, and July 27, 2015, we enrolled 44 patients, of whom ten were sequentially assigned to CUDC-907 once-daily (MTD 60 mg), 12 to twice-weekly (MTD 150 mg), 15 to three-times-weekly (MTD 150 mg), and seven to the 5/2 dosing schedule (MTD 60 mg). 37 (84%) patients had discontinued study drug as a result of progressive disease or clin. signs of progressive disease at the data cutoff.  Four DLTs occurred in three of 40 DLT-evaluable patients (diarrhoea and hyperglycemia in one patient on 60 mg once daily, hyperglycemia in one patient on 150 mg twice weekly, and diarrhoea in one patient on 150 mg three times weekly); no DLTs were reported in patients on the 5/2 schedule.  Grade 3 or worse adverse events occurred in 19 (43%) of 44 patients, the most common of which were thrombocytopenia (in nine [20%] of 44 patients), neutropenia (three [7%]), and hyperglycemia (three [7%]). 11 (25%) of 44 patients had serious adverse events, three of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycemia).  Adverse events led to dose redns. in six (14%) patients and treatment discontinuation in seven (16%).  Five (14%) of 37 response-evaluable patients achieved an objective response (two complete responses and three partial responses).  All five responses occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three occurred in those with transformed follicular lymphoma DLBCL (n=5). 21 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's lymphoma, and multiple myeloma.  On the basis of these findings, we selected CUDC-907 60 mg on the 5/2 dosing schedule as the recommended phase 2 dose.  The safety and tolerability profile of CUDC-907 and the promising preliminary evidence of response support continued development of CUDC-907 at the 60 mg 5/2 dosing schedule, alone and in combination with other therapies.  A dose-expansion trial of this dose in patients with refractory and relapsed DLBCL in particular, is ongoing.  Curis, Inc, and the Leukemia and Lymphoma Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFEt7vSuwM7Vg90H21EOLACvtfcHk0lh1oC7x3fFOqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D&md5=b759c77ac239b6ae0052d30c9bea3221</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900584-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900584-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DCopeland%26aufirst%3DA.%2BR.%26aulast%3DAkins%26aufirst%3DA.%26aulast%3DClancy%26aufirst%3DM.%2BS.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DOki%26aufirst%3DY.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520preliminary%2520activity%2520of%2520CUDC-907%252C%2520a%2520first-in-class%252C%2520oral%252C%2520dual%2520inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520lymphoma%2520or%2520multiple%2520myeloma%253A%2520an%2520open-label%252C%2520dose-escalation%252C%2520phase%25201%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D622%26epage%3D631%26doi%3D10.1016%2FS1470-2045%2815%2900584-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 54 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chien-Tien Chen, Santosh Salunke, Tzu-Tang Wei, Yen-An Tang, <span class="NLM_string-name hlFld-ContribAuthor">Yi-Ching Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorescent Nanohybrids from ZnS/CdSe Quantum Dots Functionalized with Triantennary, N-Hydroxy-p-(4-arylbutanamido)benzamide/Gallamide Dendrons That Act as Inhibitors of Histone Deacetylase for Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Bio Materials</span><span> <strong>2021,</strong> <em>4 </em>
                                    (3)
                                     , 2475-2489. <a href="https://doi.org/10.1021/acsabm.0c01438" title="DOI URL">https://doi.org/10.1021/acsabm.0c01438</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsabm.0c01438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsabm.0c01438%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Bio%2520Materials%26atitle%3DFluorescent%252BNanohybrids%252Bfrom%252BZnS%25252FCdSe%252BQuantum%252BDots%252BFunctionalized%252Bwith%252BTriantennary%25252C%252BN-Hydroxy-p-%2525284-arylbutanamido%252529benzamide%25252FGallamide%252BDendrons%252BThat%252BAct%252Bas%252BInhibitors%252Bof%252BHistone%252BDeacetylase%252Bfor%252BLung%252BCancer%26aulast%3DChen%26aufirst%3DChien-Tien%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D05112020%26date%3D26012021%26date%3D09022021%26volume%3D4%26issue%3D3%26spage%3D2475%26epage%3D2489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tingting Liu, Yichao Wan, Yuliang Xiao, Chengcai Xia, <span class="NLM_string-name hlFld-ContribAuthor">Guiyun Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 8977-9002. <a href="https://doi.org/10.1021/acs.jmedchem.0c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual-Target%252BInhibitors%252BBased%252Bon%252BHDACs%25253A%252BNovel%252BAntitumor%252BAgents%252Bfor%252BCancer%252BTherapy%26aulast%3DLiu%26aufirst%3DTingting%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D23032020%26date%3D30042020%26date%3D22042020%26volume%3D63%26issue%3D17%26spage%3D8977%26epage%3D9002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Annalisa Romanelli, Giulia Stazi, Rossella Fioravanti, Clemens Zwergel, Elisabetta Di Bello, Silvia Pomella, Clara Perrone, Cecilia Battistelli, Raffaele Strippoli, Marco Tripodi, Donatella del Bufalo, Rossella Rota, Daniela Trisciuoglio, Antonello Mai, <span class="NLM_string-name hlFld-ContribAuthor">Sergio Valente</span>. </span><span class="cited-content_cbyCitation_article-title">Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (5)
                                     , 977-983. <a href="https://doi.org/10.1021/acsmedchemlett.0c00014" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00014%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Bof%252BFirst-in-Class%252BDual%252BEZH2%25252FHDAC%252BInhibitor%25253A%252BBiochemical%252BActivity%252Band%252BBiological%252BEvaluation%252Bin%252BCancer%252BCells%26aulast%3DRomanelli%26aufirst%3DAnnalisa%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09012020%26date%3D19032020%26date%3D26032020%26date%3D19032020%26volume%3D11%26issue%3D5%26spage%3D977%26epage%3D983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Loganathan Rangasamy, Irene Ortín, José María Zapico, Claire Coderch, Ana Ramos, <span class="NLM_string-name hlFld-ContribAuthor">Beatriz de Pascual-Teresa</span>. </span><span class="cited-content_cbyCitation_article-title">New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (5)
                                     , 713-719. <a href="https://doi.org/10.1021/acsmedchemlett.9b00561" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00561%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNew%252BDual%252BCK2%25252FHDAC1%252BInhibitors%252Bwith%252BNanomolar%252BInhibitory%252BActivity%252Bagainst%252BBoth%252BEnzymes%26aulast%3DRangasamy%26aufirst%3DLoganathan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D30112019%26date%3D07042020%26date%3D10042020%26date%3D07042020%26volume%3D11%26issue%3D5%26spage%3D713%26epage%3D719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, Carina Danchik, Suiyang Liu, Pranav Shah, Amy Q. Wang, Garrett Dunn, Md Kabir, Elias C. Padilha, Xin Xu, Anton Simeonov, Surender Kharbanda, Richard Stone, <span class="NLM_string-name hlFld-ContribAuthor">Gurmit Grewal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4256-4292. <a href="https://doi.org/10.1021/acs.jmedchem.0c00193" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BQuinazolin-4-one-Based%252BHydroxamic%252BAcids%252Bas%252BDual%252BPI3K%25252FHDAC%252BInhibitors%26aulast%3DThakur%26aufirst%3DAshish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03022020%26date%3D08042020%26date%3D26032020%26volume%3D63%26issue%3D8%26spage%3D4256%26epage%3D4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lin Chen, <span class="NLM_string-name hlFld-ContribAuthor">Jin He</span>. </span><span class="cited-content_cbyCitation_article-title">DABCO-Catalyzed Michael/Alkylation Cascade Reactions Involving α-Substituted Ammonium Ylides for the Construction of Spirocyclopropyl Oxindoles: Access to the Powerful Chemical Leads against HIV-1. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (8)
                                     , 5203-5219. <a href="https://doi.org/10.1021/acs.joc.9b03164" title="DOI URL">https://doi.org/10.1021/acs.joc.9b03164</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b03164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b03164%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDABCO-Catalyzed%252BMichael%25252FAlkylation%252BCascade%252BReactions%252BInvolving%252B%2525CE%2525B1-Substituted%252BAmmonium%252BYlides%252Bfor%252Bthe%252BConstruction%252Bof%252BSpirocyclopropyl%252BOxindoles%25253A%252BAccess%252Bto%252Bthe%252BPowerful%252BChemical%252BLeads%252Bagainst%252BHIV-1%26aulast%3DChen%26aufirst%3DLin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D03122019%26date%3D03042020%26date%3D23032020%26volume%3D85%26issue%3D8%26spage%3D5203%26epage%3D5219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gábor
Zoltán Elek, Kaur Koppel, Dzmitry M. Zubrytski, Nele Konrad, Ivar Järving, Margus Lopp, <span class="NLM_string-name hlFld-ContribAuthor">Dzmitry G. Kananovich</span>. </span><span class="cited-content_cbyCitation_article-title">Divergent Access to Histone Deacetylase Inhibitory Cyclopeptides via a Late-Stage Cyclopropane Ring Cleavage Strategy. Short Synthesis of Chlamydocin. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (20)
                                     , 8473-8478. <a href="https://doi.org/10.1021/acs.orglett.9b03305" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b03305</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b03305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b03305%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDivergent%252BAccess%252Bto%252BHistone%252BDeacetylase%252BInhibitory%252BCyclopeptides%252Bvia%252Ba%252BLate-Stage%252BCyclopropane%252BRing%252BCleavage%252BStrategy.%252BShort%252BSynthesis%252Bof%252BChlamydocin%26aulast%3DElek%26aufirst%3DG%25C3%25A1bor%2BZolt%25C3%25A1n%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D18092019%26date%3D09102019%26volume%3D21%26issue%3D20%26spage%3D8473%26epage%3D8478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kehui Zhang, Fangfang Lai, Songwen Lin, Ming Ji, Jingbo Zhang, Yan Zhang, Jing Jin, Rong Fu, Deyu Wu, Hua Tian, Nina Xue, Li Sheng, Xiaowen Zou, Yan Li, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6992-7014. <a href="https://doi.org/10.1021/acs.jmedchem.9b00390" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00390%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B4-Methyl%252BQuinazoline%252BDerivatives%252Bas%252BAnticancer%252BAgents%252BSimultaneously%252BTargeting%252BPhosphoinositide%252B3-Kinases%252Band%252BHistone%252BDeacetylases%26aulast%3DZhang%26aufirst%3DKehui%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03032019%26date%3D29052019%26date%3D22052019%26volume%3D62%26issue%3D15%26spage%3D6992%26epage%3D7014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yong Chen, Xue Yuan, Wanhua Zhang, Minghai Tang, Li Zheng, Fang Wang, Wei Yan, Shengyong Yang, Yuquan Wei, Jun He, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (3)
                                     , 1577-1592. <a href="https://doi.org/10.1021/acs.jmedchem.8b01825" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01825</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01825%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BDual%252BHistone%252BDeacetylase%252Band%252BMammalian%252BTarget%252Bof%252BRapamycin%252BTarget%252BInhibitors%252Bas%252Ba%252BPromising%252BStrategy%252Bfor%252BCancer%252BTherapy%26aulast%3DChen%26aufirst%3DYong%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D22112018%26date%3D24012019%26date%3D10012019%26volume%3D62%26issue%3D3%26spage%3D1577%26epage%3D1592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Chao  Duan</span>, <span class="hlFld-ContribAuthor ">Shao-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Jing  Shi</span>, <span class="hlFld-ContribAuthor ">Lin-Feng  Jin</span>, <span class="hlFld-ContribAuthor ">Tong  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Song</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Guan</span>. </span><span class="cited-content_cbyCitation_article-title">Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113588. <a href="https://doi.org/10.1016/j.ejmech.2021.113588" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113588</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113588%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DResearch%252Bprogress%252Bof%252Bdual%252Binhibitors%252Btargeting%252Bcrosstalk%252Bbetween%252Bhistone%252Bepigenetic%252Bmodulators%252Bfor%252Bcancer%252Btherapy%26aulast%3DDuan%26aufirst%3DYing-Chao%26date%3D2021%26volume%3D222%26spage%3D113588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingming  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Chengjun  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiao  He</span>, <span class="hlFld-ContribAuthor ">Heng  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingkang  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>49 </em>, 128286. <a href="https://doi.org/10.1016/j.bmcl.2021.128286" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128286</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128286%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpyrazolopyrimidine%252Bderivatives%252Bas%252Bpotent%252BmTOR%25252FHDAC%252Bbi-functional%252Binhibitors%252Bvia%252Bpharmacophore-merging%252Bstrategy%26aulast%3DZhang%26aufirst%3DMingming%26date%3D2021%26volume%3D49%26spage%3D128286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tai-Ju  Hsu</span>, <span class="hlFld-ContribAuthor ">Kunal  Nepali</span>, <span class="hlFld-ContribAuthor ">Chi-Hao  Tsai</span>, <span class="hlFld-ContribAuthor ">Zuha  Imtiyaz</span>, <span class="hlFld-ContribAuthor ">Fan-Li  Lin</span>, <span class="hlFld-ContribAuthor ">George  Hsiao</span>, <span class="hlFld-ContribAuthor ">Mei-Jung  Lai</span>, <span class="hlFld-ContribAuthor ">Yu-Wen  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">The HDAC/HSP90 Inhibitor G570 Attenuated Blue Light-Induced Cell Migration in RPE Cells and Neovascularization in Mice through Decreased VEGF Production. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4359. <a href="https://doi.org/10.3390/molecules26144359" title="DOI URL">https://doi.org/10.3390/molecules26144359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144359%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DThe%252BHDAC%25252FHSP90%252BInhibitor%252BG570%252BAttenuated%252BBlue%252BLight-Induced%252BCell%252BMigration%252Bin%252BRPE%252BCells%252Band%252BNeovascularization%252Bin%252BMice%252Bthrough%252BDecreased%252BVEGF%252BProduction%26aulast%3DHsu%26aufirst%3DTai-Ju%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunhua  Ma</span>, <span class="hlFld-ContribAuthor ">Zhiwen  Feng</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Dandan  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Yuqin  Jiang</span>, <span class="hlFld-ContribAuthor ">Bing  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Photocatalytic transition-metal-free direct 3-alkylation of 2-aryl-2
              H
              -indazoles in dimethyl carbonate. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>8 </em>
                                    (13)
                                     , 3286-3291. <a href="https://doi.org/10.1039/D1QO00064K" title="DOI URL">https://doi.org/10.1039/D1QO00064K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1QO00064K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1QO00064K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DPhotocatalytic%252Btransition-metal-free%252Bdirect%252B3-alkylation%252Bof%252B2-aryl-2%252BH%252B-indazoles%252Bin%252Bdimethyl%252Bcarbonate%26aulast%3DMa%26aufirst%3DChunhua%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D13%26spage%3D3286%26epage%3D3291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marton  Siklos</span>, <span class="hlFld-ContribAuthor ">Stefan  Kubicek</span>. </span><span class="cited-content_cbyCitation_article-title">T
              herapeutic targeting of chromatin: status and opportunities. </span><span class="cited-content_cbyCitation_journal-name">The FEBS Journal</span><span> <strong>2021,</strong> <em>17 </em><a href="https://doi.org/10.1111/febs.15966" title="DOI URL">https://doi.org/10.1111/febs.15966</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/febs.15966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Ffebs.15966%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FEBS%2520Journal%26atitle%3DT%252Bherapeutic%252Btargeting%252Bof%252Bchromatin%25253A%252Bstatus%252Band%252Bopportunities%26aulast%3DSiklos%26aufirst%3DMarton%26date%3D2021%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marta  Szumilak</span>, <span class="hlFld-ContribAuthor ">Anna  Wiktorowska-Owczarek</span>, <span class="hlFld-ContribAuthor ">Andrzej  Stanczak</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (9)
                                     , 2601. <a href="https://doi.org/10.3390/molecules26092601" title="DOI URL">https://doi.org/10.3390/molecules26092601</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26092601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26092601%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DHybrid%252BDrugs%2525E2%252580%252594A%252BStrategy%252Bfor%252BOvercoming%252BAnticancer%252BDrug%252BResistance%25253F%26aulast%3DSzumilak%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D9%26spage%3D2601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minh Thanh  La</span>, <span class="hlFld-ContribAuthor ">Byung‐Hoon  Jeong</span>, <span class="hlFld-ContribAuthor ">Hee‐Kwon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Novel
              N
              ‐(2‐aminophenyl)benzamide Derivatives as Histone Deacetylase Inhibitors and Their Antitumor Activity Study. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2021,</strong> <em>42 </em>
                                    (5)
                                     , 740-743. <a href="https://doi.org/10.1002/bkcs.12254" title="DOI URL">https://doi.org/10.1002/bkcs.12254</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bkcs.12254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbkcs.12254%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNovel%252BN%252B%2525E2%252580%252590%2525282%2525E2%252580%252590aminophenyl%252529benzamide%252BDerivatives%252Bas%252BHistone%252BDeacetylase%252BInhibitors%252Band%252BTheir%252BAntitumor%252BActivity%252BStudy%26aulast%3DLa%26aufirst%3DMinh%2BThanh%26date%3D2021%26date%3D2021%26volume%3D42%26issue%3D5%26spage%3D740%26epage%3D743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David G.  Covell</span>, . </span><span class="cited-content_cbyCitation_article-title">Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , e0243336. <a href="https://doi.org/10.1371/journal.pone.0243336" title="DOI URL">https://doi.org/10.1371/journal.pone.0243336</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0243336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0243336%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DBioinformatic%252Banalysis%252Blinking%252Bgenomic%252Bdefects%252Bto%252Bchemosensitivity%252Band%252Bmechanism%252Bof%252Baction%26aulast%3DCovell%26aufirst%3DDavid%2BG.%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D4%26spage%3De0243336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinghua  Ren</span>, <span class="hlFld-ContribAuthor ">Wenqian  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Current status in the discovery of dual BET/HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127829. <a href="https://doi.org/10.1016/j.bmcl.2021.127829" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127829</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127829%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCurrent%252Bstatus%252Bin%252Bthe%252Bdiscovery%252Bof%252Bdual%252BBET%25252FHDAC%252Binhibitors%26aulast%3DRen%26aufirst%3DQinghua%26date%3D2021%26volume%3D38%26spage%3D127829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simin  Sun</span>, <span class="hlFld-ContribAuthor ">Wenwen  Zhao</span>, <span class="hlFld-ContribAuthor ">Yongliang  Li</span>, <span class="hlFld-ContribAuthor ">Ziwei  Chi</span>, <span class="hlFld-ContribAuthor ">Xixi  Fang</span>, <span class="hlFld-ContribAuthor ">Qiang  Wang</span>, <span class="hlFld-ContribAuthor ">Zhiwu  Han</span>, <span class="hlFld-ContribAuthor ">Yepeng  Luan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>108 </em>, 104652. <a href="https://doi.org/10.1016/j.bioorg.2021.104652" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104652%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%252Bevaluation%252Bof%252Bnovel%252BHDAC%252Binhibitors%252Bwith%252Btetrahydrobenzothiazole%252Bas%252Bthe%252Bskeleton%26aulast%3DSun%26aufirst%3DSimin%26date%3D2021%26volume%3D108%26spage%3D104652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Pedro S. M.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Carlos A. M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol‐3‐kinase (PI3K): Current and Future Prospects. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (3)
                                     , 448-457. <a href="https://doi.org/10.1002/cmdc.202000643" title="DOI URL">https://doi.org/10.1002/cmdc.202000643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000643%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DMultitarget%252BInhibition%252Bof%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252Band%252BPhosphatidylinositol%2525E2%252580%2525903%2525E2%252580%252590kinase%252B%252528PI3K%252529%25253A%252BCurrent%252Band%252BFuture%252BProspects%26aulast%3DRodrigues%26aufirst%3DDaniel%2BA.%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D448%26epage%3D457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neha  Upadhyay</span>, <span class="hlFld-ContribAuthor ">Kalpana  Tilekar</span>, <span class="hlFld-ContribAuthor ">Fulvio  Loiodice</span>, <span class="hlFld-ContribAuthor ">Natalia Yu.  Anisimova</span>, <span class="hlFld-ContribAuthor ">Tatiana S.  Spirina</span>, <span class="hlFld-ContribAuthor ">Darina V.  Sokolova</span>, <span class="hlFld-ContribAuthor ">Galina B.  Smirnova</span>, <span class="hlFld-ContribAuthor ">Jun-yong  Choe</span>, <span class="hlFld-ContribAuthor ">Franz-Josef  Meyer-Almes</span>, <span class="hlFld-ContribAuthor ">Vadim S.  Pokrovsky</span>, <span class="hlFld-ContribAuthor ">Antonio  Lavecchia</span>, <span class="hlFld-ContribAuthor ">CS  Ramaa</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>107 </em>, 104527. <a href="https://doi.org/10.1016/j.bioorg.2020.104527" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104527%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPharmacophore%252Bhybridization%252Bapproach%252Bto%252Bdiscover%252Bnovel%252Bpyrazoline-based%252Bhydantoin%252Banalogs%252Bwith%252Banti-tumor%252Befficacy%26aulast%3DUpadhyay%26aufirst%3DNeha%26date%3D2021%26volume%3D107%26spage%3D104527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun  Cheng</span>, <span class="hlFld-ContribAuthor ">Jun  Yang</span>, <span class="hlFld-ContribAuthor ">Si-Wei  Li</span>, <span class="hlFld-ContribAuthor ">Guofu  Huang</span>, <span class="hlFld-ContribAuthor ">Chenxi  Li</span>, <span class="hlFld-ContribAuthor ">Wei-Ping  Min</span>, <span class="hlFld-ContribAuthor ">Yi  Sang</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2021,</strong> <em>12 </em>
                                    (2)
                                     <a href="https://doi.org/10.1038/s41419-021-03417-0" title="DOI URL">https://doi.org/10.1038/s41419-021-03417-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-021-03417-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-021-03417-0%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DHDAC4%252Bpromotes%252Bnasopharyngeal%252Bcarcinoma%252Bprogression%252Band%252Bserves%252Bas%252Ba%252Btherapeutic%252Btarget%26aulast%3DCheng%26aufirst%3DChun%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Jenke</span>, <span class="hlFld-ContribAuthor ">Nina  Reßing</span>, <span class="hlFld-ContribAuthor ">Finn K.  Hansen</span>, <span class="hlFld-ContribAuthor ">Achim  Aigner</span>, <span class="hlFld-ContribAuthor ">Thomas  Büch</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 634. <a href="https://doi.org/10.3390/cancers13040634" title="DOI URL">https://doi.org/10.3390/cancers13040634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040634%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DAnticancer%252BTherapy%252Bwith%252BHDAC%252BInhibitors%25253A%252BMechanism-Based%252BCombination%252BStrategies%252Band%252BFuture%252BPerspectives%26aulast%3DJenke%26aufirst%3DRobert%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shunhao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanji  Gong</span>, <span class="hlFld-ContribAuthor ">Chunjie  Li</span>, <span class="hlFld-ContribAuthor ">Wenbin  Yang</span>, <span class="hlFld-ContribAuthor ">Longjiang  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Beyond regulations at DNA levels: A review of epigenetic therapeutics targeting cancer stem cells. </span><span class="cited-content_cbyCitation_journal-name">Cell Proliferation</span><span> <strong>2021,</strong> <em>54 </em>
                                    (2)
                                     <a href="https://doi.org/10.1111/cpr.12963" title="DOI URL">https://doi.org/10.1111/cpr.12963</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cpr.12963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcpr.12963%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Proliferation%26atitle%3DBeyond%252Bregulations%252Bat%252BDNA%252Blevels%25253A%252BA%252Breview%252Bof%252Bepigenetic%252Btherapeutics%252Btargeting%252Bcancer%252Bstem%252Bcells%26aulast%3DZhang%26aufirst%3DShunhao%26date%3D2021%26date%3D2020%26volume%3D54%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinghua  Ren</span>, <span class="hlFld-ContribAuthor ">Wenqian  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Current status in the discovery of dual BET/HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127671. <a href="https://doi.org/10.1016/j.bmcl.2020.127671" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127671</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127671%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCurrent%252Bstatus%252Bin%252Bthe%252Bdiscovery%252Bof%252Bdual%252BBET%25252FHDAC%252Binhibitors%26aulast%3DRen%26aufirst%3DQinghua%26date%3D2021%26volume%3D31%26spage%3D127671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gargi Nikhil  Vaidya</span>, <span class="hlFld-ContribAuthor ">Pooja  Rana</span>, <span class="hlFld-ContribAuthor ">Ashwini  Venkatesh</span>, <span class="hlFld-ContribAuthor ">Deep Rohan  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Darshan  Contractor</span>, <span class="hlFld-ContribAuthor ">Dinesh Parshuram  Satpute</span>, <span class="hlFld-ContribAuthor ">Mithilesh  Nagpure</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>, <span class="hlFld-ContribAuthor ">Dinesh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Paradigm shift of “classical” HDAC inhibitors to “hybrid” HDAC inhibitors in therapeutic interventions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112844. <a href="https://doi.org/10.1016/j.ejmech.2020.112844" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112844%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DParadigm%252Bshift%252Bof%252B%2525E2%252580%25259Cclassical%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bto%252B%2525E2%252580%25259Chybrid%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bin%252Btherapeutic%252Binterventions%26aulast%3DVaidya%26aufirst%3DGargi%2BNikhil%26date%3D2021%26volume%3D209%26spage%3D112844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amr K.A.  Bass</span>, <span class="hlFld-ContribAuthor ">Mona S.  El-Zoghbi</span>, <span class="hlFld-ContribAuthor ">El-Shimaa M.  Nageeb</span>, <span class="hlFld-ContribAuthor ">Mamdouh F.A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Mohamed  Badr</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112904. <a href="https://doi.org/10.1016/j.ejmech.2020.112904" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112904%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComprehensive%252Breview%252Bfor%252Banticancer%252Bhybridized%252Bmultitargeting%252BHDAC%252Binhibitors%26aulast%3DBass%26aufirst%3DAmr%2BK.A.%26date%3D2021%26volume%3D209%26spage%3D112904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">立园  张</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in the Research of Selective Histone deacetylase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Advances in Material Chemistry</span><span> <strong>2021,</strong> <em>09 </em>
                                    (01)
                                     , 9-23. <a href="https://doi.org/10.12677/AMC.2021.91002" title="DOI URL">https://doi.org/10.12677/AMC.2021.91002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12677/AMC.2021.91002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12677%2FAMC.2021.91002%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvances%2520in%2520Material%2520Chemistry%26atitle%3DProgress%252Bin%252Bthe%252BResearch%252Bof%252BSelective%252BHistone%252Bdeacetylase%252BInhibitors%26aulast%3D%25E5%25BC%25A0%26aufirst%3D%25E7%25AB%258B%25E5%259B%25AD%26date%3D2021%26volume%3D09%26issue%3D01%26spage%3D9%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Gao</span>, <span class="hlFld-ContribAuthor ">Hang  Zhang</span>, <span class="hlFld-ContribAuthor ">Frédéric  Lirussi</span>, <span class="hlFld-ContribAuthor ">Carmen  Garrido</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>182 </em>, 114224. <a href="https://doi.org/10.1016/j.bcp.2020.114224" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114224%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DDual%252Binhibitors%252Bof%252Bhistone%252Bdeacetylases%252Band%252Bother%252Bcancer-related%252Btargets%25253A%252BA%252Bpharmacological%252Bperspective%26aulast%3DGao%26aufirst%3DYuan%26date%3D2020%26volume%3D182%26spage%3D114224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuhong  Dong</span>, <span class="hlFld-ContribAuthor ">Hao  Hu</span>, <span class="hlFld-ContribAuthor ">Yuwei  Sun</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (23)
                                     , 127610. <a href="https://doi.org/10.1016/j.bmcl.2020.127610" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127610%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bc-Met%25252FHDAC%252Bdual%252Binhibitors%26aulast%3DDong%26aufirst%3DYuhong%26date%3D2020%26volume%3D30%26issue%3D23%26spage%3D127610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Pedro de S. M.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Fernanda S.  Sagrillo</span>, <span class="hlFld-ContribAuthor ">Maria L.  Bolognesi</span>, <span class="hlFld-ContribAuthor ">Carlos A. M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (6)
                                     , 2177-2211. <a href="https://doi.org/10.1002/med.21701" title="DOI URL">https://doi.org/10.1002/med.21701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21701%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DHistone%252Bdeacetylases%252Bas%252Btargets%252Bfor%252Bthe%252Btreatment%252Bof%252Bneurodegenerative%252Bdisorders%25253A%252BChallenges%252Band%252Bfuture%252Bopportunities%26aulast%3DRodrigues%26aufirst%3DDaniel%2BA.%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D6%26spage%3D2177%26epage%3D2211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernhard  Biersack</span>, <span class="hlFld-ContribAuthor ">Sibel  Polat</span>, <span class="hlFld-ContribAuthor ">Michael  Höpfner</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer properties of chimeric HDAC and kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2020,</strong> <em>184 </em><a href="https://doi.org/10.1016/j.semcancer.2020.11.005" title="DOI URL">https://doi.org/10.1016/j.semcancer.2020.11.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2020.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2020.11.005%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DAnticancer%252Bproperties%252Bof%252Bchimeric%252BHDAC%252Band%252Bkinase%252Binhibitors%26aulast%3DBiersack%26aufirst%3DBernhard%26date%3D2020%26volume%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kasturi  Ranganna</span>, <span class="hlFld-ContribAuthor ">Chelliah  Selvam</span>, <span class="hlFld-ContribAuthor ">Amruthesh  Shivachar</span>, <span class="hlFld-ContribAuthor ">Zivar  Yousefipour</span>. </span><span class="cited-content_cbyCitation_article-title">Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (21)
                                     , 8198. <a href="https://doi.org/10.3390/ijms21218198" title="DOI URL">https://doi.org/10.3390/ijms21218198</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21218198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21218198%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DHistone%252BDeacetylase%252BInhibitors%252Bas%252BMultitarget-Directed%252BEpi-Drugs%252Bin%252BBlocking%252BPI3K%252BOncogenic%252BSignaling%25253A%252BA%252BPolypharmacology%252BApproach%26aulast%3DRanganna%26aufirst%3DKasturi%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D21%26spage%3D8198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yiming  Chen</span>, <span class="hlFld-ContribAuthor ">Jinhong  Feng</span>, <span class="hlFld-ContribAuthor ">Yajie  Hu</span>, <span class="hlFld-ContribAuthor ">Xuejian  Wang</span>, <span class="hlFld-ContribAuthor ">Weiguo  Song</span>, <span class="hlFld-ContribAuthor ">Lei  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N-(2-Amino-4-Fluorophenyl)-4-[bis-(2-Chloroethyl)-Amino]-Benzamide as a Potent HDAC3 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fonc.2020.592385" title="DOI URL">https://doi.org/10.3389/fonc.2020.592385</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2020.592385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2020.592385%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DDiscovery%252Bof%252BN-%2525282-Amino-4-Fluorophenyl%252529-4-%25255Bbis-%2525282-Chloroethyl%252529-Amino%25255D-Benzamide%252Bas%252Ba%252BPotent%252BHDAC3%252BInhibitor%26aulast%3DChen%26aufirst%3DYiming%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changyong  Guo</span>, <span class="hlFld-ContribAuthor ">Qirong  Wang</span>, <span class="hlFld-ContribAuthor ">Xingjie  Zhang</span>, <span class="hlFld-ContribAuthor ">Fengkun  Lu</span>, <span class="hlFld-ContribAuthor ">Miao  Sun</span>, <span class="hlFld-ContribAuthor ">Peiyu  Zeng</span>, <span class="hlFld-ContribAuthor ">Linhong  Sun</span>, <span class="hlFld-ContribAuthor ">Lan  She</span>, <span class="hlFld-ContribAuthor ">Bingkai  Wang</span>, <span class="hlFld-ContribAuthor ">Yunchang  Zhang</span>, <span class="hlFld-ContribAuthor ">Chen  Wang</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Ma</span>, <span class="hlFld-ContribAuthor ">Feng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Gelated Vorinostat with inner-lysosome triggered release for tumor-targeting chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">Colloids and Surfaces B: Biointerfaces</span><span> <strong>2020,</strong> <em>194 </em>, 111144. <a href="https://doi.org/10.1016/j.colsurfb.2020.111144" title="DOI URL">https://doi.org/10.1016/j.colsurfb.2020.111144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.colsurfb.2020.111144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.colsurfb.2020.111144%26sid%3Dliteratum%253Aachs%26jtitle%3DColloids%2520and%2520Surfaces%2520B%253A%2520Biointerfaces%26atitle%3DGelated%252BVorinostat%252Bwith%252Binner-lysosome%252Btriggered%252Brelease%252Bfor%252Btumor-targeting%252Bchemotherapy%26aulast%3DGuo%26aufirst%3DChangyong%26date%3D2020%26volume%3D194%26spage%3D111144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingqing  Zhang</span>, <span class="hlFld-ContribAuthor ">Tingting  Hao</span>, <span class="hlFld-ContribAuthor ">Dandan  Hu</span>, <span class="hlFld-ContribAuthor ">Zhiyong  Guo</span>, <span class="hlFld-ContribAuthor ">Sui  Wang</span>, <span class="hlFld-ContribAuthor ">Yufang  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">RNA aptamer-driven ECL biosensing for tracing histone acetylation based on nano-prism substrate and cascade DNA amplification strategy. </span><span class="cited-content_cbyCitation_journal-name">Electrochimica Acta</span><span> <strong>2020,</strong> <em>356 </em>, 136828. <a href="https://doi.org/10.1016/j.electacta.2020.136828" title="DOI URL">https://doi.org/10.1016/j.electacta.2020.136828</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.electacta.2020.136828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.electacta.2020.136828%26sid%3Dliteratum%253Aachs%26jtitle%3DElectrochimica%2520Acta%26atitle%3DRNA%252Baptamer-driven%252BECL%252Bbiosensing%252Bfor%252Btracing%252Bhistone%252Bacetylation%252Bbased%252Bon%252Bnano-prism%252Bsubstrate%252Band%252Bcascade%252BDNA%252Bamplification%252Bstrategy%26aulast%3DZhang%26aufirst%3DQingqing%26date%3D2020%26volume%3D356%26spage%3D136828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua P.  Smalley</span>, <span class="hlFld-ContribAuthor ">Shaun M.  Cowley</span>, <span class="hlFld-ContribAuthor ">James T.  Hodgkinson</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional HDAC Therapeutics: One Drug to Rule Them All?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (19)
                                     , 4394. <a href="https://doi.org/10.3390/molecules25194394" title="DOI URL">https://doi.org/10.3390/molecules25194394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25194394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25194394%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBifunctional%252BHDAC%252BTherapeutics%25253A%252BOne%252BDrug%252Bto%252BRule%252BThem%252BAll%25253F%26aulast%3DSmalley%26aufirst%3DJoshua%2BP.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D19%26spage%3D4394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bondada Venkata Mani  Anirudh</span>, <span class="hlFld-ContribAuthor ">Devaraj  Ezhilarasan</span>. </span><span class="cited-content_cbyCitation_article-title">Reactive Oxygen Species–Mediated Mitochondrial Dysfunction Triggers Sodium Valproate–Induced Cytotoxicity in Human Colorectal Adenocarcinoma Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Gastrointestinal Cancer</span><span> <strong>2020,</strong> <em>51 </em><a href="https://doi.org/10.1007/s12029-020-00505-w" title="DOI URL">https://doi.org/10.1007/s12029-020-00505-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12029-020-00505-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12029-020-00505-w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Gastrointestinal%2520Cancer%26atitle%3DReactive%252BOxygen%252BSpecies%2525E2%252580%252593Mediated%252BMitochondrial%252BDysfunction%252BTriggers%252BSodium%252BValproate%2525E2%252580%252593Induced%252BCytotoxicity%252Bin%252BHuman%252BColorectal%252BAdenocarcinoma%252BCells%26aulast%3DAnirudh%26aufirst%3DBondada%2BVenkata%2BMani%26date%3D2020%26date%3D2020%26volume%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaoli  Ding</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Jie  Guo</span>, <span class="hlFld-ContribAuthor ">Maojun  Cheng</span>, <span class="hlFld-ContribAuthor ">Yang  Wan</span>, <span class="hlFld-ContribAuthor ">Rikang  Wang</span>, <span class="hlFld-ContribAuthor ">Yuanying  Fang</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Guan</span>, <span class="hlFld-ContribAuthor ">Yi  Jin</span>, <span class="hlFld-ContribAuthor ">Sai-Sai  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>101 </em>, 104023. <a href="https://doi.org/10.1016/j.bioorg.2020.104023" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bcoumarin-based%252BN-hydroxycinnamamide%252Bderivatives%252Bas%252Bnovel%252Bhistone%252Bdeacetylase%252Binhibitors%252Bwith%252Banticancer%252Bactivities%26aulast%3DDing%26aufirst%3DJiaoli%26date%3D2020%26volume%3D101%26spage%3D104023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel R.  de Lera</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Two-hit wonders: The expanding universe of multitargeting epigenetic agents. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>57 </em>, 135-154. <a href="https://doi.org/10.1016/j.cbpa.2020.05.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTwo-hit%252Bwonders%25253A%252BThe%252Bexpanding%252Buniverse%252Bof%252Bmultitargeting%252Bepigenetic%252Bagents%26aulast%3Dde%2BLera%26aufirst%3DAngel%2BR.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manvendra  Kumar</span>, <span class="hlFld-ContribAuthor ">Gaurav  Joshi</span>, <span class="hlFld-ContribAuthor ">Joydeep  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Raj  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal Growth Factor Receptor and its Trafficking Regulation by Acetylation: Implication in Resistance and Exploring the Newer Therapeutic Avenues in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (12)
                                     , 1105-1123. <a href="https://doi.org/10.2174/1568026620666200207100227" title="DOI URL">https://doi.org/10.2174/1568026620666200207100227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200207100227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200207100227%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DEpidermal%252BGrowth%252BFactor%252BReceptor%252Band%252Bits%252BTrafficking%252BRegulation%252Bby%252BAcetylation%25253A%252BImplication%252Bin%252BResistance%252Band%252BExploring%252Bthe%252BNewer%252BTherapeutic%252BAvenues%252Bin%252BCancer%26aulast%3DKumar%26aufirst%3DManvendra%26date%3D2020%26volume%3D20%26issue%3D12%26spage%3D1105%26epage%3D1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdallah  Hamze</span>. </span><span class="cited-content_cbyCitation_article-title">How do we improve histone deacetylase inhibitor drug discovery?. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2020,</strong> <em>15 </em>
                                    (5)
                                     , 527-529. <a href="https://doi.org/10.1080/17460441.2020.1736032" title="DOI URL">https://doi.org/10.1080/17460441.2020.1736032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2020.1736032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2020.1736032%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DHow%252Bdo%252Bwe%252Bimprove%252Bhistone%252Bdeacetylase%252Binhibitor%252Bdrug%252Bdiscovery%25253F%26aulast%3DHamze%26aufirst%3DAbdallah%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D5%26spage%3D527%26epage%3D529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Song</span>, <span class="hlFld-ContribAuthor ">Cheng  Cao</span>, <span class="hlFld-ContribAuthor ">Shanshan  Tian</span>, <span class="hlFld-ContribAuthor ">Meijing  Long</span>, <span class="hlFld-ContribAuthor ">Ling  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">USP7 Deubiquitinates and Stabilizes SIRT1. </span><span class="cited-content_cbyCitation_journal-name">The Anatomical Record</span><span> <strong>2020,</strong> <em>303 </em>
                                    (5)
                                     , 1337-1345. <a href="https://doi.org/10.1002/ar.24252" title="DOI URL">https://doi.org/10.1002/ar.24252</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ar.24252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Far.24252%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Anatomical%2520Record%26atitle%3DUSP7%252BDeubiquitinates%252Band%252BStabilizes%252BSIRT1%26aulast%3DSong%26aufirst%3DNan%26date%3D2020%26date%3D2019%26volume%3D303%26issue%3D5%26spage%3D1337%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hang  Dong</span>, <span class="hlFld-ContribAuthor ">Qifu  Xu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (4)
                                     , 263-274. <a href="https://doi.org/10.1080/13543776.2020.1725470" title="DOI URL">https://doi.org/10.1080/13543776.2020.1725470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1725470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1725470%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DHistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitors%252Bin%252Bcancer%25253A%252Ba%252Bpatent%252Breview%252B%2525282017-present%252529%26aulast%3DZhao%26aufirst%3DChunlong%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D4%26spage%3D263%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Regina  Martínez</span>, <span class="hlFld-ContribAuthor ">Bruno  Di Geronimo</span>, <span class="hlFld-ContribAuthor ">Miryam  Pastor</span>, <span class="hlFld-ContribAuthor ">José María  Zapico</span>, <span class="hlFld-ContribAuthor ">Claire  Coderch</span>, <span class="hlFld-ContribAuthor ">Rostyslav  Panchuk</span>, <span class="hlFld-ContribAuthor ">Nadia  Skorokhyd</span>, <span class="hlFld-ContribAuthor ">Maciej  Maslyk</span>, <span class="hlFld-ContribAuthor ">Ana  Ramos</span>, <span class="hlFld-ContribAuthor ">Beatriz  de Pascual-Teresa</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (7)
                                     , 1497. <a href="https://doi.org/10.3390/molecules25071497" title="DOI URL">https://doi.org/10.3390/molecules25071497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25071497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25071497%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMultitarget%252BAnticancer%252BAgents%252BBased%252Bon%252BHistone%252BDeacetylase%252Band%252BProtein%252BKinase%252BCK2%252BInhibitors%26aulast%3DMart%25C3%25ADnez%26aufirst%3DRegina%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D7%26spage%3D1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Fabiana S.  Guerra</span>, <span class="hlFld-ContribAuthor ">Fernanda S.  Sagrillo</span>, <span class="hlFld-ContribAuthor ">Pedro  Sena M. Pinheiro</span>, <span class="hlFld-ContribAuthor ">Marina A.  Alves</span>, <span class="hlFld-ContribAuthor ">Sreekanth  Thota</span>, <span class="hlFld-ContribAuthor ">Lorrane S.  Chaves</span>, <span class="hlFld-ContribAuthor ">Carlos M. R.  Sant'Anna</span>, <span class="hlFld-ContribAuthor ">Patrícia D.  Fernandes</span>, <span class="hlFld-ContribAuthor ">Carlos A. M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Pharmacological Evaluation of First‐in‐Class Multitarget
              N
              ‐Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (6)
                                     , 539-551. <a href="https://doi.org/10.1002/cmdc.201900716" title="DOI URL">https://doi.org/10.1002/cmdc.201900716</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900716%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BPharmacological%252BEvaluation%252Bof%252BFirst%2525E2%252580%252590in%2525E2%252580%252590Class%252BMultitarget%252BN%252B%2525E2%252580%252590Acylhydrazone%252BDerivatives%252Bas%252BSelective%252BHDAC6%25252F8%252Band%252BPI3K%2525CE%2525B1%252BInhibitors%26aulast%3DRodrigues%26aufirst%3DDaniel%2BA.%26date%3D2020%26volume%3D15%26issue%3D6%26spage%3D539%26epage%3D551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dandan  Hu</span>, <span class="hlFld-ContribAuthor ">Yufang  Hu</span>, <span class="hlFld-ContribAuthor ">Tianyu  Zhan</span>, <span class="hlFld-ContribAuthor ">Yudi  Zheng</span>, <span class="hlFld-ContribAuthor ">Pingjian  Ran</span>, <span class="hlFld-ContribAuthor ">Xinda  Liu</span>, <span class="hlFld-ContribAuthor ">Zhiyong  Guo</span>, <span class="hlFld-ContribAuthor ">Wenting  Wei</span>, <span class="hlFld-ContribAuthor ">Sui  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Coenzyme A-aptamer-facilitated label-free electrochemical stripping strategy for sensitive detection of histone acetyltransferase activity. </span><span class="cited-content_cbyCitation_journal-name">Biosensors and Bioelectronics</span><span> <strong>2020,</strong> <em>150 </em>, 111934. <a href="https://doi.org/10.1016/j.bios.2019.111934" title="DOI URL">https://doi.org/10.1016/j.bios.2019.111934</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bios.2019.111934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bios.2019.111934%26sid%3Dliteratum%253Aachs%26jtitle%3DBiosensors%2520and%2520Bioelectronics%26atitle%3DCoenzyme%252BA-aptamer-facilitated%252Blabel-free%252Belectrochemical%252Bstripping%252Bstrategy%252Bfor%252Bsensitive%252Bdetection%252Bof%252Bhistone%252Bacetyltransferase%252Bactivity%26aulast%3DHu%26aufirst%3DDandan%26date%3D2020%26volume%3D150%26spage%3D111934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Su</span>, <span class="hlFld-ContribAuthor ">Qiang  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Yepeng  Luan</span>. </span><span class="cited-content_cbyCitation_article-title">Novel histone deacetylase inhibitors bearing a 4‐piperidin‐4‐yl‐triazole scaffold as antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Drug Development Research</span><span> <strong>2020,</strong> <em>81 </em>
                                    (1)
                                     , 52-61. <a href="https://doi.org/10.1002/ddr.21603" title="DOI URL">https://doi.org/10.1002/ddr.21603</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ddr.21603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fddr.21603%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Development%2520Research%26atitle%3DNovel%252Bhistone%252Bdeacetylase%252Binhibitors%252Bbearing%252Ba%252B4%2525E2%252580%252590piperidin%2525E2%252580%2525904%2525E2%252580%252590yl%2525E2%252580%252590triazole%252Bscaffold%252Bas%252Bantitumor%252Bagents%26aulast%3DWang%26aufirst%3DYan%26date%3D2020%26date%3D2019%26volume%3D81%26issue%3D1%26spage%3D52%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feifei  Yang</span>, <span class="hlFld-ContribAuthor ">Na  Zhao</span>, <span class="hlFld-ContribAuthor ">Yunjie  Hu</span>, <span class="hlFld-ContribAuthor ">Cheng‐Shi  Jiang</span>, <span class="hlFld-ContribAuthor ">Hua  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2020,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1002/cbdv.201900427" title="DOI URL">https://doi.org/10.1002/cbdv.201900427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201900427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201900427%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DThe%252BDevelopment%252BProcess%25253A%252Bfrom%252BSAHA%252Bto%252BHydroxamate%252BHDAC%252BInhibitors%252Bwith%252BBranched%252BCAP%252BRegion%252Band%252BLinear%252BLinker%26aulast%3DYang%26aufirst%3DFeifei%26date%3D2020%26date%3D2019%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Di  Ge</span>, <span class="hlFld-ContribAuthor ">Lina  Han</span>, <span class="hlFld-ContribAuthor ">Feifei  Yang</span>, <span class="hlFld-ContribAuthor ">Na  Zhao</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Hua  Zhang</span>, <span class="hlFld-ContribAuthor ">Yihua  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Development of hydroxamate-based histone deacetylase inhibitors of bis-substituted aromatic amides with antitumor activities. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     , 1828-1837. <a href="https://doi.org/10.1039/C9MD00306A" title="DOI URL">https://doi.org/10.1039/C9MD00306A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00306A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00306A%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDevelopment%252Bof%252Bhydroxamate-based%252Bhistone%252Bdeacetylase%252Binhibitors%252Bof%252Bbis-substituted%252Baromatic%252Bamides%252Bwith%252Bantitumor%252Bactivities%26aulast%3DGe%26aufirst%3DDi%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D10%26spage%3D1828%26epage%3D1837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Baolei  Wang</span>, <span class="hlFld-ContribAuthor ">Xuehong  Chen</span>, <span class="hlFld-ContribAuthor ">Jianjun  Gao</span>, <span class="hlFld-ContribAuthor ">Li  Su</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Hongwei  Xu</span>, <span class="hlFld-ContribAuthor ">Yepeng  Luan</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (18)
                                     , 2638-2645. <a href="https://doi.org/10.1016/j.bmcl.2019.07.045" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.07.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.07.045%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAnti-tumor%252Bactivity%252Bevaluation%252Bof%252Bnovel%252Btubulin%252Band%252BHDAC%252Bdual-targeting%252Binhibitors%26aulast%3DWang%26aufirst%3DBaolei%26date%3D2019%26volume%3D29%26issue%3D18%26spage%3D2638%26epage%3D2645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhuang  Yang</span>, <span class="hlFld-ContribAuthor ">Mingsheng  Shen</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Wanhua  Zhang</span>, <span class="hlFld-ContribAuthor ">Xue  Cui</span>, <span class="hlFld-ContribAuthor ">Zihao  Zhang</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Yong  Li</span>, <span class="hlFld-ContribAuthor ">Mengshi  Hu</span>, <span class="hlFld-ContribAuthor ">Peng  Bai</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 116-130. <a href="https://doi.org/10.1016/j.ejmech.2019.05.089" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.089</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.089%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1%25252C2%25252C4-oxadiazole-Containing%252Bhydroxamic%252Bacid%252Bderivatives%252Bas%252Bhistone%252Bdeacetylase%252Binhibitors%252Bpotential%252Bapplication%252Bin%252Bcancer%252Btherapy%26aulast%3DYang%26aufirst%3DZhuang%26date%3D2019%26volume%3D178%26spage%3D116%26epage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zishuo  Mou</span>, <span class="hlFld-ContribAuthor ">Jianjun  Gao</span>, <span class="hlFld-ContribAuthor ">He  Miao</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Su</span>, <span class="hlFld-ContribAuthor ">Baolei  Wang</span>, <span class="hlFld-ContribAuthor ">Yepeng  Luan</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel histone deacetylase 6 inhibitors with benzyl-triazole as the core skeleton. </span><span class="cited-content_cbyCitation_journal-name">BioScience Trends</span><span> <strong>2019,</strong> <em>13 </em>
                                    (3)
                                     , 267-272. <a href="https://doi.org/10.5582/bst.2019.01054" title="DOI URL">https://doi.org/10.5582/bst.2019.01054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5582/bst.2019.01054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5582%2Fbst.2019.01054%26sid%3Dliteratum%253Aachs%26jtitle%3DBioScience%2520Trends%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252Bhistone%252Bdeacetylase%252B6%252Binhibitors%252Bwith%252Bbenzyl-triazole%252Bas%252Bthe%252Bcore%252Bskeleton%26aulast%3DMou%26aufirst%3DZishuo%26date%3D2019%26volume%3D13%26issue%3D3%26spage%3D267%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia  Stazi</span>, <span class="hlFld-ContribAuthor ">Rossella  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>, <span class="hlFld-ContribAuthor ">Andrea  Mattevi</span>, <span class="hlFld-ContribAuthor ">Sergio  Valente</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2019,</strong> <em>50 </em>, 89-100. <a href="https://doi.org/10.1016/j.cbpa.2019.03.002" title="DOI URL">https://doi.org/10.1016/j.cbpa.2019.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2019.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2019.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DHistone%252Bdeacetylases%252Bas%252Ban%252Bepigenetic%252Bpillar%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bhybrid%252Binhibitors%252Bin%252Bcancer%26aulast%3DStazi%26aufirst%3DGiulia%26date%3D2019%26volume%3D50%26spage%3D89%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Histone acetylation is regulated by HAT and HDAC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Five approved HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural features of kinase/HDAC hybrid inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Erlotinib-based hybrid HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Lapatinib-based hybrid HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. A vandetanib-based hybrid HDAC inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) The proposed binding mode of pazopanib in the ATP pocket of VEGFR-2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3CJG">3CJG</a>). (B) Pazopanib-based hybrid HDAC inhibitor <b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. A selective c-Met-derived hybrid HDAC inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Hybrid HDAC inhibitor based on the structure of imatinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of PI3K inhibitors containing a morpholine group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compound <b>21</b> binds the PI3K isoform p110γ active site with a critical H-bond (green dotted line) formed between the oxygen atom of the morpholine moiety and the hydrogen of the Val882 residue (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DBS">3DBS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of PI3K/HDAC hybrid inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. A c-Src/HDAC hybrid inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/medium/jm-2018-00189r_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. JAK2/HDAC hybrid inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b00189/20190404/images/large/jm-2018-00189r_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00189&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58447" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58447" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 96 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballestar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villar-Garea, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boix-Chornet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schotta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaldi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haydon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ropero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Rosado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calasanz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colomer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piris, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imhof, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenuwein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/ng1531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fng1531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=15765097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislCmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2005&pages=391-400&author=M.+F.+Fragaauthor=E.+Ballestarauthor=A.+Villar-Gareaauthor=M.+Boix-Chornetauthor=J.+Espadaauthor=G.+Schottaauthor=T.+Bonaldiauthor=C.+Haydonauthor=S.+Roperoauthor=K.+Petrieauthor=N.+G.+Iyerauthor=A.+Perez-Rosadoauthor=E.+Calvoauthor=J.+A.+Lopezauthor=A.+Canoauthor=M.+J.+Calasanzauthor=D.+Colomerauthor=M.+A.+Pirisauthor=N.+Ahnauthor=A.+Imhofauthor=C.+Caldasauthor=T.+Jenuweinauthor=M.+Esteller&title=Loss+of+acetylation+at+Lys16+and+trimethylation+at+Lys20+of+histone+H4+is+a+common+hallmark+of+human+cancer&doi=10.1038%2Fng1531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer</span></div><div class="casAuthors">Fraga, Mario F.; Ballestar, Esteban; Villar-Garea, Ana; Boix-Chornet, Manuel; Espada, Jesus; Schotta, Gunnar; Bonaldi, Tiziana; Haydon, Claire; Ropero, Santiago; Petrie, Kevin; Iyer, N. Gopalakrishna; Perez-Rosado, Alberto; Calvo, Enrique; Lopez, Juan A.; Cano, Amparo; Calasanz, Maria J.; Colomer, Dolors; Piris, Miguel Angel; Ahn, Natalie; Imhof, Axel; Caldas, Carlos; Jenuwein, Thomas; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">391-400</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CpG island hypermethylation and global genomic hypomethylation are common epigenetic features of cancer cells.  Less attention has been focused on histone modifications in cancer cells.  We characterized post-translational modifications to histone H4 in a comprehensive panel of normal tissues, cancer cell lines and primary tumors.  Using immunodetection, high-performance capillary electrophoresis and mass spectrometry, we found that cancer cells had a loss of mono-acetylated and tri-methylated forms of histone H4.  These changes appeared early and accumulated during the tumorigenic process, as we showed in a mouse model of multistage skin carcinogenesis.  The losses occurred predominantly at the acetylated Lys16 and tri-methylated Lys20 residues of histone H4 and were assocd. with the hypomethylation of DNA repetitive sequences, a well-known characteristic of cancer cells.  Our data suggest that the global loss of mono-acetylation and trimethylation of histone H4 is a common hallmark of human tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu31lIr4J0I7Vg90H21EOLACvtfcHk0ljBsk_iLi7yqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislCmurg%253D&md5=073e669384a63eaac751c9ad1ebf4449</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fng1531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1531%26sid%3Dliteratum%253Aachs%26aulast%3DFraga%26aufirst%3DM.%2BF.%26aulast%3DBallestar%26aufirst%3DE.%26aulast%3DVillar-Garea%26aufirst%3DA.%26aulast%3DBoix-Chornet%26aufirst%3DM.%26aulast%3DEspada%26aufirst%3DJ.%26aulast%3DSchotta%26aufirst%3DG.%26aulast%3DBonaldi%26aufirst%3DT.%26aulast%3DHaydon%26aufirst%3DC.%26aulast%3DRopero%26aufirst%3DS.%26aulast%3DPetrie%26aufirst%3DK.%26aulast%3DIyer%26aufirst%3DN.%2BG.%26aulast%3DPerez-Rosado%26aufirst%3DA.%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DLopez%26aufirst%3DJ.%2BA.%26aulast%3DCano%26aufirst%3DA.%26aulast%3DCalasanz%26aufirst%3DM.%2BJ.%26aulast%3DColomer%26aufirst%3DD.%26aulast%3DPiris%26aufirst%3DM.%2BA.%26aulast%3DAhn%26aufirst%3DN.%26aulast%3DImhof%26aufirst%3DA.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DJenuwein%26aufirst%3DT.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DLoss%2520of%2520acetylation%2520at%2520Lys16%2520and%2520trimethylation%2520at%2520Lys20%2520of%2520histone%2520H4%2520is%2520a%2520common%2520hallmark%2520of%2520human%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2005%26volume%3D37%26spage%3D391%26epage%3D400%26doi%3D10.1038%2Fng1531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ropero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">The role of histone deacetylases (HDACs) in human cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2007.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.molonc.2007.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=19383284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=19-25&author=S.+Roperoauthor=M.+Esteller&title=The+role+of+histone+deacetylases+%28HDACs%29+in+human+cancer&doi=10.1016%2Fj.molonc.2007.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histone deacetylases (HDACs) in human cancer</span></div><div class="casAuthors">Ropero, Santiago; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The balance of histone acetylation and deacetylation is an epigenetic layer with a crit. role in the regulation of gene expression.  Histone acetylation induced by histone acetyl transferases (HATs) is assocd. with gene transcription, while histone hypoacetylation induced by histone deacetylase (HDAC) activity is assocd. with gene silencing.  Altered expression and mutations of genes that encode HDACs have been linked to tumor development since they both induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell-cycle regulation and apoptosis.  Thus, HDACs are among the most promising therapeutic targets for cancer treatment, and they have inspired researchers to study and develop HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvbJD8bqroSLVg90H21EOLACvtfcHk0ljwUReLcMcFAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI&md5=d925bcde258dce7d53cbb98563e1f2ae</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2007.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2007.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DRopero%26aufirst%3DS.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520histone%2520deacetylases%2520%2528HDACs%2529%2520in%2520human%2520cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2007%26volume%3D1%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.molonc.2007.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span> <span> </span><span class="NLM_article-title">Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1002/med.21320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1002%2Fmed.21320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24782318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVClsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=63-84&author=L.+Zhangauthor=Y.+Hanauthor=Q.+Jiangauthor=C.+Wangauthor=X.+Chenauthor=X.+Liauthor=F.+Xuauthor=Y.+Jiangauthor=Q.+Wangauthor=W.+Xu&title=Trend+of+histone+deacetylase+inhibitors+in+cancer+therapy%3A+isoform+selectivity+or+multitargeted+strategy&doi=10.1002%2Fmed.21320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy</span></div><div class="casAuthors">Zhang, Lei; Han, Yantao; Jiang, Qixiao; Wang, Chunbo; Chen, Xuehong; Li, Xiaoguang; Xu, Fuming; Jiang, Yuqi; Wang, Qiang; Xu, Wenfang</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-84</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Pharmacol. inhibition of histone deacetylases (HDACs) has been successfully applied in the treatment of a wide range of disorders, including Parkinson's disease, infection, cardiac diseases, inflammation, and esp. cancer.  HDAC inhibitors (HDACIs) have been proved to be effective antitumor agents by various stages of investigation.  At present, there are two opposite focuses of HDACI design in the cancer therapy, highly selective inhibitor strategy and dual- or multitargeted inhibitors.  The former method, which is supposed to elucidate the function of individual HDAC and provide candidate inhibitors with fewer side effects, has been widely accepted by the inhibitor developer.  The latter approach, though less practiced, has promising potential for the antitumor therapy based on HDACIs.  Effective HDACIs, some of which are in clinic anticancer research, have been developed by both methods.  In order to gain insight into HDACI design, the strategies and achievements of the two diverse methods are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm6HJUNw_9dLVg90H21EOLACvtfcHk0ljwUReLcMcFAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVClsb3M&md5=791e7d6b057c92f206c8d0d75099e021</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fmed.21320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21320%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DTrend%2520of%2520histone%2520deacetylase%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520isoform%2520selectivity%2520or%2520multitargeted%2520strategy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2015%26volume%3D35%26spage%3D63%26epage%3D84%26doi%3D10.1002%2Fmed.21320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcelloni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binaschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattori, D.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: from bench to clinic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1529</span>, <span class="refDoi"> DOI: 10.1021/jm7011408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7011408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1505-1529&author=M.+Parisauthor=M.+Porcelloniauthor=M.+Binaschiauthor=D.+Fattori&title=Histone+deacetylase+inhibitors%3A+from+bench+to+clinic&doi=10.1021%2Fjm7011408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: From Bench to Clinic</span></div><div class="casAuthors">Paris, Marielle; Porcelloni, Marina; Binaschi, Monica; Fattori, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1505-1529</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Advances in the design and pharmacol. of Histone deacetylase inhibitors is discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMej4R03jKbVg90H21EOLACvtfcHk0ljwUReLcMcFAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D&md5=fd5e8c74c510835517fe5255c5c7dc5b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm7011408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7011408%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DM.%26aulast%3DPorcelloni%26aufirst%3DM.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DFattori%26aufirst%3DD.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520from%2520bench%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1505%26epage%3D1529%26doi%3D10.1021%2Fjm7011408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsin, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span> <span> </span><span class="NLM_article-title">Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">6775</span>– <span class="NLM_lpage">6791</span>, <span class="refDoi"> DOI: 10.1021/jm400564j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400564j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Slsb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6775-6791&author=C.+W.+Yuauthor=P.+T.+Changauthor=L.+W.+Hsinauthor=J.+W.+Chern&title=Quinazolin-4-one+derivatives+as+selective+histone+deacetylase-6+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm400564j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Quinazolin-4-one Derivatives as Selective Histone Deacetylase-6 Inhibitors for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Yu, Chao-Wu; Chang, Pei-Teh; Hsin, Ling-Wei; Chern, Ji-Wang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6775-6791</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel quinazolin-4-one derivs. contg. a hydroxamic acid moiety were designed and synthesized.  All compds. were subjected to histone deacetylase (HDAC) enzymic assays to identify selective HDAC6 inhibitors with nanomolar IC50 values.  (E)-3-(2-Ethyl-7-fluoro-4-oxo-3-phenethyl-3,4-dihydroquinazolin-6-yl)-N-hydroxyacrylamide (I) is the most potent HDAC6 inhibitor (IC50, 8 nM).  In vitro, these compds. induced neurite outgrowth accompanied by growth-assocd. protein 43 expression, and they enhanced the synaptic activities of PC12 and SH-SY5Y neuronal cells without producing toxic or mitogenic effects.  Several of the compds. dramatically increased nonhistone protein acetylation, specifically of α-tubulin.  Some of the more potent HDAC6 inhibitors decreased zinc-mediated β-amyloid aggregation in vitro.  N-Hydroxy-3-(2-methyl-4-oxo-3-phenethyl-3,4-dihydro-quinazolin-7-yl)-acrylamide (II) the most promising drug candidate, selectively inhibits HDAC6 (IC50, 29 nM), practically does not affect human ether-a-go-go-related membrane channel activity (IC50 >10 μM) or cytochrome P 450 activity (IC50 >6.5 μM) in vitro, and significantly improves learning-based performances of mice with β-amyloid-induced hippocampal lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ZyFO0SBaDLVg90H21EOLACvtfcHk0li3quQyRUWD4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Slsb7J&md5=bcc20d956982b1e4e9a706327087f233</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm400564j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400564j%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DP.%2BT.%26aulast%3DHsin%26aufirst%3DL.%2BW.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26atitle%3DQuinazolin-4-one%2520derivatives%2520as%2520selective%2520histone%2520deacetylase-6%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6775%26epage%3D6791%26doi%3D10.1021%2Fjm400564j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camarillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span> <span> </span><span class="NLM_article-title">The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e85570</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0085570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1371%2Fjournal.pone.0085570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24409332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFOjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=J.+Mengauthor=Y.+Liauthor=C.+Camarilloauthor=Y.+Yaoauthor=Y.+Zhangauthor=C.+Xuauthor=L.+Jiang&title=The+anti-tumor+histone+deacetylase+inhibitor+SAHA+and+the+natural+flavonoid+curcumin+exhibit+synergistic+neuroprotection+against+amyloid-beta+toxicity&doi=10.1371%2Fjournal.pone.0085570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity</span></div><div class="casAuthors">Meng, Jia; Li, Yan; Camarillo, Cynthia; Yao, Yue; Zhang, Yina; Xu, Chun; Jiang, Lihong</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e85570/1-e85570/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">With the trend of an increasing aged population worldwide, Alzheimer's disease (AD), an age-related neurodegenerative disorder, as one of the major causes of dementia in elderly people is of growing concern.  Despite the many hard efforts attempted during the past several decades in trying to elucidate the pathol. mechanisms underlying AD and putting forward potential therapeutic strategies, there is still a lack of effective treatments for AD.  The efficacy of many potential therapeutic drugs for AD is of main concern in clin. practice.  For example, large bodies of evidence show that the anti-tumor histone deacetylase (HDAC) inhibitor, suberoylanilidehydroxamic acid (SAHA), may be of benefit for the treatment of AD; however, its extensive inhibition of HDACs makes it a poor therapeutic.  Moreover, the natural flavonoid, curcumin, may also have a potential therapeutic benefit against AD; however, it is plagued by low bioavailability.  Therefore, the integrative effects of SAHA and curcumin were investigated as a protection against amyloid-beta neurotoxicity in vitro.  We hypothesized that at low doses their synergistic effect would improve therapeutic selectivity, based on expts. that showed that at low concns. SAHA and curcumin could provide comprehensive protection against Aβ25-35-induced neuronal damage in PC12 cells, strongly implying potent synergism.  Furthermore, network anal. suggested that the possible mechanism underlying their synergistic action might be derived from restoration of the damaged functional link between Akt and the CBP/p300 pathway, which plays a crucial role in the pathol. development of AD.  Thus, our findings provided a feasible avenue for the application of a synergistic drug combination, SAHA and curcumin, in the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFi8tFoPATybVg90H21EOLACvtfcHk0li3quQyRUWD4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFOjsLg%253D&md5=42024059eba2216cd6f1cf1e048a82d6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0085570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0085570%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCamarillo%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DL.%26atitle%3DThe%2520anti-tumor%2520histone%2520deacetylase%2520inhibitor%2520SAHA%2520and%2520the%2520natural%2520flavonoid%2520curcumin%2520exhibit%2520synergistic%2520neuroprotection%2520against%2520amyloid-beta%2520toxicity%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0085570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvanese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span> <span> </span><span class="NLM_article-title">Reactivation of latent HIV by histone deacetylase inhibitors</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2013.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.tim.2013.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23517573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlSjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=277-285&author=K.+Shirakawaauthor=L.+Chavezauthor=S.+Hakreauthor=V.+Calvaneseauthor=E.+Verdin&title=Reactivation+of+latent+HIV+by+histone+deacetylase+inhibitors&doi=10.1016%2Fj.tim.2013.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Reactivation of latent HIV by histone deacetylase inhibitors</span></div><div class="casAuthors">Shirakawa, Kotaro; Chavez, Leonard; Hakre, Shweta; Calvanese, Vincenzo; Verdin, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">277-285</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Latent HIV persists in CD4+ T cells in infected patients under antiretroviral therapy (ART).  Latency is assocd. with transcriptional silencing of the integrated provirus and driven, at least in part, by histone deacetylases (HDACs), a family of chromatin-assocd. proteins that regulate histone acetylation and the accessibility of DNA to transcription factors.  Remarkably, inhibition of HDACs is sufficient to reactivate a fraction of latent HIV in a variety of exptl. systems.  This basic observation led to the shock and kill idea that forcing the transcriptional activation of HIV might lead to virus expression, to virus- or host-induced cell death of the reactivated cells, and to the eradication of the pool of latently infected cells.  Such intervention might possibly lead to a cure for HIV-infected patients.  Here, we review the basic biol. of HDACs and their inhibitors, the role of HDACs in HIV latency, and recent efforts to use HDAC inhibitors to reactivate latent HIV in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQF9-sQLDUE7Vg90H21EOLACvtfcHk0li3quQyRUWD4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlSjtbk%253D&md5=39bc7bd9e112acf1217e7a5c4ba238fa</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2013.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2013.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DShirakawa%26aufirst%3DK.%26aulast%3DChavez%26aufirst%3DL.%26aulast%3DHakre%26aufirst%3DS.%26aulast%3DCalvanese%26aufirst%3DV.%26aulast%3DVerdin%26aufirst%3DE.%26atitle%3DReactivation%2520of%2520latent%2520HIV%2520by%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DTrends%2520Microbiol.%26date%3D2013%26volume%3D21%26spage%3D277%26epage%3D285%26doi%3D10.1016%2Fj.tim.2013.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vad-Nielsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laustsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogaard, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostergaard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, M. R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3984</span>– <span class="NLM_lpage">3994</span>, <span class="refDoi"> DOI: 10.1128/AAC.00574-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1128%2FAAC.00574-15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=3984-3994&author=K.+L.+Jonssonauthor=M.+Tolstrupauthor=J.+Vad-Nielsenauthor=K.+Kjaerauthor=A.+Laustsenauthor=M.+N.+Andersenauthor=T.+A.+Rasmussenauthor=O.+S.+Sogaardauthor=L.+Ostergaardauthor=P.+W.+Dentonauthor=M.+R.+Jakobsen&title=Histone+deacetylase+inhibitor+romidepsin+inhibits+de+novo+HIV-1+infections&doi=10.1128%2FAAC.00574-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FAAC.00574-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00574-15%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DK.%2BL.%26aulast%3DTolstrup%26aufirst%3DM.%26aulast%3DVad-Nielsen%26aufirst%3DJ.%26aulast%3DKjaer%26aufirst%3DK.%26aulast%3DLaustsen%26aufirst%3DA.%26aulast%3DAndersen%26aufirst%3DM.%2BN.%26aulast%3DRasmussen%26aufirst%3DT.%2BA.%26aulast%3DSogaard%26aufirst%3DO.%2BS.%26aulast%3DOstergaard%26aufirst%3DL.%26aulast%3DDenton%26aufirst%3DP.%2BW.%26aulast%3DJakobsen%26aufirst%3DM.%2BR.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520romidepsin%2520inhibits%2520de%2520novo%2520HIV-1%2520infections%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D3984%26epage%3D3994%26doi%3D10.1128%2FAAC.00574-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiattarella, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sannino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toscano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trimarco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrino, C.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>219</i></span>,  <span class="NLM_fpage">396</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1016/j.ijcard.2016.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ijcard.2016.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27362830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ltFersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2016&pages=396-403&author=G.+G.+Schiattarellaauthor=A.+Sanninoauthor=E.+Toscanoauthor=F.+Cattaneoauthor=B.+Trimarcoauthor=G.+Espositoauthor=C.+Perrino&title=Cardiovascular+effects+of+histone+deacetylase+inhibitors+epigenetic+therapies%3A+Systematic+review+of+62+studies+and+new+hypotheses+for+future+research&doi=10.1016%2Fj.ijcard.2016.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research</span></div><div class="casAuthors">Schiattarella Gabriele Giacomo; Sannino Anna; Toscano Evelina; Cattaneo Fabio; Trimarco Bruno; Esposito Giovanni; Perrino Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">396-403</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHU9cOCIEYRA8IxFYvehhofW6udTcc2eYUK1-7_-s5Jbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ltFersg%253D%253D&md5=f85f4a989a24f78a755011d554434cde</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2016.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2016.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DSchiattarella%26aufirst%3DG.%2BG.%26aulast%3DSannino%26aufirst%3DA.%26aulast%3DToscano%26aufirst%3DE.%26aulast%3DCattaneo%26aufirst%3DF.%26aulast%3DTrimarco%26aufirst%3DB.%26aulast%3DEsposito%26aufirst%3DG.%26aulast%3DPerrino%26aufirst%3DC.%26atitle%3DCardiovascular%2520effects%2520of%2520histone%2520deacetylase%2520inhibitors%2520epigenetic%2520therapies%253A%2520Systematic%2520review%2520of%252062%2520studies%2520and%2520new%2520hypotheses%2520for%2520future%2520research%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2016%26volume%3D219%26spage%3D396%26epage%3D403%26doi%3D10.1016%2Fj.ijcard.2016.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stenzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertzen, C. G.W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquardt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohlke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span> <span> </span><span class="NLM_article-title">Alkoxyurea-based histone deacetylase inhibitors increase cisplatin potency in chemoresistant cancer cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5334</span>– <span class="NLM_lpage">5348</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01538</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01538" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Kgurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5334-5348&author=K.+Stenzelauthor=A.+Hamacherauthor=F.+K.+Hansenauthor=C.+G.W.+Gertzenauthor=J.+Sengerauthor=V.+Marquardtauthor=L.+Marekauthor=M.+Marekauthor=C.+Romierauthor=M.+Remkeauthor=M.+Jungauthor=H.+Gohlkeauthor=M.+U.+Kassackauthor=T.+Kurz&title=Alkoxyurea-based+histone+deacetylase+inhibitors+increase+cisplatin+potency+in+chemoresistant+cancer+cell+lines&doi=10.1021%2Facs.jmedchem.6b01538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines</span></div><div class="casAuthors">Stenzel, Katharina; Hamacher, Alexandra; Hansen, Finn K.; Gertzen, Christoph G. W.; Senger, Johanna; Marquardt, Viktoria; Marek, Linda; Marek, Martin; Romier, Christophe; Remke, Marc; Jung, Manfred; Gohlke, Holger; Kassack, Matthias U.; Kurz, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5334-5348</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and biol. evaluation of potent hydroxamate-based dual HDAC1/6 inhibitors with modest HDAC6 preference and a novel alkoxyurea connecting unit linker region are described.  The biol. studies included the evaluation of antiproliferative effects and HDAC inhibitory activity in the human ovarian cancer cell line A2780, the human squamous carcinoma cell line Cal27, and their cisplatin resistant sublines A2780CisR and Cal27CisR.  The three most potent compds. 1g-i showed IC50 values in the low μM and sub-μM range. 1g-i revealed low nM IC50 values for HDAC6 with up to 15-fold preference over HDAC1, >3500-fold selectivity over HDAC4, and >100-fold selectivity over HDAC8.  Furthermore, their ability to enhance cisplatin sensitivity was analyzed in Cal27 and Cal27CisR cells.  Notably, a 48 h preincubation of 1g-i significantly enhanced the antiproliferative effects of cisplatin in Cal27 and Cal27CisR. 1g-i interacted synergistically with cisplatin.  These effects were more pronounced for the cisplatin resistant subline Cal27CisR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCmxo7R1pOG7Vg90H21EOLACvtfcHk0lhLKIrzhLShHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Kgurw%253D&md5=abec66940d84646599bdb4b1660a5b9e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01538%26sid%3Dliteratum%253Aachs%26aulast%3DStenzel%26aufirst%3DK.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26aulast%3DGertzen%26aufirst%3DC.%2BG.W.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DMarquardt%26aufirst%3DV.%26aulast%3DMarek%26aufirst%3DL.%26aulast%3DMarek%26aufirst%3DM.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DRemke%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DGohlke%26aufirst%3DH.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DKurz%26aufirst%3DT.%26atitle%3DAlkoxyurea-based%2520histone%2520deacetylase%2520inhibitors%2520increase%2520cisplatin%2520potency%2520in%2520chemoresistant%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5334%26epage%3D5348%26doi%3D10.1021%2Facs.jmedchem.6b01538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marson, C. M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.2174/187152009788679976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.2174%2F187152009788679976" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=661-692&author=C.+M.+Marson&title=Histone+deacetylase+inhibitors%3A+design%2C+structure-activity+relationships+and+therapeutic+implications+for+cancer&doi=10.2174%2F187152009788679976"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F187152009788679976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152009788679976%26sid%3Dliteratum%253Aachs%26aulast%3DMarson%26aufirst%3DC.%2BM.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520design%252C%2520structure-activity%2520relationships%2520and%2520therapeutic%2520implications%2520for%2520cancer%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D661%26epage%3D692%26doi%3D10.2174%2F187152009788679976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thurn, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.2217/fon.11.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.2217%2Ffon.11.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=21345145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=263-283&author=K.+T.+Thurnauthor=S.+Thomasauthor=A.+Mooreauthor=P.+N.+Munster&title=Rational+therapeutic+combinations+with+histone+deacetylase+inhibitors+for+the+treatment+of+cancer&doi=10.2217%2Ffon.11.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer</span></div><div class="casAuthors">Thurn, K. Ted; Thomas, Scott; Moore, Amy; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-283</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) regulate the acetylation of a variety of histone and nonhistone proteins, controlling the transcription and regulation of genes involved in cell cycle control, proliferation, survival, DNA repair and differentiation.  Unsurprisingly, HDAC expression is frequently altered in hematol. and solid tumor malignancies.  Two HDAC inhibitors (vorinostat and romidepsin) have been approved by the US FDA for the treatment of cutaneous T-cell lymphoma.  As single agents, treatment with HDAC inhibitors has demonstrated limited clin. benefit for patients with solid tumors, prompting the investigation of novel treatment combinations with other cancer therapeutics.  In this article, the rationales and clin. progress of several combinations with HDAC inhibitors are presented, including DNA-damaging chemotherapeutic agents, radiotherapy, hormonal therapies, DNA methyltransferase inhibitors and various small-mol. inhibitors.  The future application of HDAC inhibitors as a treatment for cancer is discussed, examg. current hurdles to overcome before realizing the potential of this new approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn7EKQGlvu_LVg90H21EOLACvtfcHk0lh15DAQdPn-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWlurs%253D&md5=193fc07f4e19bf16fcd7ee202057ef7c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2217%2Ffon.11.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.11.2%26sid%3Dliteratum%253Aachs%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DRational%2520therapeutic%2520combinations%2520with%2520histone%2520deacetylase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2011%26volume%3D7%26spage%3D263%26epage%3D283%26doi%3D10.2217%2Ffon.11.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niegisch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M. J.</span></span> <span> </span><span class="NLM_article-title">Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.4161/cbt.28469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.4161%2Fcbt.28469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24618845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A280%3ADC%252BC2crislOgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=742-757&author=L.+Rosikauthor=G.+Niegischauthor=U.+Fischerauthor=M.+Jungauthor=W.+A.+Schulzauthor=M.+J.+Hoffmann&title=Limited+efficacy+of+specific+HDAC6+inhibition+in+urothelial+cancer+cells&doi=10.4161%2Fcbt.28469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells</span></div><div class="casAuthors">Rosik Lorena; Niegisch Gunter; Schulz Wolfgang Arthur; Hoffmann Michele Janine; Fischer Ute; Jung Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Cancer biology & therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">742-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epigenetic modifiers such as histone deacetylases (HDACs) have come into focus as novel drug targets for cancer therapy due to their functional role in tumor progression.  Since common pan-HDAC inhibitors have adverse side effects and minor anti-cancer activity against solid tumors, enzyme-specific inhibitors were developed.  HDAC6 is especially well-suited for specific inhibition due to its unique domain structure and mode of action and has been suggested to provide an exceptionally suitable target for cancer therapy.  However, expression and function of HDACs have been insufficiently studied in urothelial cancers (UC), a disease urgently requiring new therapeutic approaches.  The present study sought to evaluate HDAC6 as a target for treatment of urothelial cancers with enzyme-specific inhibitors.  We observed moderate HDAC6 overexpression in urothelial cancer tissues and a broad range of expression in urothelial cancer cell lines.  In the cell lines Tubacin was the most potent inhibitor, compared with Tubastatin and ST-80, but still active only at high micromolar concentrations.  HDAC6 expression levels correlated poorly with sensitivity to enzyme inhibition.  Combined treatments with heat shock, HSP90 inhibition by 17-AAG, proteasome inhibition by bortezomib, or DNA-damaging agents did not result in significant synergistic effects.  Experiments with siRNA-mediated knockdown further underlined that urothelial cancer cells do not critically depend on HDAC6 expression for survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAn8Ee1u_sn--MdeMhXAHkfW6udTcc2eY0MsLaoE0fYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crislOgsg%253D%253D&md5=0e7ecd26290e1c9fee19259b278c940e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4161%2Fcbt.28469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.28469%26sid%3Dliteratum%253Aachs%26aulast%3DRosik%26aufirst%3DL.%26aulast%3DNiegisch%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DU.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DSchulz%26aufirst%3DW.%2BA.%26aulast%3DHoffmann%26aufirst%3DM.%2BJ.%26atitle%3DLimited%2520efficacy%2520of%2520specific%2520HDAC6%2520inhibition%2520in%2520urothelial%2520cancer%2520cells%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2014%26volume%3D15%26spage%3D742%26epage%3D757%26doi%3D10.4161%2Fcbt.28469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D. F.</span></span> <span> </span><span class="NLM_article-title">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ejmech.2017.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=28494256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=195-211&author=R.+G.+Fuauthor=Y.+Sunauthor=W.+B.+Shengauthor=D.+F.+Liao&title=Designing+multi-targeted+agents%3A+An+emerging+anticancer+drug+discovery+paradigm&doi=10.1016%2Fj.ejmech.2017.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span></div><div class="casAuthors">Fu, Rong-geng; Sun, Yuan; Sheng, Wen-bing; Liao, Duan-fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-211</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is to design ligands with max. selectivity to act on individual drug targets.  With the target-based approach, many new chem. entities have been discovered, developed, and further approved as drugs.  However, there are a large no. of complex diseases such as cancer that cannot be effectively treated or cured only with one medicine to modulate the biol. function of a single target.  As simultaneous intervention of two (or multiple) cancer progression relevant targets has shown improved therapeutic efficacy, the innovation of multi-targeted drugs has become a promising and prevailing research topic and numerous multi-targeted anticancer agents are currently at various developmental stages.  However, most multi-pharmacophore scaffolds are usually discovered by serendipity or screening, while rational design by combining existing pharmacophore scaffolds remains an enormous challenge.  In this review, four types of multi-pharmacophore modes are discussed, and the examples from literature will be used to introduce attractive lead compds. with the capability of simultaneously interfering with different enzyme or signaling pathway of cancer progression, which will reveal the trends and insights to help the design of the next generation multi-targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjXR-zscrArVg90H21EOLACvtfcHk0lh15DAQdPn-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D&md5=511561bd2cd186d5dafa905b7257bf32</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DR.%2BG.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DW.%2BB.%26aulast%3DLiao%26aufirst%3DD.%2BF.%26atitle%3DDesigning%2520multi-targeted%2520agents%253A%2520An%2520emerging%2520anticancer%2520drug%2520discovery%2520paradigm%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D195%26epage%3D211%26doi%3D10.1016%2Fj.ejmech.2017.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lgmMef9ogAwQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berube, G.</span></span> <span> </span><span class="NLM_article-title">Advances in the development of hybrid anticancer drugs</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.798296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1517%2F17460441.2013.798296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23646979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOitL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1029-1047&author=S.+Fortinauthor=G.+Berube&title=Advances+in+the+development+of+hybrid+anticancer+drugs&doi=10.1517%2F17460441.2013.798296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the development of hybrid anticancer drugs</span></div><div class="casAuthors">Fortin, Sebastien; Berube, Gervais</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1029-1047</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Hybrid anticancer drugs are of great therapeutic interests as they can potentially overcome most of the pharmacokinetic drawbacks encountered when using conventional anticancer drugs.  In fact, the future of hybrid anticancer drugs is very bright for the discovery of highly potent and selective mols. that triggers two or more cytocidal pharmacol. mechanisms of action acting in synergy to inhibit cancer tumor growth.  Areas covered: This review represents the most advanced and recent data in the field of hybrid anticancer agents covering mainly the past 5 years of research.  It also accounts for other significant reviews already published on the topic of anticancer hybrids.  The review showcases the research that is at the leading edge of hybrid anticancer drug discovery.  The main areas covered by the present review are: DNA alkylating agent hybrids (e.g., platinum(II), nitrogen mustard, etc.), vitamin-D receptor, agonist-histone deacetylase inhibitors, combi-mol. therapies and other types of hybrid anticancer agents.  Expert opinion: The current development in the field describes strategies that have never been used before for the design of hybrid anticancer drugs.  The information currently available and described in this section allows us to identify the main parameters required to design such mols.  It also provides a clear view of the future directions that must be explored for the successful development and discovery of useful hybrid anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1FoQV3stg57Vg90H21EOLACvtfcHk0lgmMef9ogAwQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOitL7E&md5=d5157ee2d3cc8778f9129b051bf52e0d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.798296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.798296%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DBerube%26aufirst%3DG.%26atitle%3DAdvances%2520in%2520the%2520development%2520of%2520hybrid%2520anticancer%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D1029%26epage%3D1047%26doi%3D10.1517%2F17460441.2013.798296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berube, G.</span></span> <span> </span><span class="NLM_article-title">An overview of molecular hybrids in drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1517/17460441.2016.1135125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1517%2F17460441.2016.1135125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=281-305&author=G.+Berube&title=An+overview+of+molecular+hybrids+in+drug+discovery&doi=10.1517%2F17460441.2016.1135125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1517%2F17460441.2016.1135125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2016.1135125%26sid%3Dliteratum%253Aachs%26aulast%3DBerube%26aufirst%3DG.%26atitle%3DAn%2520overview%2520of%2520molecular%2520hybrids%2520in%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D281%26epage%3D305%26doi%3D10.1517%2F17460441.2016.1135125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Anticancer activities of histone deacetylase inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nrd2133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+W.+Johnstone&title=Anticancer+activities+of+histone+deacetylase+inhibitors&doi=10.1038%2Fnrd2133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0lgmMef9ogAwQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DAnticancer%2520activities%2520of%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784%26doi%3D10.1038%2Fnrd2133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bots, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Rational combinations using HDAC inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3970</span>– <span class="NLM_lpage">3977</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-08-2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=19509171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntlOis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3970-3977&author=M.+Botsauthor=R.+W.+Johnstone&title=Rational+combinations+using+HDAC+inhibitors&doi=10.1158%2F1078-0432.CCR-08-2786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Combinations Using HDAC Inhibitors</span></div><div class="casAuthors">Bots, Michael; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3970-3977</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  In addn. to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis.  As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as anticancer drugs.  In numerous in vitro and preclin. settings, these compds. have shown their vast potential as single agent anticancer therapies, but unfortunately equiv. responses have not always been obsd. in patients.  Given the pleiotropic effects HDACi have on malignant cells, their true therapeutic potential most likely lies in combination with other anticancer drugs.  In this review we will focus on the anticancer effects of HDACi when combined with other cancer therapeutics with an emphasis on those combinations based on a strong mol. rationale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhLnwCXjHtPbVg90H21EOLACvtfcHk0lgmMef9ogAwQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntlOis7w%253D&md5=117c52a204aa45615eb04c8600e51c10</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2786%26sid%3Dliteratum%253Aachs%26aulast%3DBots%26aufirst%3DM.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DRational%2520combinations%2520using%2520HDAC%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3970%26epage%3D3977%26doi%3D10.1158%2F1078-0432.CCR-08-2786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frew, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. E.</span></span> <span> </span><span class="NLM_article-title">Enhancing the apoptotic and therapeutic effects of HDAC inhibitors</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2009.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.canlet.2009.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=19359091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=125-133&author=A.+J.+Frewauthor=R.+W.+Johnstoneauthor=J.+E.+Bolden&title=Enhancing+the+apoptotic+and+therapeutic+effects+of+HDAC+inhibitors&doi=10.1016%2Fj.canlet.2009.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing the apoptotic and therapeutic effects of HDAC inhibitors</span></div><div class="casAuthors">Frew, Ailsa J.; Johnstone, Ricky W.; Bolden, Jessica E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-133</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACi) are anti-cancer drugs that have moved rapidly through clin. development and in 2006 vorinostat (SAHA, Zolinza) was given FDA approval for the treatment of cutaneous T cell lymphoma.  Class I, II and IV HDACs that are targets for these compds. deacetylate histone proteins, resulting in chromatin remodelling and altered gene transcription.  In addn., numerous non-histone proteins are modified by acetylation and the inhibition of HDAC activity can therefore affect various mol. processes.  This broad effect on protein function may account for the pleiotropic anti-tumor responses elicited by HDACi that include induction of tumor cell apoptosis, cell cycle arrest, differentiation and senescence, modulation of immune responses and altered angiogenesis.  The ability of HDACi to selectively induce tumor cells to undergo apoptosis is important for the therapeutic efficacy obsd. in pre-clin. models.  Moreover, HDACi can augment the apoptotic effects of other anti-cancer agents that have diverse mol. targets.  While HDACi are promising anti-cancer drugs, particularly given the scope to combine HDACi with other agents, identifying the key mol. events that det. the biol. response of cells to HDACi treatment remains a challenge.  Herein we focus on HDACi-induced apoptosis and discuss the various proteins and pathways that are affected by HDACi to mediate this programmed cell death response.  In addn., we highlight the ability of HDACi to synergise with other anti-cancer agents to potently kill tumor cells and discuss the possible mol. processes that underpin the combination effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp45hSsI-BaJ7Vg90H21EOLACvtfcHk0lhfsxwP-K3UEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtrY%253D&md5=2c647b927be73f7882b745b4edd1791f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DFrew%26aufirst%3DA.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26atitle%3DEnhancing%2520the%2520apoptotic%2520and%2520therapeutic%2520effects%2520of%2520HDAC%2520inhibitors%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D125%26epage%3D133%26doi%3D10.1016%2Fj.canlet.2009.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauvais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levaique, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamlard, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouaissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasselouri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayat-Vignoles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mouhammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuillard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benihoud, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamze, A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tubulin and histone deacetylase inhibitor based on iso-combretastatin A-4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6574</span>– <span class="NLM_lpage">6591</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6574-6591&author=D.+Lamaaauthor=H.+P.+Linauthor=L.+Zigauthor=C.+Bauvaisauthor=G.+Bollotauthor=J.+Bignonauthor=H.+Levaiqueauthor=O.+Pamlardauthor=J.+Duboisauthor=M.+Ouaissiauthor=M.+Souceauthor=A.+Kasselouriauthor=F.+Sallerauthor=D.+Borgelauthor=C.+Jayat-Vignolesauthor=H.+Al-Mouhammadauthor=J.+Feuillardauthor=K.+Benihoudauthor=M.+Alamiauthor=A.+Hamze&title=Design+and+synthesis+of+tubulin+and+histone+deacetylase+inhibitor+based+on+iso-combretastatin+A-4&doi=10.1021%2Facs.jmedchem.8b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4</span></div><div class="casAuthors">Lamaa, Diana; Lin, Hsin-Ping; Zig, Lena; Bauvais, Cyril; Bollot, Guillaume; Bignon, Jerome; Levaique, Helene; Pamlard, Olivier; Dubois, Joelle; Ouaissi, Mehdi; Souce, Martin; Kasselouri, Athena; Saller, Francois; Borgel, Delphine; Jayat-Vignoles, Chantal; Al-Mouhammad, Hazar; Feuillard, Jean; Benihoud, Karim; Alami, Mouad; Hamze, Abdallah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6574-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs have raised considerable interest due to their advantages in the treatment of complex diseases such as cancer.  Their design constitutes a challenge in antitumor drug discovery.  The present study reports a dual inhibition of tubulin polymn. and HDAC activity.  On the basis of 1,1-diarylethylenes (isoCA-4) and belinostat, a series of hybrid mols. was successfully designed and synthesized.  In particular compds., 5f and 5h were proven to be potent inhibitors of both tubulin polymn. and HDAC8 leading to excellent antiproliferative activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGq5rq0opowLVg90H21EOLACvtfcHk0lhfsxwP-K3UEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN&md5=9d7ffe7d11f3dc2e55adcd8d0c511606</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00050%26sid%3Dliteratum%253Aachs%26aulast%3DLamaa%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DH.%2BP.%26aulast%3DZig%26aufirst%3DL.%26aulast%3DBauvais%26aufirst%3DC.%26aulast%3DBollot%26aufirst%3DG.%26aulast%3DBignon%26aufirst%3DJ.%26aulast%3DLevaique%26aufirst%3DH.%26aulast%3DPamlard%26aufirst%3DO.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DOuaissi%26aufirst%3DM.%26aulast%3DSouce%26aufirst%3DM.%26aulast%3DKasselouri%26aufirst%3DA.%26aulast%3DSaller%26aufirst%3DF.%26aulast%3DBorgel%26aufirst%3DD.%26aulast%3DJayat-Vignoles%26aufirst%3DC.%26aulast%3DAl-Mouhammad%26aufirst%3DH.%26aulast%3DFeuillard%26aufirst%3DJ.%26aulast%3DBenihoud%26aufirst%3DK.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DHamze%26aufirst%3DA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tubulin%2520and%2520histone%2520deacetylase%2520inhibitor%2520based%2520on%2520iso-combretastatin%2520A-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6574%26epage%3D6591%26doi%3D10.1021%2Facs.jmedchem.8b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gryder, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rood, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raftery, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azizi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors equipped with estrogen receptor modulation activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5782</span>– <span class="NLM_lpage">5796</span>, <span class="refDoi"> DOI: 10.1021/jm400467w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400467w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5782-5796&author=B.+E.+Gryderauthor=M.+K.+Roodauthor=K.+A.+Johnsonauthor=V.+Patilauthor=E.+D.+Rafteryauthor=L.+P.+Yaoauthor=M.+Riceauthor=B.+Aziziauthor=D.+F.+Doyleauthor=A.+K.+Oyelere&title=Histone+deacetylase+inhibitors+equipped+with+estrogen+receptor+modulation+activity&doi=10.1021%2Fjm400467w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm400467w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400467w%26sid%3Dliteratum%253Aachs%26aulast%3DGryder%26aufirst%3DB.%2BE.%26aulast%3DRood%26aufirst%3DM.%2BK.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DRaftery%26aufirst%3DE.%2BD.%26aulast%3DYao%26aufirst%3DL.%2BP.%26aulast%3DRice%26aufirst%3DM.%26aulast%3DAzizi%26aufirst%3DB.%26aulast%3DDoyle%26aufirst%3DD.%2BF.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520equipped%2520with%2520estrogen%2520receptor%2520modulation%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5782%26epage%3D5796%26doi%3D10.1021%2Fjm400467w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soden, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giblin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furze, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span> <span> </span><span class="NLM_article-title">The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">342</span>, <span class="refDoi"> DOI: 10.1039/c3md00285c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1039%2Fc3md00285c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=342&author=S.+J.+Atkinsonauthor=P.+E.+Sodenauthor=D.+C.+Angellauthor=M.+Bantscheffauthor=C.-w.+Chungauthor=K.+A.+Giblinauthor=N.+Smithersauthor=R.+C.+Furzeauthor=L.+Gordonauthor=G.+Drewesauthor=I.+Riojaauthor=J.+Witheringtonauthor=N.+J.+Parrauthor=R.+K.+Prinjha&title=The+structure+based+design+of+dual+HDAC%2FBET+inhibitors+as+novel+epigenetic+probes&doi=10.1039%2Fc3md00285c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1039%2Fc3md00285c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3md00285c%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DS.%2BJ.%26aulast%3DSoden%26aufirst%3DP.%2BE.%26aulast%3DAngell%26aufirst%3DD.%2BC.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DGiblin%26aufirst%3DK.%2BA.%26aulast%3DSmithers%26aufirst%3DN.%26aulast%3DFurze%26aufirst%3DR.%2BC.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26atitle%3DThe%2520structure%2520based%2520design%2520of%2520dual%2520HDAC%252FBET%2520inhibitors%2520as%2520novel%2520epigenetic%2520probes%26jtitle%3DMedChemComm%26date%3D2014%26volume%3D5%26spage%3D342%26doi%3D10.1039%2Fc3md00285c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taub, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antileukemic activities of piperlongumine and HDAC inhibitor hybrids against acute myeloid leukemia cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7974</span>– <span class="NLM_lpage">7990</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00772</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00772" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7974-7990&author=Y.+Liaoauthor=X.+Niuauthor=B.+Chenauthor=H.+Edwardsauthor=L.+Xuauthor=C.+Xieauthor=H.+Linauthor=L.+Polinauthor=J.+W.+Taubauthor=Y.+Geauthor=Z.+Qin&title=Synthesis+and+antileukemic+activities+of+piperlongumine+and+HDAC+inhibitor+hybrids+against+acute+myeloid+leukemia+cells&doi=10.1021%2Facs.jmedchem.6b00772"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00772%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DTaub%26aufirst%3DJ.%2BW.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520antileukemic%2520activities%2520of%2520piperlongumine%2520and%2520HDAC%2520inhibitor%2520hybrids%2520against%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7974%26epage%3D7990%26doi%3D10.1021%2Facs.jmedchem.6b00772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7965</span>– <span class="NLM_lpage">7983</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7965-7983&author=G.+Dongauthor=W.+Chenauthor=X.+Wangauthor=X.+Yangauthor=T.+Xuauthor=P.+Wangauthor=W.+Zhangauthor=Y.+Raoauthor=C.+Miaoauthor=C.+Sheng&title=Small+molecule+inhibitors+simultaneously+targeting+cancer+metabolism+and+epigenetics%3A+discovery+of+novel+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facs.jmedchem.7b00467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Dong, Guoqiang; Chen, Wei; Wang, Xia; Yang, Xinglin; Xu, Tianying; Wang, Pei; Zhang, Wannian; Rao, Yu; Miao, Chaoyu; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7965-7983</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer metab. and epigenetics are among the most intensely pursued research areas in anticancer drug discovery.  Here we report the first small mols. that simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT)and histone deacetylase (HDAC), two important targets of cancer metab. and epigenetics, resp.  Through iterative structure-based drug design, chem. synthesis, and biol. assays, a highly potent dual NAMPT and HDAC inhibitor was successfully identified.  Compd. 35 possessed excellent and balanced activities against both NAMPT (IC50 = 31 nM) and HDAC1 (IC50 = 55 nM).  It could effectively induce cell apoptosis and autophagy and ultimately led to cell death.  Importantly, compd. 35 showed excellent in vivo antitumor efficacy in the HCT116 xenograft model.  This proof-of-concept study demonstrates the feasibility of discovering an inhibitor targeting cancer metab. and epigenetics and provides an efficient strategy for multitarget antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9UvfGattu1rVg90H21EOLACvtfcHk0lig_ErOernFpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO&md5=65df0b485cbbc169886d34ae4421f814</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00467%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DC.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520inhibitors%2520simultaneously%2520targeting%2520cancer%2520metabolism%2520and%2520epigenetics%253A%2520discovery%2520of%2520novel%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7965%26epage%3D7983%26doi%3D10.1021%2Facs.jmedchem.7b00467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HuangFu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ejmech.2018.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=29567459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1OhtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=667-677&author=R.+Ojhaauthor=H.+L.+Huangauthor=W.+C.+HuangFuauthor=Y.+W.+Wuauthor=K.+Nepaliauthor=M.+J.+Laiauthor=C.+J.+Suauthor=T.+Y.+Sungauthor=Y.+L.+Chenauthor=S.+L.+Panauthor=J.+P.+Liou&title=1-Aroylindoline-hydroxamic+acids+as+anticancer+agents%2C+inhibitors+of+HSP90+and+HDAC&doi=10.1016%2Fj.ejmech.2018.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC</span></div><div class="casAuthors">Ojha, Ritu; Huang, Han-Li; Huang Fu, Wei-Chun; Wu, Yi-Wen; Nepali, Kunal; Lai, Mei-Jung; Su, Chih-Jou; Sung, Ting-Yi; Chen, Yi-Lin; Pan, Shiow-Lin; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">667-677</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 1-aroylindoline-hydroxamic acids I [n = 2 - 8] and II were synthesized.  The results of the biol. evaluation led to the identification of compd. I [n = 6] as dual HDAC6/HSP90 inhibitor.  Compd. I [n = 6] displayed striking inhibitory effects towards the HDAC6 isoform and HSP90 protein with IC50 values of 1.15 nM (HDAC6) and 46.3 nM (HSP90).  Compd. I [n = 6] also exhibited 113, 139 and 246 fold higher selectivity for HDAC6 over HDAC 1, HDAC 3 and HDAC 8 isoforms and was endowed with significant cytotoxic effects with GI50 values ranging 1.04-1.61 μM against lung A549, colorectal HCT116, leukemia HL60 and EGFR T790M mutant lung H1975 cell lines.  Another interesting finding of the study was substantial cytotoxic effects of compd. I particularly against lung H1975 (NSCLC) cell lines with IC50 = 0.26 μM which was mediated through HSP90 inhibition.  Compd. I [n = 2] as such was devoid of HDAC inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgF2Cb1sTQY7Vg90H21EOLACvtfcHk0lig_ErOernFpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1OhtLk%253D&md5=7c6b877c774d207150bf49c45f9a9303</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DOjha%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DHuangFu%26aufirst%3DW.%2BC.%26aulast%3DWu%26aufirst%3DY.%2BW.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DSu%26aufirst%3DC.%2BJ.%26aulast%3DSung%26aufirst%3DT.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D1-Aroylindoline-hydroxamic%2520acids%2520as%2520anticancer%2520agents%252C%2520inhibitors%2520of%2520HSP90%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D667%26epage%3D677%26doi%3D10.1016%2Fj.ejmech.2018.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span>; <span class="NLM_string-name">Stafford, J. A.</span></span> <i>Kinase Inhibitor Drugs</i>, <span class="NLM_edition">1st</span> ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1002%2F9780470524961" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Li&author=J.+A.+Stafford&title=Kinase+Inhibitor+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2F9780470524961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470524961%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26btitle%3DKinase%2520Inhibitor%2520Drugs%26pub%3DWiley%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caflisch, A.</span></span> <span> </span><span class="NLM_article-title">Current kinase inhibitors cover a tiny fraction of fragment space</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2372</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.bmcl.2015.04.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2372-2376&author=H.+Zhaoauthor=A.+Caflisch&title=Current+kinase+inhibitors+cover+a+tiny+fraction+of+fragment+space&doi=10.1016%2Fj.bmcl.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCaflisch%26aufirst%3DA.%26atitle%3DCurrent%2520kinase%2520inhibitors%2520cover%2520a%2520tiny%2520fraction%2520of%2520fragment%2520space%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2372%26epage%3D2376%26doi%3D10.1016%2Fj.bmcl.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defert, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span> <span> </span><span class="NLM_article-title">Rho kinase (ROCK) inhibitors and their therapeutic potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2269</span>– <span class="NLM_lpage">2300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00683</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00683" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Oqtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2269-2300&author=Y.+Fengauthor=P.+V.+LoGrassoauthor=O.+Defertauthor=R.+Li&title=Rho+kinase+%28ROCK%29+inhibitors+and+their+therapeutic+potential&doi=10.1021%2Facs.jmedchem.5b00683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential</span></div><div class="casAuthors">Feng, Yangbo; LoGrasso, Philip V.; Defert, Olivier; Li, Rongshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2269-2300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rho kinases (ROCKs) belong to the serine-threonine family, the inhibition of which affects the function of many downstream substrates.  As such, ROCK inhibitors have potential therapeutic applicability in a wide variety of pathol. conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis.  To date, two ROCK inhibitors have been approved for clin. use in Japan (fasudil and ripasudil) and one in China (fasudil).  In 1995 fasudil was approved for the treatment of cerebral vasospasm, and more recently, ripasudil was approved for the treatment of glaucoma in 2014.  In this Perspective, we present a comprehensive review of the physiol. and biol. functions for ROCK, the properties and development of over 170 ROCK inhibitors as well as their therapeutic potential, the current status, and future considerations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXh2BorYftcbVg90H21EOLACvtfcHk0liYG2RrOFz6oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Oqtb%252FJ&md5=99b0e10dca303023b1bf382fcb255771</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00683%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DLoGrasso%26aufirst%3DP.%2BV.%26aulast%3DDefert%26aufirst%3DO.%26aulast%3DLi%26aufirst%3DR.%26atitle%3DRho%2520kinase%2520%2528ROCK%2529%2520inhibitors%2520and%2520their%2520therapeutic%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2269%26epage%3D2300%26doi%3D10.1021%2Facs.jmedchem.5b00683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e73</span> <span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eZdf8s6eq4DdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avizienyte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A. P.</span></span> <span> </span><span class="NLM_article-title">Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1042/BJ20080728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1042%2FBJ20080728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=18588508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKhsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2008&pages=197-206&author=E.+Avizienyteauthor=R.+A.+Wardauthor=A.+P.+Garner&title=Comparison+of+the+EGFR+resistance+mutation+profiles+generated+by+EGFR-targeted+tyrosine+kinase+inhibitors+and+the+impact+of+drug+combinations&doi=10.1042%2FBJ20080728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations</span></div><div class="casAuthors">Avizienyte, Egle; Ward, Richard A.; Garner, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">415</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-206</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Recent clin. data indicates that the emergence of mutant drug-resistant kinase alleles may be particularly relevant for targeted kinase inhibitors.  In order to explore how different classes of targeted therapies impact upon resistance mutations, we performed EGFR (epidermal-growth-factor receptor) resistance mutation screens with erlotinib, lapatinib and CI-1033.  Distinct mutation spectra were generated with each inhibitor and were reflective of their resp. mechanisms of action.  Lapatinib yielded the widest variety of mutations, whereas mutational variability was lower in the erlotinib and CI-1033 screens.  Lapatinib was uniquely sensitive to mutations of residues located deep within the selectivity pocket, whereas mutation of either Gly796 or Cys797 resulted in a dramatic loss of CI-1033 potency.  The clin. obsd. T790M mutation was common to all inhibitors, but occurred with varying frequencies.  Importantly, the presence of C797S with T790M in the same EGFR allele conferred complete resistance to erlotinib, lapatinib and CI-1033.  The combination of erlotinib and CI-1033 effectively reduced the no. of drug-resistant clones, suggesting a possible clin. strategy to overcome drug resistance.  Interestingly, our results also indicate that co-expression of ErbB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2) has an impact upon the EGFR resistance mutations obtained, suggesting that ErbB2 may play an active role in the acquisition of drug-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQxFxDD2-BWbVg90H21EOLACvtfcHk0ljVbIYOw0qKsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKhsbnL&md5=bf7ac8190153eb07d94d67b7037be3ab</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1042%2FBJ20080728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20080728%26sid%3Dliteratum%253Aachs%26aulast%3DAvizienyte%26aufirst%3DE.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DGarner%26aufirst%3DA.%2BP.%26atitle%3DComparison%2520of%2520the%2520EGFR%2520resistance%2520mutation%2520profiles%2520generated%2520by%2520EGFR-targeted%2520tyrosine%2520kinase%2520inhibitors%2520and%2520the%2520impact%2520of%2520drug%2520combinations%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D415%26spage%3D197%26epage%3D206%26doi%3D10.1042%2FBJ20080728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. S.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">3161</span>– <span class="NLM_lpage">3168</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=22843888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kmu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=3161-3168&author=M.+J.+Kimauthor=D.+E.+Kimauthor=I.+G.+Jeongauthor=J.+Choiauthor=S.+Jangauthor=J.+H.+Leeauthor=S.+Roauthor=J.+J.+Hwangauthor=C.+S.+Kim&title=HDAC+inhibitors+synergize+antiproliferative+effect+of+sorafenib+in+renal+cell+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells</span></div><div class="casAuthors">Kim, Mi Joung; Kim, Dong Eun; Jeong, In Gab; Choi, Jene; Jang, Sejin; Lee, Je-Hwan; Ro, Seonggu; Hwang, Jung Jin; Kim, Choung-Soo</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3161-3168</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Aim: To investigate the anticancer effect of histone deacetylase inhibitors (HDACIs) in combination with sorafenib in wild-type and mutant von Hippel-Lindau (VHL)-expressing renal cell carcinomas (RCCs).  Materials and Methods: We exposed clear cell RCC cells to HDACIs (vorinostat or belinostat) or sorafenib.  We performed 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assays, western blotting, flow cytometry and enzyme-linked immunosorbent assays (ELISA) to evaluate mechanisms of cell death, and used CalcuSyn to analyze the potential synergism.  Results: HDACIs alone inhibited the growth of clear cell RCC cell lines, increased acetylation of histone 3 and of tubulin, activated caspases-8, -9, and -3, and augmented the sub-G1 population, independently of VHL and permeability glycoprotein (P-gp).  Moreover, pre-treatment of Caki-1 (wild-type VHL) and 786-O (mutant VHL) with HDACIs followed by sorafenib reduced cell viability synergistically via activation of caspases and downregulation of the levels of myeloid leukemia cell differentiation protein (MCL1), phospho-extracellular signal-regulated kinase (ERK), and secreted vascular endothelial growth factor (VEGF).  Conclusion: Sorafenib is more effective in combination with HDACIs even for clear cell RCCs harboring mutant VHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfFkuxF1uM0rVg90H21EOLACvtfcHk0ljVbIYOw0qKsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kmu77K&md5=5d9900ad6923e3a7f2f8714a72718cc6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DJeong%26aufirst%3DI.%2BG.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DJang%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DRo%26aufirst%3DS.%26aulast%3DHwang%26aufirst%3DJ.%2BJ.%26aulast%3DKim%26aufirst%3DC.%2BS.%26atitle%3DHDAC%2520inhibitors%2520synergize%2520antiproliferative%2520effect%2520of%2520sorafenib%2520in%2520renal%2520cell%2520carcinoma%2520cells%26jtitle%3DAnticancer%2520Res.%26date%3D2012%26volume%3D32%26spage%3D3161%26epage%3D3168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, S.</span></span> <span> </span><span class="NLM_article-title">EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2428</span>– <span class="NLM_lpage">2434</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-3479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F0008-5472.CAN-12-3479" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=2428-2434&author=T.+Nakagawaauthor=S.+Takeuchiauthor=T.+Yamadaauthor=H.+Ebiauthor=T.+Sanoauthor=S.+Nanjoauthor=D.+Ishikawaauthor=M.+Satoauthor=Y.+Hasegawaauthor=Y.+Sekidoauthor=S.+Yano&title=EGFR-TKI+resistance+due+to+BIM+polymorphism+can+be+circumvented+in+combination+with+HDAC+inhibition&doi=10.1158%2F0008-5472.CAN-12-3479"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-3479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-3479%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DSano%26aufirst%3DT.%26aulast%3DNanjo%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DD.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DSekido%26aufirst%3DY.%26aulast%3DYano%26aufirst%3DS.%26atitle%3DEGFR-TKI%2520resistance%2520due%2520to%2520BIM%2520polymorphism%2520can%2520be%2520circumvented%2520in%2520combination%2520with%2520HDAC%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D2428%26epage%3D2434%26doi%3D10.1158%2F0008-5472.CAN-12-3479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e810</span> <span class="refDoi"> DOI: 10.1038/cddis.2013.330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fcddis.2013.330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24052078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2mtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&author=M.+C.+Chenauthor=C.+H.+Chenauthor=J.+C.+Wangauthor=A.+C.+Tsaiauthor=J.+P.+Liouauthor=S.+L.+Panauthor=C.+M.+Teng&title=The+HDAC+inhibitor%2C+MPT0E028%2C+enhances+erlotinib-induced+cell+death+in+EGFR-TKI-resistant+NSCLC+cells&doi=10.1038%2Fcddis.2013.330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells</span></div><div class="casAuthors">Chen, M.-C.; Chen, C.-H.; Wang, J.-C.; Tsai, A.-C.; Liou, J.-P.; Pan, S.-L.; Teng, C.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Sept.</span>),
    <span class="NLM_cas:pages">e810</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR), which promotes cell survival and division, is found at abnormally high levels on the surface of many cancer cell types, including many cases of non-small cell lung cancer.  Erlotinib (Tarceva), an oral small-mol. tyrosine kinase inhibitor, is a so-called targeted drug that inhibits the tyrosine kinase domain of EGFR, and thus targets cancer cells with some specificity while doing less damage to normal cells.  However, erlotinib resistance can occur, reducing the efficacy of this treatment.  To develop more effective therapeutic interventions by overcoming this resistance problem, we combined the histone deacetylase inhibitor, MPT0E028, with erlotinib in an effort to increase their antitumor effects in erlotinib-resistant lung adenocarcinoma cells.  This combined treatment yielded significant growth inhibition, induced the expression of apoptotic proteins (PARP, γH2AX, and caspase-3), increased the levels of acetylated histone H3, and showed synergistic effects in vitro and in vivo.  These effects were independent of the mutation status of the genes encoding EGFR or K-Ras.  MPT0E028 synergistically blocked key regulators of the EGFR/HER2 signaling pathways, attenuating multiple compensatory pathways (e.g., AKT, extracellular signal-regulated kinase, and c-MET).  Our results indicate that this combination therapy might be a promising strategy for facilitating the effects of erlotinib monotherapy by activating various networks.  Taken together, our data provide compelling evidence that MPT0E028 has the potential to improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohUhwZb0vDhbVg90H21EOLACvtfcHk0ljVbIYOw0qKsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2mtb7J&md5=5fca3b66a1178f8086b61bcb42eacaa0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.330%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DTsai%26aufirst%3DA.%2BC.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DThe%2520HDAC%2520inhibitor%252C%2520MPT0E028%252C%2520enhances%2520erlotinib-induced%2520cell%2520death%2520in%2520EGFR-TKI-resistant%2520NSCLC%2520cells%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26doi%3D10.1038%2Fcddis.2013.330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1274</span>– <span class="NLM_lpage">1287</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-12-3909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24520095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXks1Ohurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1274-1287&author=C.+H.+Chenauthor=M.+C.+Chenauthor=J.+C.+Wangauthor=A.+C.+Tsaiauthor=C.+S.+Chenauthor=J.+P.+Liouauthor=S.+L.+Panauthor=C.+M.+Teng&title=Synergistic+interaction+between+the+HDAC+inhibitor%2C+MPT0E028%2C+and+sorafenib+in+liver+cancer+cells+in+vitro+and+in+vivo&doi=10.1158%2F1078-0432.CCR-12-3909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo</span></div><div class="casAuthors">Chen, Chun-Han; Chen, Mei-Chuan; Wang, Jing-Chi; Tsai, An-Chi; Chen, Ching-Shih; Liou, Jing-Ping; Pan, Shiow-Lin; Teng, Che-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1274-1287</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To investigate the antitumor activities of a histone deacetylase (HDAC) inhibitor, MPT0E028, plus sorafenib in liver cancer cells in vitro and in vivo.  Exptl. Design: Different liver cancer cell lines were exposed to sorafenib in the presence or absence of MPT0E028, and cell viability was detd. by MTT assay.  Effects of combined treatment on cell cycle and intracellular signaling pathways were assessed by flow cytometry and Western blot anal.  The Hep3B xenograft model was used to examine the antitumor activity in vivo.  Results: Our data indicate that sorafenib and MPT0E028 synergistically reduced cell viability in liver cancer cells, and also markedly induced apoptotic cell death in these cells, as evidenced by the cleavage of caspase-3, PARP, and DNA fragmentation.  MPT0E028 altered the global modifications of histone and nonhistone proteins regardless of the presence of sorafenib.  However, sorafenib blocked MPT0E028-induced Erk activation and its downstream signaling cascades, such as Stat3 phosphorylation (Ser727) and Mcl-1 upregulation.  Ectopic expression of constitutively active Mek successively reversed the apoptosis triggered by the combined treatment.  Pharmacol. inhibition of Mek by PD98059 potentiated MPT0E028-induced apoptosis, suggesting that the synergistic interaction between MPT0E028 and sorafenib occurs at least partly through inhibition of Erk signaling.  The data demonstrated that transcriptional activation of fibroblast growth factor receptor 3 (FGFR3) contributes to MPT0E028-mediated Erk phosphorylation.  Finally, MPT0E028 plus sorafenib significantly improved the tumor growth delay (TGD) in a Hep3B xenograft model.  Conclusions: These findings suggest that MPT0E028 in combination with sorafenib has significant anti-hepatocellular carcinoma activity in preclin. models, potentially suggesting a novel therapeutic strategy for patients with advanced hepatocellular carcinoma.  Clin Cancer Res; 20(5); 1274-87. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3-eBzwYVsbrVg90H21EOLACvtfcHk0lgHNstWX7bx7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXks1Ohurc%253D&md5=35005d2a12294749b98bea5966c388f9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3909%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DTsai%26aufirst%3DA.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BS.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DSynergistic%2520interaction%2520between%2520the%2520HDAC%2520inhibitor%252C%2520MPT0E028%252C%2520and%2520sorafenib%2520in%2520liver%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D1274%26epage%3D1287%26doi%3D10.1158%2F1078-0432.CCR-12-3909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greve, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeifer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubbert, M.</span></span> <span> </span><span class="NLM_article-title">The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">947</span>, <span class="refDoi"> DOI: 10.1186/s12885-015-1967-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1186%2Fs12885-015-1967-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=26675484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGls7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=947&author=G.+Greveauthor=I.+Schiffmannauthor=D.+Pfeiferauthor=M.+Panticauthor=J.+Schulerauthor=M.+Lubbert&title=The+pan-HDAC+inhibitor+panobinostat+acts+as+a+sensitizer+for+erlotinib+activity+in+EGFR-mutated+and+-wildtype+non-small+cell+lung+cancer+cells&doi=10.1186%2Fs12885-015-1967-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells</span></div><div class="casAuthors">Greve, Gabriele; Schiffmann, Insa; Pfeifer, Dietmar; Pantic, Milena; Schueler, Julia; Luebbert, Michael</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">947/1-947/10</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in NSCLC.  These mutations can be targeted by RTK inhibitors (TKIs) such as erlotinib.  Chromatin-modifying agents may offer a novel therapeutic approach by sensitizing tumor cells to TKIs.  Methods: The NSCLC cell lines HCC827 (EGFR mutant, adenocarcinoma), A549 (EGFR wt, adenocarcinoma) and NCI-H460 (EGFR wt, large cell carcinoma) were analyzed by SNP6.0 array.  Changes in proliferation after panobinostat (LBH-589, PS) and erlotinib treatment were quantified by WST-1 assay and apoptosis by Annexin V/7-AAD flow cytometry.  Abundance of target proteins and histone marks (acH3, H3K4me1/2/3) was detd. by immunoblotting.  Results: As expected, the EGFR wt cell lines A549 and NCI-H460 were quite insensitive to the growth-inhibitory effect of erlotinib (IC50 70-100 μM), compared to HCC827 (IC50 < 0.02 μM).  All three cell lines were sensitive to PS treatment (IC50: HCC827 10 nM, A549 20 nM and NCI-H460 35 nM).  The combination of both drugs further reduced proliferation in HCC827 and in A549, but not in NCI-H460.  PS alone induced differentiation and expression of p21WAF1/CIP1 and p53 and decreased CHK1 in all three cell lines, with almost no further effect when combined with erlotinib.  In contrast, combination treatment additively decreased pEGFR, pERK and pAKT in A549.  Both drugs synergistically induced acH3 in the adenocarcinoma lines.  Surprisingly, we also obsd. induction of H3K4 methylation marks after erlotinib treatment in HCC827 and in A549 that was further enhanced by combination with PS.  Conclusion: PS sensitized lung adenocarcinoma cells to the antiproliferative effects of erlotinib.  In these cell lines, the drug combination also had a robust, not previously described effect on histone H3 acetylation and H3K4 methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8pg5eIDl-d7Vg90H21EOLACvtfcHk0lgHNstWX7bx7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGls7bK&md5=d1cf2c00537c0b64419e9b00ad3bc935</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1967-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1967-5%26sid%3Dliteratum%253Aachs%26aulast%3DGreve%26aufirst%3DG.%26aulast%3DSchiffmann%26aufirst%3DI.%26aulast%3DPfeifer%26aufirst%3DD.%26aulast%3DPantic%26aufirst%3DM.%26aulast%3DSchuler%26aufirst%3DJ.%26aulast%3DLubbert%26aufirst%3DM.%26atitle%3DThe%2520pan-HDAC%2520inhibitor%2520panobinostat%2520acts%2520as%2520a%2520sensitizer%2520for%2520erlotinib%2520activity%2520in%2520EGFR-mutated%2520and%2520-wildtype%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D947%26doi%3D10.1186%2Fs12885-015-1967-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, S.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated Osimertinib resistance in EGFR-mutant lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3139</span>– <span class="NLM_lpage">3149</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-16-2271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27986747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVSqurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3139-3149&author=A.+Tanimotoauthor=S.+Takeuchiauthor=S.+Araiauthor=K.+Fukudaauthor=T.+Yamadaauthor=X.+Rocaauthor=S.+T.+Ongauthor=S.+Yano&title=Histone+deacetylase+3+inhibition+overcomes+BIM+deletion+polymorphism-mediated+Osimertinib+resistance+in+EGFR-mutant+lung+cancer&doi=10.1158%2F1078-0432.CCR-16-2271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer</span></div><div class="casAuthors">Tanimoto, Azusa; Takeuchi, Shinji; Arai, Sachiko; Fukuda, Koji; Yamada, Tadaaki; Roca, Xavier; Ong, S. Tiong; Yano, Seiji</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3139-3149</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The BIM deletion polymorphism is assocd. with apoptosis resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI), such as gefitinib and erlotinib, in non-small cell lung cancer (NSCLC) harboring EGFR mutations.  Here, we investigated whether the BIM deletion polymorphism contributes to resistance against osimertinib, a third-generation EGFR-TKI.  In addn., we detd. the efficacy of a histone deacetylase (HDAC) inhibitor, vorinostat, against this form of resistance and elucidated the underlying mechanism.  Exptl. Design: We used EGFR-mutated NSCLC cell lines, which were either heterozygous or homozygous for the BIM deletion polymorphism, to evaluate the effect of osimertinib in vitro and in vivo.  Protein expression was examd. by Western blotting.  Alternative splicing of BIM mRNA was analyzed by RT-PCR.  Results: EGFR-mutated NSCLC cell lines with the BIM deletion polymorphism exhibited apoptosis resistance to osimertinib in a polymorphism dosage-dependent manner, and this resistance was overcome by combined use with vorinostat.  Expts. with homozygous BIM deletion-pos. cells revealed that vorinostat affected the alternative splicing of BIM mRNA in the deletion allele, increased the expression of active BIM protein, and thereby induced apoptosis in osimertinib-treated cells.  These effects were mediated predominantly by HDAC3 inhibition.  In xenograft models, combined use of vorinostat with osimertinib could regress tumors in EGFR-mutated NSCLC cells homozygous for the BIM deletion polymorphism.  Moreover, this combination could induce apoptosis even when tumor cells acquired EGFR-T790M mutations.  Conclusions: These findings indicate the importance of developing HDAC3-selective inhibitors, and their combined use with osimertinib, for treating EGFR-mutated lung cancers carrying the BIM deletion polymorphism.  Clin Cancer Res; 23(12); 3139-49. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqawp9knnH7T7Vg90H21EOLACvtfcHk0lgHNstWX7bx7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVSqurbF&md5=3c08f63c5d8e2860169489294fa87f64</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2271%26sid%3Dliteratum%253Aachs%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DArai%26aufirst%3DS.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DRoca%26aufirst%3DX.%26aulast%3DOng%26aufirst%3DS.%2BT.%26aulast%3DYano%26aufirst%3DS.%26atitle%3DHistone%2520deacetylase%25203%2520inhibition%2520overcomes%2520BIM%2520deletion%2520polymorphism-mediated%2520Osimertinib%2520resistance%2520in%2520EGFR-mutant%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D3139%26epage%3D3149%26doi%3D10.1158%2F1078-0432.CCR-16-2271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilsl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span> <span> </span><span class="NLM_article-title">Generation and assessment of fusions between HDACi and TKi</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1510</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-6527-4_31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1007%2F978-1-4939-6527-4_31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27761839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFCnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1510&publication_year=2017&pages=405-412&author=S.+Mahboobiauthor=B.+Pilslauthor=A.+Sellmer&title=Generation+and+assessment+of+fusions+between+HDACi+and+TKi&doi=10.1007%2F978-1-4939-6527-4_31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Generation and assessment of fusions between HDACi and TKi</span></div><div class="casAuthors">Mahboobi, Siavosh; Pilsl, Bernadette; Sellmer, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1510</span>
        (<span class="NLM_cas:issue">HDAC/HAT Function Assessment and Inhibitor Development</span>),
    <span class="NLM_cas:pages">405-412</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Chimeric compds. combine the structural features of inhibitors of histone deacetylases (HDACi) and tyrosine kinase inhibitors (TKi), and therefore unite the effects of a dual-targeting strategy in one compd.  Here, we describe the generation of such hybrid mols.  Small mols., known as TKi, are combined with a Zn2+ chelating motive, preferentially a hydroxamic acid, in addn.  The resulting small mols. also can inhibit histone deacetylases, which are dependent on the catalytically active Zn2+.  Moreover, we summarize how the growth-inhibitory effects of these combined compds. can be detd. with a simple proliferation assay with a leukemic cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxJ_aSeCzu5LVg90H21EOLACvtfcHk0lh3Dcjejnh-gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFCnsro%253D&md5=f2e6e29292f9c26c5796d848dd39d9c8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-6527-4_31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-6527-4_31%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DPilsl%26aufirst%3DB.%26aulast%3DSellmer%26aufirst%3DA.%26atitle%3DGeneration%2520and%2520assessment%2520of%2520fusions%2520between%2520HDACi%2520and%2520TKi%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2017%26volume%3D1510%26spage%3D405%26epage%3D412%26doi%3D10.1007%2F978-1-4939-6527-4_31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.+X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.+J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDc-101%29+as+a+potent+multi-acting+HDAC%2C+EGFR%2C+and+HER2+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lh3Dcjejnh-gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDc-101%2529%2520as%2520a%2520potent%2520multi-acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munger, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepicelli, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">3647</span>– <span class="NLM_lpage">3656</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.+J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.+G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.+X.+Xuauthor=S.+DellaRoccaauthor=H.+X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0ljSPDz6eCDL6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pursell, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selmi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savagner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span> <span> </span><span class="NLM_article-title">Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">925</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1535-7163.MCT-12-1045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23536719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=925-936&author=J.+Wangauthor=N.+W.+Pursellauthor=M.+E.+Samsonauthor=R.+Atoyanauthor=A.+W.+Maauthor=A.+Selmiauthor=W.+Xuauthor=X.+Caiauthor=M.+Voiauthor=P.+Savagnerauthor=C.+J.+Lai&title=Potential+advantages+of+CUDC-101%2C+a+multitargeted+HDAC%2C+EGFR%2C+and+HER2+inhibitor%2C+in+treating+drug+resistance+and+preventing+cancer+cell+migration+and+invasion&doi=10.1158%2F1535-7163.MCT-12-1045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion</span></div><div class="casAuthors">Wang, Jing; Pursell, Natalie W.; Samson, Maria Elena S.; Atoyan, Ruzanna; Ma, Anna W.; Selmi, Abdelkader; Xu, Wanlu; Cai, Xiong; Voi, Maurizio; Savagner, Pierre; Lai, Cheng-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">925-936</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CUDC-101 is a novel, small-mol., anticancer agent targeting histone deacetylase (HDAC), EGF receptor (EGFR), and HER2.  It is currently in phase I clin. development in patients with solid tumors.  Previously, we reported that CUDC-101 has potent antiproliferative and proapoptotic activity in cultured tumor cells and in vivo xenograft models.  We now show that cancer cells that have acquired resistance to single-target EGFR inhibitors through upregulation of AXL or loss of E-cadherin remain sensitive to CUDC-101, which inhibits MET- and AXL-mediated signaling, restores E-cadherin expression, and reduces cell migration.  CUDC-101 also efficiently inhibited the proliferation of MET-overexpressing non-small cell lung cancer and gastric cancer cell lines and inhibited the migration and invasion of invasive tumor cells.  Taken together, these results suggest that coupling HDAC and HER2 inhibitory activities to an EGFR inhibitor may potentially be effective in overcoming drug resistance and preventing cancer cell migration.  Mol Cancer Ther; 12(6); 925-36. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgzk8IJVCcT7Vg90H21EOLACvtfcHk0ljSPDz6eCDL6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOks70%253D&md5=3d2d647e92c06c6f4c5293c6d0e1285d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPursell%26aufirst%3DN.%2BW.%26aulast%3DSamson%26aufirst%3DM.%2BE.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DSelmi%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DSavagner%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26atitle%3DPotential%2520advantages%2520of%2520CUDC-101%252C%2520a%2520multitargeted%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%252C%2520in%2520treating%2520drug%2520resistance%2520and%2520preventing%2520cancer%2520cell%2520migration%2520and%2520invasion%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D925%26epage%3D936%26doi%3D10.1158%2F1535-7163.MCT-12-1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mays, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laliberte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span> <span> </span><span class="NLM_article-title">Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5032</span>– <span class="NLM_lpage">5040</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-0570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-14-0570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=25107918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5032-5040&author=T.+Shimizuauthor=P.+M.+LoRussoauthor=K.+P.+Papadopoulosauthor=A.+Patnaikauthor=M.+Beeramauthor=L.+S.+Smithauthor=D.+W.+Rascoauthor=T.+A.+Maysauthor=G.+Chambersauthor=A.+Maauthor=J.+Wangauthor=R.+Laliberteauthor=M.+Voiauthor=A.+W.+Tolcher&title=Phase+I+first-in-human+study+of+CUDC-101%2C+a+multitargeted+inhibitor+of+HDACs%2C+EGFR%2C+and+HER2+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-14-0570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Shimizu, Toshio; LoRusso, Patricia M.; Papadopoulos, Kyri P.; Patnaik, Amita; Beeram, Muralidhar; Smith, Lon S.; Rasco, Drew W.; Mays, Theresa A.; Chambers, Glenda; Ma, Anna; Wang, Jing; Laliberte, Robert; Voi, Maurizio; Tolcher, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5032-5040</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This first-in-human phase I study evaluated dose-limiting toxicities (DLT) and defined a phase II recommended dose (RD) for CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 as a 1-h i.v. (i.v.) infusion for 5 consecutive days every 2 wk.  Exptl. Design: Twenty-five patients with advanced solid tumors received escalating doses of CUDC-101 (range, 75-300 mg/m2/day) following a std. 3 + 3 dose escalation design.  Results: The MTD was detd. to be 275 mg/m2.  Common grade 1/2 adverse events included nausea, fatigue, vomiting, dyspnea, pyrexia, and dry skin.  DLTs occurred in 1 patient in the 275-mg/m2 dose cohort (grade 2 serum creatinine elevation, n = 1) and 3 patients in the 300-mg/m2 dose cohort (grade 2 serum creatinine elevation, n = 2; pericarditis, n = 1), all of which were transient and reversible.  CUDC-101 exposure increased linearly with the mean max. concn. (Cmax), clearance (CL), vol. of distribution at steady-state (Vdss), area under curve (AUC), and terminal elimination half-life (t1/2) at the MTD dose of 9.3 mg/L, 51.2 L/h, 39.6 L, 9.95 h·ng/mL and 4.4 h, resp.  Acetylated histone H3 induction was obsd. in posttreatment skin samples from 3 patients in the 275-mg/m2 dose cohort, suggesting adequate systemic exposure and target inhibition.  One patient with gastric cancer had a partial response and 6 patients had stable disease.  Conclusion: CUDC-101 administered by 1-h i.v. infusion for 5 consecutive days every 2 wk was generally well tolerated with preliminary evidence of antitumor activity.  A dose of 275 mg/m2 is recommended for further clin. testing.  Clin Cancer Res; 20(19); 5032-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUrKXLHOzT6LVg90H21EOLACvtfcHk0ljSPDz6eCDL6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzP&md5=62860afa08733980f47047880e11a5ba</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0570%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DL.%2BS.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DMays%26aufirst%3DT.%2BA.%26aulast%3DChambers%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLaliberte%26aufirst%3DR.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DPhase%2520I%2520first-in-human%2520study%2520of%2520CUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520HDACs%252C%2520EGFR%252C%2520and%2520HER2%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5032%26epage%3D5040%26doi%3D10.1158%2F1078-0432.CCR-14-0570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colevas, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saba, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtness, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span> <span> </span><span class="NLM_article-title">A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1573</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-14-2820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=25573383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1566-1573&author=T.+J.+Gallowayauthor=L.+J.+Wirthauthor=A.+D.+Colevasauthor=J.+Gilbertauthor=J.+E.+Baumanauthor=N.+F.+Sabaauthor=D.+Rabenauthor=R.+Mehraauthor=A.+W.+Maauthor=R.+Atoyanauthor=J.+Wangauthor=B.+Burtnessauthor=A.+Jimeno&title=A+phase+I+study+of+CUDC-101%2C+a+multitarget+inhibitor+of+HDACs%2C+EGFR%2C+and+HER2%2C+in+combination+with+chemoradiation+in+patients+with+head+and+neck+squamous+cell+carcinoma&doi=10.1158%2F1078-0432.CCR-14-2820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma</span></div><div class="casAuthors">Galloway, Thomas J.; Wirth, Lori J.; Colevas, Alexander D.; Gilbert, Jill; Bauman, Julie E.; Saba, Nabil F.; Raben, David; Mehra, Ranee; Ma, Anna W.; Atoyan, Ruzanna; Wang, Jing; Burtness, Barbara; Jimeno, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1566-1573</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CUDC-101 is a small mol. that simultaneously inhibits the epidermal growth factor receptor (EGFR), human growth factor receptor 2 (HER2), and histone deacetylase (HDAC) with preclin. activity in head and neck squamous cell cancer (HNSCC).  The primary objective of this investigation is to det. the max. tolerated dose (MTD) of CUDC-101 with cisplatin-radiotherapy in the treatment of HNSCC.  CUDC-101 monotherapy was administered i.v. three times weekly (Monday, Wednesday, Friday) for a one-week run-in, then continued with concurrent cisplatin (100 mg/m2 every 3 wk) and external beam radiation (70 Gy to gross disease) over 7 wk.  Twelve patients with intermediate or high-risk HNSCC enrolled.  Eleven were p16INKa (p16)-neg.  The MTD of CUDC-101-based combination therapy was established at 275 mg/m2/dose.  Five patients discontinued CUDC-101 due to an adverse event (AE); only one was considered a dose-limiting toxicity (DLT), at the MTD.  Pharmacokinetic evaluation suggested low accumulation with this dosing regimen.  HDAC inhibition was demonstrated by pharmacodynamic analyses in peripheral blood mononuclear cells (PBMC), tumor biopsies, and paired skin biopsies.  Paired tumor biopsies demonstrated a trend of EGFR inhibition.  At 1.5 years of median follow-up, there has been one recurrence and two patient deaths (neither attributed to CUDC-101).  The remaining nine patients are free of progression.  CUDC-101, cisplatin, and radiation were feasible in intermediate-/high-risk patients with HNSCC, with no unexpected patterns of AE.  Although the MTD was identified, a high rate of DLT-independent discontinuation of CUDC-101 suggests a need for alternate schedules or routes of administration.  Clin Cancer Res; 21(7); 1566-73. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRDbfIvcyF87Vg90H21EOLACvtfcHk0lhnimkcHsJjXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D&md5=dd6b5663ffbf995b5def843a8b8b7556</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2820%26sid%3Dliteratum%253Aachs%26aulast%3DGalloway%26aufirst%3DT.%2BJ.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26aulast%3DGilbert%26aufirst%3DJ.%26aulast%3DBauman%26aufirst%3DJ.%2BE.%26aulast%3DSaba%26aufirst%3DN.%2BF.%26aulast%3DRaben%26aufirst%3DD.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBurtness%26aufirst%3DB.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520CUDC-101%252C%2520a%2520multitarget%2520inhibitor%2520of%2520HDACs%252C%2520EGFR%252C%2520and%2520HER2%252C%2520in%2520combination%2520with%2520chemoradiation%2520in%2520patients%2520with%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1566%26epage%3D1573%26doi%3D10.1158%2F1078-0432.CCR-14-2820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span> <span> </span><span class="NLM_article-title">Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8546</span>– <span class="NLM_lpage">8555</span>, <span class="refDoi"> DOI: 10.1021/jm100665z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100665z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8546-8555&author=S.+Mahboobiauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Novel+chimeric+histone+deacetylase+inhibitors%3A+a+series+of+lapatinib+hybrides+as+potent+inhibitors+of+epidermal+growth+factor+receptor+%28EGFR%29%2C+human+epidermal+growth+factor+receptor+2+%28HER2%29%2C+and+histone+deacetylase+activity&doi=10.1021%2Fjm100665z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrids as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity</span></div><div class="casAuthors">Mahboobi, Siavosh; Sellmer, Andreas; Winkler, Matthias; Eichhorn, Emerich; Pongratz, Herwig; Ciossek, Thomas; Baer, Thomas; Maier, Thomas; Beckers, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8546-8555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reversible lysine-specific acetylation has been described as an important posttranslational modification, regulating chromatin structure and transcriptional activity in the case of core histone proteins.  Histone deacetylases (HDAC) are considered as a promising target for anticancer drug development, with I as pan-HDAC inhibitor approved for cutaneous T-cell lymphoma therapy and several other HDAC inhibitors currently in preclin. and clin. development.  Protein kinases are a well-established target for cancer therapy with the EGFR/HER2 inhibitor II approved for treatment of advanced, HER2 pos. breast cancer as a prominent example.  The present report presents a novel strategy for cancer drug development by combination of EGFR/HER2 kinase and HDAC inhibitory activity in one mol.  By combining the structural features of II with an (E)-3-(aryl)-N-hydroxyacrylamide motif known from HDAC inhibitors like III or IV, selective inhibitors were obtained for both targets with potent cellular activity (target inhibition and cytotoxicity) of selected compds. V (X = m-phenylene, 2,5-furandiyl).  By combining two distinct pharmacol. properties in one mol., a broader activity spectrum is postulated and less likelihood of drug resistance in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEElZRNfAQZ7Vg90H21EOLACvtfcHk0lhnimkcHsJjXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I&md5=81bba7c00bb26b42c54075acce5ba525</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm100665z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100665z%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DNovel%2520chimeric%2520histone%2520deacetylase%2520inhibitors%253A%2520a%2520series%2520of%2520lapatinib%2520hybrides%2520as%2520potent%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%252C%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252C%2520and%2520histone%2520deacetylase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8546%26epage%3D8555%26doi%3D10.1021%2Fjm100665z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.bmc.2016.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27769671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=27-37&author=C.+Dingauthor=S.+Chenauthor=C.+Zhangauthor=G.+Huauthor=W.+Zhangauthor=L.+Liauthor=Y.+Z.+Chenauthor=C.+Tanauthor=Y.+Jiang&title=Synthesis+and+investigation+of+novel+6-%281%2C2%2C3-triazol-4-yl%29-4-aminoquinazolin+derivatives+possessing+hydroxamic+acid+moiety+for+cancer+therapy&doi=10.1016%2Fj.bmc.2016.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy</span></div><div class="casAuthors">Ding, Chao; Chen, Shaopeng; Zhang, Cunlong; Hu, Guangnan; Zhang, Wei; Li, Lulu; Chen, Yu Zong; Tan, Chunyan; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">By merging the crit. pharmacophore of EGFR/HER2 and HDAC inhibitors into one compd., a novel series of EGFR, HER-2, and HDAC multitarget inhibitors were synthesized.  Compds. 9a-l contained 4-anilinoquinazolines with C-6 triazole-linked long alkyl chains of hydroxamic acid and displayed excellent inhibition against these enzymes (compd. 9d exhibited the best inhibitory potency on wild-type EGFR, HDAC1, and HDAC6 with IC50 values 0.12 nM, 0.72 nM and 3.2 nM individually).  Furthermore, compds. 9b and 9d potently inhibited proliferation of five human cancer cell lines (with IC50 values between 0.49 and 8.76 μM).  Further mechanistic study revealed that compd. 9d also regulated the phosphorylation of EGFR and HER2 and histone H3 hyperacetylation on the cellular level and induced remarkable apoptosis in BT-474 cells.  Therefore, our study suggested that a system network-based multi-target drug design strategy might provided an alternate drug design method, by taking into account the synergy effect of EGFR, HER-2 and HDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Ow9m5nCSsbVg90H21EOLACvtfcHk0lhnimkcHsJjXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FO&md5=8be7d3dbffe5f5b9b305280864e5b633</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520investigation%2520of%2520novel%25206-%25281%252C2%252C3-triazol-4-yl%2529-4-aminoquinazolin%2520derivatives%2520possessing%2520hydroxamic%2520acid%2520moiety%2520for%2520cancer%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.bmc.2016.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tron, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canonico, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span> <span> </span><span class="NLM_article-title">Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1002/med.20107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1002%2Fmed.20107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=17763363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsVerurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=278-308&author=G.+C.+Tronauthor=T.+Piraliauthor=R.+A.+Billingtonauthor=P.+L.+Canonicoauthor=G.+Sorbaauthor=A.+A.+Genazzani&title=Click+chemistry+reactions+in+medicinal+chemistry%3A+applications+of+the+1%2C3-dipolar+cycloaddition+between+azides+and+alkynes&doi=10.1002%2Fmed.20107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes</span></div><div class="casAuthors">Tron, Gian Cesare; Pirali, Tracey; Billington, Richard A.; Canonico, Pier Luigi; Sorba, Giovanni; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-308</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  In recent years, there has been an ever-increasing need for rapid reactions that meet the three main criteria of an ideal synthesis: efficiency, versatility, and selectivity.  Such reactions would allow medicinal chem. to keep pace with the multitude of information derived from modern biol. screening techniques.  The present review describes one of these reactions, the 1,3-dipolar cycloaddn. ("click-reaction") between azides and alkynes catalyzed by copper (I) salts.  The simplicity of this reaction and the ease of purifn. of the resulting products have opened new opportunities in generating vast arrays of compds. with biol. potential.  The present review will outline the accomplishments of this strategy achieved so far and outline some of medicinal chem. applications in which click-chem. might be relevant in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbqDBrdkhYXrVg90H21EOLACvtfcHk0livppWckgbKTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsVerurg%253D&md5=ef565fc46c50047a6181e85711cb5c37</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fmed.20107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20107%26sid%3Dliteratum%253Aachs%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DBillington%26aufirst%3DR.%2BA.%26aulast%3DCanonico%26aufirst%3DP.%2BL.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DClick%2520chemistry%2520reactions%2520in%2520medicinal%2520chemistry%253A%2520applications%2520of%2520the%25201%252C3-dipolar%2520cycloaddition%2520between%2520azides%2520and%2520alkynes%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2008%26volume%3D28%26spage%3D278%26epage%3D308%26doi%3D10.1002%2Fmed.20107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5137</span>– <span class="NLM_lpage">5141</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.bmcl.2015.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=26475519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GkurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5137-5141&author=F.+W.+Pengauthor=T.+T.+Wuauthor=Z.+W.+Renauthor=J.+Y.+Xueauthor=L.+Shi&title=Hybrids+from+4-anilinoquinazoline+and+hydroxamic+acid+as+dual+inhibitors+of+vascular+endothelial+growth+factor+receptor-2+and+histone+deacetylase&doi=10.1016%2Fj.bmcl.2015.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase</span></div><div class="casAuthors">Peng, Fan-Wei; Wu, Ting-Ting; Ren, Zi-Wei; Xue, Jia-Yu; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5137-5141</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of hybrids derived from 4-anilinoquinazoline and hydroxamic acid were designed, synthesized, and evaluated as dual inhibitors of vascular endothelia growth factor receptor-2 (VEGFR-2) tyrosine kinase and histone deacetylase (HDAC).  Most of these compds. exhibited potent HDAC inhibition and moderate VEGFR-2 inhibition.  Among them, compd. I exhibited the most potent inhibitory activities against VEGFR-2 (IC50 = 84 nM) and HDAC (IC50 = 2.8 nM).  It also showed the most potent antiproliferative ability against MCF-7, a human breast cancer line, with IC50 of 1.2 μM.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction of compd. I at the active binding sites of VEGFR-2 and HDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojSWQqbu8Qg7Vg90H21EOLACvtfcHk0livppWckgbKTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GkurfI&md5=f20d34f8da22e171419b48299e253fb8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DHybrids%2520from%25204-anilinoquinazoline%2520and%2520hydroxamic%2520acid%2520as%2520dual%2520inhibitors%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520and%2520histone%2520deacetylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5137%26epage%3D5141%26doi%3D10.1016%2Fj.bmcl.2015.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ejmech.2015.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=26741358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=1-12&author=F.+W.+Pengauthor=J.+Xuanauthor=T.+T.+Wuauthor=J.+Y.+Xueauthor=Z.+W.+Renauthor=D.+K.+Liuauthor=X.+Q.+Wangauthor=X.+H.+Chenauthor=J.+W.+Zhangauthor=Y.+G.+Xuauthor=L.+Shi&title=Design%2C+synthesis+and+biological+evaluation+of+N-phenylquinazolin-4-amine+hybrids+as+dual+inhibitors+of+VEGFR-2+and+HDAC&doi=10.1016%2Fj.ejmech.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span></div><div class="casAuthors">Peng, Fan-Wei; Xuan, Ji; Wu, Ting-Ting; Xue, Jia-Yu; Ren, Zi-Wei; Liu, Da-Ke; Wang, Xiu-Qi; Chen, Xin-Hang; Zhang, Jia-Wei; Xu, Yun-Gen; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, a series of hybrids bearing N-phenylquinazolin-4-amine and hydroxamic acid moieties I (R1, R2 = H, F, Cl, Br, n = 2, 3, 4, 5) were designed and identified as dual VEGFR-2/HDAC inhibitors.  Compd. I (R1 = H, R2 = Br, n = 5) exhibited the most potent inhibitory activity against HDAC with IC50 of 2.2 nM and strong inhibitory effect against VEGFR-2 with IC50 of 74 nM.  It also showed the most potent inhibitory activity against a human breast cancer cell line MCF-7 with IC50 of 0.85 μM.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the active binding sites of VEGFR-2 and HDLP (Histone Deacetylase-Like Protein), which demonstrates that compd. I (R1 = H, R2 = Br, n = 5) is a potential agent for cancer therapy deserving further researching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_jbaom_UR7Vg90H21EOLACvtfcHk0livppWckgbKTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOj&md5=1a0c299ec484daa522da5969e8a35cec</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DXuan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DLiu%26aufirst%3DD.%2BK.%26aulast%3DWang%26aufirst%3DX.%2BQ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DXu%26aufirst%3DY.%2BG.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520N-phenylquinazolin-4-amine%2520hybrids%2520as%2520dual%2520inhibitors%2520of%2520VEGFR-2%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.ejmech.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowska, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartelink, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cripps, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastroserio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of Abexinostat plus Pazopanib in advanced solid tumor malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1239</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.70.5350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1200%2FJCO.2016.70.5350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=28221861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFGrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=1231-1239&author=R.+Aggarwalauthor=S.+Thomasauthor=N.+Pawlowskaauthor=I.+Bartelinkauthor=J.+Grabowskyauthor=T.+Jahanauthor=A.+Crippsauthor=A.+Harbauthor=J.+Lengauthor=A.+Reinertauthor=I.+Mastroserioauthor=T.+G.+Truongauthor=C.+J.+Ryanauthor=P.+N.+Munster&title=Inhibiting+histone+deacetylase+as+a+means+to+reverse+resistance+to+angiogenesis+inhibitors%3A+phase+I+study+of+Abexinostat+plus+Pazopanib+in+advanced+solid+tumor+malignancies&doi=10.1200%2FJCO.2016.70.5350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of abexinostat plus pazopanib in advanced solid tumor malignancies</span></div><div class="casAuthors">Aggarwal, Rahul; Thomas, Scott; Pawlowska, Nela; Bartelink, Imke; Grabowsky, Jennifer; Jahan, Thierry; Cripps, Amy; Harb, Armand; Leng, Jim; Reinert, Anne; Mastroserio, Ilaria; Truong, Thach-Giao; Ryan, Charles J.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1231-1239,S1-S2</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor by using a histone deacetylase abexinostat in combination with pazopanib to enhance response and reverse resistance.  Patients and Methods: Pazopanib was administered once a day on days 1 to 28 and abexinostat was administered orally twice a day on days 1 to 5, 8 to 12, and 15 to 19 (schedule A) or on days 1 to 4, 8 to 11, and 15 to 18 (schedule B).  Dose escalation (3 + 3 design) in all solid tumors was followed by dose expansion in renal cell carcinoma (RCC).  Results: Fifty-one patients with RCC (N = 22) were enrolled, including 30 (59%) with one or more lines of prior VEGF-targeting therapy.  Five dose-limiting toxicities, including fatigue (n = 2), thrombocytopenia (n = 2), and elevated AST/ALT (n = 1), were obsd. with schedule A; one dose-limiting toxicity was obsd. (elevated AST/ALT) was obsd. with schedule B.  Grade ≥ 3 related adverse events included fatigue (16%), thrombocytopenia (16%), and neutropenia (10%).  The recommended phase II dose was established as abexinostat 45 mg/m2 twice a day administered per schedule B plus pazopanib 800 mg/d.  Objective response rate was 21% overall and 27% in the RCC subset.  Median duration of response was 9.1 mo (1.2 to > 49 mo).  Eight patients (16%) had durable control of disease for > 12 mo.  Durable tumor regressions were obsd. in seven (70%) of 10 patients with pazopanib-refractory disease, including one patients with RCC with ongoing response > 3.5 years.  Peripheral blood histone acetylation and HDAC2 gene expression were assocd. with durable response to treatment.  Conclusion: Abexinostat is well tolerated in combination with pazopanib, allowing prolonged exposure and promising durable responses in pazopanib- and other VEGF inhibitor-refractory tumors, which supports epigenetically mediated reversal of treatment resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotzop0Tif1NLVg90H21EOLACvtfcHk0lhOFHNvPamxaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFGrt7Y%253D&md5=31cf19bad52faca73593d583c71e4a6f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.70.5350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.70.5350%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DPawlowska%26aufirst%3DN.%26aulast%3DBartelink%26aufirst%3DI.%26aulast%3DGrabowsky%26aufirst%3DJ.%26aulast%3DJahan%26aufirst%3DT.%26aulast%3DCripps%26aufirst%3DA.%26aulast%3DHarb%26aufirst%3DA.%26aulast%3DLeng%26aufirst%3DJ.%26aulast%3DReinert%26aufirst%3DA.%26aulast%3DMastroserio%26aufirst%3DI.%26aulast%3DTruong%26aufirst%3DT.%2BG.%26aulast%3DRyan%26aufirst%3DC.%2BJ.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DInhibiting%2520histone%2520deacetylase%2520as%2520a%2520means%2520to%2520reverse%2520resistance%2520to%2520angiogenesis%2520inhibitors%253A%2520phase%2520I%2520study%2520of%2520Abexinostat%2520plus%2520Pazopanib%2520in%2520advanced%2520solid%2520tumor%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D1231%26epage%3D1239%26doi%3D10.1200%2FJCO.2016.70.5350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel Pazopanib-based HDAC and VEGFR dual inhibitors targeting cancer epigenetics and angiogenesis simultaneously</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5304</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00384</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00384" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5304-5322&author=J.+Zangauthor=X.+Liangauthor=Y.+Huangauthor=Y.+Jiaauthor=X.+Liauthor=W.+Xuauthor=C.+J.+Chouauthor=Y.+Zhang&title=Discovery+of+novel+Pazopanib-based+HDAC+and+VEGFR+dual+inhibitors+targeting+cancer+epigenetics+and+angiogenesis+simultaneously&doi=10.1021%2Facs.jmedchem.8b00384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously</span></div><div class="casAuthors">Zang, Jie; Liang, Xuewu; Huang, Yongxue; Jia, Yuping; Li, Xiaoyang; Xu, Wenfang; Chou, C. James; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5304-5322</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein a novel series of pazopanib hybrids as polypharmacol. antitumor agents were developed based on the crosstalk between histone deacetylases (HDACs) and vascular endothelial growth factor (VEGF) pathway.  Among them, one ortho-aminoanilide 6d and one hydroxamic acid 13f exhibited considerable total HDACs and VEGFR-2 inhibitory activities.  The HDAC inhibitory activities endowed 6d and 13f with potent antiproliferative activities, which was not obsd. in the approved VEGFR inhibitor pazopanib.  Compds. 6d and 13f possessed comparable HDAC isoform selectivity profiles to the clin. class I HDAC inhibitor MS-275 and the approved pan-HDAC inhibitor SAHA, resp. 6d and 13f also exhibited uncompromised multiple tyrosine kinases inhibitory activities relative to pazopanib.  The intracellular dual inhibition to HDAC and VEGFR of 6d and 13f was validated by Western blot anal.  In both HUVECs tube formation assay and rat thoracic aorta rings assay, 6d and 13f showed comparable antiangiogenic potencies to pazopanib.  What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpmz6rwKiKSbVg90H21EOLACvtfcHk0lhOFHNvPamxaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D&md5=437da0a6cca1ec211219aef87a6ddbc5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520Pazopanib-based%2520HDAC%2520and%2520VEGFR%2520dual%2520inhibitors%2520targeting%2520cancer%2520epigenetics%2520and%2520angiogenesis%2520simultaneously%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5304%26epage%3D5322%26doi%3D10.1021%2Facs.jmedchem.8b00384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokudo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2011.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.phrs.2011.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=22138044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ont7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2012&pages=23-30&author=J.+Gaoauthor=Y.+Inagakiauthor=P.+Songauthor=X.+Quauthor=N.+Kokudoauthor=W.+Tang&title=Targeting+c-Met+as+a+promising+strategy+for+the+treatment+of+hepatocellular+carcinoma&doi=10.1016%2Fj.phrs.2011.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma</span></div><div class="casAuthors">Gao, Jianjun; Inagaki, Yoshinori; Song, Peipei; Qu, Xianjun; Kokudo, Norihiro; Tang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-30</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Hepatocellular carcinoma (HCC) is a severe condition that is found worldwide.  Liver transplantation, surgical resection, and local-regional therapy such as transarterial chemoembolization have made great progress and play a dominant role in HCC management.  However, the high frequency of tumor recurrence and/or metastasis after those treatments acquires systematic drug intervention.  The approval of sorafenib, an agent that targets receptor tyrosine kinases (RTKs), as the first effective drug for systemic treatment of HCC represents a milestone in treatment of this disease.  As a typical member of the RTK family, c-Met represents an intriguing target for cancer therapy.  However, the role of the c-Met signal transduction pathway is less unambiguous in HCC pathol., giving rise to concerns about the feasibility of utilizing c-Met targeting approaches for HCC treatment.  Recently, studies on des-γ-carboxy prothrombin, an abnormal cytokine secreted by HCC cells, by the current authors and other researchers have highlighted the crit. role of c-Met signaling in HCC progression.  This review takes a second look at the c-Met signal transduction pathway and discusses the possibility of targeting c-Met as a therapeutic strategy for HCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-B1kalo8HrVg90H21EOLACvtfcHk0lhOFHNvPamxaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ont7Y%253D&md5=1d65fc77f0d54bfe803a968923da0175</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2011.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2011.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DInagaki%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DP.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DKokudo%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DTargeting%2520c-Met%2520as%2520a%2520promising%2520strategy%2520for%2520the%2520treatment%2520of%2520hepatocellular%2520carcinoma%26jtitle%3DPharmacol.%2520Res.%26date%3D2012%26volume%3D65%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.phrs.2011.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okuma, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, S.</span></span> <span> </span><span class="NLM_article-title">Trends in the development of MET inhibitors for hepatocellular carcinoma</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1275</span>– <span class="NLM_lpage">1286</span>, <span class="refDoi"> DOI: 10.2217/fon.16.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.2217%2Ffon.16.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=26984595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVams7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1275-1286&author=H.+S.+Okumaauthor=S.+Kondo&title=Trends+in+the+development+of+MET+inhibitors+for+hepatocellular+carcinoma&doi=10.2217%2Ffon.16.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in the development of MET inhibitors for hepatocellular carcinoma</span></div><div class="casAuthors">Okuma, Hitomi S.; Kondo, Shunsuke</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1275-1286</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Hepatocellular carcinoma is the third most common cause of cancer-related deaths worldwide.  The multikinase inhibitor sorafenib has improved survival and is now considered the std. of care; however, the benefits are still disappointing, and thus, new effective treatments are required.  In human hepatocellular carcinoma, MET, which is encoded by the HGFR gene, is activated by amplification, overexpression or mutation, and it has recently emerged as a possible therapeutic target in various tumors including hepatocellular carcinoma.  In fact, some drugs targeting the HGF/MET axis are currently under investigation in clin. trials.  Here, we review the role of MET and trends in the development of MET inhibitors for hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUR8t9UYovhLVg90H21EOLACvtfcHk0lhZEOaEKfI-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVams7s%253D&md5=903c7e0a8977fc82c4f72f6f5fd6b666</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2217%2Ffon.16.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.16.3%26sid%3Dliteratum%253Aachs%26aulast%3DOkuma%26aufirst%3DH.%2BS.%26aulast%3DKondo%26aufirst%3DS.%26atitle%3DTrends%2520in%2520the%2520development%2520of%2520MET%2520inhibitors%2520for%2520hepatocellular%2520carcinoma%26jtitle%3DFuture%2520Oncol.%26date%3D2016%26volume%3D12%26spage%3D1275%26epage%3D1286%26doi%3D10.2217%2Ffon.16.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bahrami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidsales, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghayour-Mobarhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maftouh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassanian, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avan, A.</span></span> <span> </span><span class="NLM_article-title">C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">2657</span>– <span class="NLM_lpage">2673</span>, <span class="refDoi"> DOI: 10.1002/jcp.25794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1002%2Fjcp.25794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=28075018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslyhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2017&pages=2657-2673&author=A.+Bahramiauthor=S.+Shahidsalesauthor=M.+Khazaeiauthor=M.+Ghayour-Mobarhanauthor=M.+Maftouhauthor=S.+M.+Hassanianauthor=A.+Avan&title=C-Met+as+a+potential+target+for+the+treatment+of+gastrointestinal+cancer%3A+Current+status+and+future+perspectives&doi=10.1002%2Fjcp.25794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives</span></div><div class="casAuthors">Bahrami, Afsane; Shahidsales, Soodabeh; Khazaei, Majid; Ghayour-Mobarhan, Majid; Maftouh, Mina; Hassanian, Seyed Mahdi; Avan, Amir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2657-2673</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aberrant activation of the HGF/c-Met signalling pathways is shown to be related with cell proliferation, progression, metastasis, and worse prognosis in several tumor types, including gastrointestinal cancers, suggesting its value as a stimulating-target for cancer-therapy.  Several approaches have been developed for targeting HGF and/or c-Met, and one of them, crizotinib (dual c-Met/ALK inhibitor), is recently been approved by FDA for lung-cancers with ALK-rearrangement.  The main aim of current review is to give an overview on the role of c-Met/HGF pathway in gastrointestinal cancer, in preclin. and clin. trials.  Although several important matters is still remained to be elucidated on the mol. pathways underlying the antitumor effects of this therapy in gastrointestinal-cancers.  Further investigations are warranted to recognize the main determinants of the activity of c-Met inhibitors, for parallel targeting signalling pathway assocd./activated via MET/HGF pathway or in response to the cell resistance to anti-c-Met agents.  Addnl., identification of patients that might benefit from therapy could help to increase the selectivity and efficacy of the therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2qJr0yS7y1rVg90H21EOLACvtfcHk0lhZEOaEKfI-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslyhsrw%253D&md5=3eeaa30bae8c45950c12cc31024959a1</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fjcp.25794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.25794%26sid%3Dliteratum%253Aachs%26aulast%3DBahrami%26aufirst%3DA.%26aulast%3DShahidsales%26aufirst%3DS.%26aulast%3DKhazaei%26aufirst%3DM.%26aulast%3DGhayour-Mobarhan%26aufirst%3DM.%26aulast%3DMaftouh%26aufirst%3DM.%26aulast%3DHassanian%26aufirst%3DS.%2BM.%26aulast%3DAvan%26aufirst%3DA.%26atitle%3DC-Met%2520as%2520a%2520potential%2520target%2520for%2520the%2520treatment%2520of%2520gastrointestinal%2520cancer%253A%2520Current%2520status%2520and%2520future%2520perspectives%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2017%26volume%3D232%26spage%3D2657%26epage%3D2673%26doi%3D10.1002%2Fjcp.25794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warbrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vojtesk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D. P.</span></span> <span> </span><span class="NLM_article-title">Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.18632%2Foncotarget.1075" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1019-1036&author=J.+S.+Wongauthor=E.+Warbrickauthor=B.+Vojteskauthor=J.+Hillauthor=D.+P.+Lane&title=Anti-c-Met+antibodies+recognising+a+temperature+sensitive+epitope%2C+inhibit+cell+growth&doi=10.18632%2Foncotarget.1075"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1075%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DJ.%2BS.%26aulast%3DWarbrick%26aufirst%3DE.%26aulast%3DVojtesk%26aufirst%3DB.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DD.%2BP.%26atitle%3DAnti-c-Met%2520antibodies%2520recognising%2520a%2520temperature%2520sensitive%2520epitope%252C%2520inhibit%2520cell%2520growth%26jtitle%3DOncotarget%26date%3D2013%26volume%3D4%26spage%3D1019%26epage%3D1036%26doi%3D10.18632%2Foncotarget.1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetsch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oleksijew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boghaert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappano, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhathena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naumovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvaia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, E. B.</span></span> <span> </span><span class="NLM_article-title">Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.1186/s12885-016-2138-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1186%2Fs12885-016-2138-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=26879245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisFWmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=105&author=J.+Wangauthor=L.+Goetschauthor=L.+Tuckerauthor=Q.+Zhangauthor=A.+Gonzalezauthor=K.+S.+Vaidyaauthor=A.+Oleksijewauthor=E.+Boghaertauthor=M.+Songauthor=I.+Sokolovaauthor=E.+Pestovaauthor=M.+Andersonauthor=W.+N.+Pappanoauthor=P.+Ansellauthor=A.+Bhathenaauthor=L.+Naumovskiauthor=N.+Corvaiaauthor=E.+B.+Reilly&title=Anti-c-Met+monoclonal+antibody+ABT-700+breaks+oncogene+addiction+in+tumors+with+MET+amplification&doi=10.1186%2Fs12885-016-2138-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification</span></div><div class="casAuthors">Wang, Jieyi; Goetsch, Liliane; Tucker, Lora; Zhang, Qian; Gonzalez, Alexandra; Vaidya, Kedar S.; Oleksijew, Anatol; Boghaert, Erwin; Song, Minghao; Sokolova, Irina; Pestova, Ekaterina; Anderson, Mark; Pappano, William N.; Ansell, Peter; Bhathena, Anahita; Naumovski, Louie; Corvaia, Nathalie; Reilly, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105/1-105/14</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: c-Met is the receptor tyrosine kinase for hepatocyte growth factor (HGF) encoded by the MET proto-oncogene.  Aberrant activation of c-Met resulting from MET amplification and c-Met overexpression is assocd. with poor clin. outcome in multiple malignancies underscoring the importance of c-Met signaling in cancer progression.  Several c-Met inhibitors have advanced to the clinic; however, the development of inhibitory c-Met-directed therapeutic antibodies has been hampered by inherent agonistic activity.  Method: We generated and tested a bivalent anti-c-Met monoclonal antibody ABT-700 in vitro for binding potency and antagonistic activity and in vivo for antitumor efficacy in human tumor xenografts.  Human cancer cell lines and gastric cancer tissue microarrays were examd. for MET amplification by fluorescence in situ hybridization (FISH).  Results: ABT-700 exhibits a distinctive ability to block both HGF-independent constitutive c-Met signaling and HGF-dependent activation of c-Met.  Cancer cells addicted to the constitutively activated c-Met signaling driven by MET amplification undergo apoptosis upon exposure to ABT-700.  ABT-700 induces tumor regression and tumor growth delay in preclin. tumor models of gastric and lung cancers harboring amplified MET.  ABT-700 in combination with chemotherapeutics also shows additive antitumor effect.  Amplification of MET in human cancer tissues can be identified by FISH.  Conclusions: The preclin. attributes of ABT-700 in blocking c-Met signaling, inducing apoptosis and suppressing tumor growth in cancers with amplified MET provide rationale for examg. its potential clin. utility for the treatment of cancers harboring MET amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotNem_0ds2IbVg90H21EOLACvtfcHk0ljV-RYPKNyVwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisFWmtL8%253D&md5=d7fc415d4f21e39d3f112511fcc38e5f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1186%2Fs12885-016-2138-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-016-2138-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DTucker%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGonzalez%26aufirst%3DA.%26aulast%3DVaidya%26aufirst%3DK.%2BS.%26aulast%3DOleksijew%26aufirst%3DA.%26aulast%3DBoghaert%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DSokolova%26aufirst%3DI.%26aulast%3DPestova%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DPappano%26aufirst%3DW.%2BN.%26aulast%3DAnsell%26aufirst%3DP.%26aulast%3DBhathena%26aufirst%3DA.%26aulast%3DNaumovski%26aufirst%3DL.%26aulast%3DCorvaia%26aufirst%3DN.%26aulast%3DReilly%26aufirst%3DE.%2BB.%26atitle%3DAnti-c-Met%2520monoclonal%2520antibody%2520ABT-700%2520breaks%2520oncogene%2520addiction%2520in%2520tumors%2520with%2520MET%2520amplification%26jtitle%3DBMC%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D105%26doi%3D10.1186%2Fs12885-016-2138-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">c-MET kinase inhibitors: a patent review (2011 - 2013)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.864279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1517%2F13543776.2014.864279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=24266843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=217-230&author=K.+Zhuauthor=X.+Kongauthor=D.+Zhaoauthor=Z.+Liangauthor=C.+Luo&title=c-MET+kinase+inhibitors%3A+a+patent+review+%282011+-+2013%29&doi=10.1517%2F13543776.2014.864279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">c-MET kinase inhibitors: a patent review (2011 - 2013)</span></div><div class="casAuthors">Zhu, Kongkai; Kong, Xiangqian; Zhao, Dan; Liang, Zhongjie; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-230</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The receptor tyrosine kinase c-MET displays aberrant activation in the malignant phenotype of various tumors, and thus, has drawn considerable attention as drug target for cancer therapy.  Many c-MET inhibitors are now under clin. investment, and one of them - Cabozantinib - has been approved by US FDA in 2012 for the treatment of medullary thyroid cancer, which further proved the feasibility of c-MET inhibition method in cancer therapy.  Areas covered: This article briefly outlines the role of c-MET in oncogenesis and provides a broad overview of the assays used to characterize new inhibitors.  Then, a series of representative small-mol. inhibitors of c-MET, esp. from the published patent literature from 2011 to 2013, are recorded.  Herein, the challenges in the kinase inhibitor design, such as the inhibitor selectivity and resistance mutations, are also discussed.  Expert opinion: Up to now, at least 17 inhibitors of c-MET are under clin. evaluation, and several agents exhibit encouraging results.  Thus, inhibiting c-MET signaling has major therapeutic value in cancer therapy.  Focus on the selectivity of both types of inhibitors, with potent selectivity or multi-targets, have demonstrated antitumor efficacy.  The network pharmacol. and clin. trials integrated would provide powerful tools to further evaluate the superiority of both inhibitors in continued efficacy and toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQQxUsT3aF2LVg90H21EOLACvtfcHk0ljV-RYPKNyVwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlWgug%253D%253D&md5=1408de34b8567924107b45a0765ad60d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.864279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.864279%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3Dc-MET%2520kinase%2520inhibitors%253A%2520a%2520patent%2520review%2520%25282011%2520-%25202013%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D217%26epage%3D230%26doi%3D10.1517%2F13543776.2014.864279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimassa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borbath, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvagni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laethem, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Vlierberghe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolligs, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasbarrini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lencioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicalese, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gridelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggisch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerken, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Personeni, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassoun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadessa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Roemeling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamar, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span> <span> </span><span class="NLM_article-title">Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(12)70490-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2FS1470-2045%2812%2970490-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23182627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2nug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=55-63&author=A.+Santoroauthor=L.+Rimassaauthor=I.+Borbathauthor=B.+Danieleauthor=S.+Salvagniauthor=J.+L.+Van+Laethemauthor=H.+Van+Vlierbergheauthor=J.+Trojanauthor=F.+T.+Kolligsauthor=A.+Weissauthor=S.+Milesauthor=A.+Gasbarriniauthor=M.+Lencioniauthor=L.+Cicaleseauthor=M.+Shermanauthor=C.+Gridelliauthor=P.+Buggischauthor=G.+Gerkenauthor=R.+M.+Schmidauthor=C.+Boniauthor=N.+Personeniauthor=Z.+Hassounauthor=G.+Abbadessaauthor=B.+Schwartzauthor=R.+Von+Roemelingauthor=M.+E.+Lamarauthor=Y.+Chenauthor=C.+Porta&title=Tivantinib+for+second-line+treatment+of+advanced+hepatocellular+carcinoma%3A+a+randomised%2C+placebo-controlled+phase+2+study&doi=10.1016%2FS1470-2045%2812%2970490-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study</span></div><div class="casAuthors">Santoro, Armando; Rimassa, Lorenza; Borbath, Ivan; Daniele, Bruno; Salvagni, Stefania; Van Laethem, Jean Luc; Van Vlierberghe, Hans; Trojan, Joerg; Kolligs, Frank T.; Weiss, Alan; Miles, Steven; Gasbarrini, Antonio; Lencioni, Monica; Cicalese, Luca; Sherman, Morris; Gridelli, Cesare; Buggisch, Peter; Gerken, Guido; Schmid, Roland M.; Boni, Corrado; Personeni, Nicola; Hassoun, Ziad; Abbadessa, Giovanni; Schwartz, Brian; Von Roemeling, Reinhard; Lamar, Maria E.; Chen, Yinpu; Porta, Camillo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-63</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumor activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib.  We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma.  Methods: In this completed, multicenter, randomized, placebo-controlled, double-blind, phase 2 study, we enrolled patients with advanced hepatocellular carcinoma and Child-Pugh A cirrhosis who had progressed on or were unable to tolerate first-line systemic therapy.  We randomly allocated patients 2:1 to receive tivantinib (360 mg twice-daily) or placebo until disease progression.  The tivantinib dose was amended to 240 mg twice-daily because of high incidence of treatment-emergent grade 3 or worse neutropenia.  Randomisation was done centrally by an interactive voice-response system, stratified by Eastern Cooperative Oncol. Group performance status and vascular invasion.  The primary endpoint was time to progression, according to independent radiol. review in the intention-to-treat population.  We assessed tumor samples for MET expression with immunohistochem. (high expression was regarded as ≥2+ in ≥50% of tumor cells).  This study is registered with ClinicalTrials.gov, no. NCT00988741.  Findings: 71 patients were randomly assigned to receive tivantinib (38 at 360 mg twice-daily and 33 at 240 mg twice-daily); 36 patients were randomly assigned to receive placebo.  At the time of anal., 46 (65%) patients in the tivantinib group and 26 (72%) of those in the placebo group had progressive disease.  Time to progression was longer for patients treated with tivantinib (1·6 mo [95% CI 1·4-2·8]) than placebo (1·4 mo [1·4-1·5]; hazard ratio [HR] 0·64, 90% CI 0·43-0·94; p=0·04).  For patients with MET-high tumors, median time to progression was longer with tivantinib than for those on placebo (2·7 mo [95% CI 1·4-8·5] for 22 MET-high patients on tivantinib vs 1·4 mo [1·4-1·6] for 15 MET-high patients on placebo; HR 0·43, 95% CI 0·19-0·97; p=0·03).  The most common grade 3 or worse adverse events in the tivantinib group were neutropenia (ten patients [14%] vs none in the placebo group) and anemia (eight [11%] vs none in the placebo group).  Eight patients (21%) in the tivantinib 360 mg group had grade 3 or worse neutropenia compared with two (6%) patients in the 240 mg group.  Four deaths related to tivantinib occurred from severe neutropenia. 24 (34%) patients in the tivantinib group and 14 (39%) patients in the placebo group had serious adverse events.  Interpretation: Tivantinib could provide an option for second-line treatment of patients with advanced hepatocellular carcinoma and well-compensated liver cirrhosis, particularly for patients with MET-high tumors.  Confirmation in a phase 3 trial is needed, with a starting dose of tivantinib 240 mg twice-daily.  Funding: ArQule, Daiichi Sankyo (Daiichi Sankyo Group).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQJjnKdNvQorVg90H21EOLACvtfcHk0lgL7zQ5IAbD8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2nug%253D%253D&md5=a2d552b7cd69b578b76962d015bfac2a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970490-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970490-4%26sid%3Dliteratum%253Aachs%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DRimassa%26aufirst%3DL.%26aulast%3DBorbath%26aufirst%3DI.%26aulast%3DDaniele%26aufirst%3DB.%26aulast%3DSalvagni%26aufirst%3DS.%26aulast%3DVan%2BLaethem%26aufirst%3DJ.%2BL.%26aulast%3DVan%2BVlierberghe%26aufirst%3DH.%26aulast%3DTrojan%26aufirst%3DJ.%26aulast%3DKolligs%26aufirst%3DF.%2BT.%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DMiles%26aufirst%3DS.%26aulast%3DGasbarrini%26aufirst%3DA.%26aulast%3DLencioni%26aufirst%3DM.%26aulast%3DCicalese%26aufirst%3DL.%26aulast%3DSherman%26aufirst%3DM.%26aulast%3DGridelli%26aufirst%3DC.%26aulast%3DBuggisch%26aufirst%3DP.%26aulast%3DGerken%26aufirst%3DG.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26aulast%3DBoni%26aufirst%3DC.%26aulast%3DPersoneni%26aufirst%3DN.%26aulast%3DHassoun%26aufirst%3DZ.%26aulast%3DAbbadessa%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DVon%2BRoemeling%26aufirst%3DR.%26aulast%3DLamar%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DPorta%26aufirst%3DC.%26atitle%3DTivantinib%2520for%2520second-line%2520treatment%2520of%2520advanced%2520hepatocellular%2520carcinoma%253A%2520a%2520randomised%252C%2520placebo-controlled%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D55%26epage%3D63%26doi%3D10.1016%2FS1470-2045%2812%2970490-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lachenmayer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toffanin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabellos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsinet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minguez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llovet, J. M.</span></span> <span> </span><span class="NLM_article-title">Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1343</span>– <span class="NLM_lpage">1350</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2012.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.jhep.2012.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=22322234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt12mtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=1343-1350&author=A.+Lachenmayerauthor=S.+Toffaninauthor=L.+Cabellosauthor=C.+Alsinetauthor=Y.+Hoshidaauthor=A.+Villanuevaauthor=B.+Minguezauthor=H.+W.+Tsaiauthor=S.+C.+Wardauthor=S.+Thungauthor=S.+L.+Friedmanauthor=J.+M.+Llovet&title=Combination+therapy+for+hepatocellular+carcinoma%3A+additive+preclinical+efficacy+of+the+HDAC+inhibitor+panobinostat+with+sorafenib&doi=10.1016%2Fj.jhep.2012.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib</span></div><div class="casAuthors">Lachenmayer, Anja; Toffanin, Sara; Cabellos, Laia; Alsinet, Clara; Hoshida, Yujin; Villanueva, Augusto; Minguez, Beatriz; Tsai, Hung-Wen; Ward, Stephen C.; Thung, Swan; Friedman, Scott L.; Llovet, Josep M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1343-1350</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy.  Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is still unknown.  We analyzed the expression of 11 HDACs in human HCCs and assessed the efficacy of the pan-HDAC inhibitor panobinostat alone and in combination with sorafenib in preclin. models of liver cancer.  Methods: Gene expression and copy no. changes were analyzed in a cohort of 334 human HCCs, while the effects of panobinostat and sorafenib were evaluated in three liver cancer cell lines and a murine xenograft model.  Results: Aberrant HDAC expression was identified and validated in 91 and 243 HCCs, resp.  Upregulation of HDAC3 and HDAC5 mRNAs was significantly correlated with DNA copy no. gains.  Inhibiting HDACs with panobinostat led to strong anti-tumoral effects in vitro and vivo, enhanced by the addn. of sorafenib.  Cell viability and proliferation declined, while apoptosis and autophagy increased.  Panobinostat increased histone H3 and HSP90 acetylation, downregulated BIRC5 (survivin) and upregulated CDH1.  Combination therapy with panobinostat and sorafenib significantly decreased vessel d., and most significantly decreased tumor vol. and increased survival in HCC xenografts.  Conclusions: Aberrant expression of several HDACs and copy no. gains of HDAC3 and HDAC5 occur in HCC.  Treatment with panobinostat combined with sorafenib demonstrated the highest preclin. efficacy in HCC models, providing the rationale for clin. studies with this novel combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZoC3lwqUXBrVg90H21EOLACvtfcHk0lgL7zQ5IAbD8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt12mtrc%253D&md5=ac47fb06e16c2b7ec1f4c868a983b752</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DLachenmayer%26aufirst%3DA.%26aulast%3DToffanin%26aufirst%3DS.%26aulast%3DCabellos%26aufirst%3DL.%26aulast%3DAlsinet%26aufirst%3DC.%26aulast%3DHoshida%26aufirst%3DY.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DMinguez%26aufirst%3DB.%26aulast%3DTsai%26aufirst%3DH.%2BW.%26aulast%3DWard%26aufirst%3DS.%2BC.%26aulast%3DThung%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DS.%2BL.%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26atitle%3DCombination%2520therapy%2520for%2520hepatocellular%2520carcinoma%253A%2520additive%2520preclinical%2520efficacy%2520of%2520the%2520HDAC%2520inhibitor%2520panobinostat%2520with%2520sorafenib%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D56%26spage%3D1343%26epage%3D1350%26doi%3D10.1016%2Fj.jhep.2012.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>436</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2013.05.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.bbrc.2013.05.088" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2013&pages=259-264&author=X.+Liauthor=Y.+Zhuauthor=H.+Heauthor=L.+Louauthor=W.+Yeauthor=Y.+Chenauthor=J.+Wang&title=Synergistically+killing+activity+of+aspirin+and+histone+deacetylase+inhibitor+valproic+acid+%28VPA%29+on+hepatocellular+cancer+cells&doi=10.1016%2Fj.bbrc.2013.05.088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.05.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.05.088%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLou%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DSynergistically%2520killing%2520activity%2520of%2520aspirin%2520and%2520histone%2520deacetylase%2520inhibitor%2520valproic%2520acid%2520%2528VPA%2529%2520on%2520hepatocellular%2520cancer%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D436%26spage%3D259%26epage%3D264%26doi%3D10.1016%2Fj.bbrc.2013.05.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span> <span> </span><span class="NLM_article-title">Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.18632%2Foncotarget.6352" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=402-417&author=M.+C.+Chenauthor=H.+H.+Huangauthor=C.+Y.+Laiauthor=Y.+J.+Linauthor=J.+P.+Liouauthor=M.+J.+Laiauthor=Y.+H.+Liauthor=C.+M.+Tengauthor=C.+R.+Yang&title=Novel+histone+deacetylase+inhibitor+MPT0G009+induces+cell+apoptosis+and+synergistic+anticancer+activity+with+tumor+necrosis+factor-related+apoptosis-inducing+ligand+against+human+hepatocellular+carcinoma&doi=10.18632%2Foncotarget.6352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6352%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DHuang%26aufirst%3DH.%2BH.%26aulast%3DLai%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DY.%2BJ.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26aulast%3DYang%26aufirst%3DC.%2BR.%26atitle%3DNovel%2520histone%2520deacetylase%2520inhibitor%2520MPT0G009%2520induces%2520cell%2520apoptosis%2520and%2520synergistic%2520anticancer%2520activity%2520with%2520tumor%2520necrosis%2520factor-related%2520apoptosis-inducing%2520ligand%2520against%2520human%2520hepatocellular%2520carcinoma%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D402%26epage%3D417%26doi%3D10.18632%2Foncotarget.6352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of the first c-Met/HDAC inhibitors based on pyridazinone derivatives</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">830</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00172</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00172" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=830-834&author=D.+Luauthor=J.+Yanauthor=L.+Wangauthor=H.+Liuauthor=L.+Zengauthor=M.+Zhangauthor=W.+Duanauthor=Y.+Jiauthor=J.+Caoauthor=M.+Gengauthor=A.+Shenauthor=Y.+Hu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+the+first+c-Met%2FHDAC+inhibitors+based+on+pyridazinone+derivatives&doi=10.1021%2Facsmedchemlett.7b00172"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00172%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520the%2520first%2520c-Met%252FHDAC%2520inhibitors%2520based%2520on%2520pyridazinone%2520derivatives%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D830%26epage%3D834%26doi%3D10.1021%2Facsmedchemlett.7b00172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ejmech.2015.03.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=302-312&author=W.+Xingauthor=J.+Aiauthor=S.+Jinauthor=Z.+Shiauthor=X.+Pengauthor=L.+Wangauthor=Y.+Jiauthor=D.+Luauthor=Y.+Liuauthor=M.+Gengauthor=Y.+Hu&title=Enhancing+the+cellular+anti-proliferation+activity+of+pyridazinones+as+c-met+inhibitors+using+docking+analysis&doi=10.1016%2Fj.ejmech.2015.03.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DW.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DEnhancing%2520the%2520cellular%2520anti-proliferation%2520activity%2520of%2520pyridazinones%2520as%2520c-met%2520inhibitors%2520using%2520docking%2520analysis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D302%26epage%3D312%26doi%3D10.1016%2Fj.ejmech.2015.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nimmanapalli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bali, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparetto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glozak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscinski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5126</span>– <span class="NLM_lpage">5135</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=12941844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms12ntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=5126-5135&author=R.+Nimmanapalliauthor=L.+Fuinoauthor=P.+Baliauthor=M.+Gasparettoauthor=M.+Glozakauthor=J.+Taoauthor=L.+Moscinskiauthor=C.+Smithauthor=J.+Wuauthor=R.+Joveauthor=P.+Atadjaauthor=K.+Bhalla&title=Histone+deacetylase+inhibitor+LAQ824+both+lowers+expression+and+promotes+proteasomal+degradation+of+Bcr-Abl+and+induces+apoptosis+of+imatinib+mesylate-sensitive+or+-refractory+chronic+myelogenous+leukemia-blast+crisis+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells</span></div><div class="casAuthors">Nimmanapalli, Ramadevi; Fuino, Lianne; Bali, Purva; Gasparetto, Maura; Glozak, Michele; Tao, Jianguo; Moscinski, Lynn; Smith, Clayton; Wu, Jie; Jove, Richard; Atadja, Peter; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5126-5135</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Treatment with LAQ824, a cinnamyl hydroxamic acid analog inhibitor of histone deacetylases, depleted the mRNA and protein expression of Bcr-Abl in human chronic myeloid leukemia blast crisis (CML-BC) cells.  Exposure to LAQ824 induced the expression of the cell cycle-dependent kinase inhibitors p21 and p27 and caused cell cycle G1-phase accumulation and apoptosis of CML-BC cells.  LAQ824 also induced acetylation of heat shock protein 90.  This inhibited the chaperone assocn. of Bcr-Abl with heat shock protein 90, thereby promoting the proteasomal degrdn. of Bcr-Abl.  Cotreatment with LAQ824 increased imatinib mesylate-induced apoptosis of CML-BC cells.  Addnl., LAQ824 down-regulated the levels of mutant Bcr-Abl possessing the T315I point mutation, as well as induced apoptosis of imatinib-refractory primary CML-BC cells.  Therefore, LAQ824 may be a promising therapeutic agent in the treatment of imatinib-sensitive or -refractory human leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ6KT6nvt9-bVg90H21EOLACvtfcHk0lg9i6yhi_qMYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms12ntro%253D&md5=a908e21560e9ec289e8a8ab651ba4e24</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNimmanapalli%26aufirst%3DR.%26aulast%3DFuino%26aufirst%3DL.%26aulast%3DBali%26aufirst%3DP.%26aulast%3DGasparetto%26aufirst%3DM.%26aulast%3DGlozak%26aufirst%3DM.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DMoscinski%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520LAQ824%2520both%2520lowers%2520expression%2520and%2520promotes%2520proteasomal%2520degradation%2520of%2520Bcr-Abl%2520and%2520induces%2520apoptosis%2520of%2520imatinib%2520mesylate-sensitive%2520or%2520-refractory%2520chronic%2520myelogenous%2520leukemia-blast%2520crisis%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D5126%26epage%3D5135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nimmanapalli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stobaugh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span> <span> </span><span class="NLM_article-title">Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">3236</span>– <span class="NLM_lpage">3239</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-08-2675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1182%2Fblood-2002-08-2675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=12446442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtFCqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3236-3239&author=R.+Nimmanapalliauthor=L.+Fuinoauthor=C.+Stobaughauthor=V.+Richonauthor=K.+Bhalla&title=Cotreatment+with+the+histone+deacetylase+inhibitor+suberoylanilide+hydroxamic+acid+%28SAHA%29+enhances+imatinib-induced+apoptosis+of+Bcr-Abl-positive+human+acute+leukemia+cells&doi=10.1182%2Fblood-2002-08-2675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells</span></div><div class="casAuthors">Nimmanapalli, Ramadevi; Fuino, Lianne; Stobaugh, Corinne; Richon, Victoria; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3236-3239</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Here we demonstrate that treatment with SAHA (suberoylanilide hydroxamic acid), a known inhibitor of histone deacetylases (HDACs), alone induced p21 and/or p27 expressions but decreased the mRNA and protein levels of Bcr-Abl, which was assocd. with apoptosis of Bcr-Abl-expressing K562 and LAMA-84 cells.  Co-treatment with SAHA and imatinib (Gleevec) caused more down-regulation of the levels and auto-tyrosine phosphorylation of Bcr-Abl and apoptosis of these cell types, as compared with treatment with either agent alone (P <.05).  This finding was also assocd. with a greater decline in the levels of phospho-AKT and Bcl-xL.  Significantly, treatment with SAHA also down-regulated Bcr-Abl levels and induced apoptosis of CD34+ leukemia blast progenitor cells derived from patients who had developed progressive blast crisis (BC) of chronic myelocytic leukemia (CML) while receiving therapy with imatinib.  Taken together, these findings indicate that cotreatment with SAHA enhances the cytotoxic effects of imatinib and may have activity against imatinib-refractory CML-BC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbMV3jjXO6LVg90H21EOLACvtfcHk0lgCux5ATmTa1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtFCqtbg%253D&md5=539966340cce2f4cacc9fe29c9796b58</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-08-2675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-08-2675%26sid%3Dliteratum%253Aachs%26aulast%3DNimmanapalli%26aufirst%3DR.%26aulast%3DFuino%26aufirst%3DL.%26aulast%3DStobaugh%26aufirst%3DC.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DCotreatment%2520with%2520the%2520histone%2520deacetylase%2520inhibitor%2520suberoylanilide%2520hydroxamic%2520acid%2520%2528SAHA%2529%2520enhances%2520imatinib-induced%2520apoptosis%2520of%2520Bcr-Abl-positive%2520human%2520acute%2520leukemia%2520cells%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D3236%26epage%3D3239%26doi%3D10.1182%2Fblood-2002-08-2675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dove, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span> <span> </span><span class="NLM_article-title">Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2279</span>, <span class="refDoi"> DOI: 10.1021/jm800988r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800988r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFemurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2265-2279&author=S.+Mahboobiauthor=S.+Doveauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Design+of+chimeric+histone+deacetylase-+and+tyrosine+kinase-inhibitors%3A+a+series+of+imatinib+hybrides+as+potent+inhibitors+of+wild-type+and+mutant+BCR-ABL%2C+PDGF-Rbeta%2C+and+histone+deacetylases&doi=10.1021%2Fjm800988r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases</span></div><div class="casAuthors">Mahboobi, Siavosh; Dove, Stefan; Sellmer, Andreas; Winkler, Matthias; Eichhorn, Emerich; Pongratz, Herwig; Ciossek, Thomas; Baer, Thomas; Maier, Thomas; Beckers, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2265-2279</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of histone deacetylases are a new class of cancer therapeutics with possibly broad applicability.  Combinations of HDAC inhibitors with the kinase inhibitor 1 (Imatinib) in recent studies showed additive and synergistic effects.  Here we present a new concept by combining inhibition of protein kinases and HDACs, two independent pharmacol. activities, in one synthetic small mol.  In general, the HDAC inhibition profile, the potencies, and the probable binding modes to HDAC1 and HDAC6 were similar as for 6 (SAHA).  Inhibition of Abl kinase in biochem. assays was maintained for most compds., but in general the kinase selectivity profile differed from that of 1 with nearly equipotent inhibition of the wild-type and the Imatinib resistant Abl T315I mutant.  A potent cellular inhibition of PDGFR and cytotoxicity toward EOL-1 cells, a model for idiopathic hypereosinophilic syndrome (HES), are restored or enhanced for selected analogs (12b, 14b, and 18b).  Cytotoxicity was evaluated by using a broad panel of tumor cell lines, with selected analogs displaying mean IC50 values between 3.6 and 7.1 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCa_uPm33uzLVg90H21EOLACvtfcHk0liK6ZSDJHkJyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFemurc%253D&md5=2e65e8c0cf3daed2cc7415173209d630</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm800988r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800988r%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DDove%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DDesign%2520of%2520chimeric%2520histone%2520deacetylase-%2520and%2520tyrosine%2520kinase-inhibitors%253A%2520a%2520series%2520of%2520imatinib%2520hybrides%2520as%2520potent%2520inhibitors%2520of%2520wild-type%2520and%2520mutant%2520BCR-ABL%252C%2520PDGF-Rbeta%252C%2520and%2520histone%2520deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2265%26epage%3D2279%26doi%3D10.1021%2Fjm800988r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7524</span>– <span class="NLM_lpage">7538</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00930</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00930" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7524-7538&author=F.+Beaufilsauthor=N.+Cmiljanovicauthor=V.+Cmiljanovicauthor=T.+Bohnackerauthor=A.+Meloneauthor=R.+Maroneauthor=E.+Jacksonauthor=X.+Zhangauthor=A.+Seleauthor=C.+Borsariauthor=J.+Mestanauthor=P.+Hebeisenauthor=P.+Hillmannauthor=B.+Gieseauthor=M.+Zvelebilauthor=D.+Fabbroauthor=R.+L.+Williamsauthor=D.+Rageotauthor=M.+P.+Wymann&title=5-%284%2C6-Dimorpholino-1%2C3%2C5-triazin-2-yl%29-4-%28trifluoromethyl%29pyridin-2-amine+%28PQR309%29%2C+a+potent%2C+brain-penetrant%2C+orally+bioavailable%2C+pan-class+I+PI3K%2FmTOR+inhibitor+as+clinical+candidate+in+oncology&doi=10.1021%2Facs.jmedchem.7b00930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology</span></div><div class="casAuthors">Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jurgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7524-7538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR).  Here we describe the preclin. characterization of compd. 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concns.  No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays.  Moreover, 1 did not bind tubulin, which was obsd. for the structurally related 4 (BKM120, buparlisib).  Compd. 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs.  Compd. 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model.  This, together with the compd.'s safety profile, identifies 1 as a clin. candidate with a broad application range in oncol., including treatment of brain tumors or CNS metastasis.  Compd. 1 is currently in phase II clin. trials for advanced solid tumors and refractory lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtvYAarVqsarVg90H21EOLACvtfcHk0liK6ZSDJHkJyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP&md5=54d4db75f6a8bda3f12eaf1d196352fd</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00930%26sid%3Dliteratum%253Aachs%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3D5-%25284%252C6-Dimorpholino-1%252C3%252C5-triazin-2-yl%2529-4-%2528trifluoromethyl%2529pyridin-2-amine%2520%2528PQR309%2529%252C%2520a%2520potent%252C%2520brain-penetrant%252C%2520orally%2520bioavailable%252C%2520pan-class%2520I%2520PI3K%252FmTOR%2520inhibitor%2520as%2520clinical%2520candidate%2520in%2520oncology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7524%26epage%3D7538%26doi%3D10.1021%2Facs.jmedchem.7b00930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The phosphoinositide 3-kinase pathway</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1126/science.296.5573.1655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1126%2Fscience.296.5573.1655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=12040186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=1655-1657&author=L.+C.+Cantley&title=The+phosphoinositide+3-kinase+pathway&doi=10.1126%2Fscience.296.5573.1655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphoinositide 3-kinase pathway</span></div><div class="casAuthors">Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5573</span>),
    <span class="NLM_cas:pages">1655-1657</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 8 refs.  Phosphorylated lipids are produced at cellular membranes during signaling events and contribute to the recruitment and activation of various signaling components.  The role of phosphoinositide 3-kinase (PI3K), which catalyzes the prodn. of phosphatidylinositol 3,4,5-trisphosphate, in cell survival pathways; the regulation of gene expression and cell metab.; and cytoskeletal rearrangements are highlighted.  The PI3K pathway is implicated in human diseases including diabetes and cancer, and understanding the intricacies of this pathway may provide new avenues for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9pxSplxmS1rVg90H21EOLACvtfcHk0liK6ZSDJHkJyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D&md5=110c8a351448aed6ab938b9ccf90a655</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1126%2Fscience.296.5573.1655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.296.5573.1655%26sid%3Dliteratum%253Aachs%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520phosphoinositide%25203-kinase%2520pathway%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D1655%26epage%3D1657%26doi%3D10.1126%2Fscience.296.5573.1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heavey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuffe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVeigh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gately, K.</span></span> <span> </span><span class="NLM_article-title">In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">79526</span>– <span class="NLM_lpage">79543</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.18632%2Foncotarget.12755" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=79526-79543&author=S.+Heaveyauthor=S.+Cuffeauthor=S.+Finnauthor=V.+Youngauthor=R.+Ryanauthor=S.+Nicholsonauthor=N.+Leonardauthor=N.+McVeighauthor=M.+Barrauthor=K.+O%E2%80%99Byrneauthor=K.+Gately&title=In+pursuit+of+synergy%3A+An+investigation+of+the+PI3K%2FmTOR%2FMEK+co-targeted+inhibition+strategy+in+NSCLC&doi=10.18632%2Foncotarget.12755"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12755%26sid%3Dliteratum%253Aachs%26aulast%3DHeavey%26aufirst%3DS.%26aulast%3DCuffe%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DV.%26aulast%3DRyan%26aufirst%3DR.%26aulast%3DNicholson%26aufirst%3DS.%26aulast%3DLeonard%26aufirst%3DN.%26aulast%3DMcVeigh%26aufirst%3DN.%26aulast%3DBarr%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DGately%26aufirst%3DK.%26atitle%3DIn%2520pursuit%2520of%2520synergy%253A%2520An%2520investigation%2520of%2520the%2520PI3K%252FmTOR%252FMEK%2520co-targeted%2520inhibition%2520strategy%2520in%2520NSCLC%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D79526%26epage%3D79543%26doi%3D10.18632%2Foncotarget.12755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutzman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Noll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voest, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.M.</span></span> <span> </span><span class="NLM_article-title">A phase I dose-escalation study of the safety and pharmacokinetics of Pictilisib in combination with Erlotinib in patients with advanced solid tumors</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1499</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2017-0090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1634%2Ftheoncologist.2017-0090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=28798270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovFCnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1491-1499&author=S.+Leongauthor=R.+A.+Mossauthor=D.+W.+Bowlesauthor=J.+A.+Wareauthor=J.+Zhouauthor=J.+M.+Spoerkeauthor=M.+R.+Lacknerauthor=G.+Shankarauthor=J.+L.+Schutzmanauthor=R.+van+der+Nollauthor=E.+E.+Voestauthor=J.+H.M.+Schellens&title=A+phase+I+dose-escalation+study+of+the+safety+and+pharmacokinetics+of+Pictilisib+in+combination+with+Erlotinib+in+patients+with+advanced+solid+tumors&doi=10.1634%2Ftheoncologist.2017-0090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Leong, Stephen; Moss, Rebecca A.; Bowles, Daniel W.; Ware, Joseph A.; Zhou, Jing; Spoerke, Jill M.; Lackner, Mark R.; Shankar, Geetha; Schutzman, Jennifer L.; van der Noll, Ruud; Voest, Emile E.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1491-1499</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1549-490X</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Background : Epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K) are involved in the proliferation and survival of many cancer types.  Enhanced antitumor activity may be achieved through combined inhibition of these pathways.  We report results for pictilisib (GDC-0941, a class I pan-PI3K inhibitor) plus erlotinib (an EGFR tyrosine kinase inhibitor) in patients with advanced solid tumors.  Materials and Methods : A 3 + 3 dose-escalation study was carried out at a starting daily dose of 60 mg pictilisib on days 1-21 of a 28-day cycle and 150 mg erlotinib from day 2 of cycle 1.  The primary objectives of the study were to assess safety and tolerability, identify dose-limiting toxicities (DLTs), est. the max. tolerated dose, and identify the recommended phase II dose (RP2D).  Evaluation of a dose-expansion cohort at the RP2D was performed.  Results : Fifty-seven patients were treated in the study.  All patients experienced at least one adverse event (AE).  Grade ≥3 AEs, serious AEs, and deaths were reported in 38 (66.7%), 19 (33.3%), and 4 (7.0%) patients, resp.  DLTs occurred in nine patients across eight cohorts and the RP2D was detd. to be 340 mg pictilisib on a "5 days on, 2 days off" schedule plus 100 mg erlotinib.  Two patients (3.5%) experienced partial response and 19 (33.3%) had stable disease.  Conclusion : Combining pictilisib with erlotinib in patients with advanced solid tumors is feasible; however, antitumor activity is limited.  Addnl. studies may identify patients likely to benefit from combined inhibition of EGFR and PI3K pathways.  Implications for Practice : Combining drugs targeting different signaling pathways in cancer growth and survival could overcome drug resistance and improve antitumor activity.  In this first-in-human study for the combination, addn. of the PI3K inhibitor pictilisib to the EGFR tyrosine kinase inhibitor erlotinib resulted in toxicity that led to dose and schedule modifications to identify a tolerable recommended phase II dose of 340 mg pictilisib on a "5 days on, 2 days off" schedule plus 100 mg erlotinib daily.  The limited antitumor activity obsd., however, suggests that addnl. studies are needed to identify patients most likely to benefit from combined EGFR and PI3K inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-IZe4X1hOO7Vg90H21EOLACvtfcHk0li_xKZTA1417A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovFCnt7o%253D&md5=848e95827934194af997498bdccb4c2d</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2017-0090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2017-0090%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DS.%26aulast%3DMoss%26aufirst%3DR.%2BA.%26aulast%3DBowles%26aufirst%3DD.%2BW.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DShankar%26aufirst%3DG.%26aulast%3DSchutzman%26aufirst%3DJ.%2BL.%26aulast%3Dvan%2Bder%2BNoll%26aufirst%3DR.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.M.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520study%2520of%2520the%2520safety%2520and%2520pharmacokinetics%2520of%2520Pictilisib%2520in%2520combination%2520with%2520Erlotinib%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DOncologist%26date%3D2017%26volume%3D22%26spage%3D1491%26epage%3D1499%26doi%3D10.1634%2Ftheoncologist.2017-0090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmigiani, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: molecular mechanisms of action</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5541</span>– <span class="NLM_lpage">5552</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fsj.onc.1210620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=17694093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFersrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5541-5552&author=W.+S.+Xuauthor=R.+B.+Parmigianiauthor=P.+A.+Marks&title=Histone+deacetylase+inhibitors%3A+molecular+mechanisms+of+action&doi=10.1038%2Fsj.onc.1210620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: molecular mechanisms of action</span></div><div class="casAuthors">Xu, W. S.; Parmigiani, R. B.; Marks, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5541-5552</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  This review focuses on the mechanisms of action of histone deacetylase (HDAC) inhibitors (HDACi), a group of recently discovered targeted' anticancer agents.  There are 18 HDACs, which are generally divided into four classes, based on sequence homol. to yeast counterparts.  Classical HDACi such as the hydroxamic acid-based vorinostat (also known as SAHA and Zolinza) inhibits classes I, II and IV, but not the NAD+-dependent class III enzymes.  In clin. trials, vorinostat has activity against hematol. and solid cancers at doses well tolerated by patients.  In addn. to histones, HDACs have many other protein substrates involved in regulation of gene expression, cell proliferation and cell death.  Inhibition of HDACs causes accumulation of acetylated forms of these proteins, altering their function.  Thus, HDACs are more properly called 'lysine deacetylases.'.  HDACi induces different phenotypes in various transformed cells, including growth arrest, activation of the extrinsic and/or intrinsic apoptotic pathways, autophagic cell death, reactive oxygen species (ROS)-induced cell death, mitotic cell death and senescence.  In comparison, normal cells are relatively more resistant to HDACi-induced cell death.  The plurality of mechanisms of HDACi-induced cell death reflects both the multiple substrates of HDACs and the heterogeneous patterns of mol. alterations present in different cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ircqtUCkCLVg90H21EOLACvtfcHk0li_xKZTA1417A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFersrY%253D&md5=227a7c5d26028e99d412441596ba02ae</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210620%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%2BS.%26aulast%3DParmigiani%26aufirst%3DR.%2BB.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520molecular%2520mechanisms%2520of%2520action%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5541%26epage%3D5552%26doi%3D10.1038%2Fsj.onc.1210620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S. C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs</span>. <i>Am. J. Transl Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=21416059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtVSqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=166-179&author=H.+J.+Kimauthor=S.+C.+Bae&title=Histone+deacetylase+inhibitors%3A+molecular+mechanisms+of+action+and+clinical+trials+as+anti-cancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs</span></div><div class="casAuthors">Kim, Hyun-Jung; Bae, Suk-Chul</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">166-179</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells.  Recently, their use has been clin. validated in cancer patients resulting in the approval of two HDAC inhibitors, vorinostat and depsipetide, by the FDA.  Also, clin. trials of several HDAC inhibitors for use as anti-cancer drugs (alone or in combination with other anti-cancer therapeutics) are ongoing.  However, the mol. mechanisms underlying the response to HDAC inhibitors in cancer patients are not fully understood.  In this review, we summarize our understanding of the mol. and biol. events that underpin the anti-cancer effects of HDAC inhibitors and the outcomes of recent clin. trials involving these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6o4vH0OXL7bVg90H21EOLACvtfcHk0li_xKZTA1417A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtVSqur0%253D&md5=2f4388dec15ec9b517836f4f3b225641</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DBae%26aufirst%3DS.%2BC.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520molecular%2520mechanisms%2520of%2520action%2520and%2520clinical%2520trials%2520as%2520anti-cancer%2520drugs%26jtitle%3DAm.%2520J.%2520Transl%2520Res.%26date%3D2011%26volume%3D3%26spage%3D166%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horinaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinnoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span> <span> </span><span class="NLM_article-title">A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1080</span>– <span class="NLM_lpage">1086</span>, <span class="refDoi"> DOI: 10.3892/ijo.2013.2042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.3892%2Fijo.2013.2042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23900601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CmsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=1080-1086&author=T.+Yamadaauthor=M.+Horinakaauthor=M.+Shinnohauthor=T.+Yoshiokaauthor=T.+Mikiauthor=T.+Sakai&title=A+novel+HDAC+inhibitor+OBP-801+and+a+PI3K+inhibitor+LY294002+synergistically+induce+apoptosis+via+the+suppression+of+survivin+and+XIAP+in+renal+cell+carcinoma&doi=10.3892%2Fijo.2013.2042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma</span></div><div class="casAuthors">Yamada, Takeshi; Horinaka, Mano; Shinnoh, Masahide; Yoshioka, Takashi; Miki, Tsuneharu; Sakai, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1080-1086</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Renal cell carcinoma (RCC) is resistant to traditional cancer therapies such as radiation therapy and chemotherapy.  The use of targeted therapies has improved the clin. outcomes of patients with metastatic RCC.  However, most patients acquire resistance against targeted therapies over time.  We report that the combination of the novel histone deacetylase (HDAC) inhibitor OBP-801, also known as YM753 and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 synergistically inhibits cell growth and induces apoptosis in RCC cells.  This combination activated caspase-3, -8 and -9 and the pan-caspase inhibitor zVAD-fmk significantly reduced the apoptotic response to the treatment with OBP-801 and LY294002.  Moreover, the combined treatment induced intracellular reactive oxygen species (ROS) and the radical scavenger N-acetyl-L-cysteine (NAC) blocked the intracellular ROS and apoptosis induced by OBP-801 and LY294002.  The co-treatment with OBP-801 and LY294002 markedly decreased survivin and the X-linked inhibitor of apoptosis protein (XIAP) protein levels, but Bcl-2 family members were not altered by the OBP-801/LY294002 co-treatment.  These alterations were restored by NAC treatment.  The transient transfection of survivin and XIAP reduced the apoptotic response to the OBP-801/LY294002 co-treatment.  Addnl., OBP-801 was significantly more effective than SAHA, another HDAC inhibitor, in the combination with LY294002 against 786-O cells.  Taken together, these results strongly suggest the combination of OBP-801 and LY294002 to be a promising treatment for RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsaAUuVoRqkrVg90H21EOLACvtfcHk0lgOaQSpqzaOPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CmsbjK&md5=3f17423d3b17adaa7dd319da8024ec5f</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.3892%2Fijo.2013.2042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2013.2042%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DHorinaka%26aufirst%3DM.%26aulast%3DShinnoh%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DT.%26atitle%3DA%2520novel%2520HDAC%2520inhibitor%2520OBP-801%2520and%2520a%2520PI3K%2520inhibitor%2520LY294002%2520synergistically%2520induce%2520apoptosis%2520via%2520the%2520suppression%2520of%2520survivin%2520and%2520XIAP%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2013%26volume%3D43%26spage%3D1080%26epage%3D1086%26doi%3D10.3892%2Fijo.2013.2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasorsa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azabdaftari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pili, R.</span></span> <span> </span><span class="NLM_article-title">Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2225</span>– <span class="NLM_lpage">2236</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.18632%2Foncotarget.1314" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=2225-2236&author=L.+Ellisauthor=S.+Y.+Kuauthor=S.+Ramakrishnanauthor=E.+Lasorsaauthor=G.+Azabdaftariauthor=A.+Godoyauthor=R.+Pili&title=Combinatorial+antitumor+effect+of+HDAC+and+the+PI3K-Akt-mTOR+pathway+inhibition+in+a+Pten+defecient+model+of+prostate+cancer&doi=10.18632%2Foncotarget.1314"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1314%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DKu%26aufirst%3DS.%2BY.%26aulast%3DRamakrishnan%26aufirst%3DS.%26aulast%3DLasorsa%26aufirst%3DE.%26aulast%3DAzabdaftari%26aufirst%3DG.%26aulast%3DGodoy%26aufirst%3DA.%26aulast%3DPili%26aufirst%3DR.%26atitle%3DCombinatorial%2520antitumor%2520effect%2520of%2520HDAC%2520and%2520the%2520PI3K-Akt-mTOR%2520pathway%2520inhibition%2520in%2520a%2520Pten%2520defecient%2520model%2520of%2520prostate%2520cancer%26jtitle%3DOncotarget%26date%3D2013%26volume%3D4%26spage%3D2225%26epage%3D2236%26doi%3D10.18632%2Foncotarget.1314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogosawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitawaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span> <span> </span><span class="NLM_article-title">Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2013.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ygyno.2013.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23403163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFeqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2013&pages=425-432&author=T.+Yoshiokaauthor=S.+Yogosawaauthor=T.+Yamadaauthor=J.+Kitawakiauthor=T.+Sakai&title=Combination+of+a+novel+HDAC+inhibitor+OBP-801%2FYM753+and+a+PI3K+inhibitor+LY294002+synergistically+induces+apoptosis+in+human+endometrial+carcinoma+cells+due+to+increase+of+Bim+with+accumulation+of+ROS&doi=10.1016%2Fj.ygyno.2013.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS</span></div><div class="casAuthors">Yoshioka, Takashi; Yogosawa, Shingo; Yamada, Takeshi; Kitawaki, Jo; Sakai, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">In most endometrial carcinoma, it has been obsd. that the PI3K/Akt pathway is abnormally accelerated in assocn. with mutations in PIK3CA and PTEN.  The present study aimed to examine the combined effect of a novel histone deacetylase (HDAC) inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 against human endometrial carcinoma cells.The effects of OBP-801/YM753 and LY294002 on the growth of human endometrial carcinoma HEC-1A cells were examd. using WST-8 and colony formation assays.  The distribution of the cell cycle or apoptosis was analyzed by flow cytometry.  The accumulation of intracellular reactive oxygen species (ROS) was measured with a 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) dye.  The expression of apoptosis-related proteins was investigated by Western blotting.  Mice engrafted with 1 × 108 HEC-1A cells were treated with OBP-801/YM753, LY294002 or the combination, and tumor vols. were measured.The combination of OBP-801/YM753 and LY294002 significantly inhibited the cell growth on comparison with each agent alone and synergistically increased apoptosis with the induction of Bim, a well-known apoptosis inducer.  Addnl., the apoptosis induced by the combination was shown to be dependent on intracellular ROS accumulation and Bim induction.  Moreover, the apoptosis-inducing effect of OBP-801/YM753 with LY294002 was more potent than that of SAHA with LY294002.  Combined treatment with OBP-801/YM753 and LY294002 significantly suppressed tumor growth compared to the control in vivo.The combination of OBP-801/YM753 and LY294002 is effective on the inhibition of the growth of HEC-1A cells, and we suggest that this combination is promising a novel therapeutic strategy for endometrial carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-9GAbjAPJsbVg90H21EOLACvtfcHk0lgOaQSpqzaOPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFeqtbo%253D&md5=dc05b4fab8cc8157d8ccb6234a3dc6ed</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2013.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2013.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DYoshioka%26aufirst%3DT.%26aulast%3DYogosawa%26aufirst%3DS.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DKitawaki%26aufirst%3DJ.%26aulast%3DSakai%26aufirst%3DT.%26atitle%3DCombination%2520of%2520a%2520novel%2520HDAC%2520inhibitor%2520OBP-801%252FYM753%2520and%2520a%2520PI3K%2520inhibitor%2520LY294002%2520synergistically%2520induces%2520apoptosis%2520in%2520human%2520endometrial%2520carcinoma%2520cells%2520due%2520to%2520increase%2520of%2520Bim%2520with%2520accumulation%2520of%2520ROS%26jtitle%3DGynecol.%2520Oncol.%26date%3D2013%26volume%3D129%26spage%3D425%26epage%3D432%26doi%3D10.1016%2Fj.ygyno.2013.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span> <span> </span><span class="NLM_article-title">Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4104</span>– <span class="NLM_lpage">4113</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&author=C.+Qianauthor=C.+J.+Laiauthor=R.+Baoauthor=D.+G.+Wangauthor=J.+Wangauthor=G.+X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samsonauthor=B.+Zifcakauthor=A.+W.+Maauthor=S.+DellaRoccaauthor=M.+Borekauthor=H.+X.+Zhaiauthor=X.+Caiauthor=M.+Voi&title=Cancer+network+disruption+by+a+single+molecule+inhibitor+targeting+both+histone+deacetylase+activity+and+phosphatidylinositol+3-kinase+signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0lj0FNfxeNIJ1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DBorek%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DCancer%2520network%2520disruption%2520by%2520a%2520single%2520molecule%2520inhibitor%2520targeting%2520both%2520histone%2520deacetylase%2520activity%2520and%2520phosphatidylinositol%25203-kinase%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodny, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1021/jm501026z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501026z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=41-71&author=M.+Andrsauthor=J.+Korabecnyauthor=D.+Junauthor=Z.+Hodnyauthor=J.+Bartekauthor=K.+Kuca&title=Phosphatidylinositol+3-Kinase+%28PI3K%29+and+phosphatidylinositol+3-kinase-related+kinase+%28PIKK%29+inhibitors%3A+importance+of+the+morpholine+ring&doi=10.1021%2Fjm501026z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring</span></div><div class="casAuthors">Andrs, Martin; Korabecny, Jan; Jun, Daniel; Hodny, Zdenek; Bartek, Jiri; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-71</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related protein kinases (PIKKs) are two related families of kinases that play key roles in regulation of cell proliferation, metab., migration, survival, and responses to diverse stresses including DNA damage.  To design novel efficient strategies for treatment of cancer and other diseases, these kinases have been extensively studied.  Despite their different nature, these two kinase families have related origin and share very similar kinase domains.  Therefore, chem. inhibitors of these kinases usually carry analogous structural motifs.  The most common feature of these inhibitors is a crit. hydrogen bond to morpholine oxygen, initially present in the early nonspecific PI3K and PIKK inhibitor 3 (LY294002), which served as a valuable chem. tool for development of many addnl. PI3K and PIKK inhibitors.  While several PI3K pathway inhibitors have recently shown promising clin. responses, inhibitors of the DNA damage-related PIKKs remain thus far largely in preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPlvsq-HTebVg90H21EOLACvtfcHk0lj0FNfxeNIJ1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE&md5=a8c22f580691084554036dec7d0cc95b</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm501026z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501026z%26sid%3Dliteratum%253Aachs%26aulast%3DAndrs%26aufirst%3DM.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DJun%26aufirst%3DD.%26aulast%3DHodny%26aufirst%3DZ.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DPhosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520and%2520phosphatidylinositol%25203-kinase-related%2520kinase%2520%2528PIKK%2529%2520inhibitors%253A%2520importance%2520of%2520the%2520morpholine%2520ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D41%26epage%3D71%26doi%3D10.1021%2Fjm501026z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellarocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Dual HDAC and PI3K inhibitor CUDC-907 downregulates MYC and suppresses growth of MYC-dependent cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F1535-7163.MCT-16-0390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27980108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=285-299&author=K.+Sunauthor=R.+Atoyanauthor=M.+A.+Borekauthor=S.+Dellaroccaauthor=M.+E.+Samsonauthor=A.+W.+Maauthor=G.+X.+Xuauthor=T.+Pattersonauthor=D.+P.+Tuckauthor=J.+L.+Vinerauthor=A.+Fattaeyauthor=J.+Wang&title=Dual+HDAC+and+PI3K+inhibitor+CUDC-907+downregulates+MYC+and+suppresses+growth+of+MYC-dependent+cancers&doi=10.1158%2F1535-7163.MCT-16-0390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers</span></div><div class="casAuthors">Sun, Kaiming; Atoyan, Ruzanna; Borek, Mylissa A.; Dellarocca, Steven; Samson, Maria Elena S.; Ma, Anna W.; Xu, Guang-Xin; Patterson, Troy; Tuck, David P.; Viner, Jaye L.; Fattaey, Ali; Wang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-299</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs that promote cell growth and proliferation.  Preclin. studies have suggested that individually targeting upstream regulators of MYC, such as histone deacetylases (HDAC) and phosphoinositide 3-kinases (PI3K), can reduce MYC protein levels and suppress the growth of MYC-driven cancers.  Synergy between HDAC and PI3K inhibition in inducing cancer cell death has also been reported, but the involvement of MYC regulation is unclear.  In this study, we demonstrated that HDAC and PI3K inhibition synergistically downregulates MYC protein levels and induces apoptosis in "double-hit" (DH) diffuse large B-cell lymphoma (DLBCL) cells.  Furthermore, CUDC-907, a small-mol. dual-acting inhibitor of both class I and II HDACs and class I PI3Ks, effectively suppresses the growth and survival of MYC-altered or MYC-dependent cancer cells, such as DH DLBCL and BRD-NUT fusion-pos. NUT midline carcinoma (NMC) cells, and MYC protein downregulation is an early event induced by CUDC-907 treatment.  Consistently, the antitumor activity of CUDC-907 against multiple MYC-driven cancer types was also demonstrated in animal models, including DLBCL and NMC xenograft models, Myc transgenic tumor syngeneic models, and MYC-amplified solid tumor patient-derived xenograft (PDX) models.  Our findings suggest that dual function HDAC and PI3K inhibitor CUDC-907 is an effective agent targeting MYC and thus may be developed as potential therapy for MYC-dependent cancers.  Mol Cancer Ther; 16(2); 285-99. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo82AzF-jV397Vg90H21EOLACvtfcHk0lj0FNfxeNIJ1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D&md5=d4ffd5f39546fa076448dbfb36406183</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0390%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DK.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DBorek%26aufirst%3DM.%2BA.%26aulast%3DDellarocca%26aufirst%3DS.%26aulast%3DSamson%26aufirst%3DM.%2BE.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DPatterson%26aufirst%3DT.%26aulast%3DTuck%26aufirst%3DD.%2BP.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDual%2520HDAC%2520and%2520PI3K%2520inhibitor%2520CUDC-907%2520downregulates%2520MYC%2520and%2520suppresses%2520growth%2520of%2520MYC-dependent%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D285%26epage%3D299%26doi%3D10.1158%2F1535-7163.MCT-16-0390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derenzini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asgari, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinberg, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14017</span>– <span class="NLM_lpage">14028</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.18632%2Foncotarget.14876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=28147336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A280%3ADC%252BC1c3hslamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14017-14028&author=P.+Mondelloauthor=E.+Derenziniauthor=Z.+Asgariauthor=J.+Philipauthor=E.+J.+Breaauthor=V.+Seshanauthor=R.+C.+Hendricksonauthor=E.+de+Stanchinaauthor=D.+A.+Scheinbergauthor=A.+Younes&title=Dual+inhibition+of+histone+deacetylases+and+phosphoinositide+3-kinase+enhances+therapeutic+activity+against+B+cell+lymphoma&doi=10.18632%2Foncotarget.14876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma</span></div><div class="casAuthors">Mondello Patrizia; Derenzini Enrico; Asgari Zahra; Younes Anas; Philip John; Hendrickson Ronald C; Brea Elliott J; Scheinberg David A; Seshan Venkatraman; de Stanchina Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">14017-14028</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) and Myc are known to cooperate in promoting the survival and growth of a variety of B-cell lymphomas.  While currently there are no small molecule inhibitors of Myc protein, histone deacetylase (HDAC) inhibitors have been shown to reduce levels of Myc protein by suppressing its transcription.  We assessed the efficacy of CUDC-907, a new rationally designed dual inhibitor of PI3K and HDACs, in a panel of lymphoma cell lines.  CUDC-907 treatment resulted in a dose- and time-dependent growth inhibition and cell death of DLBCL cell lines, irrespective of the cell of origin.  CUDC-907 treatment down-regulated the phosphorylation of PI3K downstream targets, including AKT, PRAS40, S6, and 4EBP1, increased histone 3 acetylation, and decreased Myc protein levels.  SILAC-based quantitative mass spectrometry demonstrated that CUDC-907 treatment decreased the protein levels of several components of the B cell receptor (BCR) and Toll like receptor (TLR) pathways, including BTK, SYK, and MyD88 proteins.  These cellular changes were associated with an inhibition of NF-kB activation.  CUDC-907 demonstrated in vivo efficacy with no significant toxicity in a human DLBCL xenograft mouse model.  Collectively, these data provide a mechanistic rationale for evaluating CUDC-907 for the treatment of patients with Myc and PI3K-dependent lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHhpmYpq2kzUwlCcfExbvbfW6udTcc2eZcDL8uHC3QqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3hslamtg%253D%253D&md5=57e637ca88cd4a23c0c069a8564404d1</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14876%26sid%3Dliteratum%253Aachs%26aulast%3DMondello%26aufirst%3DP.%26aulast%3DDerenzini%26aufirst%3DE.%26aulast%3DAsgari%26aufirst%3DZ.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DBrea%26aufirst%3DE.%2BJ.%26aulast%3DSeshan%26aufirst%3DV.%26aulast%3DHendrickson%26aufirst%3DR.%2BC.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DScheinberg%26aufirst%3DD.%2BA.%26aulast%3DYounes%26aufirst%3DA.%26atitle%3DDual%2520inhibition%2520of%2520histone%2520deacetylases%2520and%2520phosphoinositide%25203-kinase%2520enhances%2520therapeutic%2520activity%2520against%2520B%2520cell%2520lymphoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D14017%26epage%3D14028%26doi%3D10.18632%2Foncotarget.14876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. S.</span></span> <span> </span><span class="NLM_article-title">Human ATP-binding cassette transporter ABCG2 confers resistance to CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol 3-kinase</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00687</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00687" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=784-794&author=C.+P.+Wuauthor=Y.+J.+Hsiehauthor=S.+H.+Hsiaoauthor=C.+Y.+Suauthor=Y.+Q.+Liauthor=Y.+H.+Huangauthor=C.+W.+Huangauthor=C.+H.+Hsiehauthor=J.+S.+Yuauthor=Y.+S.+Wu&title=Human+ATP-binding+cassette+transporter+ABCG2+confers+resistance+to+CUDC-907%2C+a+dual+inhibitor+of+histone+deacetylase+and+phosphatidylinositol+3-kinase&doi=10.1021%2Facs.molpharmaceut.5b00687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase</span></div><div class="casAuthors">Wu, Chung-Pu; Hsieh, Ya-Ju; Hsiao, Sung-Han; Su, Ching-Ya; Li, Yan-Qing; Huang, Yang-Hui; Huang, Chiun-Wei; Hsieh, Chia-Hung; Yu, Jau-Song; Wu, Yu-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-794</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CUDC-907 is a novel, dual-acting small mol. compd. designed to simultaneously inhibit the activity of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).  Treatment with CUDC-907 led to sustained inhibition of HDAC and PI3K activity, inhibition of RAF-MEK-MAPK signaling pathway, and inhibition of cancer cell growth.  CUDC-907 is currently under evaluation in phase I clin. trials in patients with lymphoma or multiple myeloma, and in patients with advanced solid tumors.  However, the risk of developing acquired resistance to CUDC-907 can present a significant therapeutic challenge to clinicians in the future and should be investigated.  The overexpression of ATP-binding cassette (ABC) drug transporter ABCB1, ABCC1, or ABCG2 is one of the most common mechanisms of developing multidrug resistance (MDR) in cancers and a major obstacle in chemotherapy.  In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells.  Moreover, although CUDC-907 affects the transport function of ABCG2, it was not potent enough to reverse drug resistance mediated by ABCG2 or affect the expression level of ABCG2 in human cancer cells.  Taken together, our findings indicate that ABCG2-mediated CUDC-907 resistance can have serious clin. implications and should be further investigated.  More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn2RGaHVNxGrVg90H21EOLACvtfcHk0liOXQ4kVMJIHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOjsLY%253D&md5=036e089fb6690dde8c3de691140dff9b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00687%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BP.%26aulast%3DHsieh%26aufirst%3DY.%2BJ.%26aulast%3DHsiao%26aufirst%3DS.%2BH.%26aulast%3DSu%26aufirst%3DC.%2BY.%26aulast%3DLi%26aufirst%3DY.%2BQ.%26aulast%3DHuang%26aufirst%3DY.%2BH.%26aulast%3DHuang%26aufirst%3DC.%2BW.%26aulast%3DHsieh%26aufirst%3DC.%2BH.%26aulast%3DYu%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BS.%26atitle%3DHuman%2520ATP-binding%2520cassette%2520transporter%2520ABCG2%2520confers%2520resistance%2520to%2520CUDC-907%252C%2520a%2520dual%2520inhibitor%2520of%2520histone%2520deacetylase%2520and%2520phosphatidylinositol%25203-kinase%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D784%26epage%3D794%26doi%3D10.1021%2Facs.molpharmaceut.5b00687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whye, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efimenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Keersmaecker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordon-Cardo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dave, U. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span> <span> </span><span class="NLM_article-title">Targeting nonclassical oncogenes for therapy in T-ALL</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.ccr.2012.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=22516257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVSnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=459-472&author=P.+S.+Subramaniamauthor=D.+W.+Whyeauthor=E.+Efimenkoauthor=J.+Chenauthor=V.+Toselloauthor=K.+De+Keersmaeckerauthor=A.+Kashishianauthor=M.+A.+Thompsonauthor=M.+Castilloauthor=C.+Cordon-Cardoauthor=U.+P.+Daveauthor=A.+Ferrandoauthor=B.+J.+Lannuttiauthor=T.+G.+Diacovo&title=Targeting+nonclassical+oncogenes+for+therapy+in+T-ALL&doi=10.1016%2Fj.ccr.2012.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Nonclassical Oncogenes for Therapy in T-ALL</span></div><div class="casAuthors">Subramaniam, Prem S.; Whye, Dosh W.; Efimenko, Evgeni; Chen, Jianchung; Tosello, Valeria; De Keersmaecker, Kim; Kashishian, Adam; Thompson, Mary Ann; Castillo, Mireia; Cordon-Cardo, Carlos; Dave, Utpal P.; Ferrando, Adolfo; Lannutti, Brian J.; Diacovo, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-472</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Constitutive phosphoinositide 3-kinase (PI3K)/Akt activation is common in T cell acute lymphoblastic leukemia (T-ALL).  Although four distinct class I PI3K isoforms (α, β, γ, δ) could participate in T-ALL pathogenesis, none has been implicated in this process.  We report that in the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed tumor formation.  The reliance of PTEN null T-ALL on the combined activities of PI3Kγ/δ was further demonstrated by the ability of a dual inhibitor to reduce disease burden and prolong survival in mice as well as prevent proliferation and promote activation of proapoptotic pathways in human tumors.  These results support combined inhibition of PI3Kγ/δ as therapy for T-ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosNmXI2hkyJLVg90H21EOLACvtfcHk0liOXQ4kVMJIHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVSnsr8%253D&md5=398af95a5213dd668b882bf33b222a8c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DSubramaniam%26aufirst%3DP.%2BS.%26aulast%3DWhye%26aufirst%3DD.%2BW.%26aulast%3DEfimenko%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTosello%26aufirst%3DV.%26aulast%3DDe%2BKeersmaecker%26aufirst%3DK.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DM.%2BA.%26aulast%3DCastillo%26aufirst%3DM.%26aulast%3DCordon-Cardo%26aufirst%3DC.%26aulast%3DDave%26aufirst%3DU.%2BP.%26aulast%3DFerrando%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26atitle%3DTargeting%2520nonclassical%2520oncogenes%2520for%2520therapy%2520in%2520T-ALL%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D21%26spage%3D459%26epage%3D472%26doi%3D10.1016%2Fj.ccr.2012.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolev, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricono, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padval, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span> <span> </span><span class="NLM_article-title">PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1158%2F0008-5472.CAN-14-1223" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=446-455&author=V.+N.+Kolevauthor=Q.+G.+Wrightauthor=C.+M.+Vidalauthor=J.+E.+Ringauthor=I.+M.+Shapiroauthor=J.+Riconoauthor=D.+T.+Weaverauthor=M.+V.+Padvalauthor=J.+A.+Pachterauthor=Q.+Xu&title=PI3K%2FmTOR+dual+inhibitor+VS-5584+preferentially+targets+cancer+stem+cells&doi=10.1158%2F0008-5472.CAN-14-1223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1223%26sid%3Dliteratum%253Aachs%26aulast%3DKolev%26aufirst%3DV.%2BN.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DVidal%26aufirst%3DC.%2BM.%26aulast%3DRing%26aufirst%3DJ.%2BE.%26aulast%3DShapiro%26aufirst%3DI.%2BM.%26aulast%3DRicono%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DD.%2BT.%26aulast%3DPadval%26aufirst%3DM.%2BV.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DXu%26aufirst%3DQ.%26atitle%3DPI3K%252FmTOR%2520dual%2520inhibitor%2520VS-5584%2520preferentially%2520targets%2520cancer%2520stem%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D446%26epage%3D455%26doi%3D10.1158%2F0008-5472.CAN-14-1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5488</span>– <span class="NLM_lpage">5504</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00579</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00579" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XotVyks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5488-5504&author=Y.+Chenauthor=X.+Wangauthor=W.+Xiangauthor=L.+Heauthor=M.+Tangauthor=F.+Wangauthor=T.+Wangauthor=Z.+Yangauthor=Y.+Yiauthor=H.+Wangauthor=T.+Niuauthor=L.+Zhengauthor=L.+Leiauthor=X.+Liauthor=H.+Songauthor=L.+Chen&title=Development+of+purine-based+hydroxamic+acid+derivatives%3A+potent+histone+deacetylase+inhibitors+with+marked+in+vitro+and+in+vivo+antitumor+activities&doi=10.1021%2Facs.jmedchem.6b00579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities</span></div><div class="casAuthors">Chen, Yong; Wang, Xiaoyan; Xiang, Wei; He, Lin; Tang, Minghai; Wang, Fang; Wang, Taijin; Yang, Zhuang; Yi, Yuyao; Wang, Hairong; Niu, Ting; Zheng, Li; Lei, Lei; Li, Xiaobin; Song, Hang; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5488-5504</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present study, a series of novel histone deacetylase (HDAC) inhibitors using the morpholinopurine as the capping group were designed and synthesized.  Several compds. demonstrated significant HDAC inhibitory activities and antiproliferative effects against diverse human tumor cell lines.  Among them, compd. 10o was identified as a potent class I and class IIb HDAC inhibitor with good pharmaceutical profile and druglike properties.  Western blot anal. further confirmed that 10o more effectively increased acetylated histone H3 than panobinostat (LBH-589) and vorinostat (SAHA) at the same concn. in vitro.  In in vivo efficacy evaluations of HCT116, MV4-11, Ramos, and MM1S xenograft models, 10o showed higher efficacy than SAHA or LBH-589 without causing significant loss of body wt. and toxicity.  All the results indicated that 10o could be a suitable candidate for treatment of both solid and hematol. cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIrTRI5NXFfLVg90H21EOLACvtfcHk0li4LXW3hj_hEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotVyks7w%253D&md5=3400d6c13519392827c72bba6f044121</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00579%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520purine-based%2520hydroxamic%2520acid%2520derivatives%253A%2520potent%2520histone%2520deacetylase%2520inhibitors%2520with%2520marked%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5488%26epage%3D5504%26doi%3D10.1021%2Facs.jmedchem.6b00579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alper, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden, E. T.</span></span> <span> </span><span class="NLM_article-title">Novel insights into c-Src</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1130</span>, <span class="refDoi"> DOI: 10.2174/1381612053507576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.2174%2F1381612053507576" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1119-1130&author=O.+Alperauthor=E.+T.+Bowden&title=Novel+insights+into+c-Src&doi=10.2174%2F1381612053507576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.2174%2F1381612053507576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612053507576%26sid%3Dliteratum%253Aachs%26aulast%3DAlper%26aufirst%3DO.%26aulast%3DBowden%26aufirst%3DE.%2BT.%26atitle%3DNovel%2520insights%2520into%2520c-Src%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2005%26volume%3D11%26spage%3D1119%26epage%3D1130%26doi%3D10.2174%2F1381612053507576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostyniuk, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonham, K.</span></span> <span> </span><span class="NLM_article-title">The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6340</span>– <span class="NLM_lpage">6347</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fsj.onc.1205787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=12214274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1yrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=6340-6347&author=C.+L.+Kostyniukauthor=S.+M.+Dehmauthor=D.+Battenauthor=K.+Bonham&title=The+ubiquitous+and+tissue+specific+promoters+of+the+human+SRC+gene+are+repressed+by+inhibitors+of+histone+deacetylases&doi=10.1038%2Fsj.onc.1205787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases</span></div><div class="casAuthors">Kostyniuk, Calley L.; Dehm, Scott M.; Batten, Danielle; Bonham, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">6340-6347</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors have generated keen interest as potential chemopreventive and chemotherapeutic agents due to their ability to induce cell cycle arrest, differentiation, and apoptosis in a diverse group of cancer derived cell lines.  Activation of the 60 kDa non-receptor tyrosine kinase, c-Src, has been a consistent finding in many tumors and tumor derived cell lines, and has been implicated in these same cellular processes.  We have shown that the histone deacetylase inhibitors, sodium butyrate and Trichostatin A, repressed c-Src mRNA and protein expression in a dose-dependent manner in cell lines derived from cancers of the colon, breast and liver.  Our group has previously identified two distinct promoters that are responsible for SRC transcription, sepd. by a distance of approx. 1 kb.  Sodium butyrate and Trichostatin A strongly inhibited activity of each of these highly disparate SRC promoters, demonstrating histone deacetylase inhibitors directly repress SRC transcription.  This repression did not require protein neosynthesis and was not assocd. with a decrease in binding of protein factors essential for either promoter's activity.  Our finding that sodium butyrate and Trichostatin A inhibit both SRC promoters suggest this oncogene may be a major target of these agents, and may explain in part their anti-cancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMGOnAYoAa6bVg90H21EOLACvtfcHk0li4LXW3hj_hEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1yrsrY%253D&md5=8ee01116950b182b849d5d84ce1213fc</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205787%26sid%3Dliteratum%253Aachs%26aulast%3DKostyniuk%26aufirst%3DC.%2BL.%26aulast%3DDehm%26aufirst%3DS.%2BM.%26aulast%3DBatten%26aufirst%3DD.%26aulast%3DBonham%26aufirst%3DK.%26atitle%3DThe%2520ubiquitous%2520and%2520tissue%2520specific%2520promoters%2520of%2520the%2520human%2520SRC%2520gene%2520are%2520repressed%2520by%2520inhibitors%2520of%2520histone%2520deacetylases%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D6340%26epage%3D6347%26doi%3D10.1038%2Fsj.onc.1205787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandvold, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Development of a chimeric c-Src kinase and HDAC inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.1021/ml400175d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400175d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=779-783&author=K.+S.+Koauthor=M.+E.+Steffeyauthor=K.+R.+Brandvoldauthor=M.+B.+Soellner&title=Development+of+a+chimeric+c-Src+kinase+and+HDAC+inhibitor&doi=10.1021%2Fml400175d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Chimeric c-Src Kinase and HDAC Inhibitor</span></div><div class="casAuthors">Ko, Kristin S.; Steffey, Michael E.; Brandvold, Kristoffer R.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">779-783</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of synergism obsd. between a selective c-Src kinase inhibitor with an HDAC inhibitor, the development of the first chimeric c-Src kinase and HDAC inhibitor is described.  The optimized chimeric inhibitor is shown to be a potent c-Src and HDAC inhibitor.  Chimeric inhibitor (I) is further shown to be highly efficacious in cancer cell lines and significantly more efficacious than a dual-targeting strategy using discrete c-Src and HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzi2suGn-7ErVg90H21EOLACvtfcHk0ljaPFQmDNOkxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL&md5=5f34ce3b1f65a8ac1a4341f563a5e1d9</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fml400175d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400175d%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DK.%2BS.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DBrandvold%26aufirst%3DK.%2BR.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520chimeric%2520c-Src%2520kinase%2520and%2520HDAC%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D779%26epage%3D783%26doi%3D10.1021%2Fml400175d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4839</span>– <span class="NLM_lpage">4853</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.03.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2Fj.bmc.2008.03.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=4839-4853&author=P.+C.+Chenauthor=V.+Patilauthor=W.+Guerrantauthor=P.+Greenauthor=A.+K.+Oyelere&title=Synthesis+and+structure-activity+relationship+of+histone+deacetylase+%28HDAC%29+inhibitors+with+triazole-linked+cap+group&doi=10.1016%2Fj.bmc.2008.03.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.03.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.03.050%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%2BC.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DGreen%26aufirst%3DP.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520of%2520histone%2520deacetylase%2520%2528HDAC%2529%2520inhibitors%2520with%2520triazole-linked%2520cap%2520group%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D4839%26epage%3D4853%26doi%3D10.1016%2Fj.bmc.2008.03.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedenburg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors through click chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7417</span>– <span class="NLM_lpage">7427</span>, <span class="refDoi"> DOI: 10.1021/jm8005355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8005355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7417-7427&author=J.+Shenauthor=R.+Woodwardauthor=J.+P.+Kedenburgauthor=X.+Liuauthor=M.+Chenauthor=L.+Fangauthor=D.+Sunauthor=P.+G.+Wang&title=Histone+deacetylase+inhibitors+through+click+chemistry&doi=10.1021%2Fjm8005355"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm8005355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8005355%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DWoodward%26aufirst%3DR.%26aulast%3DKedenburg%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DP.%2BG.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520through%2520click%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7417%26epage%3D7427%26doi%3D10.1021%2Fjm8005355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mwakwari, S.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tekwani, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurard-Levin, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrksich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6100</span>– <span class="NLM_lpage">6111</span>, <span class="refDoi"> DOI: 10.1021/jm100507q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100507q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6100-6111&author=S.%0AC.+Mwakwariauthor=W.+Guerrantauthor=V.+Patilauthor=S.+I.+Khanauthor=B.+L.+Tekwaniauthor=Z.+A.+Gurard-Levinauthor=M.+Mrksichauthor=A.+K.+Oyelere&title=Non-peptide+macrocyclic+histone+deacetylase+inhibitors+derived+from+tricyclic+ketolide+skeleton&doi=10.1021%2Fjm100507q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide Skeleton</span></div><div class="casAuthors">Mwakwari, Sandra C.; Guerrant, William; Patil, Vishal; Khan, Shabana I.; Tekwani, Babu L.; Gurard-Levin, Zachary A.; Mrksich, Milan; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6100-6111</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of histone deacetylase (HDAC) function is a validated therapeutic strategy for cancer treatment.  Of the several structurally distinct small mol. histone deacetylase inhibitors (HDACi) reported, macrocyclic depsipeptides possess the most complex cap groups and have demonstrated excellent HDAC inhibition potency and isoform selectivity.  Unfortunately, the development of macrocyclic depsipeptides has been hampered in part because of development problems characteristic of large peptides and the complex reaction schemes required for their synthesis.  Herein we report that tricyclic ketolide TE-802 is an excellent mimetic for the peptide backbone of macrocyclic HDACi.  Compds. derived from this template are particularly selective against HDACs 1 and 2 with nanomolar inhibitory activity.  Interrogation of the assocn. between a subset of these compds. and key HDAC isoforms, using AutoDock, enables a mol. description of the interaction between the HDAC enzyme's outer rim and the inhibitors' macrocyclic cap group that are responsible for compd. affinity and presumably isoform selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt9QPKI33jvbVg90H21EOLACvtfcHk0ljaPFQmDNOkxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtLk%253D&md5=6407dc82e9fb2dab6313d32956600659</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm100507q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100507q%26sid%3Dliteratum%253Aachs%26aulast%3DMwakwari%26aufirst%3DS.%2BC.%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DKhan%26aufirst%3DS.%2BI.%26aulast%3DTekwani%26aufirst%3DB.%2BL.%26aulast%3DGurard-Levin%26aufirst%3DZ.%2BA.%26aulast%3DMrksich%26aufirst%3DM.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DNon-peptide%2520macrocyclic%2520histone%2520deacetylase%2520inhibitors%2520derived%2520from%2520tricyclic%2520ketolide%2520skeleton%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6100%26epage%3D6111%26doi%3D10.1021%2Fjm100507q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trelinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span> <span> </span><span class="NLM_article-title">JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">1161</span>, <span class="refDoi"> DOI: 10.2174/0929867311320090004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.2174%2F0929867311320090004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=23317159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslGlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1147-1161&author=J.+Trelinskiauthor=T.+Robak&title=JAK+inhibitors%3A+pharmacology+and+clinical+activity+in+chronic+myeloprolipherative+neoplasms&doi=10.2174%2F0929867311320090004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms</span></div><div class="casAuthors">Trelinski, J.; Robak, T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1147-1161</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (JAKs), JAK1, JAK2, JAK3, and TYK2, are involved in cell growth, survival, development, and differentiation of a variety of cells, particularly immune cells and hematopoietic cells.  They form a subgroup of the non-receptor protein tyrosine kinases.  Activating mutations within each of the JAKs is assocd. with malignant transformations; the most common are mutations of JAK2 in polycythemia vera (PV) and other myeloproliferative neoplasms (MPN).  Identification of the V617F mutation of the JAK2 gene (JAK2 V617F) led to an important breakthrough in the understanding of MPN disease pathogenesis.  The JAK2 V617F mutation is present in the majority of PV patients, and about 50% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF) are affected.  This mutation leads to hyperactivation of JAK2, cytokine-independent signaling, and subsequent activation of downstream signaling networks.  JAK2 ATP-competitive inhibitors that indirectly inhibit the JAK-STAT pathway are new candidates for the treatment of MPN.  JAK2 inhibitors in development for the treatment of MPN have demonstrated clin. activity with minimal toxicity.  These agents consistently alleviate constitutional symptoms and reduce spleen size in PMF and other MPN.  However, some of these inhibitors have addnl. unique effects.  Ruxolitinib causes a significant redn. in the level of pro-inflammatory cytokines.  Another inhibitor, CYT387, improves anemia.  Many other JAK2 inhibitors such as TG101348 or SAR302503, SB1518, CEP701 and LY2784544 are now under investigation for MPN development.  In contrast tasocitinib, a predominantly JAK3 inhibitor, is being evaluated in a no. of inflammatory and immunol. diseases, including rheumatoid arthritis, psoriasis, ulcerative colitis, dry eye disease and in kidney transplant patients.  In conclusion the use of JAK inhibitors in MPN and some of the immune-mediated disorders is a promising new strategy for therapy.  However, definitive data from ongoing and future preclin. and clin. trials will aid in better defining the status of these drugs in the treatment of these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqknrRTtegtubVg90H21EOLACvtfcHk0liHkMJLdM4tAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslGlsbY%253D&md5=a79da3c1d67f0b2be73ff1a80203f90c</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.2174%2F0929867311320090004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320090004%26sid%3Dliteratum%253Aachs%26aulast%3DTrelinski%26aufirst%3DJ.%26aulast%3DRobak%26aufirst%3DT.%26atitle%3DJAK%2520inhibitors%253A%2520pharmacology%2520and%2520clinical%2520activity%2520in%2520chronic%2520myeloprolipherative%2520neoplasms%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1147%26epage%3D1161%26doi%3D10.2174%2F0929867311320090004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crispino, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moliterno, A. R.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms</span>. <i>Curr. Opin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1097/CCO.0b013e32834d1b22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1097%2FCCO.0b013e32834d1b22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=21993415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12rtrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=609-616&author=B.+L.+Steinauthor=J.+D.+Crispinoauthor=A.+R.+Moliterno&title=Janus+kinase+inhibitors%3A+an+update+on+the+progress+and+promise+of+targeted+therapy+in+the+myeloproliferative+neoplasms&doi=10.1097%2FCCO.0b013e32834d1b22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms</span></div><div class="casAuthors">Stein, Brady L.; Crispino, John D.; Moliterno, Alison R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">609-616</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The discovery of the JAK2 V617F mutation in the classical myeloproliferative neoplasms (MPNs) essential thrombocytosis, polycythemia vera, and primary myelofibrosis has ushered in a new era of scientific discovery in these diseases, resulting in a mol. classification and an improved understanding of disease pathogenesis.  Alongside this period of discovery has been the rapid development of targeted therapy and, here, we summarize results from clin. trials involving these small mol. Janus family of tyrosine kinase (JAK) inhibitors.  Recent findings: The JAK inhibitors consistently alleviate constitutional symptoms and reduce spleen size.  Early phase testing indicates that some of these inhibitors have addnl. unique effects: INCB018424 results in a significant redn. in the level of pro-inflammatory cytokines; TG101348 may modify disease burden as assessed by JAK2 allele measurements; and CYT387 ameliorates anemia.  Summary: The initial enthusiasm for these agents has been tempered by recognition that JAK2 V617F may represent only one component of lesions driving the heterogeneity of the MPN.  Clin. trial design cannot address important disease endpoints such as thrombosis or leukemia transformation, but it appears that JAK inhibitors will offer an important palliative option and because of the mol. complexity in these diseases, it might be rational to give these inhibitors along with other agents that target alternate mechanisms of the disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9CHRkn6f18LVg90H21EOLACvtfcHk0liHkMJLdM4tAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12rtrjE&md5=3e285c17603fc94799264d6fbc9fa6eb</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e32834d1b22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e32834d1b22%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DB.%2BL.%26aulast%3DCrispino%26aufirst%3DJ.%2BD.%26aulast%3DMoliterno%26aufirst%3DA.%2BR.%26atitle%3DJanus%2520kinase%2520inhibitors%253A%2520an%2520update%2520on%2520the%2520progress%2520and%2520promise%2520of%2520targeted%2520therapy%2520in%2520the%2520myeloproliferative%2520neoplasms%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2011%26volume%3D23%26spage%3D609%26epage%3D616%26doi%3D10.1097%2FCCO.0b013e32834d1b22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellacasa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carobbio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Introna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaldi, A.</span></span> <span> </span><span class="NLM_article-title">The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2405049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1038%2Fsj.leu.2405049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=18079739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=740-747&author=V.+Gueriniauthor=V.+Barbuiauthor=O.+Spinelliauthor=A.+Salviauthor=C.+Dellacasaauthor=A.+Carobbioauthor=M.+Intronaauthor=T.+Barbuiauthor=J.+Golayauthor=A.+Rambaldi&title=The+histone+deacetylase+inhibitor+ITF2357+selectively+targets+cells+bearing+mutated+JAK2%28V617F%29&doi=10.1038%2Fsj.leu.2405049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F</span></div><div class="casAuthors">Guerini, V.; Barbui, V.; Spinelli, O.; Salvi, A.; Dellacasa, C.; Carobbio, A.; Introna, M.; Barbui, T.; Golay, J.; Rambaldi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-747</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors investigated the activity of ITF2357, a novel histone deacetylase inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2V617F mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line.  The clonogenic activity of JAK2V617F mutated cells was inhibited by low concns. of ITF2357 (IC50 0.001-0.01 μ), 100- to 250-fold lower than required to inhibit growth of normal or tumor cells lacking this mutation.  Under these conditions, ITF2357 allowed a seven fold increase in the outgrowth of unmutated over mutated colonies.  By western blotting the authors showed that in HEL cells, ITF2357 led to the disappearance of total and phosphorylated JAK2V617F as well as pSTAT5 and pSTAT3, but it did not affect the wild-type JAK2 or STAT proteins in the control K562 cell line.  By real-time PCR, the authors showed that, upon exposure to ITF2357, JAK2V617F mRNA was not modified in granulocytes from PV patients while the expression of the PRV-1 gene, a known target of JAK2, was rapidly downmodulated.  Altogether, the data presented suggest that ITF2357 inhibits proliferation of cells bearing the JAK2V617F mutation through a specific down-modulation of the JAK2V617F protein and inhibition of its downstream signaling.  Leukemia (2008) 22, 740-747; doi:10.1038/sj.leu.2405049; published online 13 Dec. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJVQmHmDb8RLVg90H21EOLACvtfcHk0liHkMJLdM4tAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D&md5=de59fdaf20ec85e733052c09733b9193</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2405049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2405049%26sid%3Dliteratum%253Aachs%26aulast%3DGuerini%26aufirst%3DV.%26aulast%3DBarbui%26aufirst%3DV.%26aulast%3DSpinelli%26aufirst%3DO.%26aulast%3DSalvi%26aufirst%3DA.%26aulast%3DDellacasa%26aufirst%3DC.%26aulast%3DCarobbio%26aufirst%3DA.%26aulast%3DIntrona%26aufirst%3DM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DGolay%26aufirst%3DJ.%26aulast%3DRambaldi%26aufirst%3DA.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520ITF2357%2520selectively%2520targets%2520cells%2520bearing%2520mutated%2520JAK2%2528V617F%2529%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D740%26epage%3D747%26doi%3D10.1038%2Fsj.leu.2405049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on Pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+Janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+Pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0ljiiB0N2r2Kqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520Pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>– <span class="NLM_lpage">10846</span>, <span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+design+and+simple+chemistry+yield+a+superior%2C+neuroprotective+HDAC6+inhibitor%2C+tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0ljiiB0N2r2Kqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520design%2520and%2520simple%2520chemistry%2520yield%2520a%2520superior%252C%2520neuroprotective%2520HDAC6%2520inhibitor%252C%2520tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X.T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of Janus kinase (JAK) and histone deacetylase (HDAC) based on Ruxolitinib and Vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+Janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+Ruxolitinib+and+Vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0ljiiB0N2r2Kqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.T.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.Y.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520Ruxolitinib%2520and%2520Vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClure, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inks, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span> <span> </span><span class="NLM_article-title">Development of allosteric hydrazide-containing class I histone deacetylase inhibitors for use in acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9942</span>– <span class="NLM_lpage">9959</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01385</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01385" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs12gtbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9942-9959&author=J.+J.+McClureauthor=C.+Zhangauthor=E.+S.+Inksauthor=Y.+K.+Petersonauthor=J.+Liauthor=C.+J.+Chou&title=Development+of+allosteric+hydrazide-containing+class+I+histone+deacetylase+inhibitors+for+use+in+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.6b01385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia</span></div><div class="casAuthors">McClure, Jesse J.; Zhang, Cheng; Inks, Elizabeth S.; Peterson, Yuri K.; Li, Jiaying; Chou, C. James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9942-9959</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the biggest hurdles yet to be overcome for the continued improvement of Histone Deacetylase (HDAC) inhibitors is finding alternative motifs equipotent to the classic and ubiquitously used hydroxamic acid.  The N-hydroxyl group of this motif is highly subject to sulfation/glucoronidation-based inactivation in humans; compds. contg. this motif require much higher dosing in clinic to achieve therapeutic concns.  With the goal of developing a second generation of HDAC inhibitors, lacking this hydroxamate, the authors designed a series of potent and selective class I HDAC inhibitors using a hydrazide motif.  These inhibitors are impervious to glucuronidation and demonstrate allosteric inhibition.  In vitro and ex vivo characterization of the authors' lead analogs' efficacy, selectivity, and toxicity profiles demonstrate they possess low nanomolar activity against models of Acute Myeloid Leukemia (AML) and are at least 100-fold more selective for AML than solid immortalized cells such as HEK293 or human peripheral blood mononuclear cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdee-0DZN6zbVg90H21EOLACvtfcHk0ljioTMvN7Vx_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs12gtbrE&md5=52d5222010a0de3cfecde9a04c3efb84</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01385%26sid%3Dliteratum%253Aachs%26aulast%3DMcClure%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DInks%26aufirst%3DE.%2BS.%26aulast%3DPeterson%26aufirst%3DY.%2BK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26atitle%3DDevelopment%2520of%2520allosteric%2520hydrazide-containing%2520class%2520I%2520histone%2520deacetylase%2520inhibitors%2520for%2520use%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9942%26epage%3D9959%26doi%3D10.1021%2Facs.jmedchem.6b01385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00584-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=10.1016%2FS1470-2045%2815%2900584-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=27049457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=622-631&author=A.+Younesauthor=J.+G.+Berdejaauthor=M.+R.+Patelauthor=I.+Flinnauthor=J.+F.+Gerecitanoauthor=S.+S.+Neelapuauthor=K.+R.+Kellyauthor=A.+R.+Copelandauthor=A.+Akinsauthor=M.+S.+Clancyauthor=L.+Gongauthor=J.+Wangauthor=A.+Maauthor=J.+L.+Vinerauthor=Y.+Oki&title=Safety%2C+tolerability%2C+and+preliminary+activity+of+CUDC-907%2C+a+first-in-class%2C+oral%2C+dual+inhibitor+of+HDAC+and+PI3K%2C+in+patients+with+relapsed+or+refractory+lymphoma+or+multiple+myeloma%3A+an+open-label%2C+dose-escalation%2C+phase+1+trial&doi=10.1016%2FS1470-2045%2815%2900584-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span></div><div class="casAuthors">Younes, Anas; Berdeja, Jesus G.; Patel, Manish R.; Flinn, Ian; Gerecitano, John F.; Neelapu, Sattva S.; Kelly, Kevin R.; Copeland, Amanda R.; Akins, Amy; Clancy, Myles S.; Gong, Lucy; Wang, Jing; Ma, Anna; Viner, Jaye L.; Oki, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-631</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited.  CUDC-907 is an oral, first-in-class, small mol. that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematol. malignancies.  We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma.  This open-label, first-in-man, phase 1 trial recruited adult patients (aged ≥18 years) with lymphoma or multiple myeloma who were refractory to or had relapsed after two or more previous regimens, from four US cancer centers.  CUDC-907 was orally administered in a std. 3 + 3 dose-escalation design at four different dosing schedules, to which participants were sequentially assigned as follows: once daily, intermittently (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day break (5/2), in 21-day cycles.  Dosing started at 30 mg for the once-daily schedule and 60 mg for other schedules, escalating in 30 mg increments.  Patients continued to receive CUDC-907 until disease progression or until other treatment discontinuation criteria were met.  The primary objective was to det. the max. tolerated dose (MTD) and recommended phase 2 dose, assessed in patients who received at least 66% of cycle 1 doses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irresp. of dose modification.  We assessed safety in all patients who received at least one dose of study drug.  This ongoing trial is registered at ClinicalTrials.gov, no. NCT01742988.  Between Jan 23, 2013, and July 27, 2015, we enrolled 44 patients, of whom ten were sequentially assigned to CUDC-907 once-daily (MTD 60 mg), 12 to twice-weekly (MTD 150 mg), 15 to three-times-weekly (MTD 150 mg), and seven to the 5/2 dosing schedule (MTD 60 mg). 37 (84%) patients had discontinued study drug as a result of progressive disease or clin. signs of progressive disease at the data cutoff.  Four DLTs occurred in three of 40 DLT-evaluable patients (diarrhoea and hyperglycemia in one patient on 60 mg once daily, hyperglycemia in one patient on 150 mg twice weekly, and diarrhoea in one patient on 150 mg three times weekly); no DLTs were reported in patients on the 5/2 schedule.  Grade 3 or worse adverse events occurred in 19 (43%) of 44 patients, the most common of which were thrombocytopenia (in nine [20%] of 44 patients), neutropenia (three [7%]), and hyperglycemia (three [7%]). 11 (25%) of 44 patients had serious adverse events, three of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycemia).  Adverse events led to dose redns. in six (14%) patients and treatment discontinuation in seven (16%).  Five (14%) of 37 response-evaluable patients achieved an objective response (two complete responses and three partial responses).  All five responses occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three occurred in those with transformed follicular lymphoma DLBCL (n=5). 21 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's lymphoma, and multiple myeloma.  On the basis of these findings, we selected CUDC-907 60 mg on the 5/2 dosing schedule as the recommended phase 2 dose.  The safety and tolerability profile of CUDC-907 and the promising preliminary evidence of response support continued development of CUDC-907 at the 60 mg 5/2 dosing schedule, alone and in combination with other therapies.  A dose-expansion trial of this dose in patients with refractory and relapsed DLBCL in particular, is ongoing.  Curis, Inc, and the Leukemia and Lymphoma Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFEt7vSuwM7Vg90H21EOLACvtfcHk0ljioTMvN7Vx_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D&md5=b759c77ac239b6ae0052d30c9bea3221</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900584-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900584-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DCopeland%26aufirst%3DA.%2BR.%26aulast%3DAkins%26aufirst%3DA.%26aulast%3DClancy%26aufirst%3DM.%2BS.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DOki%26aufirst%3DY.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520preliminary%2520activity%2520of%2520CUDC-907%252C%2520a%2520first-in-class%252C%2520oral%252C%2520dual%2520inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520lymphoma%2520or%2520multiple%2520myeloma%253A%2520an%2520open-label%252C%2520dose-escalation%252C%2520phase%25201%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D622%26epage%3D631%26doi%3D10.1016%2FS1470-2045%2815%2900584-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3CJG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3CJG','PDB','3CJG'); return false;">PDB: 3CJG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DBS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DBS','PDB','3DBS'); return false;">PDB: 3DBS</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00189&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00189%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-7%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00189" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679916645dc1123e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
